

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 7/02, 7/04, 15/48, C12Q 1/68, 1/70, A61K 39/21		(11) International Publication Number: WO 95/21912
A1		(43) International Publication Date: 17 August 1995 (17.08.95)
(21) International Application Number: PCT/AU95/00063		(74) Agents: HUGHES, E. John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).
(22) International Filing Date: 14 February 1995 (14.02.95)		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(30) Priority Data: PM 3864 14 February 1994 (14.02.94) AU PM 4002 21 February 1994 (21.02.94) AU PN 0284 23 December 1994 (23.12.94) AU		Published With international search report.
(71) Applicants (for all designated States except US): THE MACFARLANE BURNET CENTRE FOR MEDICAL RESEARCH LIMITED [AU/AU]; Yarra Bend Road, Fairfield, VIC 3078 (AU). AUSTRALIAN RED CROSS SOCIETY (NSW DIVISION) [AU/AU]; 153 Clarence Street, Sydney, NSW 2000 (AU).		
(72) Inventors; and (75) Inventors/Applicants (for US only): DEACON, Nicholas, John [AU/AU]; 51 Elliott Avenue, Balwyn, VIC 3105 (AU). LEARMONT, Jennifer, Catherine [AU/AU]; 88 Patongo Street, Patongo, NSW 2256 (AU). McPHEE, Dale, Alan [AU/AU]; 14 Freeman Street, Fitzroy, VIC 3065 (AU). CROWE, Suzanne [AU/AU]; 1 Palermo Street, South Yarra, VIC 3141 (AU). COOPER, David [AU/AU]; 7 Carrington Avenue, Bellvue Hill, NSW 2023 (AU).		

(54) Title: NON-PATHOGENIC STRAINS OF HIV-1



(57) Abstract

The present invention relates to non-pathogenic strains of HIV-1 and to components, parts, fragments and derivatives thereof and to genetic sequences derived therefrom and their use in the development of diagnostic and therapeutic compositions for the treatment and prophylaxis of AIDS and AIDS-related disorders. The present invention also relates to a method for attenuating pathogenic strains of HIV-1 by mutagenizing particular regions of the HIV-1 genome.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

NON-PATHOGENIC STRAINS OF HIV-1

5 The present invention relates to non-pathogenic strains of HIV-1 and to components, parts, fragments and derivatives thereof and to genetic sequences derived therefrom and their use in the development of diagnostic and therapeutic compositions for the treatment and prophylaxis of AIDS and AIDS-related disorders. The present invention also relates to a method for attenuating pathogenic strains of HIV-1 by mutagenizing particular
10 regions of the HIV-1 genome.

Bibliographic details of the publications referred to in this specification are collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined
15 following the bibliography.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but
20 not the exclusion of any other element or integer or group of elements or integers.

Genomic nucleotide sequences of HIV-1 strains referred to herein are represented by their corresponding DNA sequence.

25 Exemplary viral isolates referred to herein as "C18" and "C98" were deposited at the PHLS Centre for Applied Microbiology and Research, European Collection of Animal Cell Cultures (ECACC), Division of Biologies, Porton Down, Salisbury, Wiltshire SP4 OJG. C18 was deposited on 17 October, 1994 under Provisional Accession Number V94101706 and C98 was deposited on 31 October, 1994 under Provisional Accession
30 Number V941031169. Viral isolate "C54" was deposited at ECACC on 14 February, 1995 under Provisional Accession Number _____.

A summary of particular deletion mutants of HIV-1 of the present invention referred to herein is given in Figure 11.

5 Acquired Immune Deficiency Syndrome (AIDS) and AIDS related disorders are the clinical result of infection by Human Immunodeficiency Virus type I (HIV-1) (Barre-Sinoussi *et al*, 1983). Infection by HIV-1 is generally characterised by progressive immune system damage (Teeuwssen *et al*, 1990; Clerici *et al*, 1989) leading to opportunistic infections, malignancies or wasting syndrome that constitute clinically-defined AIDS (Busch *et al*, 1991; Klaslow *et al*, 1990).

10

The high mortality rate of individuals infected with HIV-1 together with the social and economic consequences of the continuing HIV-1 epidemic has created an urgent need for a safe and effective treatment and/or prophylaxis against the devastating effects of AIDS. However, despite over a decade of high level scientific research into the pathogenesis of HIV-1 and the clinical manifestations of the disease, together with a detailed molecular analysis of the virus, there has been little success in the development of an effective vaccine. To date, the most effective therapy is treatment with zidovudine (AZT) which delays the onset of full blown AIDS and alleviates to some extent the symptoms of HIV-1 infection. However, AZT is not an innocuous compound and AZT, metabolic products thereof or impurities therein can cause a number of side effects which limit long term treatment with the drug. Furthermore, AZT resistant isolates have been reported during treatment. Clearly, therefore, a need exists to develop alternative strategies in preventing and treating HIV-1 infection.

25 The initial phases of HIV-1 infection are summarised by Levy (1993) as involving attachment, fusion and nucleocapsid entry. These phases have been the traditional foci in research into development of antiviral strategies. The molecular events at the virus genomic level have also been the subject of intense scientific research with an aim being the development of a live attenuated vaccine as a possible approach for the treatment or prophylaxis of HIV-1 infection.

30

There is a high variable rate of progression from initial HIV-1 infection to AIDS which reflects a rapidly changing pathogen and variable immune response of the host to infection (Sheppard *et al*, 1993). With regards to the latter, HIV-1 can be considered
5 as a heterogenous group of viruses differing at the genetic level with concomitant variable pathogenicity. For example, HIV-1 strains can differ in their capacity to kill cells. Furthermore, it appears that HIV-1 strains evolve in a host after infection and that the evolution varies depending on the tissues infected by the virus. The major sites in the genome apparently responsible for biological and pathological variation are the
10 highly variable envelope region (Cheng-Mayer *et al*, 1991; Shioda *et al*, 1992; Hwang, *et al* 1991; Sullivan *et al*, 1993; Groenink *et al*, 1993) and the viral regulatory regions such as *tat* (Leguern *et al*, 1993). The genetic complexity of the HIV-1 group of viruses together with their variable pathogenicity, are major difficulties in the development of live vaccines, genetic vaccines or component vaccines.

15 Notwithstanding the highly pathogenic nature of HIV-1, there are some reports of long term survival of subjects infected with the virus (Learmont *et al*, 1992; Levy, 1993; Sheppard *et al*, 1993; Lifson *et al* 1991). It is not always clear, however, whether a benign course following HIV-1 infection is due to host factors, viral factors or other
20 unknown factors. There are reports that most infected people have at least laboratory evidence of progressive immune system damage in the form of CD4+ cell loss (Lang *et al*, 1989) and defective immune responses (Clerici *et al*, 1989).

Although simian monkeys have been used as an *in vivo* model for HIV and Simian
25 Immunodeficiency Virus (SIV) infection, a major handicap in AIDS research has been the absence of suitable *in vivo* models to study the pathogenesis of the disease and, in particular, to study the viruses involved in benign infection. The need for a suitable *in vivo* model is heightened by the fact that results obtained *in vitro* cannot necessarily be extrapolated to what occurs *in vivo*. This was clearly observed by Mosier *et al* (1993)
30 where conflicting results were obtained in animals compared to cell cultures.

Despite the absence of suitable *in vivo* models, considerable scientific research has been directed to attenuating HIV-1 strains by mutagenesis of the virus genome. Deletions in the *nef* gene have been implicated in attenuated strains of SIV and their use in providing protective effects in monkeys (Daniel *et al*, 1992). However, there are conflicting reports on the possible negative influence the *nef* gene product has on the rate or extent of virus replication (Terwilliger *et al*, 1986; Luciw *et al*, 1987; Niederman *et al*, 1989; Kim *et al*, 1989; Hammes *et al*, 1989). In fact, Kim *et al* (1989) found that *nef* did not affect HIV-1 replication or HIV-1 long terminal repeat (LTR)-driven CAT expression. Kestler III *et al* (1991) found that the *nef* gene is required for full pathogenic potential in SIV. However, such is the complexity of the HIV-1 group of viruses and the variability of immune responses between individuals let alone different species, that it is far from clear whether *nef* deleted strains of HIV-1 would behave similarly to *nef* deleted strains of SIV-I. There is a need, therefore, in order to investigate the possibility of *nef* deleted HIV-1 strain as a vaccine candidate, to identify individuals infected with such modified viruses.

Learmont *et al* (1992) reported that a cohort of five persons infected with blood products from a single HIV-1 infected donor have remained asymptomatic from up to about 10-14 years after infection. Subsequently, a sixth person has been identified as being part of the cohort. Both the donor and recipients were HIV-1 seropositive but with no indications of clinical symptoms of HIV-1 related disease and CD4+ cell number and β_2 -microglobulin levels have remained in the normal range. The identification of this cohort of benignly infected individuals provides a unique *in vivo* model in which the pathogenesis of HIV-1 infection can be studied at the clinical and molecular biological levels.

However, it has not always possible using conventional isolation procedures to routinely and reproducibly isolate viral strains from the above mentioned donor or recipients which has frustrated efforts to investigate the cause of the asymptomatic individuals. In accordance with the present invention, methods have now been established to isolate viruses from the above individuals. It has been determined, in accordance with the

- 5 -

present invention, that the six individuals of the cohort are infected by non-pathogenic strains of HIV-1. Furthermore, the non-pathogenic strains of HIV-1 carry one or more nucleotide mutations. The non-pathogenic strains of the present invention enable the generation of a range of therapeutic, diagnostic and targeting agents against HIV-1 infection. The present invention also enables the attenuation of previously pathogenic strains of HIV-1.

Accordingly, one aspect of the present invention contemplates a non-pathogenic isolate of HIV-1 or a component, part, fragment or derivative thereof.

10

In a related embodiment, there is provided a novel isolate of HIV-1 or a component, part, fragment or derivative thereof wherein said HIV-1 isolate is capable of stimulating in a human or primate subject an immune response such as a humoral immune response to at least one HIV-1 glycoprotein such as but not limited to gp41-45, gp120 and/or gp160 while not substantially reducing in said human or primate subject proliferative responses and cytokine production to a mitogen, alloantigen and/or recall antigen compared to a healthy, non-infected human or primate subject. Preferably, the cytokine is IL-2. Preferably, the mitogen is ConA or PHA and the recall antigen is influenza or tetanus toxoid. Preferably, the HIV-1 isolate is non-pathogenic.

20

More particularly, the present invention relates to an isolated HIV-1 strain which:

- (i) is substantially non-pathogenic in human subjects; and
- (ii) carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one pathogenic HIV-1-derived polypeptide or protein.

25

Even more particularly, the present invention provides an isolated HIV-1 strain which:

- (i) is substantially non-pathogenic in human subjects; and
- (ii) carries a mutation in the *nef* gene and/or a long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome.

30

- 6 -

Still even more particularly, the present invention is directed to an isolated virus which:

- (i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1;
- 5 (ii) is substantially non-pathogenic in human subjects;
- (iii) carries one or more deletion mutations in a region of its genome corresponding to a *nef* gene in said pathogenic strain of HIV-1; and
- (iv) optionally carries a mutation in one or both LTR regions.

10 In a related embodiment, there is provided an isolated virus which:

- (i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1;
- (ii) is substantially non-pathogenic in human subjects;
- (iii) carries one or more deletion mutations in an LTR region of its genome; and
- 15 (iv) optionally carries a mutation in a region corresponding to a *nef* gene in said pathogenic strain of HIV-1.

In a further related embodiment, there is provided an isolated virus which:

- (i) has a genome which is capable of hybridising under medium stringency
- 20 conditions to complementary nucleic acid from a pathogenic strain of HIV-1;
- (ii) is substantially non-pathogenic in human subjects; and
- (iii) carries one or more deletion mutations in a region of its genome corresponding to a region which contains *nef* coding sequences and LTR nucleotide sequences.

25 In a particularly preferred embodiment, the present invention provides non-pathogenic HIV-1 isolate C18 deposited at the ECACC on 17 October, 1994 under Provisional Accession Number V94101706.

In a related embodiment, the present invention provides non-pathogenic HIV-1 isolate

30 C98 deposited at the ECACC on 31 October, 1994 under Provisional Accession Number V941031169.

- 7 -

In another embodiment, the present invention provides non-pathogenic HIV-1 isolate C54 deposited at ECACC on 14 February, 1995 under Provisional Accession No. _____.

- Although pathogenicity is a relative term, it is used herein in relation to the capacity of a strain of HIV-1 to induce AIDS or AIDS-related disorders in an individual over time. Accordingly, a "non-pathogenic" strain of HIV-1 is a strain which, at the clinical level, does not lead to the development of AIDS, at least within the median time of 6-10 years following infection with HIV-1. At the laboratory level, a non-pathogenic strain of HIV-1 is considered not to alter CD4+ cell counts or β_2 -microglobulin concentrations.
- 10 In addition, a non-pathogenic strain of HIV-1 may not alter CD8+ and CD3+ cell counts and would not alter lymphocyte counts. CD4+:CD8+ ratios also remain unchanged relative to normal non-infected individuals. Furthermore, generally, a non-pathogenic strain of HIV-1 does not induce p24 antigenaemia. A non-pathogenic HIV-1 of the present invention is generally still infectious but individuals infected with the virus
- 15 remain free of symptoms for at least 6-10 years after infection.

- A laboratory classified non-pathogenic strain of HIV-1 may be determined at any time after infection. The term "non-pathogenic" is not to be considered as a strain that is never pathogenic under any conditions as this might depend on the host individual, the level of immune responsiveness in that individual and the extent or otherwise of other, for example, immune comprising disorders. Accordingly, a "non-pathogenic" HIV-1 isolate of the present invention may also be considered a "low virulent" strain of the virus. A non-pathogenic strain of HIV-1 as contemplated herein may be isolated from an asymptomatic individual or may be derived from a pathogenic strain by mutation.
- 20 Although the present invention is not to be limited to any particular pathogenic strain of HIV-1, for reference purposes, an example of a pathogenic strain is HIV-1 NL4-3 strain as described by Myers *et al* (1992).

- The non-pathogenic nature of the HIV-1 of the present invention is conveniently evidenced by the cohort of seven individuals comprising one donor and six recipients which have remained free of symptoms or signs of HIV-1 infection for greater than the median time of 6-10 years. However, the individuals of the cohort are seropositive for
- 30

HIV-1 following infection with the virus as determined by Western blot analysis and genetic analysis (e.g. using PCR techniques). A seropositive individual is one showing reactivity to at least one HIV-1 glycoprotein (such as but not limited to gp 41-45, gp120, gp160) and at least three other virus-specific bands.

5

In accordance with the present invention, a non-pathogenic HIV-1 isolate is also a strain of HIV-1 which:

- (i) induces an immune response in a human or primate subject; and
- (ii) does not substantially reduce proliferative responses or cytokine production to a
10 mitogen, alloantigen and/or recall antigen relative to a healthy, non-infected subject.

Preferably, the immune response such as to a glycoprotein, for example gp41-45, gp120 and/or gp160. Preferably, the cytokine monitored is an interleukin, such as IL-2.

- 15 Preferably, the recall antigen is influenza or tetanus toxoid. A non-pathogenic HIV-1 isolate is also one which:

- (iii) does not substantially alter proliferative responses or cytokine production to allogeneic mononuclear cells.

- 20 The genomes or complementary DNA therefrom of the non-pathogenic HIV-1 isolates of the present invention are capable of hybridising under medium stringency conditions to the corresponding genome or complementary DNA of a pathogenic strain of HIV-1 (e.g. HIV-1 strain NL4-3). The ability to hybridise to a pathogenic strain of HIV-1 only applies to a comparison of the entire genome/complementary DNA of a non-pathogenic
25 strain or a fragment which includes genetic material corresponding to a region in the genome 3' of the *nef* gene in a pathogenic strain of HIV-1.

For the purposes of reference only, a suitable genomic nucleotide sequence from a pathogenic HIV-1 strain is set forth in SEQ ID NO: 1 from HIV-1 strain NL4-3 (Myers

- 30 *et al*, 1992):

```

1  TGAAGGGCTAATTTGGTCCAAAAAGACAAGAGATCCTTGATCTGTGG
51  ATCTACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGG
101 GCCAGGGATCAGATATCCACTGACCTTTGGATGGTGCTTCAAGTTAGTAC

```


151 CAGTTGAACCAGAGCAAGTAGAAGAGGCCAAATAAGGAGAGAAGAACAGC
201 TTGTTACACCCTATGAGCCAGCATGGGATGGAGGACCCGGAGGGAGAAGT
251 ATTAGTGTGGAAGTTTGACAGCCTCCTAGCATTTTCGTACATGGCCCGAG
301 AGCTGCATCCGGAGTACTACAAAGACTGCTGACATCGAGCTTTCTACAAG
5 351 GGACTTTCCGCTGGGGACTTTCCAGGGAGGTGTGGCCTGGGCGGGACTGG
401 GGAGTGGCGAGCCCTCAGATGCTACATATAAGCAGCTGCTTTTTCCTGT
451 ACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTA
501 ACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCCTGAGTGCTCA
551 AAGTAGTGTGTGCCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC
10 601 AGACCCTTTTAGTCAGTGTGAAAATCTCTAGCAGTGGCGCCCGAACAGG
651 GACTTGAAAGCGAAAGTAAAGCCAGAGGAGATCTCTCGACGCAGGACTCG
701 GCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTA
751 CGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAG
801 AGCGTCGGTATTAAGCGGGGAGAATTAGATAAATGGGAAAAAATTCGGT
15 851 TAAGGCCAGGGGAAAGAAACAATATAAACTAAAACATATAGTATGGGCA
901 AGCAGGGAGCTAGAACGATTTCGAGTTAATCCTGGCCTTTTAGAGACATC
951 AGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAG
1001 GATCAGAAGAACTTAGATCATTATATAATACAATAGCAGTCCTCTATTGT
1051 GTGCATCAAAGGATAGATGTAAAAGACACCAAGGAAGCCTTAGATAAGAT
20 1101 AGAGGAAGAGCAAAACAAAAGTAAGAAAAAGGCACAGCAAGCAGCAGCTG
1151 ACACAGGAAACAACAGCCAGGTCAGCCAAAATTACCCTATAGTGCAAGAC
1201 CTCCAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGC
1251 ATGGGTAAAAGTAGTAGAAGAGAAGGCTTTTCAGCCCAGAAGTAATACCCA
1301 TGTTTTTCAGCATTATCAGAAGGAGCCACCCACAAGATTTAAATACCATG
25 1351 CTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAGAGAC
1401 CATCAATGAGGAAGCTGCAGAATGGGATAGATTGCATCCAGTGATGCAG
1451 GGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCA
1501 GGAATACTAGTACCCTTCAGGAACAAATAGGATGGATGACACATAATCC
1551 ACCTATCCCAGTAGGAGAAATCTATAAAAGATGGATAATCCTGGGATTAA
30 1601 ATAAAATAGTAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAA
1651 GGACCAAAGGAACCCCTTTAGAGACTATGTAGACCGATTCTATAAACTCT
1701 AAGAGCCGAGCAAGCTTCACAAGAGGTAAAAAATTGGATGACAGAAACCT
1751 TGTTGGTCCAAAATGCGAACCCAGATTGTAAGACTATTTTAAAGCATTG
1801 GGACCAGGAGCGACACTAGAAGAAATGATGACAGCATGTCAGGGAGTGGG
35 1851 GGGACCCGGCCATAAAGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAA
1901 CAAATCCAGCTACCATAATGATACAGAAAGGCAATTTTAGGAACCAAAGA
1951 AAGACTGTTAAGTGTTCATTTGTGGCAAAGAAGGGCACATAGCCAAAAA
2001 TTGCAGGGCCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGGAC

- 10 -

2051 ACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATC
2101 TGGCCTTCCCACAAGGGAAGGCCAGGGAATTTTCTTCAGAGCAGACCAGA
2151 GCCAACAGCCCCACCAGAAGAGAGCTTCAGGTTTGGGGAAGAGACAACAA
2201 CTCCCTCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAGCT
5 2251 TCCCTCAGATCACTCTTTGGCAGCGACCCCTCGTCACAATAAAGATAGGG
2301 GGGCAATTAAAGGAAGCTCTATTAGATACAGGAGCAGATGATACAGTATT
2351 AGAAGAAATGAATTTGCCAGGAAGATGGAAACCAAAATGATAGGGGGAA
2401 TTGGAGGTTTTATCAAAGTAGGACAGTATGATCAGATACTCATAGAAATC
2451 TGCGGACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTCAA
10 2501 CATAATTGGAAGAAATCTGTTGACTCAGATTGGCTGCACTTTAAATTTTC
2551 CCATTAGTCCTATTGAGACTGTACCACTAAAATTAAAGCCAGGAATGGAT
2601 GGCCCAAAGTTAAACAATGGCCATTGACAGAAGAAAAATAAAAGCATT
2651 AGTAGAAATTTGTACAGAAATGGAAAAGGAAGGAAAAATTTCAAAATTG
2701 GGCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAGAC
15 2751 AGTACTAAATGGAGAAAATTAGTAGATTTAGAGAACTTAATAAGAGAAC
2801 TCAAGATTTCTGGGAAGTTCAATTAGGAATACCACATCCTGCAGGGTTAA
2851 AACAGAAAAATCAGTAACAGTACTGGATGTGGGCGATGCATATTTTTCA
2901 GTTCCCTTAGATAAAGACTTCAGGAAGTATACTGCATTTACCATACCTAG
2951 TATAACAATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCAC
20 3001 AGGGATGGAAGGATCACCAGCAATATTCAGTGTAGCATGACAAAATC
3051 TTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTCATCTATCAATACAT
3101 GGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAA
3151 AAATAGAGGAACTGAGACAACATCTGTTGAGGTGGGGATTTACCACACCA
3201 GACAAAAACATCAGAAAGAACCTCCATTCTTTGGATGGGTATGAACT
25 3251 CCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAGGACA
3301 GCTGGACTGTCAATGACATACAGAAATTAGTGGGAAAATTGAATTGGGCA
3351 AGTCAGATTTATGCAGGGATTAAAGTAAGGCAATTATGTAAACTTCTTAG
3401 GGGAAACCAAGCACTAACAGAAGTAGTACCACTAACAGAAGAAGCAGAGC
3451 TAGAACTGGCAGAAAACAGGGAGATTCTAAAAGAACCGGTACATGGAGTG
30 3501 TATTATGACCCATCAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCA
3551 AGGCCAATGGACATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAA
3601 CAGGAAAATATGCAAGAATGAAGGGTGCCCACTAATGATGTGAAACAA
3651 TTAACAGAGGCAGTACAAAAATAGCCACAGAAAGCATAGTAATATGGGG
3701 AAAGACTCCTAAATTTAAATTACCCATACAAAAGGAAACATGGGAAGCAT
35 3751 GGTGGACAGAGTATTGGCAAGCCACCTGGATTCTGAGTGGGAGTTTGTC
3801 AATACCCCTCCCTTAGTGAAGTTATGGTACCAGTTAGAGAAAGAACCCAT
3851 AATAGGAGCAGAACTTTCTATGTAGATGGGGCAGCCAATAGGGAAACTA
3901 AATTAGGAAAAGCAGGATATGTAAGTACAGAGGAAGACAAAAGTTGTC

3951 CCCCTAACGGACACAACAAATCAGAAGACTGAGTTACAAGCAATTCATCT
4001 AGCTTTGCAGGATTCGGGATTAGAAGTAAACATAGTGACAGACTCACAAT
4051 ATGCATTGGGAATCATTCAAGCACAAACCAGATAAGAGTGAATCAGAGTTA
4101 GTCAGTCAAATAATAGAGCAGTTAATAAAAAAGGAAAAAGTCTACCTGGC
5 4151 ATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATGGGT
4201 TGGTCAGTGCTGGAATCAGGAAAGTACTATTTTTAGATGGAATAGATAAG
4251 GCCCAAGAAGAACATGAGAAATATCACAGTAATTGGAGAGCAATGGCTAG
4301 TGATTTTAACCTACCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTG
4351 ATAAATGTCAGCTAAAAGGGGAAGCCATGCATGGACAAGTAGACTGTAGC
10 4401 CCAGGAATATGGCAGCTAGATTGTACACATTTAGAAGGAAAAGTTATCTT
4451 GGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTAATTCAG
4501 CAGAGACAGGGCAAGAAACAGCATACTTCCTCTTAAAATTAGCAGGAAGA
4551 TGGCCAGTAAAAACAGTACATACAGACAATGGCAGCAATTTACCAGTAC
4601 TACAGTTAAGGCCGCTGTTGGTGGGCGGGGATCAAGCAGGAATTTGGCA
15 4651 TTCCCTACAATCCCCAAAGTCAAGGAGTAATAGAATCTATGAATAAAGAA
4701 TTAAAGAAAATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGAC
4751 AGCAGTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGA
4801 TTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGAC
4851 ATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCG
20 4901 GGTTTATTACAGGGACAGCAGAGATCCAGTTTGGAAAGGACCAGCAAAGC
4951 TCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGATAATAGTGACATA
5001 AAAGTAGTGCCAAGAAGAAAAGCAAAGATCATCAGGGATTATGGAAAACA
5051 GATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAACACA
5101 TGGAAAAGATTAGTAAAACACCATATGTATATTTCAAGGAAAGCTAAGGA
25 5151 CTGGTTTTATAGACATCACTATGAAAGTACTAATCCAAAATAAGTTCAG
5201 AAGTACACATCCCCTAGGGGATGCTAAATTAGTAATAACAACATATTGG
5251 GGTCTGCATACAGGAGAAAGAGACTGGCATTGTTGGGTGAGGGAGTCTCCAT
5301 AGAATGGAGGAAAAAGAGATATAGCAACAAGTAGACCCTGACCTAGCAG
5351 ACCAACTAATTCATCTGCACTATTTTGATTGTTTTTCAGAATCTGCTATA
30 5401 AGAAATACCATATTAGGACGTATAGTTAGTCCTAGGTGTGAATATCAAGC
5451 AGGACATAACAAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCATTA
5501 TAAACCAAACAGATAAAGCCACCTTTGCCTAGTGTTAGGAAACTGACA
5551 GAGGACAGATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCA
5601 TACAATGAATGGACACTAGAGCTTTTAGAGGAACTTAAGAGTGAAGCTGT
35 5651 TAGACATTTTCTAGGATATGGCTCCATAACTTAGGACAACATATCTATG
5701 AAACTTACGGGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTG
5751 CAACAACCTGCTGTTTATCCATTTTCAAGATTGGGTGTGACATAGCAGAAT
5801 AGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGA

5851 CTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGACCAA
5901 TTGCTATTGTAAAAAGTGTGCTTTCATTGCCAAGTTTGTTCATGACAA
5951 AAGCCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGA
6001 GCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTATCAAAGCAGTAAGT
5 6051 AGTACATGTAATGCAACCTATAATAGTAGCAATAGTAGCATTAGTAGTAG
6101 CAATAATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGG
6151 AAAATATTAAGACAAAGAAAAATAGACAGGTTAATTGATAGACTAATAGA
6201 AAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAGTATCAGCACTTG
6251 TGGAGATGGGGGTGGAAATGGGGCACCATGCTCCTTGGGATATTGATGAT
10 6301 CTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTG
6351 TGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCA
6401 TATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCAC
6451 AGACCCCAACCCACAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTA
6501 ACATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGT
15 6551 TTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTCTGTGT
6601 TAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTA
6651 GCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAACTGCTCTTTCAAT
6701 ATCAGCACAAGCATAAGAGATAAGGTGCAGAAAGAATATGCATTCTTTTA
6751 TAAACTTGATATAGTACCAATAGATAATACCAGCTATAGGTTGATAAGTT
20 6801 GTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCA
6851 ATTCCCATACATTATTGTGCCCGGCTGGTTTTGCGATTCTAAAATGTAA
6901 TAATAAGACGTTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTAC
6951 AATGTACACATGGAATCAGGCCAGTAGTATCAACTCAACTGCTGTAAAT
7001 GGCAGTCTAGCAGAAGAAGATGTAGTAATTAGATCTGCCAATTTACAGA
25 7051 CAATGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATT
7101 GTACAAGACCCAACAACAATAACAAGAAAAAGTATCCGTATCCAGAGGGGA
7151 CCAGGGAGAGCATTGTGTTACAATAGGAAAAATAGGAAATATGAGACAAGC
7201 ACATTGTAACATTAGTAGAGCAAAATGGAATGCCACTTTAAACAGATAG
7251 CTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAG
30 7301 CAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGG
7351 AGGGGAATTTTTCTACTGTAATTCAACACAACCTGTTTAATAGTACTTGGT
7401 TTAATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGAC
7451 ACAATCACACTCCCATGCAGAATAAAACAATTTATAAACATGTGGCAGGA
7501 AGTAGGAAAAGCAATGTATGCCCCCTCCCATCAGTGGACAAATTAGATGTT
35 7551 CATCAAATATTACTGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC
7601 AATGGGTCCGAGATCTTCAGACCTGGAGGAGGCGATATGAGGGACAATTG
7651 GAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAG
7701 TAGCACCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAGAGCA

7751 GTGGGAATAGGAGCTTTGTTCTTGGGTTCTTGGGAGCAGCAGGAAGCAC
7801 TATGGGCTGCACGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGT
7851 CTGATATAGTGCAGCAGCAGAACAAATTTGCTGAGGGCTATTGAGGCGCAA
7901 CAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAACAGCTCCAGGCAAG
5 7951 AATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTT
8001 GGGGTTGCTCTGGAAACTCATTTCACCACTGCTGTGCCTTGAATGCT
8051 AGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATAACATGACCTGGAT
8101 GGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAA
8151 TTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAA
10 8201 TTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAAACATAACAAATTGGCT
8251 GTGGTATATAAAATTATTTCATAATGATAGTAGGAGGCTTGGTAGGTTTAA
8301 GAATAGTTTTTGTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATAT
8351 TCACCATTATCGTTTCAGACCCACCTCCCAATCCCGAGGGGACCCGACAG
8401 GCCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCA
15 8451 TTCGATTAGTGAACGGATCCTTAGCACTTATCTGGGACGATCTGCGGAGC
8501 CTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTAAC
8551 GAGGATTGTGGAACCTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATT
8601 GGTGGAATCTCCTACAGTATTGGAGTCAGGAACTAAAGAATAGTGCTGTT
8651 AACTTGCTCAATGCCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGT
20 8701 TATAGAAGTATTACAAGCAGCTTATAGAGCTATTTCGCCACATACCTAGAA
8751 GAATAAGACAGGGCTTGGAAAGGATTTTGTCTATAAGATGGGTGGCAAGTG
8801 GTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTAAGGGAAAGAATGAGAC
8851 GAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAA
8901 AAACATGGAGCAATCACAGTAGCAATACAGCAGCTAACAAATGCTGCTTG
25 8951 TGCCTGGCTAGAAGCACAGAGGAGGAAGAGGTGGGTTTTCCAGTCACAC
9001 CTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGC
9051 CACTTTTTTAAAGAAAAGGGGGGACTGGAAGGGCTAATTCCTCCAAAG
9101 AAGACAAGATATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCC
9151 CTGATTGGCAGAACTACACACCAGGGCCAGGGGTGAGATATCCACTGACC
30 9201 TTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGA
9251 GGCCAATAAAGGAGAGAAACACCAGCTTGTTACACCCTGTGAGCCTGCATG
9301 GAATGGATGACCCTGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGC
9351 CTAGCATTTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAA
9401 CTGCTGACATCGAGCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAG
35 9451 GGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATGCTGC
9501 ATATAAGCAGCTGCTTTTTGCTGTACTGGGTCTCTCTGGTTAGACCAGA
9551 TCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT
9601 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCCGTCTGTTGTG

- 14 -

9651 TGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAA
9701 TCTCTAGCA

However, for the purposes of comparing the nucleotide sequences of non-pathogenic
5 HIV-1 strains including the ability to hybridise to a reference strain, the present
invention extends to a genomic nucleotide sequence from any pathogenic strain of HIV-
1.

Accordingly, in a particularly preferred embodiment, there is provided a viral isolate
10 which:

- (i) carries a genome which is capable of hybridising under medium stringency conditions to SEQ ID NO: 1 or a complementary form thereof or an analogous sequence from another pathogenic strain of HIV-1; and
- (ii) carries a deletion mutation in a region corresponding to the *nef* gene and/or in
15 an LTR region. Generally, such an HIV-1 isolate is non-pathogenic as hereinbefore defined.

In a related embodiment, there is provided an isolated virus which:

- (i) has a genome which is capable of hybridising under medium stringency
20 conditions to complementary nucleic acid from a pathogenic strain of HIV-1;
and
- (ii) carries one or more deletion mutations in a region of its genome corresponding to a region which contains *nef* coding sequences and LTR nucleotide sequences.

25 For the purposes of defining the level of stringency, reference can conveniently be made to Maniatis *et al* (1982) at pages 387-389 which is herein incorporated by reference where the washing steps disclosed are considered high stringency. A low stringency is defined herein as being in 1-3X SSC/0.1-0.5% w/v SDS at 37-50°C for 2-3 hours. Depending on the source and concentration of nucleic acid involved in the hybridisation,
30 alternative conditions of stringency may be employed such as medium stringent conditions which are considered herein to be 0.1-1X SSC/0.25-0.5% w/v SDS at $\geq 45^\circ\text{C}$ for 2-3 hours or high stringent conditions considered herein to be 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

- 15 -

In a particularly preferred embodiment of the present invention, the non-pathogenic strain of HIV-1 carries a mutation in the *nef* gene and/or LTR region of the genome.

A "mutation" is considered herein to include a single or multiple nucleotide substitution, deletion and/or addition. Most preferred mutations are single or multiple deletions of at least one, most preferably at least ten and even more preferably at least twenty contiguous nucleotides from a region corresponding to the *nef* gene and/or the LTR region. When the non-pathogenic virus carries a mutation in the LTR region, this generally occurs 5' of the Sp1 sites.

10

According to a preferred aspect of the present invention, there is provided a viral isolate which:

- (i) is reactive to antibodies to a glycoprotein from HIV-1 such as at least one of gp41-45, gp120 and/or gp160;
- 15 (ii) is substantially non-pathogenic in human subjects; and
- (iii) carries a deletion mutation of at least ten nucleotides in a region corresponding to the *nef* gene and/or LTR region of a pathogenic strain of HIV-1.

In another embodiment, there is provided a viral isolate which:

- 20 (i) is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env*;
- (ii) is substantially non-pathogenic in human subjects; and
- (iii) carries a deletion mutation of at least ten nucleotides in a region corresponding to the *nef* gene and/or LTR region of a pathogenic strain of HIV-1.

25 Preferably, in respect of the latter embodiment, the immune response is an antibody or a cell mediated response. In a most preferred embodiment, the immune response is a humoral immune response.

The nucleotide sequence of the *nef* gene in HIV-1 NL4-3 is defined in SEQ ID NO: 30 650:

ATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTAAGGGAAAGAAT
GAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAAAAAC
ATGGAGCAATCACAAGTAGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGCTAGAA

- 16 -

GCACAAGAGGAGGAAGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAAT
 GACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAG
 GGCTAATTCACCTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACACACAA
 GGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGGTGAGATATCCACTGAC
 5 CTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATA
 AAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGATGACCCTGAG
 AGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTTCATCACGTGGCCCGAGA
 GCTGCATCCGGAGTACTTCAAGAACTGCTGA

- 10 The present invention extends to any or all single or multiple nucleotide deletions to a contiguous series of at least ten nucleotides from the *nef* gene which render the strain avirulent. The deletions may encompass the entire gene or parts thereof and may represent a single deletion or two or more deletions. Put in alternative terms, the non-pathogenic HIV-1 isolates of the present invention comprise a nucleotide sequence at the
- 15 corresponding *nef* gene region non-identifiable to SEQ ID NO: 650, said non-identity comprising at least 5%, more preferably at least 10% and even more preferably at least 20% variation thereon.

In a preferred embodiment, therefore, the present invention contemplates a viral isolate
 20 which:

- (i) is reactive to antibodies to a glycoprotein from HIV-1 such as at least one of gp41-45, gp120 and/or gp160;
- (ii) carries a genome or a part or fragment thereof capable of hybridising under medium stringency conditions to a nucleotide sequence as set forth in SEQ ID
 25 NO: 1 or a complementary form thereof or an analogous sequence from another pathogenic strain of HIV-1;
- (iii) carries a deletion of at least ten nucleotides in a region corresponding to the *nef* gene in HIV-1 NL4-3; and

wherein said deletion encompasses one or more of the following decanucleotides from
 30 the *nef* gene of HIV-1 NL4-3 or corresponding sequences from another pathogenic strain of HIV-1:

ATGGGTGGCA (SEQ ID NO: 2);	TGGGTGGCAA (SEQ ID NO: 3);
GGGTGGCAAG (SEQ ID NO: 4);	GGTGGCAAGT (SEQ ID NO: 5);
GTGGCAAGTG (SEQ ID NO: 6);	TGGCAAGTGG (SEQ ID NO: 7);

- 17 -

GGCAAGTGGT (SEQ ID NO: 8); GCAAGTGGTC (SEQ ID NO: 9);
 CAAGTGGTCA (SEQ ID NO: 10); AAGTGGTCAA (SEQ ID NO: 11);
 AGTGGTCAAA (SEQ ID NO: 12); GTGGTCAAAA (SEQ ID NO: 13);
 TGGTCAAAAA (SEQ ID NO: 14); GGTCAAAAAG (SEQ ID NO: 15);
 5 GTCAAAAAGT (SEQ ID NO: 16); TCAAAAAGTA (SEQ ID NO: 17);
 CAAAAAGTAG (SEQ ID NO: 18); AAAAAGTAGT (SEQ ID NO: 19);
 AAAAGTAGTG (SEQ ID NO: 20); AAAGTAGTGT (SEQ ID NO: 21);
 AAGTAGTGTG (SEQ ID NO: 22); AGTAGTGTGA (SEQ ID NO: 23);
 GTAGTGTGAT (SEQ ID NO: 24); TAGTGTGATT (SEQ ID NO: 25);
 10 AGTGTGATTG (SEQ ID NO: 26); GTGTGATTGG (SEQ ID NO: 27);
 TGTGATTGGA (SEQ ID NO: 28); GTGATTGGAT (SEQ ID NO: 29);
 TGATTGGATG (SEQ ID NO: 30); GATTGGATGG (SEQ ID NO: 31);
 ATTGGATGGC (SEQ ID NO: 32); TTGGATGGCC (SEQ ID NO: 33);
 TGGATGGCCT (SEQ ID NO: 34); GGATGGCCTG (SEQ ID NO: 35);
 15 GATGGCCTGC (SEQ ID NO: 36); ATGGCCTGCT (SEQ ID NO: 37);
 TGGCCTGCTG (SEQ ID NO: 38); GGCCTGCTGT (SEQ ID NO: 39);
 GCCTGCTGTA (SEQ ID NO: 40); CCTGCTGTAA (SEQ ID NO: 41);
 CTGCTGTAAG (SEQ ID NO: 42); TGCTGTAAGG (SEQ ID NO: 43);
 GCTGTAAGGG (SEQ ID NO: 44); CTGTAAGGGA (SEQ ID NO: 45);
 20 TGTAAGGGAA (SEQ ID NO: 46); GTAAGGGAAA (SEQ ID NO: 47);
 TAAGGGAAAG (SEQ ID NO: 48); AAGGGAAAGA (SEQ ID NO: 49);
 AGGGAAAGAA (SEQ ID NO: 50); GGGAAAGAAT (SEQ ID NO: 51);
 GGAAAGAATG (SEQ ID NO: 52); GAAAGAATGA (SEQ ID NO: 53);
 AAAGAATGAG (SEQ ID NO: 54); AAGAATGAGA (SEQ ID NO: 55);
 25 AGAATGAGAC (SEQ ID NO: 56); GAATGAGACG (SEQ ID NO: 57);
 AATGAGACGA (SEQ ID NO: 58); ATGAGACGAG (SEQ ID NO: 59);
 TGAGACGAGC (SEQ ID NO: 60); GAGACGAGCT (SEQ ID NO: 61);
 AGACGAGCTG (SEQ ID NO: 62); GACGAGCTGA (SEQ ID NO: 63);
 ACGAGCTGAG (SEQ ID NO: 64); CGAGCTGAGC (SEQ ID NO: 65);
 30 GAGCTGAGCC (SEQ ID NO: 66); AGCTGAGCCA (SEQ ID NO: 67);
 GCTGAGCCAG (SEQ ID NO: 68); CTGAGCCAGC (SEQ ID NO: 69);
 TGAGCCAGCA (SEQ ID NO: 70); GAGCCAGCAG (SEQ ID NO: 71);
 AGCCAGCAGC (SEQ ID NO: 72); GCCAGCAGCA (SEQ ID NO: 73);
 CCAGCAGCAG (SEQ ID NO: 74); CAGCAGCAGA (SEQ ID NO: 75);
 35 AGCAGCAGAT (SEQ ID NO: 76); GCAGCAGATG (SEQ ID NO: 77);
 CAGCAGATGG (SEQ ID NO: 78); AGCAGATGGG (SEQ ID NO: 79);
 GCAGATGGGG (SEQ ID NO: 80); CAGATGGGGT (SEQ ID NO: 81);
 AGATGGGGTG (SEQ ID NO: 82); GATGGGGTGG (SEQ ID NO: 83);

- 18 -

ATGGGGTGGG (SEQ ID NO: 84); TGGGGTGGGA (SEQ ID NO: 85);
 GGGGTGGGAG (SEQ ID NO: 86); GGGTGGGAGC (SEQ ID NO: 87);
 GGTGGGAGCA (SEQ ID NO: 88); GTGGGAGCAG (SEQ ID NO: 89);
 TGGGAGCAGT (SEQ ID NO: 90); GGGAGCAGTA (SEQ ID NO: 91);
 5 GGAGCAGTAT (SEQ ID NO: 92); GAGCAGTATC (SEQ ID NO: 93);
 AGCAGTATCT (SEQ ID NO: 94); GCAGTATCTC (SEQ ID NO: 95);
 CAGTATCTCG (SEQ ID NO: 96); AGTATCTCGA (SEQ ID NO: 97);
 GTATCTCGAG (SEQ ID NO: 98); TATCTCGAGA (SEQ ID NO: 99);
 ATCTCGAGAC (SEQ ID NO: 100); TCTCGAGACC (SEQ ID NO: 101);
 10 CTCGAGACCT (SEQ ID NO: 102); TCGAGACCTA (SEQ ID NO: 103);
 CGAGACCTAG (SEQ ID NO: 104); GAGACCTAGA (SEQ ID NO: 105);
 AGACCTAGAA (SEQ ID NO: 106); GACCTAGAAA (SEQ ID NO: 107);
 ACCTAGAAAA (SEQ ID NO: 108); CCTAGAAAAA (SEQ ID NO: 109);
 CTAGAAAAAC (SEQ ID NO: 110); TAGAAAAACA (SEQ ID NO: 111);
 15 AGAAAAACAT (SEQ ID NO: 112); GAAAAACATG (SEQ ID NO: 113);
 AAAAACATGG (SEQ ID NO: 114); AAAACATGGA (SEQ ID NO: 115);
 AAACATGGAG (SEQ ID NO: 116); AACATGGAGC (SEQ ID NO: 117);
 ACATGGAGCA (SEQ ID NO: 118); CATGGAGCAA (SEQ ID NO: 119);
 ATGGAGCAAT (SEQ ID NO: 120); TGGAGCAATC (SEQ ID NO: 121);
 20 GGAGCAATCA (SEQ ID NO: 122); GAGCAATCAC (SEQ ID NO: 123);
 AGCAATCACA (SEQ ID NO: 124); GCAATCACAA (SEQ ID NO: 125);
 CAATCACAAG (SEQ ID NO: 126); AATCACAAGT (SEQ ID NO: 127);
 ATCACAAGTA (SEQ ID NO: 128); TCACAAGTAG (SEQ ID NO: 129);
 CACAAGTAGC (SEQ ID NO: 130); ACAAGTAGCA (SEQ ID NO: 131);
 25 CAAGTAGCAA (SEQ ID NO: 132); AAGTAGCAAT (SEQ ID NO: 133);
 AGTAGCAATA (SEQ ID NO: 134); GTAGCAATAC (SEQ ID NO: 135);
 TAGCAATACA (SEQ ID NO: 136); AGCAATACAG (SEQ ID NO: 137);
 GCAATACAGC (SEQ ID NO: 138); CAATACAGCA (SEQ ID NO: 139);
 AATACAGCAG (SEQ ID NO: 140); ATACAGCAGC (SEQ ID NO: 141);
 30 TACAGCAGCT (SEQ ID NO: 142); ACAGCAGCTA (SEQ ID NO: 143);
 CAGCAGCTAA (SEQ ID NO: 144); AGCAGCTAAC (SEQ ID NO: 145);
 GCAGCTAACA (SEQ ID NO: 146); CAGCTAACAA (SEQ ID NO: 147);
 AGCTAACAAT (SEQ ID NO: 148); GCTAACAATG (SEQ ID NO: 149);
 CTAACAATGC (SEQ ID NO: 150); TAACAATGCT (SEQ ID NO: 151);
 35 AACAAATGCTG (SEQ ID NO: 152); ACAATGCTGC (SEQ ID NO: 153);
 CAATGCTGCT (SEQ ID NO: 154); AATGCTGCTT (SEQ ID NO: 155);
 ATGCTGCTTG (SEQ ID NO: 156); TGCTGCTTGT (SEQ ID NO: 157);
 GCTGCTTGTG (SEQ ID NO: 158); CTGCTTGTGC (SEQ ID NO: 159);

- 19 -

TGCTTGTGCC (SEQ ID NO: 160); GCTTGTGCCT (SEQ ID NO: 161);
CTTGTGCCTG (SEQ ID NO: 162); TTGTGCCTGG (SEQ ID NO: 163);
TGTGCCTGGC (SEQ ID NO: 164); GTGCCTGGCT (SEQ ID NO: 165);
TGCCTGGCTA (SEQ ID NO: 166); GCCTGGCTAG (SEQ ID NO: 167);
5 CCTGGCTAGA (SEQ ID NO: 168); CTGGCTAGAA (SEQ ID NO: 169);
TGGCTAGAAG (SEQ ID NO: 170); GGCTAGAAGC (SEQ ID NO: 171);
GCTAGAAGCA (SEQ ID NO: 172); CTAGAAGCAC (SEQ ID NO: 173);
TAGAAGCACA (SEQ ID NO: 174); AGAAGCACAA (SEQ ID NO: 175);
GAAGCACAAG (SEQ ID NO: 176); AAGCACAAGA (SEQ ID NO: 177);
10 AGCACAAGAG (SEQ ID NO: 178); GCACAAGAGG (SEQ ID NO: 179);
CACAAAGAGG (SEQ ID NO: 180); ACAAGAGGAG (SEQ ID NO: 181);
CAAGAGGAGG (SEQ ID NO: 182); AAGAGGAGGA (SEQ ID NO: 183);
AGAGGAGGAA (SEQ ID NO: 184); GAGGAGGAAG (SEQ ID NO: 185);
AGGAGGAAGA (SEQ ID NO: 186); GGAGGAAGAG (SEQ ID NO: 187);
15 GAGGAAGAGG (SEQ ID NO: 188); AGGAAGAGGT (SEQ ID NO: 189);
GGAAGAGGTG (SEQ ID NO: 190); GAAGAGGTGG (SEQ ID NO: 191);
AAGAGGTGGG (SEQ ID NO: 192); AGAGGTGGGT (SEQ ID NO: 193);
GAGGTGGGTT (SEQ ID NO: 194); AGGTGGGTTT (SEQ ID NO: 195);
GGTGGGTTTT (SEQ ID NO: 196); GTGGGTTTTT (SEQ ID NO: 197);
20 TGGGTTTTTCC (SEQ ID NO: 198); GGGTTTTTCCA (SEQ ID NO: 199);
GGTTTTTCCAG (SEQ ID NO: 200); GTTTTTCCAGT (SEQ ID NO: 201);
TTTTTCCAGTC (SEQ ID NO: 202); TTTCCAGTCA (SEQ ID NO: 203);
TTCCAGTCAC (SEQ ID NO: 204); TCCAGTCACA (SEQ ID NO: 205);
CCAGTCACAC (SEQ ID NO: 206); CAGTCACACC (SEQ ID NO: 207);
25 AGTCACACCT (SEQ ID NO: 208); GTCACACCTC (SEQ ID NO: 209);
TCACACCTCA (SEQ ID NO: 210); CACACCTCAG (SEQ ID NO: 211);
ACACCTCAGG (SEQ ID NO: 212); CACCTCAGGT (SEQ ID NO: 213);
ACCTCAGGTA (SEQ ID NO: 214); CCTCAGGTAC (SEQ ID NO: 215);
CTCAGGTACC (SEQ ID NO: 216); TCAGGTACCT (SEQ ID NO: 217);
30 CAGGTACCTT (SEQ ID NO: 218); AGGTACCTTT (SEQ ID NO: 219);
GGTACCTTTA (SEQ ID NO: 220); GTACCTTTAA (SEQ ID NO: 221);
TACCTTTAAG (SEQ ID NO: 222); ACCTTTAAGA (SEQ ID NO: 223);
CCTTTAAGAC (SEQ ID NO: 224); CTTTAAGACC (SEQ ID NO: 225);
TTTAAGACCA (SEQ ID NO: 226); TTAAGACCAA (SEQ ID NO: 227);
35 TAAGACCAAT (SEQ ID NO: 228); AAGACCAATG (SEQ ID NO: 229);
AGACCAATGA (SEQ ID NO: 230); GACCAATGAC (SEQ ID NO: 231);
ACCAATGACT (SEQ ID NO: 232); CCAATGACTT (SEQ ID NO: 233);
CAATGACTTA (SEQ ID NO: 234); AATGACTTAC (SEQ ID NO: 235);

- 20 -

ATGACTTACA (SEQ ID NO: 236); TGA CTTACAA (SEQ ID NO: 237);
GACTTACAAG (SEQ ID NO: 238); ACTTACAAGG (SEQ ID NO: 239);
CTTACAAGGC (SEQ ID NO: 240); TTACAAGGCA (SEQ ID NO: 241);
TACAAGGCAG (SEQ ID NO: 242); ACAAGGCAGC (SEQ ID NO: 243);
5 CAAGGCAGCT (SEQ ID NO: 244); AAGGCAGCTG (SEQ ID NO: 245);
AGGCAGCTGT (SEQ ID NO: 246); GGCAGCTGTA (SEQ ID NO: 247);
GCAGCTGTAG (SEQ ID NO: 248); CAGCTGTAGA (SEQ ID NO: 249);
AGCTGTAGAT (SEQ ID NO: 250); GCTGTAGATC (SEQ ID NO: 251);
CTGTAGATCT (SEQ ID NO: 252); TGTAGATCTT (SEQ ID NO: 253);
10 GTAGATCTTA (SEQ ID NO: 254); TAGATCTTAG (SEQ ID NO: 255);
AGATCTTAGC (SEQ ID NO: 256); GATCTTAGCC (SEQ ID NO: 257);
ATCTTAGCCA (SEQ ID NO: 258); TCTTAGCCAC (SEQ ID NO: 259);
CTTAGCCACT (SEQ ID NO: 260); TTAGCCACTT (SEQ ID NO: 261);
TAGCCACTTT (SEQ ID NO: 262); AGCCACTTTT (SEQ ID NO: 263);
15 GCCACTTTTT (SEQ ID NO: 264); CCACTTTTTA (SEQ ID NO: 265);
CACTTTTTAA (SEQ ID NO: 266); ACTTTTTAAA (SEQ ID NO: 267);
CTTTTTTAAA (SEQ ID NO: 268); TTTTTTAAAAG (SEQ ID NO: 269);
TTTTTAAAGA (SEQ ID NO: 270); TTTTAAAGAA (SEQ ID NO: 271);
TTAAAGAAA (SEQ ID NO: 272); TAAAGAAAA (SEQ ID NO: 273);
20 AAAAGAAAAG (SEQ ID NO: 274); AAAGAAAAGG (SEQ ID NO: 275);
AAGAAAAGGG (SEQ ID NO: 276); AGAAAAGGGG (SEQ ID NO: 277);
GAAAAGGGGG (SEQ ID NO: 278); AAAAGGGGGG (SEQ ID NO: 279);
AAAGGGGGGA (SEQ ID NO: 280); AAGGGGGGAC (SEQ ID NO: 281);
AGGGGGGACT (SEQ ID NO: 282); GGGGGGACTG (SEQ ID NO: 283);
25 GGGGGACTGG (SEQ ID NO: 284); GGGGACTGGA (SEQ ID NO: 285);
GGGACTGGA (SEQ ID NO: 286); GGACTGGAAG (SEQ ID NO: 287);
GACTGGAAGG (SEQ ID NO: 288); ACTGGAAGGG (SEQ ID NO: 289);
CTGGAAGGGC (SEQ ID NO: 290); TGAAGGGCT (SEQ ID NO: 291);
GGAAGGGCTA (SEQ ID NO: 292); GAAGGGCTAA (SEQ ID NO: 293);
30 AAGGGCTAAT (SEQ ID NO: 294); AGGGCTAATT (SEQ ID NO: 295);
GGGCTAATTC (SEQ ID NO: 296); GGCTAATTCA (SEQ ID NO: 297);
GCTAATTCAC (SEQ ID NO: 298); CTAATTCACT (SEQ ID NO: 299);
TAATTCACTC (SEQ ID NO: 300); AATTCACTCC (SEQ ID NO: 301);
ATTCACTCCC (SEQ ID NO: 302); TTCACTCCCA (SEQ ID NO: 303);
35 TCACTCCCAA (SEQ ID NO: 304); CACTCCCAAA (SEQ ID NO: 305);
ACTCCCAAAG (SEQ ID NO: 306); CTCCCAAAGA (SEQ ID NO: 307);
TCCCAAAGAA (SEQ ID NO: 308); CCCAAAGAAG (SEQ ID NO: 309);
CCAAAGAAGA (SEQ ID NO: 310); CAAAGAAGAC (SEQ ID NO: 311);

- 21 -

AAAGAAGACA (SEQ ID NO: 312); AAGAAGACAA (SEQ ID NO: 313);
AGAAGACAAG (SEQ ID NO: 314); GAAGACAAGA (SEQ ID NO: 315);
AAGACAAGAT (SEQ ID NO: 316); AGACAAGATA (SEQ ID NO: 317);
GACAAGATAT (SEQ ID NO: 318); ACAAGATATC (SEQ ID NO: 319);
5 CAAGATATCC (SEQ ID NO: 320); AAGATATCCT (SEQ ID NO: 321);
AGATATCCTT (SEQ ID NO: 322); GATATCCTTG (SEQ ID NO: 323);
ATATCCTTGA (SEQ ID NO: 324); TATCCTTGAT (SEQ ID NO: 325);
ATCCTTGATC (SEQ ID NO: 326); TCCTTGATCT (SEQ ID NO: 327);
CCTTGATCTG (SEQ ID NO: 328); CTTGATCTGT (SEQ ID NO: 329);
10 TTGATCTGTG (SEQ ID NO: 330); TGATCTGTGG (SEQ ID NO: 331);
GATCTGTGGA (SEQ ID NO: 332); ATCTGTGGAT (SEQ ID NO: 333);
TCTGTGGATC (SEQ ID NO: 334); CTGTGGATCT (SEQ ID NO: 335);
TGTGGATCTA (SEQ ID NO: 336); GTGGATCTAC (SEQ ID NO: 337);
TGGATCTACC (SEQ ID NO: 338); GGATCTACCA (SEQ ID NO: 339);
15 GATCTACCAC (SEQ ID NO: 340); ATCTACCACA (SEQ ID NO: 341);
TCTACCACAC (SEQ ID NO: 342); CTACCACACA (SEQ ID NO: 343);
TACCACACAC (SEQ ID NO: 344); ACCACACACA (SEQ ID NO: 345);
CCACACACAA (SEQ ID NO: 346); CACACACAAG (SEQ ID NO: 347);
ACACACAAGG (SEQ ID NO: 348); CACACAAGGC (SEQ ID NO: 349);
20 ACACAAGGCT (SEQ ID NO: 350); CACAAGGCTA (SEQ ID NO: 351);
ACAAGGCTAC (SEQ ID NO: 352); CAAGGCTACT (SEQ ID NO: 353);
AAGGCTACTT (SEQ ID NO: 354); AGGCTACTTC (SEQ ID NO: 355);
GGCTACTTCC (SEQ ID NO: 356); GCTACTTCCC (SEQ ID NO: 357);
CTACTTCCCT (SEQ ID NO: 358); TACTTCCCTG (SEQ ID NO: 359);
25 ACTTCCCTGA (SEQ ID NO: 360); CTTCCCTGAT (SEQ ID NO: 361);
TTCCCTGATT (SEQ ID NO: 362); TCCCTGATTG (SEQ ID NO: 363);
CCCTGATTGG (SEQ ID NO: 364); CCTGATTGGC (SEQ ID NO: 365);
CTGATTGGCA (SEQ ID NO: 366); TGATTGGCAG (SEQ ID NO: 367);
GATTGGCAGA (SEQ ID NO: 368); ATTGGCAGAA (SEQ ID NO: 369);
30 TTGGCAGAAC (SEQ ID NO: 370); TGGCAGAACT (SEQ ID NO: 371);
GGCAGAACTA (SEQ ID NO: 372); GCAGAACTAC (SEQ ID NO: 373);
CAGAACTACA (SEQ ID NO: 374); AGAACTACAC (SEQ ID NO: 375);
GAACTACACA (SEQ ID NO: 376); AACTACACAC (SEQ ID NO: 377);
ACTACACACC (SEQ ID NO: 378); CTACACACCA (SEQ ID NO: 379);
35 TACACACCAG (SEQ ID NO: 380); ACACACCAGG (SEQ ID NO: 381);
CACACCAGGG (SEQ ID NO: 382); ACACCAGGGC (SEQ ID NO: 383);
CACCAGGGCC (SEQ ID NO: 384); ACCAGGGCCA (SEQ ID NO: 385);
CCAGGGCCAG (SEQ ID NO: 386); CAGGGCCAGG (SEQ ID NO: 387);

- 22 -

AGGGCCAGGG (SEQ ID NO: 388); GGGCCAGGGG (SEQ ID NO: 389);
GGCCAGGGGT (SEQ ID NO: 390); GCCAGGGGTC (SEQ ID NO: 391);
CCAGGGGTCA (SEQ ID NO: 392); CAGGGGTCAG (SEQ ID NO: 393);
AGGGGTCAGA (SEQ ID NO: 394); GGGGTCAGAT (SEQ ID NO: 395);
5 GGGTCAGATA (SEQ ID NO: 396); GGTCAGATAT (SEQ ID NO: 397);
GTCAGATATC (SEQ ID NO: 398); TCAGATATCC (SEQ ID NO: 399);
CAGATATCCA (SEQ ID NO: 400); AGATATCCAC (SEQ ID NO: 401);
GATATCCACT (SEQ ID NO: 402); ATATCCACTG (SEQ ID NO: 403);
TATCCACTGA (SEQ ID NO: 404); ATCCACTGAC (SEQ ID NO: 405);
10 TCCACTGACC (SEQ ID NO: 406); CCACTGACCT (SEQ ID NO: 407);
CACTGACCTT (SEQ ID NO: 408); ACTGACCTTT (SEQ ID NO: 409);
CTGACCTTTG (SEQ ID NO: 410); TGACCTTTGG (SEQ ID NO: 411);
GACCTTTGGA (SEQ ID NO: 412); ACCTTTGGAT (SEQ ID NO: 413);
CCTTTGGATG (SEQ ID NO: 414); CTTTGGATGG (SEQ ID NO: 415);
15 TTTGGATGGT (SEQ ID NO: 416); TTGGATGGTG (SEQ ID NO: 417);
TGGATGGTGC (SEQ ID NO: 418); GGATGGTGCT (SEQ ID NO: 419);
GATGGTGCTA (SEQ ID NO: 420); ATGGTGCTAC (SEQ ID NO: 421);
TGGTGCTACA (SEQ ID NO: 422); GGTGCTACAA (SEQ ID NO: 423);
GTGCTACAAG (SEQ ID NO: 424); TGCTACAAGC (SEQ ID NO: 425);
20 GCTACAAGCT (SEQ ID NO: 426); CTACAAGCTA (SEQ ID NO: 427);
TACAAGCTAG (SEQ ID NO: 428); ACAAGCTAGT (SEQ ID NO: 429);
CAAGCTAGTA (SEQ ID NO: 430); AAGCTAGTAC (SEQ ID NO: 431);
AGCTAGTACC (SEQ ID NO: 432); GCTAGTACCA (SEQ ID NO: 433);
CTAGTACCAG (SEQ ID NO: 434); TAGTACCAGT (SEQ ID NO: 435);
25 AGTACCAGTT (SEQ ID NO: 436); GTACCAGTTG (SEQ ID NO: 437);
TACCAGTTGA (SEQ ID NO: 438); ACCAGTTGAG (SEQ ID NO: 439);
CCAGTTGAGC (SEQ ID NO: 440); CAGTTGAGCC (SEQ ID NO: 441);
AGTTGAGCCA (SEQ ID NO: 442); GTTGAGCCAG (SEQ ID NO: 443);
TTGAGCCAGA (SEQ ID NO: 444); TGAGCCAGAT (SEQ ID NO: 445);
30 GAGCCAGATA (SEQ ID NO: 446); AGCCAGATAA (SEQ ID NO: 447);
GCCAGATAAG (SEQ ID NO: 448); CCAGATAAGG (SEQ ID NO: 449);
CAGATAAGGT (SEQ ID NO: 450); AGATAAGGTA (SEQ ID NO: 451);
GATAAGGTAG (SEQ ID NO: 452); ATAAGGTAGA (SEQ ID NO: 453);
TAAGGTAGAA (SEQ ID NO: 454); AAGGTAGAAG (SEQ ID NO: 455);
35 AGGTAGAAGA (SEQ ID NO: 456); GGTAGAAGAG (SEQ ID NO: 457);
GTAGAAGAGG (SEQ ID NO: 458); TAGAAGAGGC (SEQ ID NO: 459);
AGAAGAGGCC (SEQ ID NO: 460); GAAGAGGCCA (SEQ ID NO: 461);
AAGAGGCCAA (SEQ ID NO: 462); AGAGGCCAAT (SEQ ID NO: 463);

- 23 -

GAGGCCAATA (SEQ ID NO: 464); AGGCCAATAA (SEQ ID NO: 465);
GGCCAATAAA (SEQ ID NO: 466); GCCAATAAAG (SEQ ID NO: 467);
CCAATAAAGG (SEQ ID NO: 468); CAATAAAGGA (SEQ ID NO: 469);
AATAAAGGAG (SEQ ID NO: 470); ATAAAGGAGA (SEQ ID NO: 471);
5 TAAAGGAGAG (SEQ ID NO: 472); AAAGGAGAGA (SEQ ID NO: 473);
AAGGAGAGAA (SEQ ID NO: 474); AGGAGAGAAC (SEQ ID NO: 475);
GGAGAGAACA (SEQ ID NO: 476); GAGAGAACAC (SEQ ID NO: 477);
AGAGAACACC (SEQ ID NO: 478); GAGAACACCA (SEQ ID NO: 479);
AGAACACCAG (SEQ ID NO: 480); GAACACCAGC (SEQ ID NO: 481);
10 AACACCAGCT (SEQ ID NO: 482); ACACCAGCTT (SEQ ID NO: 483);
CACCAGCTTG (SEQ ID NO: 484); ACCAGCTTGT (SEQ ID NO: 485);
CCAGCTTGTT (SEQ ID NO: 486); CAGCTTGTTA (SEQ ID NO: 487);
AGCTTGTTAC (SEQ ID NO: 488); GCTTGTTACA (SEQ ID NO: 489);
CTTGTTACAC (SEQ ID NO: 490); TTGTTACACC (SEQ ID NO: 491);
15 TGTTACACCC (SEQ ID NO: 492); GTTACACCCT (SEQ ID NO: 493);
TTACACCCTG (SEQ ID NO: 494); TACACCCTGT (SEQ ID NO: 495);
ACACCCTGTG (SEQ ID NO: 496); CACCCTGTGA (SEQ ID NO: 497);
ACCCTGTGAG (SEQ ID NO: 498); CCCTGTGAGC (SEQ ID NO: 499);
CCTGTGAGCC (SEQ ID NO: 500); CTGTGAGCCT (SEQ ID NO: 501);
20 TGTGAGCCTG (SEQ ID NO: 502); GTGAGCCTGC (SEQ ID NO: 503);
TGAGCCTGCA (SEQ ID NO: 504); GAGCCTGCAT (SEQ ID NO: 505);
AGCCTGCATG (SEQ ID NO: 506); GCCTGCATGG (SEQ ID NO: 507);
CCTGCATGGA (SEQ ID NO: 508); CTGCATGGAA (SEQ ID NO: 509);
TGCATGGAAT (SEQ ID NO: 510); GCATGGAATG (SEQ ID NO: 511);
25 CATGGAATGG (SEQ ID NO: 512); ATGGAATGGA (SEQ ID NO: 513);
TGGAATGGAT (SEQ ID NO: 514); GGAATGGATG (SEQ ID NO: 515);
GAATGGATGA (SEQ ID NO: 516); AATGGATGAC (SEQ ID NO: 517);
ATGGATGACC (SEQ ID NO: 518); TGGATGACCC (SEQ ID NO: 519);
GGATGACCCT (SEQ ID NO: 520); GATGACCCTG (SEQ ID NO: 521);
30 ATGACCCTGA (SEQ ID NO: 522); TGACCCTGAG (SEQ ID NO: 523);
GACCCTGAGA (SEQ ID NO: 524); ACCCTGAGAG (SEQ ID NO: 525);
CCCTGAGAGA (SEQ ID NO: 526); CCTGAGAGAG (SEQ ID NO: 527);
CTGAGAGAGA (SEQ ID NO: 528); TGAGAGAGAA (SEQ ID NO: 529);
GAGAGAGAAG (SEQ ID NO: 530); AGAGAGAAGT (SEQ ID NO: 531);
35 GAGAGAAGTG (SEQ ID NO: 532); AGAGAAGTGT (SEQ ID NO: 533);
GAGAAGTGTT (SEQ ID NO: 534); AGAAGTGTTA (SEQ ID NO: 535);
GAAGTGTTAG (SEQ ID NO: 536); AAGTGTTAGA (SEQ ID NO: 537);
AGTGTTAGAG (SEQ ID NO: 538); GTGTTAGAGT (SEQ ID NO: 539);

- 24 -

TGTTAGAGTG (SEQ ID NO: 540); GTTAGAGTGG (SEQ ID NO: 541);
TTAGAGTGGA (SEQ ID NO: 542); TAGAGTGGAG (SEQ ID NO: 543);
AGAGTGGAGG (SEQ ID NO: 544); GAGTGGAGGT (SEQ ID NO: 545);
AGTGGAGGTT (SEQ ID NO: 546); GTGGAGGTTT (SEQ ID NO: 547);
5 TGGAGGTTTG (SEQ ID NO: 548); GGAGGTTTGA (SEQ ID NO: 549);
GAGGTTTGAC (SEQ ID NO: 550); AGGTTTGACA (SEQ ID NO: 551);
GGTTTGACAG (SEQ ID NO: 552); GTTTGACAGC (SEQ ID NO: 553);
TTTGACAGCC (SEQ ID NO: 554); TTGACAGCCG (SEQ ID NO: 555);
TGACAGCCGC (SEQ ID NO: 556); GACAGCCGCC (SEQ ID NO: 557);
10 ACAGCCGCCT (SEQ ID NO: 558); CAGCCGCCTA (SEQ ID NO: 559);
AGCCGCCTAG (SEQ ID NO: 560); GCCGCCTAGC (SEQ ID NO: 561);
CCGCCTAGCA (SEQ ID NO: 562); CGCCTAGCAT (SEQ ID NO: 563);
GCCTAGCATT (SEQ ID NO: 564); CCTAGCATTT (SEQ ID NO: 565);
CTAGCATTTT (SEQ ID NO: 566); TAGCATTTCA (SEQ ID NO: 567);
15 AGCATTTTCAT (SEQ ID NO: 568); GCATTTTCATC (SEQ ID NO: 569);
CATTTTCATCA (SEQ ID NO: 570); ATTTTCATCAC (SEQ ID NO: 571);
TTTCATCACG (SEQ ID NO: 572); TTCATCACGT (SEQ ID NO: 573);
TCATCACGTG (SEQ ID NO: 574); CATCACGTGG (SEQ ID NO: 575);
ATCACGTGGC (SEQ ID NO: 576); TCACGTGGCC (SEQ ID NO: 577);
20 CACGTGGCCC (SEQ ID NO: 578); ACGTGGCCCG (SEQ ID NO: 579);
CGTGGCCCGA (SEQ ID NO: 580); GTGGCCCGAG (SEQ ID NO: 581);
TGGCCCGAGA (SEQ ID NO: 582); GGCCCGAGAG (SEQ ID NO: 583);
GCCCGAGAGC (SEQ ID NO: 584); CCCGAGAGCT (SEQ ID NO: 585);
CCGAGAGCTG (SEQ ID NO: 586); CGAGAGCTGC (SEQ ID NO: 587);
25 GAGAGCTGCA (SEQ ID NO: 588); AGAGCTGCAT (SEQ ID NO: 589);
GAGCTGCATC (SEQ ID NO: 590); AGCTGCATCC (SEQ ID NO: 591);
GCTGCATCCG (SEQ ID NO: 592); CTGCATCCGG (SEQ ID NO: 593);
TGCATCCGGA (SEQ ID NO: 594); GCATCCGGAG (SEQ ID NO: 595);
CATCCGGAGT (SEQ ID NO: 596); ATCCGGAGTA (SEQ ID NO: 597);
30 TCCGGAGTAC (SEQ ID NO: 598); CCGGAGTACT (SEQ ID NO: 599);
CGGAGTACTT (SEQ ID NO: 600); GGAGTACTTC (SEQ ID NO: 601);
GAGTACTTCA (SEQ ID NO: 602); AGTACTTCAA (SEQ ID NO: 603);
GTACTTCAAG (SEQ ID NO: 604); TACTTCAAGA (SEQ ID NO: 605);
ACTTCAAGAA (SEQ ID NO: 606); CTTCAAGAAC (SEQ ID NO: 607);
35 TTCAAGAACT (SEQ ID NO: 608); TCAAGAACTG (SEQ ID NO: 609);
CAAGAACTGC (SEQ ID NO: 610); AAGAACTGCT (SEQ ID NO: 611);
AGAACTGCTG (SEQ ID NO: 612); GAACTGCTGA (SEQ ID NO: 613).

Generally, the subject HIV-1 isolate is non-pathogenic as hereinbefore defined. Additionally, reference herein to "a deletion" includes reference to a contiguous or non-contiguous series of two or more deletions.

- 5 The non-pathogenic isolate may carry a single decanucleotide deletion or may carry more than one decanucleotide deletion. Where it carries multiple deletions these may all correspond to a contiguous sequence or be from different parts of the *nef* gene. Furthermore, the terminal end portions of a deletion may lie within a decanucleotide as defined above. It is emphasised that the present invention extends to analogous
10 sequences from other pathogenic strains of HIV-1 which might carry *nef* genes with a slightly altered sequence relative to HIV-1 strain NL4-3.

In a most preferred embodiment of the present invention, there is provided a non-pathogenic strain of HIV-1 carrying a nucleotide sequence in its genome as set forth
15 in SEQ ID No. 614:

GAAGAGATTTGGGAGAACATGACCTGGATGCAGTGGGAAAAAGAAATTCACAATCACAC
AAAATACATATACTCCTTACTTGAAAAATCGCAGAACCAACAAGAAAAGAATGAACAAG
AACTATTGGAATTGGATCAATGGGCAAGTTTGTGGAATTGGTTTGACATAACAAAATGG
CTGTGGTATATAAAAATATTCATAATGGTAGTAGGAGGCTTGATAGGTTTAAGAATAGT
20 TTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTGTCTGTTTC
AGACCCTCCTCCCAACCCGAGGGGACCCGACAGGCCCGAAGGAATCGAAGAAGAAGGT
GGAGAGAGAGACAGAGACAGATCCACTCGATTAGTACACGGATTCTTAGCACTTTTCTG
GGACGACCTGAGGAGCCTGTGCCTCTTCCTCTACCACCACCTTGAGAGACTTACTCTTGA
TTGTAACAAGGATTGTGGAACCTCTGGGACGCAGGGGATGGGAAGCCCTCAAATATTGG
25 TGGAACCTCCTAAAGTATTGGAGCCAGGAAGTGCAGAAGAGTGCTGTTATCTTGCTCAA
TGCCACCGCCATAGCAGTAGCTGAGGGGACAGATAGAGTTT TAGAAGTATTACAAAGAG
CTTATAGAGCTATCCTCCACATACCTAGAAGAATAAGACAGGGCCTCGAAATGGCTTTG
CTATAAAATGGGTGGCAAGTGAGCAAAAAGTAGTGTAGTCAGATAGCATGCATCATAAG
GGGTGGGGGCCAACAACCTAACAATGCTGATCGTGCCTGGCTAGAAGCACAGAGAAGGA
30 AGAAGCGGGTTTTCCAGTCAAACCTCAGGTAGCTGTAGATCTTAGCCACTTTTTAAAG
AAAAGGGGGGACTGGAAGGGCTAATCACTCCCAAAGAAGACAAGATACACAGTGCTGC
AACTATTACCACTGGAGTCAGCGAAGATAGAAGAGGCCAATGGAGGAGAAAACACAG
ATTGTTCTGTGGGGACTTTCCATCCGTTGGGGACTTTCCAAGGCGGCGTGGCCTGGGT
GACTAGTTCCGGTGGGGACTTTCCAAGAAGGCGCGGCCTGGGCGGGACTGGGGAGTGGC
35 GAGCCCTCAGATGCTGCATATAAGCAGCTGCTTTCTGCTGTTACTGGGTCTCTCGGGTT

AGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTC
AATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCCGTCTGTTGTGTGACTCTGGT
ATCTAGA;

5 and/or SEQ ID NO: 615:

GAAACAATTTGGGATAACATGACCTGGATGCAGTGGGAAAGAGAAATTGACAATTACAC
AAACATAATATACACCTTAATTGAAGAATCGCAGAACCAACAAGAAAAAATGAACTAG
AATTATTGGAATTGGATAAATGGGCAAATTTGTGGAATTGGTTTAGTATATCAAACCTGG
CTATGGTATATAAAATTATTATAATGGTAGTAGGAGGCTTGGTAGGTTTAAGAATAGT
10 TTTTACTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTGTCTGTTTC
AGACCCACCTCCCAACCCCGAAGGGACCCGACAGGCCAGAAGGAATCGAAGAAGAAGGT
GGAGAGAGAGACAGAGGCAGCTCCACTCGATTAGTGCACGGATTCTTAGCACTTTTCTG
GGACGACCTGAGGAGTCTGTGCCTCTTCAGCTACCACCACTTGAGAGACTTACTCTTGA
TTGTAACGAGGATTGTGGAACCTTCTGGGACGCAGGGGATGGGAAGCCCTCAAATACTGG
15 TGAATCTCCTGCAGTATTGGAGGCAGGAACCTACAGAAGAGTGCTGTAGCTTGTTCAA
TGGCACGGCCATAGCAGTAGCTGAGGGGACAGATAGAGTTATAGAAGCTTTACGAAGGG
CTTATAGAGCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTAGAAAGGGCTTTG
CTATAAAATGGGTGGCAAGTGGTCAGAAAGTAGTGTGGTTAGAAGGCATGTACCTTTAA
GACAAGGCAGCTATAGATCTTAGCCGCTTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCT
20 AATTCACTCACAGAGAAGATCAGTTGAACCAGAAGAAGATAGAAGAGGCCATGAAGAAG
AAAACAACAGATTGTTCCGTTTGTTCGTTGGGGACTTTCCAGGAGACGTGGCCTGAGT
GATAAGCCGCTGGGGACTTTCCGAAGAGGCGTGACGGGACTTTCCAAGGCGACGTGGCC
TGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATGCTGCATATAAGCAGCTGCTTTCTGC
CTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAG
25 GGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCC
CGTCTGTTGTGTGACTCTGGTATCTAGA.

The present invention, however, extends to HIV-1 isolates which are non-pathogenic;
carry genomes capable of hybridising under low stringency conditions to SEQ ID NO:
30 614 or SEQ ID NO: 615; and which do not direct the synthesis of a full length *nef* gene
product.

In a further embodiment the present invention contemplates a viral isolate which:

- (i) is reactive to antibodies to a glycoprotein from HIV-1 such as at least one of
35 gp41-45, gp120 and/or gp160;
- (ii) carries a genome or a part or fragment thereof capable of hybridising under

- 27 -

medium stringency conditions to a nucleotide sequence as set forth in SEQ ID NO: 1 or a complementary form thereof or an analogous sequence from another pathogenic strain of HIV-1;

- (iii) carries a deletion of at least ten nucleotides in a region corresponding to the LTR region in HIV-1 NL4-3; and

5

wherein said deletion encompasses one or more of the following decanucleotides from the LTR region of HIV-1 NL4-3 or corresponding sequences from another pathogenic strain of HIV-1:

- | | | |
|----|------------------------------|------------------------------|
| 10 | GCTTTTGGCC (SEQ ID NO: 652); | CTTTTGCCT (SEQ ID NO: 653); |
| | TTTTGCCTG (SEQ ID NO: 654); | TTTGCCTGT (SEQ ID NO: 655); |
| | TTTGCCTGTA (SEQ ID NO: 656); | TTGCCTGTAC (SEQ ID NO: 657); |
| | TGCCTGTACT (SEQ ID NO: 658); | GCCTGTACTG (SEQ ID NO: 659); |
| | CCTGTACTGG (SEQ ID NO: 660); | CTGTACTGGG (SEQ ID NO: 661); |
| 15 | TGTACTGGGT (SEQ ID NO: 662); | GTACTGGGTC (SEQ ID NO: 663); |
| | TACTGGGTCT (SEQ ID NO: 664); | ACTGGGTCTC (SEQ ID NO: 665); |
| | CTGGGTCTCT (SEQ ID NO: 666); | TGGGTCTCTC (SEQ ID NO: 667); |
| | GGGTCTCTCT (SEQ ID NO: 668); | GGTCTCTCTG (SEQ ID NO: 669); |
| | GTCTCTCTGG (SEQ ID NO: 670); | TCTCTCTGGT (SEQ ID NO: 671); |
| 20 | CTCTCTGGTT (SEQ ID NO: 672); | TCTCTGGTTA (SEQ ID NO: 673); |
| | CTCTGGTTAG (SEQ ID NO: 674); | TCTCTGGTTA (SEQ ID NO: 675); |
| | CTGGTTAGAC (SEQ ID NO: 676); | TGGTTAGACC (SEQ ID NO: 677); |
| | GGTTAGACCA (SEQ ID NO: 678); | GTTAGACCAG (SEQ ID NO: 679); |
| | TTAGACCAGA (SEQ ID NO: 680); | TAGACCAGAT (SEQ ID NO: 681); |
| 25 | AGACCAGATC (SEQ ID NO: 682); | GACCAGATCT (SEQ ID NO: 683); |
| | ACCAGATCTG (SEQ ID NO: 684); | CCAGATCTGA (SEQ ID NO: 685); |
| | CAGATCTGAG (SEQ ID NO: 686); | AGATCTGAGC (SEQ ID NO: 687); |
| | GATCTGAGCC (SEQ ID NO: 688); | ATCTGAGCCT (SEQ ID NO: 689); |
| | TCTGAGCCTG (SEQ ID NO: 690); | CTGAGCCTGG (SEQ ID NO: 691); |
| 30 | TGAGCCTGGG (SEQ ID NO: 692); | GAGCCTGGGA (SEQ ID NO: 693); |
| | AGCCTGGGAG (SEQ ID NO: 694); | GCCTGGGAGC (SEQ ID NO: 695); |
| | CCTGGGAGCT (SEQ ID NO: 696); | CTGGGAGCTC (SEQ ID NO: 697); |
| | TGGGAGCTCT (SEQ ID NO: 698); | GGGAGCTCTC (SEQ ID NO: 699); |
| | GGAGCTCTCT (SEQ ID NO: 700); | GAGCTCTCTG (SEQ ID NO: 701); |
| 35 | AGCTCTCTGG (SEQ ID NO: 702); | GCTCTCTGGC (SEQ ID NO: 703); |
| | CTCTCTGGCT (SEQ ID NO: 704); | TCTCTGGCTA (SEQ ID NO: 705); |

CTCTGGCTAA (SEQ ID NO: 706); TCTGGCTAAC (SEQ ID NO: 707);
 CTGGCTAACT (SEQ ID NO: 708); TGGCTAACTA (SEQ ID NO: 709);
 GGCTAACTAG (SEQ ID NO: 710); GCTAACTAGG (SEQ ID NO: 711);
 CTAAGCTAGGG (SEQ ID NO: 712); TAACTAGGGA (SEQ ID NO: 713);
 5 AACTAGGGAA (SEQ ID NO: 714); ACTAGGGAA (SEQ ID NO: 715);
 CTAGGGGAACC (SEQ ID NO: 716); TAGGGGAACCC (SEQ ID NO: 717);
 AGGGGAACCCA (SEQ ID NO: 718); GGGGAACCCAC (SEQ ID NO: 719);
 GGAACCCACT (SEQ ID NO: 720); GAACCCACTG (SEQ ID NO: 721);
 AACCCACTGC (SEQ ID NO: 722); ACCCACTGCT (SEQ ID NO: 723);
 10 CCCACTGCTT (SEQ ID NO: 724); CCACTGCTTA (SEQ ID NO: 725);
 CACTGCTTAA (SEQ ID NO: 726); ACTGCTTAAG (SEQ ID NO: 727);
 CTGCTTAAGC (SEQ ID NO: 728); TGCTTAAGCC (SEQ ID NO: 729);
 GCTTAAGCCT (SEQ ID NO: 730); CTTAAGCCTC (SEQ ID NO: 731);
 TTAAGCCTCA (SEQ ID NO: 732); TAAGCCTCAA (SEQ ID NO: 733);
 15 AAGCCTCAAT (SEQ ID NO: 734); AGCCTCAATA (SEQ ID NO: 735);
 GCCTCAATAA (SEQ ID NO: 736); CCTCAATAAA (SEQ ID NO: 737);
 CTCAATAAAG (SEQ ID NO: 738); TCAATAAAGC (SEQ ID NO: 739);
 CAATAAAGCT (SEQ ID NO: 740); AATAAAGCTT (SEQ ID NO: 741);
 ATAAAGCTTG (SEQ ID NO: 742); TAAAGCTTGC (SEQ ID NO: 743);
 20 AAAGCTTGCC (SEQ ID NO: 744); AAGCTTGCCT (SEQ ID NO: 745);
 AGCTTGCCTT (SEQ ID NO: 746); GCTTGCCTTG (SEQ ID NO: 747);
 CTTGCCTTGA (SEQ ID NO: 748); TTGCCTTGAG (SEQ ID NO: 749);
 TGCCTTGAGT (SEQ ID NO: 750); GCCTTGAGTG (SEQ ID NO: 751);
 CCTTGAGTGC (SEQ ID NO: 752); CTTGAGTGCT (SEQ ID NO: 753);
 25 TTGAGTGCTT (SEQ ID NO: 754); TGAGTGCTTC (SEQ ID NO: 755);
 GAGTGCTTCA (SEQ ID NO: 756); AGTGCTTCAA (SEQ ID NO: 757);
 GTGCTTCAAG (SEQ ID NO: 758); TGCTTCAAGT (SEQ ID NO: 759);
 GCTTCAAGTA (SEQ ID NO: 760); CTTCAAGTAG (SEQ ID NO: 761);
 TTCAAGTAGT (SEQ ID NO: 762); TCAAGTAGTG (SEQ ID NO: 763);
 30 CAAGTAGTGT (SEQ ID NO: 764); AAGTAGTGTG (SEQ ID NO: 765);
 AGTAGTGTGT (SEQ ID NO: 766); GTAGTGTGTG (SEQ ID NO: 767);
 TAGTGTGTGC (SEQ ID NO: 768); AGTGTGTGCC (SEQ ID NO: 769);
 GTGTGTGCCC (SEQ ID NO: 770); TGTGTGCCCCG (SEQ ID NO: 771);
 GTGTGCCCCG (SEQ ID NO: 772); TGTGCCCCGTC (SEQ ID NO: 773);
 35 GTGCCCCGTCT (SEQ ID NO: 774); TGCCCCGTCTG (SEQ ID NO: 775);
 GCCCCGTCTGT (SEQ ID NO: 776); CCCGTCTGTG (SEQ ID NO: 777);
 CCGTCTGTTG (SEQ ID NO: 778); CGTCTGTTGT (SEQ ID NO: 779);
 GTCTGTTGTG (SEQ ID NO: 780); TCTGTTGTGT (SEQ ID NO: 781);

CTGTTGTGTG (SEQ ID NO: 782); TGTGTGTGA (SEQ ID NO: 783);
 GTTGTGTGAC (SEQ ID NO: 784); TTGTGTGACT (SEQ ID NO: 785);
 TGTGTGACTC (SEQ ID NO: 786); GTGTGACTCT (SEQ ID NO: 787);
 TGTGTGACTC (SEQ ID NO: 788); GTGTGACTCT (SEQ ID NO: 789);
 5 TGTGACTCTG (SEQ ID NO: 790); GTGACTCTGG (SEQ ID NO: 791);
 TGACTCTGGT (SEQ ID NO: 792); GACTCTGGTA (SEQ ID NO: 793);
 ACTCTGGTAA (SEQ ID NO: 794); CTCTGGTAAC (SEQ ID NO: 795);
 TCTGGTAACT (SEQ ID NO: 796); CTGGTAACTA (SEQ ID NO: 797);
 TGGTAACTAG (SEQ ID NO: 798); GGTAAC TAGA (SEQ ID NO: 799).

10

The non-pathogenic isolate may carry a single decanucleotide deletion in the LTR region or may carry multiple deletions in the same region or in the LTR region and another region such as the *nef* gene. In particular, the mutation may be in the LTR/*nef* overlap region. Where it carries multiple deletions, these may correspond to a contiguous
 15 sequence or be from different parts of the LTR region and/or *nef* gene. Furthermore, the terminal end portions of a deletion may lie within a decanucleotide as defined above.

Yet another aspect of the present invention provides an infectious molecular clone comprising genetic sequences derived from the non-pathogenic HIV-1 isolates as
 20 hereinbefore described and includes genetic sequences encoding major structural proteins such as *gag*, *env* and *pol*. Infectious molecular clones are particularly useful as genetic compositions capable of "infecting" host cells without need of viral coat. The infectious molecular clones of the present invention may also be derived from pathogenic HIV-1 strains rendered non-pathogenic as hereindescribed.

25

According to this latter embodiment, there is contemplated a method of attenuating a pathogenic strain of HIV-1, said method comprising inducing a mutation in the *nef* gene and/or an LTR region to generate a non-pathogenic HIV-1 strain as hereinbefore described. Preferred mutations are deletions of at least ten nucleotides such as one or
 30 more of the decanucleotides as hereinbefore described. The mutations may also constitute substitutions and/or insertions of heterologous nucleic acid molecules in the *nef* and/or LTR regions such as the incorporation of a sense (i.e. co-suppression) antisense or ribozyme molecule (see below).

- 30 -

In still yet another embodiment of the present invention, there is provided an isolated, non-pathogenic strain of HIV-1 comprising a deletion in its genome of at least 10 nucleotide within the region of nucleotide 8787 and 9709 and more particularly within the region 8800 and 9700 and even more preferably within the region 8800 and 9410,
5 using the nucleotide numbering of HIV-1 NL4-3.

In one embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3):

- | | | |
|------------|-------|----------------|
| nucleotide | (i) | 8830-8862; |
| 10 | (ii) | 9009-9035; |
| | (iii) | 9019-9029; and |
| | (iv) | 9033-9049. |

In another embodiment, the deletion of at least 10 nucleotides is from within a region
15 selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3):

- | | | |
|------------|--------|----------------|
| nucleotide | (v) | 9281-9371; |
| | (vi) | 9281-9362; |
| | (vii) | 9105-9224; and |
| | (viii) | 9271-9370. |

20

In yet another embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3):

- | | | |
|------------|-------|----------------|
| nucleotide | (ix) | 8882-8928; |
| 25 | (x) | 8850-9006; |
| | (xi) | 8792-9041; and |
| | (xii) | 9112-9204. |

In still yet another embodiment, the deletion of at least 10 nucleotides is from within a
30 region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3):

nucleotide (xiii) 9105-9224;
(xiv) 9389-9395; and
(xv) 9281-9366.

5

The above embodiments including any combinations thereof or functional equivalents thereof. Most preferred variants of HIV-1 are defined in Table 3.

Reference herein to the non-pathogenic HIV-1 strains of the present invention includes
10 reference to components, parts, fragments and derivatives thereof including both genetic and non-genetic material. Furthermore, the non-pathogenic HIV-1 strains may be in isolated form or resident in peripheral blood mononuclear cells (PBMCs) or other like cells where the genome of the HIV-1 strains is integrated as DNA from said HIV-1 strains such as proviral DNA. In addition, the present invention extends to recombinant
15 virus such as from (or resident in) prokaryotes or eukaryotes as well as in the form of infectious molecular clones.

Accordingly, the present invention provides for the non-pathogenic HIV-1 isolate, genomic material therefrom, complementary proviral DNA, molecular infectious clones,
20 recombinant viral particles or genetic sequences therefrom or cells expressing same or blood cells carrying proviral DNA or to any mutants, derivatives, components, fragments, parts, homologues or analogues of the foregoing.

The non-pathogenic HIV-1 strains of the present invention are particularly useful in the
25 development of therapeutic compositions, therapeutic molecules and/or diagnostic reagents. With regards to the former, the non-pathogenic HIV-1 strain may be considered as a live attenuated vaccine where individuals carrying DNA derived from said non-pathogenic HIV-1 strain such as proviral DNA in target cells are protected from infection by a corresponding pathogenic strain. The term "vaccine" is used in its broadest
30 sense as a therapeutic composition or molecule which prevents or reduces HIV-1 infection or risk of infection or which ameliorates the symptoms of infection. It may involve the stimulation of an immune response or may involve blocking HIV-1 cells

- 32 -

receptors and/or the use of genetic compositions, for example, to introduce ribozymes or antisense molecules to HIV-1 directed genetic sequences or to prepare infectious molecular clones. For convenience, all such compositions are referred hereinafter to "therapeutic compositions".

5

Accordingly, the present invention contemplates a method for inhibiting or reducing the risk of infection by a pathogenic strain of HIV-1, said method comprising administering to a subject a non-pathogenic HIV-1 as hereinbefore defined in an amount effective to infect target cells and to generate target cells carrying proviral DNA from said non-pathogenic HIV-1. More particularly, the present invention contemplates a method for inhibiting or reducing productive infection of an individual by a pathogenic strain of HIV-1, said method comprising administering to a subject a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying proviral DNA from said non-pathogenic HIV-1. By "productive infection" as used in the specification and claims herein is meant the infection of a cell or cells by a pathogenic strain of HIV-1 which leads ultimately to the symptomology of AIDS or AIDS related diseases. A cell infected productively produces pathogenic virions. By definition, infection of an individual by a non-pathogenic strain of HIV-1 would not lead to productive infection. Non pathogenic HIV-1 strains generally replicate to a sufficient extent to protect cells against challenge by virulent or pathogenic strains. The methods of the present invention are applicable prophylactically (i.e. to prevent *de novo* infection) or therapeutically (i.e. to reduce or slow disease progression).

The present invention further provides a method for vaccinating an individual against the development of AIDS or AIDS related diseases, said method comprising administering to said individual a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying proviral DNA from said non-pathogenic HIV-1. The term "vaccinating" should not be taken as limiting the invention to the prevention of HIV-1 infection by solely immunological means. The term "vaccinating" includes any means of preventing productive infection of an individual by pathogenic HIV-1.

As an alternative to the above methods, a therapeutic composition as hereinbefore defined is administered. The non-pathogenic isolate may be administered *inter alia* as an isolated viral preparation or *via* infected blood cells. Another aspect of the invention provides a therapeutic composition for inhibiting or reducing the risk of infection by a pathogenic strain of HIV-1 said therapeutic composition comprising a non-pathogenic strain of HIV-1 or genetic sequences derived therefrom as hereinbefore described and optionally one or more pharmaceutically acceptable carriers and/or diluents. The therapeutic composition of the present invention is generally suitable for intravenous, intraperitoneal, intramuscular, intramucosal (e.g. nasal spray, respiratory spray) or other forms of parenteral administration. The therapeutic composition might also be administered *via* an implant or rectally or orally. In addition to the mutations contemplated above, the non-pathogenic HIV-1 strain may also contain one or more other mutations to further reduce the risk of reversion to virulence and/or to insert a genetic sequence capable of providing directly or indirectly an identifiable signal, having further anti-HIV-1 properties and/or immunostimulatory or cell regulatory properties.

For example, the non-pathogenic HIV-1 isolate in the therapeutic composition may comprise additional genetic material capable of directing expression of antisense nucleotide sequences to inhibit expression of one or more proteins encoded by a pathogenic strain of HIV-1. Alternatively, sense co-suppression may be employed. Preferred sense or antisense molecules would reduce expression of the *nef* gene or affect normal functioning of the LTR region.

According to this embodiment, the non-pathogenic HIV-1 strain may be considered as a targeting agent to introduce genetic constructs capable of reducing expression of one or more HIV-1 proteins or polypeptides. In this embodiment there is provided a viral isolate which:

- (i) is genetically or immunologically related to a pathogenic strain of HIV-1;
- (ii) is substantially non-pathogenic in human subjects;
- (iii) comprises a first nucleotide sequence constituting its genome which is capable of hybridising under medium stringency conditions to SEQ ID NO: 1 or a complementary form thereof; and

- 34 -

- (iv) comprises a second nucleotide sequence within said first nucleotide sequence and which second nucleotide sequence directs expression of a mRNA molecule capable of inhibiting, reducing or otherwise down-regulating translation of a protein or polypeptide encoded by a pathogenic strain of HIV-1 or inhibit, reduce or otherwise down regulate operation of a non-protein encoding a region of a pathogenic strain of HIV-1.

Preferred proteins or polypeptides targeted for reduced expression are those encoded by one or more of the following: *gag*, *pol*, *env*, *tat*, *rev*, *vpu*, *vpr*, *vif* and/or *nef* genes. The most preferred protein or polypeptide targeted for reduced expression is the product of the *nef* gene. Alternatively, the target nucleotide sequence does not encode a polypeptide or protein but is required for other functions such as integration or excision from the human genome or expression of genes on the viral genome. An example of such a nucleotide sequence is the LTR region. Accordingly, the present invention extends to disruption to the function of such regions.

The above aspect relates to use of antisense technology. The present invention extends, however, to use of ribozymes and/or co-suppression to achieve the same results. In an alternative embodiment, or in addition to, the second (or optionally a third) nucleotide sequence encodes an antiviral agent (e.g. interferon) and/or an immune enhancing agent.

The identification of deletions *inter alia* in the *nef* gene and/or LTR region in asymptomatic subjects provides a unique opportunity to study the *in vivo* effects of attenuated HIV-1 strains carrying one or more mutations in selected genetic regions. In particular, the present invention provides a means for designing therapeutic compositions directed to inhibiting expression of a *nef* gene and/or LTR region in a pathogenic HIV-1 strain (such as contemplated above) as well as developing a therapeutic regimen aimed at inhibiting the activity of the *nef* gene product for the function of the LTR region. According to this latter embodiment, the present invention provides a therapeutic composition comprising a molecule capable of inhibiting the intracellular activity of the *nef* gene product and/or LTR region, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.

- 35 -

The molecule contemplated by the above aspect of the subject invention may be a protein, polypeptide, peptide, chemical compound, sugar moiety or derivative of the *nef* gene product. The molecule will need to be capable of entering an infected cell. Where the molecule is a protein, polypeptide or peptide, it may be encoded by the second
5 nucleotide sequence on the targeting vector as contemplated above. Alternatively, the molecule may be a nucleic acid molecule capable of targeting the *nef* gene or LTR region.

The deletion mutants of the present invention may result in a modified *nef* gene product
10 either having no readily discernable activity or having activity different to the naturally occurring *nef* protein. In any event, if a mutant *nef* gene product is produced, it will generally have a lower molecular weight than the naturally occurring *nef* protein and will have a different overall amino acid sequence. This provides, therefore, for a means for diagnosing individuals with benign HIV-1 infection by, for example, assaying for a
15 modified *nef* protein or screening for a modified *nef* gene sequence. Alternatively, benign HIV-1 infection may be detected by assaying for a modified LTR region such as an altered nucleotide sequence.

According to one embodiment, there is provided a method for determining the
20 pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising contacting a biological sample from said individual with an effective amount of an antibody specific to a *nef* protein from a non-pathogenic strain of HIV-1 (as hereinbefore defined) for a time and under conditions sufficient to form an antibody-modified *nef* protein complex and then detecting said complex. The
25 presence of said complex is indicative of a modified *nef* gene product and of the non-pathogenicity of the strain of HIV-1. The biological sample is a sample likely to contain the modified *nef* gene product such as tissue extract or cell extract of an infected cell. However, where the modified *nef* gene product is capable of permeation or transport out of the cell, suitable biological fluid would include serum, whole blood, lymph and
30 mucosal secretion amongst other fluids. Many variations in the subject assay are possible and are contemplated herein. For example, an assay could be based on the inability for a *nef* specific antibody to bind to a modified *nef* protein. For the purposes

of the present invention the term "contacting" including "mixing".

The presence of a modified *nef* molecule in biological fluid can be detected using a wide range of immunoassay techniques such as those described in US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. These include both single-site and two-site, or "sandwich", assays of the non-competitive types, as well as in the traditional competitive binding assays and include ELISA and RIA techniques. Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, and by way of example only, in a typical forward assay, a modified *nef* product-specific antibody is immobilised onto a solid substrate to form a first complex and the sample to be tested for modified *nef* product brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-modified *nef* product secondary complex, a second modified *nef* protein antibody, labelled with a reporter molecule capable of producing a detectable signal, is then added and incubated, allowing time sufficient for the formation of a tertiary complex of antibody-modified *nef* product-antibody. Any unreacted material is washed away, and the presence of the tertiary complex is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal or may be quantitated by comparison with a control sample containing known amounts of hapten. Variations of the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody, or a reverse assay in which the labelled antibody and sample to be tested are first combined, incubated and then added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, and the possibility of minor variations will be readily apparent. The antibodies used above may be monoclonal or polyclonal.

The solid substrate is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs or microplates, or any other

- 37 -

surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing the molecule to the insoluble carrier.

- 5 By "reporter molecule", as used in the present specification, is meant a molecule which, by its chemical nature, produces an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecule in this type of assay re either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes). In the case of an
- 10 enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognised, however, a wide variety of different conjugation techniques exist which are readily available to one skilled in the art. Commonly used enzymes include horseradish peroxidase, glucose oxidase, β -galactosidase and alkaline phosphatase, amongst others. The substrates to be
- 15 used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. It is also possible to employ fluorogenic substrates, which yield a fluorescent product.

- Alternatively, fluorescent compounds, such as fluorescein and rhodamine, may be
- 20 chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the
- 25 first antibody-hapten complex. After washing off the unbound reagent, the remaining complex is then exposed to the light of the appropriate wavelength, the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope,
- 30 chemiluminescent or bioluminescent molecules, may also be employed. It will be readily apparent to the skilled technician how to vary the procedure to suit the required purpose. It will also be apparent that the foregoing can be used to label a modified *nef*

- 38 -

product and to use same directly in the detection of, for example, circulatory antibodies specific to said modified *nef* product.

Alternatively, genetic assays may be conducted to screen for aberrations in the *nef* gene and/or LTR region. Such a genetic assay may be by Southern or Northern blot analysis, 5 PCR analysis or the like using oligonucleotides specific to a deleted region of a *nef* gene and/or LTR region.

According to this embodiment there is provided a method for determining the 10 pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising determining directly or indirectly the presence of a deletion mutation in the genome of said HIV-1 wherein the presence of a such a mutation is indicative of the presence of a non-pathogenic strain of HIV-1. The deletion mutation may result in the genome being unable to synthesise a polypeptide or protein from a 15 pathogenic strain of HIV-1 or may direct the synthesis of a truncated form of said polypeptide or protein. The mutation may also lead to altered expression of a polypeptide detectable by, for example, decreased synthesis of a particular protein, such as the *nef* gene product. Alternatively, the deletion mutation affects the LTR region or a regulatory region of the HIV-1 genome. In either case, affected viruses may also be 20 detected by, for example, observing low viral copy numbers such as low viral loads.

Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.

25

Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- | | | |
|------------|-------|----------------|
| nucleotide | (i) | 8830-8862; |
| | (ii) | 9009-9035; |
| 30 | (iii) | 9019-9029; and |
| | (iv) | 9033-9049. |

- 39 -

Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- 5 nucleotide (v) 9281-9371;
(vi) 9281-9362;
(vii) 9105-9224; and
(viii) 9271-9370.

Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- 10 nucleotide (ix) 8882-8928;
(x) 8850-9006;
(xi) 8792-9041; and
(xii) 9112-9204.

15 Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- nucleotide (xiii) 9105-9224;
(xiv) 9389-9395; and
(xv) 9281-9366.

20

The above nucleotide numbers are based on the nucleotide numbering in the NL4-3 genome.

25 Particularly preferred oligonucleotides are based on the deleted regions of the *nef* gene and/or LTR region such as but not limited to one or more oligonucleotides based on SEQ ID NO: 2 to SEQ ID NO: 613 and/or SEQ ID NO: 652 to SEQ ID NO: 799.

30 The present invention further extends to kits for the diagnosis of infection by pathogenic strains of HIV-1 or for determining the pathogenicity of infecting virus. The kits would be in compartmental form each comprising one or more suitable reagents for conducting the assay.

The present invention is further described by the following non-limiting Figures and Examples.

In the Figures:

5

Figure 1 is a representation showing the alignment of the nucleotide sequences from donor D36 peripheral blood mononuclear cell (PBMC) [D36P] and non-pathogenic HIV-1 from recipient C18 HIV_{SIV} [C18S], C18 HIV_{MBC} [C18M] and C98 HIV [C98H] and C54 PBMC [C54P] with the equivalent region of HIV-1 NL4-3. Sequences labelled
10 PBMC are from patient PBMC, those labelled HIV are from virus isolated from patient PBMC and grown in culture. Numbering for HIV-1 NL4-3 is as per Myer *et al* (1992) where nucleotide 1 is the first nucleotide of the complete proviral DNA sequence. D36P, C18S, C18M, C98H and C54P are numbered from the start of the region sequenced. Identity with NL4-3 sequence is shown by (*). Deleted nucleotides are
15 shown by (-). Spaces introduced to maximise alignment are shown by (.). Features in NL4-3 are marked by overlining the sequence, features in D36 and C18 are marked by underlining the sequence.

Figure 2 shows the alignment of encoded amino acid sequences of (a) *tat* exon 3 and
20 (b) *rev* exon 3 from HIV-1 NL4-3, D36 PBMC, C18 HIV_{SIV} and C98 HIV. In-phase termination codons (*) and NL4-3 encoded amino acid numbers are shown.

Figure 3 is a representation showing the alignment of C-terminal envelope glycoprotein gp41 amino acid sequences encoded by D36 PMBC, C18 HIV_{SIV}, C18 HIV_{MBC} and
25 C98 HIV. Numbering is that of the amino acid sequence of the mature envelope glycoprotein of HIV NL4-3. Termination in shown by (#).

Figure 4 is a representation showing alignment of amino acid sequences encoded by the *nef* genes of HIV-1 NL4-3, D36 PBMC, C18 HIV_{SIV}, C18 HIV_{MBC} and C98 HIV. In
30 phase termination codons are shown by (#). Identical amino acids are shown by (*). Residues underlined are those immediately before a deletion.

- 41 -

Figure 5 shows a duplication of NF κ B and Sp1 sequences in D36 PBMC, C18 HIV_{Stv}, C18 HIV_{MBC} and C98 HIV demonstrated by alignment of their low homology region sequences with the NF κ B-Sp1 region of HIV-1 NL4-3. Nucleotide numbering according to Figure 1. Identity with NL4-3 sequence shown by (*) and NF κ B and Sp1 sites in NL4-3 overlined. Position of *nef*/LTR region sequence deletion shown by (Δ).

Figure 6 is a graphical representation showing replication of C18 and C98 viral isolates and D36 PBMCs from asymptomatic patients in PHA-stimulated PBMCs.

10





Figure 7 is a graphical representation showing replication of viral isolates from asymptomatic patients in non-PHA stimulated PBMCs.

15




20

228200 is an Australian isolate of HIV-1 described by Kiernan, R. *et al* (1990). Its characteristics include being T cell trophic, with fast kinetics, high producer of HIV-1 and/or SI phenotype.

Figure 8 is a graphical representation of cell surface receptor expression for syncytia-inducing (SI)/ non-syncytia-inducing (NSI)/asymptomatic patient isolates.

25



30

228200 is defined in the legend to Figure 7. 243925 is a viral isolate of HIV-1 which is monocyte/macrophage trophic and exhibits NSI phenotype (Dr Karen Coats-Fryer, PhD thesis entitled "Viral determinants of HIV-1 syncytium formation", the University of Melbourne, Parkville, Victoria, Australia.

Figure 9 is a representation of the nucleotide sequence of C18 HIV-1_{MBC} (SEQ ID NO: 800).

- 10 Figure 10(a) - (g) are graphical representations showing clinical immunology of cohort; (a) CD3; (b)(i) CD4 (ii) CD4%; (c)(i) CD8; (ii) CD8%; (d) lymphocyte count; (e) CD4/CD8 ratio; (f) β -2-microglobulin; and (g) Kaplan-Meier estimates of time to disease progression (Cox & Oakes, 1989).
- 15 Figure 11 is a schematic representation of the deletion mutants of the present invention.

A summary of the SEQ ID Nos. used in the subject specification is shown below:

5	SEQ ID NO:	DESCRIPTION
	1	Nucleotide sequence of HIV-1 strain NL4-3 genome
	2-613	Decanucleotides of <i>nef</i> gene from HIV-1 strain NL4-3
10	614	Partial nucleotide sequence of D36 HIV-1 isolate
	615	Partial nucleotide sequence of C18 HIV-1 _{MBC} isolate
	616-625	PCR primers shown in Table 1
	626-633	Sequence primers shown in Table 2
	634	Amino acid residues 15-27 of HIV-1 NL4-3 <i>nef</i> protein
15	635	HIV-1 NL4-3 <i>tat</i> exons (Figure 2)
	636	HIV-1 D36 <i>tat</i> exons (Figure 2)
	637	HIV-1 C18 <i>tat</i> exons (Figure 2)
	638	HIV-1 NL4-3 <i>rev</i> exons (Figure 2)
	639	HIV-1 D36 <i>rev</i> exons (Figure 2)
20	640	HIV-1 C18 <i>rev</i> exons (Figure 2)
	641	HIV-1 NL4-3 C-terminal of gp41 (Figure 3)
	642	HIV-1 D36 C-terminal of gp41 (Figure 3)
	643	HIV-1 C18 C-terminal of gp41 (Figure 3)
	644	HIV-1 NL4-3 <i>nef</i> gene (Figure 4)
25	645	HIV-1 D36 <i>nef</i> gene (Figure 4)
	646	HIV-1 C18 <i>nef</i> gene (Figure 4)
	647	HIV-1 NL4-3 NFkB/SP1 sequence (Figure 5)
	648	HIV-1 D36 NFkB/SP1 sequence (Figure 5)
	649	HIV-1 C18 NFkB/SP1 sequence (Figure 5)
30	650	Nucleotide sequence of <i>nef</i> gene from HIV-1 strain NL4-3
	651	Nucleotide sequence of <i>env</i> and <i>nef</i> regions of NL4-3
	652-799	Decanucleotides of LTR region from HIV-1 strain NL4-3
	800	Nucleotide sequence of C18 HIV-1 _{MBC}

EXAMPLE 1*Source Material*

For the purposes of the following examples, a non-pathogenic HIV-1 strain was isolated
5 from a recipient of HIV-1 infected blood. The recipient is designated "C18". Other
recipients are defined as "C54" and "C98". The donor is identified herein as "D36".
The place of isolation may be indicated after the abbreviation of "HIV". For example,
St Vincents Hospital, Sydney (HIV_{SV}) or Macfarlane Burnet Centre of Medical
Research, Melbourne (HIV_{MBC}).

10

Exemplary viral isolates referred to herein as "C18" and "C98" were deposited at the
PHLS Centre for Applied Microbiology and Research, European Collection of Animal
Cell Cultures (ECACC), Division of Biologies, Porton Down, Salisbury, Wiltshire SP4
OJG. C18 was deposited on 17 October, 1994 under Provisional Accession Number
15 V94101706 and C98 was deposited on 31 October, 1994 under Provisional Accession
Number V941031169.

Figure 11 is a summary of the deletion mutants of the present invention.

20 Viruses were isolated by the following procedures:

1. Infected peripheral blood mononuclear cells (PBMCs) were co-cultured with
HIV-1 seronegative donor PBMCs. A convenient source of seronegative donor
PBMCs is a blood bank. The supernatants and cells are harvested every 7 days
and fresh medium added with CD8 depleted PBMCs. CD8 depletion promotes
25 the ability to isolate HIV-1. The culture and procedure is continued for up to
approximately 5 weeks;
2. The infected PBMCs are purified from whole blood and these cells are cultured
alone for up to 5 weeks. PMBCs alone are used because the virus is more likely
30 to be monocytotropic. Fresh medium is added weekly and supernatant fluid is
harvested at this time;

- 45 -

3. Supernatant fluids are harvested every approximately 7 days, fresh medium and fresh HIV-1 seronegative CD8 depleted PBMCs are added at this time;
4. HIV-1 seronegative PBMCs are pretreated with M-CSF for approximately 72 hours prior to the addition of infected PBMCs. M-CSF has been shown to enhance HIV-1 replication in monocytes (Gendelman *et al*, 1988); or
5. The supernatant fluid is harvested from the cultures of step 4 every approximately 7 days, fresh medium added together with HIV-1 seronegative stimulated CD8 depleted PBMCs. The virus is isolated from the infected PBMCs.

EXAMPLE 2

DNA Preparation and PCR Amplification

- 15 Non-pathogenic HIV-1 (e.g. strain C18) infected peripheral blood mononuclear cells (PBMC) were harvested 4 days after infection of phytohaemagglutinin (PHA) stimulated HIV-1 negative donor PBMC cultured by the method of Neate *et al* (1987) and washed in phosphate buffered saline (PBS). PBMC from Donor D36 and Recipients C18, C54 and C98 were prepared by Ficoll isopaque centrifugation of buffy coat cells and washed with PBS.

Approximately 10^7 cells were lysed in 1ml lysis solution (0.45% v/v NP40, 0.45% v/v Tween 20, 10mM Tris-HCl pH 8.3, 40mM KCl 2.5 mM $MgCl_2$) and digested with 60µg/ml proteinase K (Boehringer Mannheim) at 55°C for 1 hour followed by 100°C for 10 minutes. Lysates were stored at -20°C.

All polymerase chain reaction (PCR) primers (Table 1) and sequencing primers (Table 2) were synthesised using an Applied Biosystems model 391 DNA synthesiser using phosphoramidite chemistry.

Strict physical separation was maintained for sample, PCR reagent mix and PCR reaction preparations as well as amplification and analysis. Final reaction mixes (50µl) contained

- 46 -

2 µl neat or diluted cell lysate, 0.2µM each primer, 200mM dNTPs and 1.25 units Taq polymerase (Boehringer Mannheim) in PCR buffer, (10mM Tris-HCl pH8.3, 50mM KCl, 100µg/ml gelatine) adjusted to the optimum MgCl₂ concentration for the primer pair (1.5-3.0mM). Aliquoted reagent mix was overlaid with 50µl mineral oil prior to
5 addition of DNA template lysate. After template denaturation at 94°C for 3 min amplification was achieved with 30 cycles of 94°C, 1 min; 55°C, 1 min; 72°C, 2 mins. A final elongation reaction was conducted at 72°C for 7 minutes. For double PCR amplification 2 µl of first round product was added to the second reagent mix and amplified as before.

10

PCR amplified DNA was checked for quality, quantity and fragment size by agarose gel electrophoresis in Tris-Acetate-EDTA buffer (Sambrook et al, 1989) stained in ethidium bromide and viewed by UV transillumination.

15

EXAMPLE 3

DNA Sequence Analysis

The DNA sequence of PCR amplified HIV-1 regions was determined by the dideoxynucleotide method (Sanger et al, 1997) using Sequenase T7 polymerase (United States Biochemicals).

20

PCR amplified DNA was purified by PCR Magic prep resin chromatography (Promega). Approximately 2 to 7 µg purified DNA plus 10ng specific primer (Table 2) were denatured by boiling for 3 mins and snap frozen to -20°C. The initial labelling reaction was for 3 minutes at 22°C (room temperature) with ³⁵SdNTP (500Ci/mmol; Dupont)
25 followed by dideoxynucleotide termination reactions at 37°C for 5 minutes. NP40, to 0.45% v/v, was included in denaturation and reaction mixes (Bachman et al, 1990). Sequencing reaction products were denatured in formamide and resolved on a 6% w/v polyacrylamide gel containing 8M urea, fixed in 10% v/v acetic acid, 10% v/v methanol and dried. Following autoradiography on XK1 film (Kodak) the gel sequences were
30 read assembled, translated to protein and aligned using the PC/GENE suite of programs (IntelliGenetics, USA).

TABLE 1
PCR PRIMERS

PRIMER	SEQUENCE ^{1, 3}	POSITION ²
5 CI-1	TGGAAGGGCTAATTGGT(616)	1-18
CI-2	ATCTTCCCTAAAAAATTAGCCTGTC(617)	2099-2075
LTR-3'	AGGCTCAGATCTGGTCTAAC(618)	9559-9540
SK68	AGCAGCAGGAAGCACTATGG(619)	7786-7805
CI-6	TGCTAGAGATTTCCACAC(620)	9709-9691
10 KS-2	AGTGAATAGAGTTAGGCAGG(621)	8326-8345
RT5'-v3	GTAAGACAGTATGATCAGATA(622)	2418-2438
RT3'-v2	TTGTAGGGAATTCCAAATTCC(623)	4660-4640
RT5'-v2	CAGGATCCTACACCTGTCAACATAAT(624)	2487-2506
15 RT3'-v1	GGGAATTCCTTATTCCTGCTTG(625)	4655-4634

1. Sequence is presented from 5' to 3' of the primer.
2. Position is according to the numbering of HIV NL4-3 in Myers *et al* (1992).
3. SEQ ID NOs are given in parentheses.

TABLE 2
SEQUENCING PRIMERS

5	PRIMER	SEQUENCE ^{1, 3}	POSITION ²
	KS3	CCAGAAGTTCCACAATCC(626)	8570-8553
	KS4	TTCTTCTAGGTATGTGGAG(627)	8753-8735
	KS5	AGTGAATTAGCCCTTCCAG(628)	9093-9075
	KS6	TGCTAGAGATTTTCCACAC(629)	9709-9691
10	SP2	TGCTCTGGAAACTCAT(630)	8006-8022
	SP3	CTTTCTATAGTGAATAGAG(631)	8318-8336
	SP4	TATTGGAGTCAGGAACT(632)	8618-8634
	SPR	GGTCTAACCAGAGAGAC(633)	9547-9531

- 15 1. Sequence is presented from 5' to 3' of the primer.
2. Position is according to the numbering of HIV NL4-3 in Myers *et al* (1992).
3. SEQ ID NOs are given in parentheses.

EXAMPLE 4

20 *Cells and Cell Culture*

Peripheral blood was obtained from HIV-1 sero-negative volunteers and mononuclear cells prepared by centrifugation on a Ficoll/Hypaque density gradient (Peper *et al*, 1968). PBMC were activated with phytohemagglutinin (PHA; 10 μ g/10⁶ cells) for 48 h at 37°C washed and then cultured in RPMI 1640 medium containing 10% v/v heat inactivated foetal calf serum, 15mM HEPES, 0.1% v/v sodium bicarbonate, 25 μ g/ml polybrene (Sigma), 10% v/v interleukin 2 (Boehringer Mannheim) and 1:1000 anti-interferon (Miles) (IL-2 medium). Non-PHA stimulated cells were prepared in a similar manner except they were cultured in medium lacking PHA and IL-2.

EXAMPLE 5*Antipeptide-antisera*

Antibodies specific for HIV-1 Nef were raised against a peptide corresponding to the predicted amino acid residues 15-27 (AVRERMRRRAEPAA SEQ ID NO: 634) of Nef
5 encoded by the HIV-1 clone pNL4.3 (Kemp et al, 1988). The peptide was conjugated to keyhole limpet hemocyanin (KLH; Calbiochem, Behring Diagnostics, CA) via glutaraldehyde and this complex used to immunise sheep (0.5mg peptide conjugate/sheep). Antibodies to the peptide were purified by affinity chromatography. Reactivity of the antibodies with recombinant HIV-1 Nef 25 and 27 was demonstrated
10 by immunoblotting.

EXAMPLE 6*Reactivity of anti-Nef₍₁₅₋₂₇₎ with HIV C18-infected Cells in Immunoblotting*

Seven days post-infection HIV-1 C18-infected PBMCs and mock - infected cells were
15 washed in PBS then lysed (0.5% w/v NP-40, 0.5% w/v sodium deoxycholate, 50mM NaCl, 25mM Tris-HCl, 10mM EDTA, 0.01% w/v sodium azide and 10mM phenylmethylsulphonylfluoride). After nuclei were spun out lysates were electrophoresed in a 13% w/v SDS-polyacrylamide gel (SDS-PAGE) and subsequently transferred to Hybond-C nitrocellulose (Amersham, Buckinghamshire, England) for 1
20 h at 100 V using a Bio-Rad protein transfer cell (Bio-Rad, Richmond, Ca). Membranes were pre-incubated with 1% w/v BSA/PBS for 2 h at room temperature and then reacted with affinity purified sheep anti-Nef₍₁₅₋₂₇₎, diluted 1:100, overnight at room temperature. After three washes in 1% w/v BSA/PBS, the blots were incubated with donkey anti-sheep Ig conjugated to biotin (Amersham, diluted 1:500) for 1 h at room temperature.
25 After extensive washing as described above the membranes were incubated with streptavidin-conjugated horse radish peroxidase (Amersham; diluted 1:500 for 1 h at room temperature. All dilutions were made with 1% w/v BSA in PBS. After further washing the membrane was developed with phenylenediamine substrate (Dako, Dapopatts, Denmark). The antibody preparation used in the immunoblotting experiments
30 was free of detectable antibodies to the immunogenic carrier protein and coupling reagent.

- 50 -

EXAMPLE 7*Analysis by Polymerase Chain Reaction Amplification*

A 5' fragment defined by primers Cl-1 and Cl-2 containing the 5' LTR and part of the *gag* gene was amplified. DNA from HIV-1 C18 infected PBMC gave an amplified
5 fragment (amplimer) of about 1.9 kb compared with 2.1kb for pHXB2 control template, implying a deletion of about 200bp from HIV C18. Further amplification of this fragment with primers defining the U3 region of the LTR (Cl-1 and LTR-3') gave amplimers of about 300 bp for HIV-1 C18 infected PBMC DNA compared with 340bp for C18 and D36 PBMC DNA and 484 bp for pHXB2 control. This implies the loss of
10 approximately 140 to 180bp from the U3 region of these proviral DNAs.

To analyse the *nef*-gene-3' LTR region, the nested primer pairs SK68-Cl-6 and KS-2-LTR-3' were used in a double PCR. Amplimers of approximately 830bp were obtained for HIV-1 C18 infected PBMC DNA as well as for PBMC DNA from Donor D36 and
15 Recipients C18, C54 and C98 compared with approximately 1230bp for pHXB2 DNA. These results suggest that about 400bp of DNA have been deleted from the Donor and Recipient proviral DNAs.

In comparison, amplification of the polymerase gene region by double PCR with the
20 nested primer pairs RT5'-v3-RT3'-v2 and RT5'-v2-RT3'-v1 gave a fragment (approximately 2.1 kb) the same size as the molecular clone pHXB2 fragment for HIV-1 C18 infected PBMC DNA, suggesting that deletions from this region were unlikely.

EXAMPLE 8**25** *Nucleotide Sequence of the nef-3' LTR Region*

PCR amplification experiments indicated an approximately 200bp nucleotide deletion from both the *nef* gene and LTR regions of Donor D36 PBMC and Recipient C18 HIV-1 proviral DNA. To further analyse these regions, the DNA sequence was determined for the PCR amplified *nef*-3'-LTR region of D36 PBMC, C18 isolates HIV_{MBC} and HIV_{Stv}
30 as well as isolate C98 HIV infected PBMC proviral DNA. The 3' region was amplified with outer primers (SK68-Cl6) and inner primers (SK68-LTR 3' or KS2-Cl6) and sequenced directly using a number of internal sequencing primers based on the HIV-1

NL4-3 nucleotide sequence (Table 2).

Alignment of the nucleotide sequences of the amplified 3' region of donor D36 PBMC and recipient C18 isolates HIV_{MBC} and HIV_{Stv} and C98 HIV (Fig 1) showed a number
 5 of nucleotide sequences changes, including deletions, relative to the nucleotide sequence of wild-type infectious HIV-1 (HIV-1 NL4-3). In the region of alignment, D36 PBMC lacked 291 nucleotides, C18 HIV_{Stv} differed in size by 388 nucleotides (comprising deletions of 397 nucleotides and an insertion of 9 nucleotides), C18 HIV_{MBC} differed by 456 nucleotides and C98 HIV lacked 158 nucleotides compared with HIV-1 NL4-3.
 10 The overall identity with HIV-1 NL4-3 nucleotide sequence of D36 PBMC, C18 HIV_{Stv}, HIV_{MBC} and C98 HIV nucleotide sequences, including deletions, was 73% (1157/1596), 67% (1459/1592), 62% (982/1592) and 79% (1105/1399), respectively.

The D36 PBMC sequence differed from HIV-1 NL4-3 in a number of features. A
 15 change in the wild type *tat* termination codon from TAG to TCG (Ser) extended the third *tat* exon (which starts at splice acceptor 10) by a further 15 amino acids to terminate at a conserved TAG (Fig 1). The resulting C-terminal peptide is rich in charged amino acids (8/15) (Fig 2a). The wild type *rev* termination codon has also changed (TAG to GAG, Glu) and the third *rev* exon is extended for 14 codons to
 20 terminate at a conserved TAG (Fig 2b). The encoded extra amino acids are mainly polar (11/14) and charged in nature (Fig 2b). The sequence also encodes the C-terminal 237 amino acids of Env gp41 (Fig 3) terminating at the normal termination codon. The D36 PBMC Env amino acid sequence has 85% identity with the HIV NL4-3 sequence, increasing to 89% if similarities are included.

25

There are significant differences from HIV-1 NL4-3 downstream of the *env* (gp41) gene. A change in the fifth *nef* codon, from TGG (Trp) to TGA (Fig 1), introduces an early termination in the D36 PBMC *nef* gene. The encoded Nef protein is identical to the N-terminal 4 amino acids of NL4-3 Nef (Fig 4). Following the early termination there are
 30 deletions of 33, 47, 93 and 91 nucleotides and a region of low sequence homology, compared with HIV NL4-3, prior to the wild type *nef* termination codon site (HIV NL4-3 nts 9405-9407). As well as removing a significant part of the *nef* gene, these deletions

also bring into phase a further 6 termination codons. While the polypurine tract (plus strand primer binding site) and the first 38 nucleotides of the LTR U3 region are perfectly conserved, downstream U3 region sequences are disrupted by the 93 and 91 nucleotide deletions and the low homology region. The resulting U3 region lacks
5 recognition sequences for the transcription factors *c-myb*, USF and TCF1 α as well as one of the suggested NF-AT sites (Gaynor et al, 1992). Downstream from the 91 nucleotide deletion, a 59 nucleotide region of low homology contains two extra NF κ B enhancer sites 19 nucleotides upstream of the usual site of a pair of NF κ B sites, the upstream one of which is altered in its 5'-half in D36. Sequences further downstream
10 are highly conserved with respect to HIV-1 NL4-3, including the position and number of Sp1 basal promoter sites, TATA box, TAR and polyadenylation signal sequences.

Similar to D36 PBMC, the C18 HIV_{SIV} and HIV_{MBC} sequences show the *tat* third exon to be extended by 15 codons. All but two codons (altered by point mutations) are
15 identical to those of D36 PBMC (Fig 2a). The *rev* third exon of both C18 isolates is also extended (Fig 2b) but by only three codons, identical to the first three codons of the D36 PBMC *rev* extension. The same 237 amino acid coding region of Env gp41 is found in both the C18 HIV DNA sequences (Fig 3) and shows 85% identity, increasing to 88% if similarities are included, with the same region of the NL4-3 Env gp41.

20

It is in the *nef* gene and LTR regions that the major differences from wild-type HIV-1 arise, just as in D36 PBMC. The *nef* gene of C18 HIV_{SIV} encodes 24 amino acids with 9 of the 10 N-terminal being identical to the NL4-3 Nef protein (Fig 4). Thereafter, deletions of 177 and 11 nucleotides cause a frameshift and termination at the 25th codon
25 (Fig 1). Downstream deletions of 120, 82 and 7 nucleotides cause further loss of wild type *nef* gene sequence and bring into phase a further three termination codons.

The *nef* gene of C18 HIV_{MBC} encodes only 7 amino acids with only the initiator methionine identical to the NL4-3 Nef protein. This loss of identity and early
30 termination is brought about by a 250 nucleotide deletion after the fifth nucleotide of the *nef* gene. Downstream deletions of 120 and 86 nucleotides cause further loss of wild-type *nef* gene sequences. In both C18 isolates there is perfect conservation of the

- 53 -

polypurine tract and 29/31 nucleotides at the 5' end of the U3 region immediately before the 120 nucleotide deletion (Fig 1). This deletion together with the downstream 82 and 7 nucleotide deletions in HIV_{stV} and 86 nucleotide deletion in HIV_{MBC} and the low homology region cause the loss of the 5' half of the NRT-1 site (Yamamoto et al 1992) and the downstream NFAT site. A third NFKB site is present 31 (HIV_{stV}) and 33 (HIV_{MBC}) nucleotides upstream of the expected pair of NFKB sites which are themselves separated by 13 nucleotides instead of the 4 nucleotides in HIV-1 NL4-3. The 5'-most Sp1 site sequence is slightly altered but sequences downstream including the other 2 Sp1 sites, the TATA box, TAR and polyadenylation signal sequences are identical to HIV-1 NL4-3 sequence.

The three sequences, D36 PBMC, C18 HIV_{stV} and C18 HIV_{MBC} show a number of similarities consistent with the transmission of virus from person D36 to person C18 as well as a number of differences indicating post-transmission divergence of sequence. All three have *tat* open reading frames (ORFs) extended by 15 codons. All three have extended *rev* ORFs. The new *rev* termination codon in both C18 HIV-1 isolates, three codons downstream of the NL4-3 *rev* termination codon, has a point mutation in D36 PBMC to make a Glu codon so that it continues for a further 11 codons (Fig 2b) to terminate at a conserved TGA. The partial Env gp41 amino acid sequences are more closely related to each other (86% identity or 90% including similarities) than to HIV NL4-3 (85% and 89%, respectively).

The nucleotide sequence of the *nef* and LTR region of the HIV-1 isolate from recipient C98 (C98 HIV) is 90.3% identical (1264/1399) to the HIV NL4-3 sequence, ignoring deletions. Similar to the D36 PBMC and C18 HIV_{stV} and HIV_{MBC} isolates the C98 HIV sequence shows the third exon of *tat* to be extended by 15 codons with all but one being identical to the D36 PBMC *tat* extension. Also, the *rev* gene is extended by 3 codons, 2 of which are identical to the first 2 codons of the D36 PBMC *rev* extension. The sequence also encodes the C-terminal 223 amino acids of Env gp41 terminating at the normal termination codon. The C98 HIV Env amino acid sequence has 89% identity with HIV NL4-3 Env sequence, increasing to 92% if similarities are included.

- As with the D36 PBMC and the C98 HIV isolate sequences it is the *nef* gene and LTR regions that major differences from the HIV NL4-3 sequence arise. The *nef* gene open reading frame of C98 HIV is much longer than in D36 PBMC, C18 HIV_{Stv} and HIV_{MBC} encoding 85 amino acids compared with 206 amino acids for NL4-3. Sixty
- 5 eight of those 85 amino acids are identical to the N-terminal sequence of NL4-3 Nef. The single, small deletion (16 nucleotides) in the C98 HIV *nef*-alone regions (Table 3) occurs after *nef* codon 82 causing a frameshift and termination after a further 3 codons at the start of the highly conserved polypurine tract sequence immediately before the 3'-LTR. The *nef*/LTR region has two deletions totalling 142 nucleotides. The 5'-most
- 10 deletion of 42 nucleotides includes the splice acceptor 12 sequence. The NRT-1, dyad symmetry and *myb* response element sequences are all intact. However, the downstream 100 nucleotide deletion includes sequences from the 3' end of the 5'-NF-AT and all of the 3' NF-AT sequences as well as the USF transcription factor recognition sequence. The downstream low homology region of 77 nucleotides lacks the TCF-1 α sequence but
- 15 has two additional NF κ B sites 13 nucleotides apart and 26 nucleotides upstream of the 3'-half-remnant of the normal 5'-NF κ B site. Sequence downstream, including the 3'-NF κ B site, the 3 Sp1 sites, TATA box TAR and polyadenylation signal sequences are all highly conserved.
- 20 The main feature of the sequences is the series of deletions, with respect to HIV NL4-3, in the *nef* gene-3'-LTR region. These can be grouped into two regions namely the *nef*-alone region, that part of the *nef* gene upstream of the LTR, and the *nef*/LTR region, where the *nef* gene and LTR U3 regions overlap. The deletions in these regions of each of the sequences start and end at the same or similar positions (Table 3). The deletions
- 25 are larger in C18 HIV_{Stv} and C18 HIV_{MBC} sequences where totals of 397 and 456 nucleotides have been deleted (relative to NL4-3) compared to 291 nucleotides, from D36 and 158 nucleotides from C98 HIV. In the *nef*-alone region the two deletions in C18 HIV_{Stv} and the single deletion in C18 HIV_{MBC} occupy the same region as the three deletions in D36 PBMC. Similarly, the *nef*/LTR region in the three deletions in the C18
- 30 HIV_{Stv}, the two deletions in the C18 HIV_{MBC} and the D36 PBMC sequences occupy the same region. These findings indicate that mutant virus was transmitted from D36 to C18 after which further deletions and rearrangements occurred. Similarly, the

sequence of C98 HIV in the *nef*/LTR region indicates two deletions occupying the same region as the *nef*/LTR deletions in D36 and the C18 sequences. However, the size (only 16 nucleotides) and the position of the deletion in the *nef*-alone region of C98 HIV are distinct from those of the D36 PBMC and C18 sequences.

5

The timing of transmission of virus by transfusion was that recipient C18 was transfused approximately 19 months after C98. Consistent with the relative timing of transmission and the sequence similarities and differences is the suggestion that at the time of transmission to C98, the D36 sequence had deletions in the *nef*/LTR region but not in
10 *nef*-alone region. After transmission to C98, the C98 virus developed further deletions and rearrangements, including the deletion in the *nef*-alone region. The D36 virus evolved so that at the time of transmission to C18, further deletions and rearrangements had occurred including deletion of sequence from the *nef*-alone region distinct from the C98 HIV *nef*-alone region deletion. After transmission to C18, further deletions and
15 rearrangements occurred in the C18 virus giving rise to at least two sequences (HIV_{SIV} and HIV_{MBC}).

The *nef*-alone deletion region may be a mutation or recombination "hotspot" as it includes sequences that were found to be variably duplicated in 28 out of 54 Nef protein
20 sequences derived from 8 of 12 patients analysed in a study (Shugars *et al* 1993). The sequence between the *nef*-alone and the *nef*/LTR region deletions is highly conserved and is important in provirus integration into the infected cell genome and interacts with a number of cellular proteins. It is interesting that the sequence equivalent to NL4-3 nucleotides 9209 to 9225 is retained in D36 and C98 HIV but lost in the C18 HIV
25 sequences. This includes part of a sequence of dyad symmetry (9210 to 9231) and is a significant part of the binding site for NRT-1 (Yamamoto *et al* 1991) which has been shown to have a negative regulatory effect on HIV-1 expression. The presence of this sequence in D36 and C98 HIV and its absence from the C18 isolates may correlate with the inability to isolate virus from D36 PBMC and the poor replication of C98 HIV but
30 the ability to isolate HIV-1 from C18 PBMC. The deletion of sequence equivalent to nucleotides 9281 to 9395 of NL4-3 causes the loss of some transcription factor binding sites including NFAT and USF from the D36, C18 HIV and C98 HIV sequences.

- 56 -

A further similarity between the D36, C18 HIV_{SI}, C18 HIV_{MBC} and C98 HIV sequences is a region of low homology to HIV-1 NL4-3 extending downstream of the *nef*/LTR deleted region to the NFkB enhancer/Sp1 promoter site region. This low homology region in fact consists of incomplete duplications of part of the NFkB/Sp1 region (Fig 5) resulting in D36 and C98 HIV having 2 extra NFkB sites upstream of an altered 5' NFkB site while the C18 sequences have one extra NFkB site and altered spacing between the 5' and 3' wild type NFkB sites due to an insertion of 9 nucleotides.

For the C18 and C98 HIV-1 isolates virus replication was assessed in PHA-stimulated and non-stimulated PBMCs (Figs 6 and 7). In PHA-stimulated PBMCs we also studied cell surface CD4 and IL-2R expression (Fig 8). In comparison with HIV-1 wild type SI and NSI isolates clearly both C18 HIV_{MBC} and C98 viruses are replication competent, though C98 HIV replicates more poorly than C18 HIV_{MBC} and are of the NSI phenotype when syncytium formation and CD4 and IL-2R surface expression are taken into account. Additionally, and more surprisingly, these two viruses replicated almost as efficiently in non-PHA stimulated PBMCs when compared to a typical local wild type SI isolate (HIV-1 228200, Fig 7).

When protein expression was assessed for C18 HIV_{MBC} and C98 HIV_{MBC} although structural proteins were identified, no typical Nef protein was seen in infected cells. However, analysis of cell lysates prepared from PBMC infected with C18 HIV_{MBC} or PBMC infected with C98 HIV_{MBC} (which were subsequently stimulated by UV irradiation, see Valerie *et al*, 1988) by Western immunoblotting using two antibodies specific for the N-terminal region of Nef showed the presence of smaller proteins of 19 kDa and 21 kDa, respectively. These proteins were not observed in mock-injected control PBMC lysates and were not observed when the infected-cell lysates were probed were probed with antibodies reactive with the C-terminus of Nef.

Thus, although the C18 and C98 HIV isolates are replication competent *in vitro* they clearly replicate differently using different conditions for cell activation and from the known functions of HIV-1 Nef protein and the LTR show that the major deletion in the *nef* gene and/or the LTR is at least in part responsible for the outcome of infection,

- 57 -

implicating the importance of Nef and/or the LTR in the clinical outcome of infection *in vivo*.

EXAMPLE 9

5 *Determination of Degree of Relatedness Between Viruses*

To determine the degree of relatedness between viruses such as between mutants or between mutants and a wild-type virus and to ascertain putative infected patients, the method of Delwart *et al* was employed.

10 EXAMPLE 10

Immune responsiveness of subjects infected by non-pathogenic HIV-1 isolate

In this example, the donor and recipients of the cohort were tissue typed and assessed for basic cellular immune responses. Proliferative responses and IL-2 production to the mitogens ConA and PHA, to allogeneic mononuclear cells (irradiated pooled
15 mononuclear cells from 20 random donors) and to recall antigens (e.g. influenza and tetanus toxoid) were within normal ranges. While at the immunogenetic level, HLA typing failed to identify a consistently common allele or haplotype within the group.

The conservation of CD4+ counts observed in the cohort, the relative integrity of their
20 immune system and the varied HLA types of the donor and recipients further supports the fact that the symptomless condition of the cohort members is due to a non-pathogenic strain of HIV-1 or a strain of low virulence.

Accordingly, this provides a screening procedure for subjects putatively infected by a
25 non-pathogenic HIV-1 isolate where such subjects are seropositive for HIV-1 (e.g. have antibodies to an HIV-1 glycoprotein) yet have normal proliferative responses and cytokine production to mitogens, allogeneic mononuclear cells and to recall antigens.

EXAMPLE 11*Clinical Immunology of Cohort*

To establish that the donor and the recipients belonging to the cohort exhibit normal immunological profiles, members of the cohort were assayed for CD3, CD4, CD8, lymphocyte count, CD4/CD8 ratio and β -2-microglobulin over time since seroconversion.

Parameters considered normal in non-infected individuals range as follows:

<u>Parameter</u>		
CD3	55-82%	620-2200 ($\times 10^6/L$)
CD4	29-58%	420-1410 ($\times 10^6/L$)
CD8	12-43%	200-980 ($\times 10^6/L$)
Lymphocyte count	1000-3500 ($\times 10^6/L$)	
CD4/CD8	0.7-3.7	
β -2-microglobulin	0.00-2.20 mg/L	

The results are shown in Figures 10(a)-(g) and clearly show that the immunological profiles of cohort members are substantially normal further highlighting the non-pathogenicity of the HIV-1 isolates of the present invention. Figure 10(g) shows a graph of the Kaplan-Meier (Ox and Oates, 1989) estimates of time to disease progression (AIDS or $CD4 > 250$). The results demonstrate that the difference is large in spite of the conservative bias, with a median time to progression of 6.2 years in the main database. An exact logrank test (Cytel Software Corporation, 1989, StatXact: Statistical Software for Exact Nonparametric Inference. Cambridge, Massachusetts.) was performed, demonstrating that the difference between the groups was highly statistically significant (logrank statistic 11.8, $p < 0.0001$).

Table 3
Deletions and their sizes in the *nef*-alone and the *nef*/LTR regions of the Long-Term Asymptomatic HIV-1 Sequences

Sequence	<i>nef</i> -alone Region	Region Deletion (nt)	<i>nef</i> /LTR Region	Region Deletion (nt)	Total Deletion (nt)
D36 PBMC	8830-8862 (33)		9112-9204 (93)		
	8882-8928 (47)		9281-9371 (91)	184	291
	9009-9035 (27)	107			
C18 HIV _{StV}	8830-9006 (177)		9105-9224 (120)		
	9019-9029 (11)	188	9281-9362 (82)	202	390
C18 HIV _{MBC}	8792-9041 (250)	250	9105-9224 (120)		
			9281-9366 (86)	206	456
C98 HIV	9033-9048 (16)	16	9148-9189 (42)		
			9271-9370 (100)	142	158
C54 PBMC	incomplete	?	9281-9375 (95)	95	95 +

Sequence numbering relates to the equivalent position in HIV-1 NL4-3. Numbers in brackets are the deletion sizes in nucleotides (nt).
The *nef* ORF starts at nt 8787 and the 3'-LTR starts at nt 9074 in HIV-1 NL4-3.

EXAMPLE 12*Sequencing of isolate HIV-1 C18_{MBC}*

The genome of variant HIV-1 designated C18 HIV-1_{MBC} was amplified by the
5 polymerase chain reaction (PCR) as 7 overlapping fragments using the sets of inner and
outer oligonucleotide primers, designed using the programme PCRPLAN
(IntelliGenetics), listed in Table 5 and either UITma (Applied Biosystems) or a mixture
of KlenTaq and Pfu (KlenTaq LA, Ab Peptides Inc) polymerases (for faithful
amplification of long fragments). The resulting fragments were cloned into the SmaI
10 site of the plasmid vector pGEM7Zf+. Insert-containing clones representing each region
of the full length variant HIV-1 were sequenced by a nested deletion strategy (Gou &
Wu, 1982) and cycle sequencing with Taq polymerase and dye labelled primers
complimentary to the T7 or SP6 sites within the cloning vector. Nucleotide sequences
were entered and collated by ASSEMBLER and SEQIN (IntelliGenetics) and SEQED
15 (Applied Biosystems) and translated to the encoded amino acid sequences using
TRANSL (IntelliGenetics) programmes. Sequence alignments used NALIGN,
CLUSTAL (IntelliGenetics) and SEQED programmes.

The full length sequence (Fig 9; SEQ ID NO:800) of isolate HIV-1 C18_{MBC} is 9207
20 nucleotides long which is 506 nucleotides shorter than the HIV NL4-3 sequence. This
size difference is comprised of 126 nucleotides of insertions and 632 nucleotides of
deletions, see Table 6. The most extensive differences between the HIV-1 C18_{MBC}
sequence and HIV-1 NL4-3 are in the U3 region of the LTR and in the *nef* gene, as
hereinafter described.

25

The 5' LTR has deletions of 120 and 87 nucleotides and a region of low sequence
homology, which is the result of an imperfect duplication of the downstream NFκB and
Sp1 response sequences. These result in the loss of sequence from a number sites
important in the regulation of transcription of HIV-1 genes, including the negative
30 response element (NRE) and the response elements for a number of transcription factors
including NF-AT, NRT-1, USF and TCF-1α. Furthermore, the low homology region
contains an extra NFκB and Sp1 sites as well as an insertion of 9 nucleotides between

the usual NF κ B sites. Downstream of the NF κ B sites the sequence of the LTR has a high level of homology (96.2%) with the same region of HIV NL4-3.

The *gag* gene contains 3 insertions, which represent direct repetitions of adjacent
5 sequences. The first is a perfect repeat of 15 nucleotides after the equivalent of nucleotide 1134 of HIV-1 NL4-3 and adds 5 amino acids to the C-terminus region of p17^{gag}. The remaining 2 insertions are imperfect and perfect repeats of 30 and 6 nucleotides, respectively, after the equivalent of HIV NL4-3 nucleotides 2163 and 2232, respectively. These encode an extra 12 amino acids in the C-terminus region of p15^{gag}
10 just downstream of the *gag* to *pol* frameshift sequences. The variation in sequence length of the *gag* gene at these two positions is unusual. The homology of the encoded amino acid sequence of HIV-1 C18_{MBC} and HIV NL4-3 for the *gag* p17, p24, and p15 proteins is 87.1%, 93.5% and 94.3%, respectively.

15 In the *pol* ORF, the encoded proteins have high homology with the NL4-3 sequences being 95.5% overall comprising p10 protease 92.9%, p66 reverse transcriptase 95.4% and p34 integrase 95.8%. The amino acid sequence of the p61 RT lacks the mutations associated with resistance to the nucleoside (AZT, ddI, ddC) and non-nucleoside (Nevirapine) analogue drugs used in the treatment of HIV-1-infected persons.

20

The *vif* gene encodes a 192 amino acid protein with 88.0% homology with that of HIV-1 NL4-3. The *vpr* gene encodes a 96 amino acid protein with 89.6% homology with that of HIV-1 NL4-3.

25 There are 2 insertions and 1 deletion of sequences in the *vpu* gene. The insertions of 3 and 9 nucleotides are after the equivalent of nucleotide 6071 and 6234, respectively, of HIV-1 NL4-3. These add 1 amino acid after amino acid 3, and 3 amino acids after amino acid 59 of the encoded *Vpu* protein. The deletion of 12 nucleotides after the equivalent of HIV-1 NL4-3 nucleotide 6261 deletes 4 amino acids from the C-terminal
30 region of *Vpu* as well as from the signal peptide of the *env* polyprotein, which is encoded by an overlapping reading frame. Amino acid sequence homology of HIV-1 C18_{MBC} *Vpu* with NL4-3 is 85.2%.

The sequence encoding the *env* gp120 has 9 insertions totalling 45 nucleotides (encoding 15 amino acids) and the deletion of a total of 18 nucleotides (encoding 6 amino acids). These are listed in Table 6. All of these events (insertions and deletions) are at positions in the *env* gene. This is within the *env* V3 coding region, immediately upstream of the sequence encoding the so called V3 tip (or loop) amino acid sequence, Gly Pro Gly Arg. The V3 region sequence is that of a typical clade B subtype (North America, Europe and Australia) being identical to the clade B consensus sequence (based on 186 *env* sequences) at 29/35 positions. The type of amino acid at positions 11 and 28 of the V3 loop region (where position 1 is the Cys at amino acid 266 of the *env* gp120) is predictive of the viral non-syncytium / syncytium forming phenotype (Fouchier et al, 1992). The HIV-1 C18_{MBC} *env* gene encoded amino acid sequence has Ser at position 11 and Ile at position 28 of the V3 loop region. The lack of a positively charged amino acid at both positions is strongly indicative of a non-syncytium viral phenotype. The overall amino acid sequence homology with HIV-1 NL4-3 (ignoring deletions and insertions) is 86.1%, comprising 85.5% for the gp120 region and 87.6% for the gp41 region.

Both the *tat* and *rev* second exon open reading frames (ORF) are longer than in HIV-1 NL4-3. A change of the *tat* termination codon from TAG to TCG extends the *tat* ORF to a downstream in phase termination codon extending the encoded *tat* amino acid sequence by 15 residues, compared with the 86 amino acid long NL4-3 *tat* protein, to a total length of 101 amino acids. However, this is the usual length of the HIV-1 *tat* protein.

Similarly, the normal *rev* termination codon is changed from TAG to GAG. This extends the *rev* ORF to an in-phase termination codon 3 codons downstream so that the encoded Rev protein is 119 amino acids long instead of the usual 116.

As mentioned above the most extensive differences between the sequences of the isolate HIV-1 C18_{MBC} and HIV-1 NL4-3 are in the *nef* gene and the LTR region. While the *nef* gene overlaps the 3' LTR, these differences are found in both the *nef* alone and the *nef* / LTR overlap regions. The HIV C18_{MBC}-encoded *nef* protein is only 24 amino

acids long compared with the normal length of 206 amino acids. This severe shortening of the *nef* protein is due to the deletion of 188 nucleotides (the 177 and 11 nucleotide deletions) from the *nef*-alone region which also brings into phase a termination codon, TAG, at the resulting 25th codon. Downstream there is further loss of potential *nef* gene sequences by the 120 and 87 nucleotide deletions situated in the *nef* / LTR overlap region. The resulting 24 amino acid *nef* protein is identical to the N-terminus of the HIV-1 NL4-3 *nef* at 9 of the first 10 positions. Thereafter, homology is lost completely.

- Some sequences used in the generation of mature mRNAs are altered or lost in C18_{MBC}.
- 10 The dinucleotide immediately after the splice donor site 2 (SD2) at nts 4818-4819 (NL4-3 equivalent nts 4963-4964) is changed from the conserved GT to GC. It is expected that this change would lead to loss of function of this site as a splice donor. Splice donor 2 is used in the processing of HIV-1 transcripts to some of the mRNAs that encode Tat, Rev and *nef* proteins. Similarly the splice acceptor site 7 (SA7) sequence
- 15 at nts 6477-6478 (NL4-3 equivalent nts 6602-6603) is changed from the conserved AG dinucleotide to TC. This change is expected to lead to loss of function of this site as a splice acceptor. While this SA site is used in HIV-1 mRNA processing it is not a major site and is not used in the production of the regulatory proteins (Tat, Rev or *nef*) mRNAs. The splice donor 12 site is absent from the C18_{MBC} sequence (NL43 equivalent nts 9161-9162) as it is within the first deletion region in the *nef* / LTR overlap region which occurs at nt 8797 and results in the loss of NL43 nucleotides 9105 to 9224. It is significant that the SA12 site is absent from the sequence of all of the cohort virus isolates so far obtained as well as from the sequence of D36 PBMC, however, the C54 PBMC sequence does contain the SA12 site. SA12 is not used in the
- 25 processing of mRNAs that encode the viral regulatory proteins. Normally SA12 is used in splicing in conjunction with SD1, 2, 3 and 4 and the resulting spliced RNA is probably not a mRNA but may have a regulatory role involving binding to cellular proteins (Smith et al, 1992).
- 30 An interesting feature of the sequence of the HIV-1 C18_{MBC} isolate is the deletion and rearrangement of sequence from the 5'-LTR U3 region and the deletion of sequence from the *nef* gene (both *nef* alone and *nef* / 3' LTR regions). These being the only

- 64 -

features of the sequence distinct from disease-causing HIV-1. The lack of AIDS or AIDS-like symptoms in the patient C18 is attributed to the effects of the loss of LTR sequence and / or the loss of *nef* coding sequences and their role in the pathogenesis of AIDS.

5

TABLE 4

Primers used to Amplify Overlapping regions of HIV-1 C18_{MBC}

10	Primer	5'- Coordinate	Direction (+/-)	Primer Length	(nt)	Sequence
15	CL 1A	1	+	30		TGGAAGGGCTAATTACTCCAAAAAGAC
	CL 14	896	-	25		AATCGITCTAGCTCCCTGCTTGCCC
	CL 1B	1	+	30		<u>AATCCCGGGTGGAGGGCTAATTACTCCC</u>
	CL 13	796	-	31		<u>CCCTCTAGACCGCTTAATACTGACGCTCTGCG</u>
20	CL 11	682	+	23		TCTCTGACGCGAGGACTCGGCTT
	CL 18	3440	-	30		CTGTTTCTGCCAGTTCIAGCTCTGCTTCT
	CL 12A	732	+	26		<u>TTTCCCGGGCGGCGACTGGGTGAGTAC</u>
	CL 17	3330	-	32		<u>CCCTCTAGACTTGCCCAATTCAATTTTCCAC</u>
25	CL 26	3193	+	39		CCACACCAGACAAAAAGCATCAGBAAGAACCCCATTC
	CL 6B	9671	-	39		TGCTAGAGATTTTCCACACCGACTAAATGGTCTGAGGG
30	CL 27	3251	+	39		CCATCCTGATAAATGGACAGTACACCCATGTAAGTCC
	CL 28	639	-	37		TGGCCCAACATTATGTACCTCTGCATCATATGC
	CL 19	5448	+	30		AGCAGGACATAACAAGGTAGGATCTCTACA
	CL 24	8422	-	28		GGATCTGTCTCTGTCTCTCTCTCCACCT

35

Underlined sequences depict added restriction enzyme site

+ and - orientations refer to sense and antisense strands of the double stranded DNA sequence

TABLE 5
Sequence Deletions and Insertions in HIV-1 C18_{MBC}
Compared with HIV-1 NL43

5	Gene or Region	Position (nt)		Deletions (nt)	Insertions (nt)
		C18 _{MBC}	NL43		
10	5'-LTR U3	29	29	120	-
	5'-LTR U3	85	205	87	-
	5'-LTR U3	154	360	-	9
	<i>gag</i> p17	939	1134	-	15
15	<i>gag</i> p15	1982	2163	-	30
	<i>gag</i> p15	2081	2232	-	6
	<i>vpu</i>	5927	6062	-	3
	<i>vpu/env</i>	6092	6234	-	9
	<i>vpu/env</i>	6128	6261	12	-
20	<i>env</i>	6483	6628	-	6
	<i>env</i>	6514	6653	2	-
	<i>env</i>	6524	6665	1	-
	<i>env</i>	6630	6772	-	9
	<i>env</i>	6646	6778	-	3
25	<i>env</i>	7011	7141	6	-
	<i>env</i>	7140	7276	3	-
	<i>env</i>	7195	7334	-	6
	<i>env</i>	7266	7399	3	-
	<i>env</i>	7278	7414	-	6
30	<i>env</i>	7290	7420	-	2
	<i>env</i>	7300	7429	-	1
	<i>env</i>	7314	7441	3	-
	<i>env</i>	7463	7593	-	3
	<i>env</i>	7471	7598	-	9
35	<i>nef</i>	8711	8829	177	-
	<i>nef</i>	8723	9018	11	-
	<i>nef</i> / LTR	8798	9104	120	-
	<i>nef</i> / LTR	8854	9280	87	-
	LTR U3	8923	9435	-	9
40				<u>632</u>	<u>126</u>

EXAMPLE 13*Macrophage Isolates of HIV-1 C18 and HIV-1 C98*

- 5 HIV-1 has been isolated from the macrophages of patients C18 and C98.

Patient monocytes were prepared as follows. Whole blood was spun at 2000rpm for 10 minutes. Plasma was removed into a separate tube and the remaining cells were diluted 1:2 in PBS⁻ (magnesium and calcium free phosphate buffered saline). This was
10 underlaid with 10 ml of Ficoll Isopaque and spun at 2000rpm for 20 minutes. Cells were collected from the interphase and washed three times with PBS⁻. These cells were then seeded into a 6 well Costar tray at a concentration of 1.0×10^7 /ml and allowed to adhere for 1 hour. Any non-adherent cells were removed by aspiration.

- 15 Donor HIV-1 negative macrophages for use in co-cultivation were prepared as follows. Peripheral blood mononuclear cells were purified from whole blood using Ficoll/Isopaque density gradient. These cells were seeded at a concentration of 2.0×10^6 /ml in teflon. PBMC were cultured in the presence of $3\mu\text{g/ml}$ of PHA and 1000U/ml of M-CSF 3 days prior to co-culture.

20

- On day of co-culture, donor PBMC were CD8 depleted. Dyna beads coated with anti-CD8 were used for this purpose. Dyna beads were washed once in PBS⁻ and then applied to a magnet for 3 minutes. Supernatant was removed and the beads were then resuspended in $250\mu\text{l}$ of RF-10. Aliquots of 2.0×10^8 patient cells were then added to
25 $250\mu\text{l}$ (3 beads : 1 CD8 T-cell) of Dyna beads and allowed to incubate for 30 minutes on ice with occasional mixing. After 30 minutes the cell suspension was placed onto a magnet for 3 minutes. The supernatant was then removed placed into a second tube containing $142\mu\text{l}$ (1 bead : 1 CD8 T-cell) of Dyna beads. This suspension was placed on ice for an additional 30 minutes with occasional mixing. After 30 minutes cell
30 suspension was placed onto a magnet for 3 minutes. Supernatant was removed and washed once in RF-10.

- 67 -

For co-culture, CD8 depleted PBMC were then added to patient monocytes. Half media changes were done every 7 days for a period of 21 days. Aliquots of 2.5 ml of medium was removed from these cultures and replaced with CD8 depleted donor PBMC in Iscoves containing 10% HuS (Human serum), 5% v/v FCS and 5% w/v IL-2 and
5 1000U/ml of M-CSF. Harvested supernatants were spun at 1400 rpm for 10 minutes and stored as 1ml aliquots. Cell pellets were lysed in 200 μ l of lysis buffer for PCR analysis. Infection was quantitated using a p24 EIA Kit.

Cells were harvested from the co-cultures and used to prepare DNA as described above.
10 The *nef*/ 3'-LTR region of both virus isolates was amplified by PCR using the above described primer sets and conditions (Example 12). The resulting amplimers were cloned into the plasmid vector pT7T3U19 and the nucleotide sequence determined by the Taq cycle sequencing method with dye-labelled primers.

15 The C18 macrophage sequence has 3 deletions starting and finishing at positions within 3 nucleotides of the same deletions in C18_{MBC}. The encoded *nef* protein is 3 amino acids long compared with 7 amino acids for C18_{MBC}. The low homology region of the LTR U 3 region of C18 macrophage is very similar in sequence to C18_{MBC} and similarly it has one extra upstream NF κ B site.

20

On the other hand, the sequence of C98 macrophage has a number of differences from the C98 isolate. While it has exactly the same first deletion of 16 nucleotides just upstream of the polypurine tract (PPT), in the *nef*-alone region, and exactly the same second deletion (position and size) it has an extra deletion of 18 nucleotides at NL4-3
25 equivalent nucleotides 9206 to 9223. The final deletion is in approximately the same position as in the C98 isolate but is 5 nucleotides longer. The encoded *nef* protein is 34 amino acids long compared with 86 amino acids for the C98 isolate. The low homology region is very similar to the C98 isolate, having the same 2 extra upstream NF κ B sites and completely lacking the normal 5'-NF κ B site.

30

EXAMPLE 14

Construction and Use of an Infectious Molecular Clone

- 5 Molecular biological techniques can be used to construct a molecular clone of, for example, HIV-1 C18_{MBC}. Two schemes may be used. In the first scheme genomic DNA, extracted from either the CD4 positive PBMC of the patient C18 or donor PBMC that have been infected with the isolate HIV-1 C18_{MBC}, is used as the template for polymerase chain reaction amplification, using thermostable polymerase of high
10 transcriptional fidelity (eg UITma polymerase or KlenTaq/Pfu polymerase mixture), of long (6 to 7 kb) overlapping fragments representing the 5'- and 3'-parts of the HIV-1 C18_{MBC} proviral genome of total length 9207nts. The amplified fragments may then be ligated together after digestion with a restriction enzyme that cleaves at a unique site common to the overlapping region of the amplified fragments, for example the unique
15 Bgl I or Nco I sites. Ligation of this full length proviral DNA into a plasmid vector will allow its propagation in *E coli* and the subsequent preparation of large (mg) quantities of this molecularly cloned proviral DNA.

- In the second scheme donor PBMC that have been infected with the isolate HIV-1
20 C18_{MBC} are used as a source of non-integrated proviral DNA which can be extracted from the infected cells by the Hirt extraction method (Hirt, 1967). Circular proviral DNA molecules may be linearised by digestion with a restriction enzyme that cleaves at a unique position in the genome (eg the Bgl I or Nco I sites). The resulting linearised molecules can be ligated into a plasmid or, more usually, a bacteriophage lambda (λ)
25 based vector (eg Charon 4a, λ WES) after modification of the end to provide blunt or cohesive ends compatible with the vector. Transformation or transduction of *E coli* with the recombinant plasmid or bacteriophage material, respectively allows the propagation of the proviral DNA. Clones of *E coli* containing proviral DNA may be selected and DNA prepared. Molecular clones of retroviral genomes prepared in this way are often
30 permuted. Rearrangement to the functional arrangement of sequences is achieved by restriction enzyme cleavage and religation of fragments to reconstruct the correctly permuted proviral genome.

- 69 -

The molecularly cloned DNA products of both schemes can be used to prepare variant proviral genomes that may be used as the basis of a biologically attenuated HIV-1 vaccine strain. Similarly, they may be modified to contain extra DNA sequences in the *nef*-alone deletion region that may deliver sequences that may be of therapeutic advantage (eg antisense or ribozyme sequences).

Infectious virus particles of HIV-1 C18_{MBC}, or modified virus, can be produced by transfection of human cells (eg HeLa cells) which will produce, and release to the culture medium, virus particles of HIV-1 C18_{MBC}, or modified virus. These virus particles can be used to infect a variety of CD4 positive cells for further propagation or experimentation.

EXAMPLE 15

In vivo Primate Model

Following construction of infectious molecular clones of the mutant HIV-1 strains, studies are then undertaken in primates to establish attenuation, immunogenicity and vaccine prophylactic efficacy. All studies compare mutant clones of HIV-1 with isogenic wild-type (WT) virus. Initial studies are performed using the macaque (*M. nemistrina*) model of HIV-1 infection. Macaque-infectious WT HIV-1 and mutant clones are compared with respect to duration of viremia, anatomic sites of replication, and cellular and humoral immune responses. Where the mutant HIV-1 clones induce an immune response in the macques infected, challenge studies with WT virus are also performed. Studies are performed in a limited number of chimpanzees, generally in parallel with the macaque studies. Relevant mutations are engineered into WT HIV-1 clones previously shown to produce chronic infection in chimps, and the course of chimp infection with mutant clones compared with historical controls. If infection is established, WT challenge studies is also performed.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The
5 invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

- BACHMANN B, LÜKE W AND HUNSMANN G (1990). *Nucl Acids Res* 18: 1309.
- 5 BARRE-SINOUSSE F, CHERMANN JC, REY F, *et al* (1983) *Science* 220: 868-871.
- BUSCH MP, EL AMAD Z, SHEPPARD HW, ASCHER MS, LANG W (1991) *N Engl J Med* 325: 733-735.
- 10 CHENG-MAYER C, SHIODA T, LEVY JA (1991) *J Virol* 65: 6931-6941.
- CLERICI M, STOCKS NI, ZAJAC RA, *et al* (1989) *J Clin Invest* 84: 1892-1899.
- 15 COX and OAKES (1989) *Survival Analysis, Chapman & Hall*.
- DANIEL MD, KIRCHHOFF F, CZAJAK SC, SEHGAL P AND DESROSIERS RC (1992). *Science* 258: 1938-1941.
- 20 DELWART EL, *et al* (1993) *Science* 262: 1257-1261.
- FOUCHER RAM, *et al* (1992) *J. Virol.* 66: 3183-3187.
- GAYNOR R (1992). *AIDS* 6m 347-363.
- 25 GOU L-H and WU R. (1982) *Nucleic Acids Research* 10: 2065-2084.
- GREENWAY *et al* (1994) *Virology* 198: 245-256.
- 30 GROENINK M, FOUCHIER RAM, BROERSEN S, *et al* (1993) *Science* 260: 1513-1515.

- 72 -

- HAMMES SR, DIXON EP, MALIM MH, CULLEN BR and GREENE WC, (1989)
Proc Natl Acad Sci USA 86: 9549-9553.
- HIRT B. (1967) *J Mol Biol* 26: 365-369.
- 5 HWANG SS, BOYLE TJ, LYERLY HK, CULLEN BR (1991) *Science* 253: 71-74.
- KASLOW RA, DUQUESNOY R, VAN RADEN M, KINGSLEY L, MARRARI M.
(1990) *Lancet* 335: 927-930.
- 10 KEMP BE, RYLATT DB, BUNDESEN PG, DOHERTY RR, MCPHEE DA,
STAPLETON D, COTTIS LE, WILSON K, JOHN MA, KHAN JM, DINH DP, MILES
S & HILLYARD CJ (1988). *Science* 241: 1352-1354.
- KESTLER HW, RINGLER DJ, MORI K, PANICALI DL, SEHGAL PK, DANIEL MD
15 & DESROSIERS RC (1991). *Cell* 65: 651-662.
- KIERNAN R, et al (1990) *AIDS Res. Hum. Retroviruses* 6: 743-752.
- KIM S, IKEUCHI K, BYRN R, GROOPMAN J and BALTIMORE D (1989) *Proc Natl*
20 *Acad Sci USA* 86: 9544-9548.
- LANG W, PERKINS H, ANDERSON RE, ROYCE R, JEWELL N. WILKELSTEIN
W. (1989) *J Acquir Immune Defic Syndr* 2: 63-69.
- 25 LEARMONT J, TINDALL B, EVANS L, CUNNINGHAM A, CUNNINGHAM P,
WELLS J, PENNY R, KALDOR J AND COOPER DA. (1992). *Lancet* 340: 863-867.
- LEGUERN M, SHIODA T, LEVY JA, CHENG-MAYER C. (1993) *Virology* 195: 441-
447.
- 30 LEVY JA, (1993) *AIDS* 7: 1401-1410.

- 73 -

- LIFSON AR, BUCHBINDER SP, SHEPPARD HW, *et al* (1991) *J infect Dis* 163: 959-965.
- LUCIW PA, CHENG-MAYER C and LEVY JA (1987) *Proc Natl Acad Sci USA* 84: 1434-1438.
- MANIATIS T *et al* (1982). Molecular cloning. A Laboratory Manual, 1st edition Pub. Cold Spring Harbor Laboratory Press.
- 10 MOSIER DE, GULIZIA RJ, MACISAAC PD, TORBETT BE, LEVY JA (1993) *Science* 260: 689-692.
- MYERS A, KORBAR B, BERZOFKY JA, SMITH RF & PAVLAKIS SA eds (1992; 1993). Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences. Pub Theoretical Biology and Biophysics Group. Los Alamos National Laboratory, Los Alamos, NM USA.
- 15 NEATE EV, HEALY DS, PRINGLE RC, GUST ID, AND JOWLETT JMB (1987). *Aust NZ J Med* 17: 461-466.
- 20 NIEDERMAN TMJ, THIELAN BJ, and RATNER L. (1989) *Proc Natl Acad Sci USA* 86: 1128-1132.
- PEPER RJ, TINA WZ, & MICHELSON MM (1968). *J Lab Clin Med* 72: 842-846.
- 25 SANGER F, NICKLEN S AND COULSON AR (1977). *Proc Natl Acad Sci USA* 4: 5463-67.
- SHEPPARD HW, LANG W, ASCHER MS, VITTINGHOF E and WINKELSTEIN W. 30 (1993) *AIDS* 7: 1159-1166.

SHIODA T, LEVY JA, CHENG-MAYER C (1992) *Proc Natl Acad Sci USA* 89: 9434-9438.

- 5 SHUGARS DC, SMITH MS, GLUECK DH, NANTERMET PV, SEILLIER-MOISEWITSCH F AND SWANSTROM R (1993). *J Virol* 67: 4639-4650.

SMITH J, AZAD AA, and DEACON NJ (1992) *J Gen Virol* 73: 1825-1828.

- 10 SULLIVAN N, THALI M, FURMAN C, HO DD, SODROSKI J (1993) *J Virol* 67: 3674-3679.

TEEUWSEN VJP, SIEBELINK KHJ, DE WOLF F, GOUDSMIT J, UYTDEHAAG FGCM, OSTERHAUS ADME (1990) *AIDS* 4: 77-81.

15

TERSNETTE M, DE GOEDE REY, BERT JM, *et al* (1988) *J Virol* 62: 2026-2032.

TERWILLIGER E, SODROSKI JG, ROSEN CA, and HASELTINE WA, (1986) *J Virol* 60: 754-760.

20

YAMANO K MORI S, OKAMOTO T, SHINOTOHNO K AND KYOGOKU Y (1991). *Nucl Acids Res* 22: 6107-6112.

YANISCH-PERRON C, VIEIRA J, and MESSING J *Gene* 13: 103-119.

- 75 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i)(a) APPLICANT: (Other than US)

THE MACFARLANE BURNET CENTRE FOR MEDICAL RESEARCH LIMITED and
AUSTRALIAN RED CROSS SOCIETY (NSW DIVISION)

(b) INVENTORS/APPLICANTS (US only):

DEACON, N; LEARMONT, J; McPHEE, D; CROWE, S and COOPER, D.

(ii) TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1

(iii) NUMBER OF SEQUENCES: 800

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: DAVIES COLLISON CAVE

(B) STREET: 1 LITTLE COLLINS STREET

(C) CITY: MELBOURNE

(D) STATE: VICTORIA

(E) COUNTRY: AUSTRALIA

(F) ZIP: 3000

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT INTERNATIONAL

(B) FILING DATE: 14-FEB-1995

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: PM3864 (AU)

(B) FILING DATE: 14-FEB-1994

(A) APPLICATION NUMBER: PM4002 (AU)

(B) FILING DATE: 21-FEB-1994

(A) APPLICATION NUMBER: PN0284 (AU)

(B) FILING DATE: 23-DEC-1994

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: HUGHES, Dr E JOHN L

(C) REFERENCE/DOCKET NUMBER: EIH/EK

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +61 3 254 2777

(B) TELEFAX: +61 3 254 2770

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9709 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TCGAAGGGCT AATTGGTCC CAAAAAGAC AAGAGATCCT TGATCTGTG ATCTACACA	60
CACAAGGCTA CTTCCCTGAT TGGCAGACT ACACACCAGG GCCAGGGATC AGATATCCAC	120
TGACCTTTGG ATGGTGCTTC AAGTGTATAC CAGTTGAAAC AGAGCAAGTA GAAGAGGCCA	180
AATAAGGAGA GAAGAACAGC TTGTATACCC CTATGAGCCA GCATGGGATG GAGGACCCCG	240
AGGGAGAAGT ATTAGTGTGG AAGTTTGACA GCGTCTTAGC ATTTCTTCAC ATGGCCCGAG	300
AGCTGCATCC GGAGTACTAC AAGACTGCT GACATGAGC TTTCTACAG GACTTTCCG	360
CTGGGGACTT TCCAGGAGG TGTGGCCTGG GCGGAGTGG GAGTGGCCA GCGCTCAGAT	420
GCTACATAA AGCAGCTGCT TTTGCCCTGT ACTGGGTCTC TCTGTTAGA CAGATCTGA	480
GCTGGGAGC TCTCTGGCTA ACTAGGGAAC CCACTGCTTA AGCCTCAATA AAGCTTGCT	540
TGAGTGTCTA AAGTATGTG TGGCCGTCTG TTGTGTGACT CTGGTAACTA GAGATCCCTC	600
AGACCCCTTT AGTCATGTG GAAATCTCT AGCAGTGGGG CCGAAGCAGG GACTTGAAG	660
CGAAGTAAA GCCAGGGAG ATCTCTGAC GCAGGACTGG GCTTCTGAA GCGGCGACGG	720
CAGAGGGCGA GGGGCGCGA CTGGTGAGTA GCGCAAAAT TTTGACTAGC GGAGGCTAGA	780
AGGAGAGAGA TGGGTGCGAG AGCTTCGGTA TTAAGCGGG GGAATTTAGA TAAATGGGAA	840
AAAATTGGT TAAGGCCAGG GGAAGAGAA CAATATAAC TAAACATAT AGTATGGGCA	900
AGCAGGGAGC TAGAACGTT GCAATTAA TCTGGCCTTT TAGAGCATC AGAAGGCTGT	960
AGACAATAC TGGGACAGCT ACAACCATCC CTTGAGACG GATCAGAGA ACTTAGATCA	1020
TTATATAATA CAATAGCGT CCTCATTTGT GTGCATCAA GGTAGATGT AAAGACACC	1080
AAGGAAGCCT TAGATAGAT AGAGGAAGAG CAAACAAA GTAAGAAAA GGCACAGCAA	1140
GCAAGCAGCT ACACAGGAA CACAGCCAG GTACGCCAA ATTACCTAT AGTCAGAAC	1200
CTCCAGGGC AATGGTACA TCAGGCATA TCACCTGAA CTTAAATGC ATGGGTAAAA	1260
GTATAGAGAG AGAAGGCTTT CAGCCAGAA GTAAACCCA TTTTTTACG ATTATCAGAA	1320
GGAGCCACC CACAGATT AATACCATG CTAACACAG TGGGGGACA TCAGCAGGCC	1380
ATGCAAATGT TAAAGAGAC CATCAATGAG GAAGCTGAG AATGGGATG ATTGCATCCA	1440
GTGCATGCAG GGCCTATTCC ACCAGGCCAG ATGAGGAAAC CAGGGGGAG TGACATAGCA	1500
GCACTACTA GTACCTTCA GGAACAAATA GGTATGATGA CACTAATCC ACCTATCCCA	1560
GTAGGAGAAA TCTATAAAG ATGGATATC CTGGATTAA ATAAATAGT AAGAAATAT	1620
AGCCCTACCA GCATTCTGA CATAGACAA GGAACAAAG AACCCCTTAC AGACTATGTA	1680
GACCGATTCT ATAAACTCT AAGAGCCGAG CAGCTTCAC AAGAGGTAAA AAATTGGATG	1740
ACAGAAACCT TTTTGTCCA AATGGGAC CAGATTGTA AGCTATTTT AAAGCATTG	1800
GGACCAAGAG CCACTATGA AGAATGATG ACAGCATGTC AGGAGTGGG GGGACCCGCG	1860
CATAAGGAAA GAGTTTGGC TGAAGCAATG AGCCAGTAA CAATCCAGC TACCATAATG	1920
ATACAGAAAG GCAATTTAG GAACCAAGA AAGACTGTTA AGTGTTCGA TTGTGGCAA	1980
GAAGGSCAA TAGCCAAAA TTGCAGGCC CCTAGAAAA AGGCTGTTG GAATGTGGA	2040
AAGGAAGAC ACCAATGAA AGATTGTACT GAGAGACAGG CTAATTTTT AGGGAAGATC	2100
TGGCTTCCC ACAGGGGAG GCCAGGGAT TTTCTTGA GCAAGACGA GCCACAGCC	2160
CCGCCAGAG AGAGCTTCA GTTTGGGAA GAGACACAA CTCCCTTCA GAGCAGGAG	2220
CGGTAGACA AGAAGTGA TCGTTAGCT TCCCTCAGAT CACTCTTGG CAGGACCCC	2280

TCGTCACAAAT AAGATAGGG GGGCAATTAA AGGAAGCTCT ATTAGATACA GGAGCAGATG	2340
ATACAGTATT AGAAGAAATG AATTTCGCCG GAAGATGGAA ACCAAAAATG ATAAGGGGAA	2400
TTGGAGGTTT TATCAAGTA GGACAGTATG ATCAGATACT CATAGAAATC TCGGACATA	2460
AAGCTATAGG TACAGTATTA GTAGGACCTA CACCTGTCAA CATAAATGGA AGAAATCTGT	2520
TGACTCAGAT TGGCTGCAC TTAATTTTC CCATTAGTCC TATTGAGACT GTACCAATA	2580
AATTAAAGCC AGAATGGAT GGGCCAAAG TTAACCAATG GCCATTGACA GAAGAAAAA	2640
TAAAGCAAT AGTAGAATT TGTACAGAA TGGAAAGGA AGGAAAAAT TCAAAATG	2700
GGCTGAAA TCCATACAACT ACTCCAGTAT TTGCCATAA GAAAAAGAC AGTACTAAT	2760
GGAGAAAT AGTAGATT AGAGACTTA ATAAGGAAC TCAGATTTC TGGAGTTTC	2820
AATTAGGAT ACCCATCT GCAGGTTAA AACGAAAAA ATCAGTACA GTACTGGATG	2880
TGGGCGATG ATATTTTCA GTTCCCTTAG ATAAGACTT CAGGAAGTAT ACTGCATTA	2940
CCATACCTAG TATAACAT GAGACACCAG GGATTAGATA TCAGTACAA GTGCTCCAC	3000
AGGATGGAA AGGATCACC GCATATTCC AGTGTAGCAT GACAAAAATC TTAGAGCCTT	3060
TTAGAAACA AATCCAGAC ATAGTCATCT ATCAATACAT GGATGATTG TATGTAGGAT	3120
CTGACTTAGA AATAGGGCG CATAGACAA AATAGAGGA ACTGAGACAA CATCTGTGA	3180
GGTGGGATT TACCACCA GACAAAAAC ATCAGAAGA ACCTCCATTC CTTTGGATG	3240
GTATGAACT CCATCTGAT AATGGACAG TACAGCTAT AGTGTCTCCA GAAAGGACA	3300
GCTGAGCTGT CAATGACATA CAGAATTAG TGGAAATG GAATGGGCA AGTCAGATT	3360
ATGACGGAT TAAATAGAG CAATTATGA AACTTCTAG GGGACCCAA GCCTAACAG	3420
AGTAGTACC ACTACAGAA GAGCAGAGC TAGAACTGC AGAAACAGG GAGATTCTA	3480
AGGACCGGT ACATGGAGT TATTATGAC CATCAAGA CTAATAGCA GAATACAGA	3540
AGCAGGGCA AGGCCATG ACATATCAA TTTATCAGA GCGTTTAA AATCTGAAA	3600
CAGAAATA TGCAGAAAT AGGGTGCC ACCTAATGA TGTGAACAA TTACAGAGG	3660
CGTACAAA AATAGCCACA GAAGCATAG TAATATGGG AAGACTCT AATTTAAT	3720
TACCATACA AAGGAACA TGGAGCAT GTTGACAG GTATTGCCA GCTACCTGA	3780
TTCTGAGT GGAATTGTC AATACCCCT CCTTAGTGA GTTAGGTAC CAGTTAGGA	3840
AAGAACCAT AATAGGACA GAACCTTCT ATGTAGATG GGCAGCCAT AGGGAACCTA	3900
AATTAGAAA AGCAGATAT GTAACTGACA GAGGAAGACA AAATTTGTC CCGCTAACG	3960
ACACACAAA TCGAGACT GAGTTACAG CAATTCATCT AGCTTGCAG GATTCGGAT	4020
TAGATGAAA CATAGTACA GACTCAGAT ATGCATTGG AATCATTCA GCACACCAG	4080
ATAGAGTGA ATCAGATTA GTCAATCAA TAAAGAGCA GTTAATAAA AAGGAAAAA	4140
TCTACCTGC ATGGTACCA GCACCAAG GAATTGAGG AATGACAA GTAGATGGT	4200
TGTCAGTGC TGAATCAGG AAGTACTAT TTTAGATG ATAGATAG GCCAGAGG	4260
AACATGAAA ATATCAGT AATTGAGAG CAATGGCTAG TGATTTAAC CTACACCTG	4320
TAGTAGCAA AGAATAGTA GCGAGCTGT ATAAATGCA GCTAAAGGG GAGGCTATG	4380
ATGACAAAT AGCTGTAGC CCGAATAT GCGAGCTAGA TTGTACAT TTAGAGGAA	4440
AGTTATCTT GTTAGAGTT CATGTAGCA GTGATATAT AGAAGCAGAA GTATTCCAG	4500
CGAGACAGG GCAAGAAACA GCATACCTC TCTAAAT AGCAGGAGA TGGCAGTAA	4560
AAACGTACA TACAGCAAT GCGAGCAAT TCACCATAC TACAGTTAG GCGGCTGTT	4620
GGTGGCGGG GATCAGCAG GAATTGGCA TTCCCTACA TCCCAAGT CAGGAGTAA	4680
TAGATCTAT GATTAAGAA TTAAGAAA TTATAGGCA GTTAAGAT CAGGCTGAC	4740
ATCTTAGAC AGCAOTACA ATGCGATAT TCATCCACA TTTTAAAGA AAGGGGGGA	4800
TTGGGGGTA CAGTCAGGG GAAGATAG TAGACATAT AGCAACAGAC ATACAACTA	4860
AGGATACA AAACAAAT ACMAAATTC AAAATTTG GTTTATAC AGGACAGCA	4920
GGATCCAGT TTGAAAGA CCAGCAAGC TCCTTGGA AGGTGAGGG GCAGTAGTAA	4980
TACAGATA TAGTGACATA AAGTATGC CAGGAAGA AGCAAGATC ATCAGGAT	5040
ATGAAAAA GATGCGAGT GATGATTGT TGGCAAGT AGCAGGATAG GATTACACA	5100

TGGAAAGAT TAGTAAACA CCATATGTAT ATTTCMAGGA AAGCTAAGGA CTGGTTTTAT	5160
AGACATCTACT ATGAAGTAC TAATCCAAA ATAAGTTCAG AAGTACACAT CCCACTAGGG	5220
GATGCTAAAT TAGTAATAAC AACATATTGG GGTCTGCATA CAGGAGAAAG AGACTGGCAT	5280
TTGGGTCAAG GAGTCTCCAT AGAATGGAGG AAAAGAGAT ATAGCACACA AGTAGACCCCT	5340
GACCTAGCAG ACCAACTAAT TCATCTGCAC TATTTTGATT GTTTTTCAGA ATCTGCTATA	5400
AGAAATACCA TATTAGGACG TATAGTTAGT CCTAGGTGTG AATATCAAGC AGGACATAAC	5460
AAGGTAGGAT CTCTACAGTA CTTGGCACTA GCAGCAATTAA TAAACCTAAA ACAGATAAAG	5520
CCACCTTTGC CTAGTGTAG GAAACTGACA GAGGACAGAT GGAACAGGCC CTGGAAGGCC	5580
AAGGCTCACA GAGGGAGCCA TACAATGAAT GGACACTAGA GCCTTTAGAG GAACCTAAGA	5640
GTGAAGCTGT TAGACATTTT OCTAGGATAT GGCTCCATAA CITAGGACAA CATATCTATG	5700
AAACTTACCG GGATCTTGG GCAGGAGTGG AAGCCATAAT AAGAAITCTG CAACACTGTC	5760
TGTTTATCCA TTTTCAATTT GGGTGTGAC ATAGCAGAT AGGCTTACT GACAGAGGA	5820
GAGCAAGAAA TGGAGCCAGT AGATCCTAGA CTAGAGCCCT GGAAGCATCC AGGAAGTCAG	5880
CCTAAAACAG CTGTACCAA TTGCTATTGT AAAAGTGTG GCTTTTATG CCAAGTTTGT	5940
TTATGACAA AAGCCTTAGG CATCTCTAT GGCAGGAGA AGCGAGACA GCGACGAGA	6000
GCTCATCAGA ACASTCAGAC TCATCAGCT TCTCTATCAA AGCAGTAAGT AGTACATOTA	6060
ATGCACCTTA TAATAGTAGC AATAGTAGCA TTAGTAGTAG CAATATTAAT AGCAATAGTT	6120
GTGTTGTTCA TAGTAATCAT AGAATATAGG AAAATATTAA GACAAAGAAA AATAGACAGG	6180
TTAATTGATA GACTAATAGA AAGAGCAGAA GACAGTGGCA ATGAGAGTGA AGGAGAGOTA	6240
TCAGCACTTG TGGAGATGG GGTGGAATG GGGCACCATG CTCCTTGGGA TATTGATGAT	6300
CTGTAGTGCT ACAGAAAAAT TGTGGGTGAC AGTCTATTAT GGGTACCTG TGTGGAGGA	6360
AGCAACCCAC ACTCTATTTT GTGCATCAGA TGCTAAGCA TATGATACAG AGGTACATAA	6420
TGTTTGGGCC ACACATGCCT GTGTACCCAC AGACCCCAAC CCACAGAGAG TAGTATTGGT	6480
AAATGTGACA GAAATTTTA ACATGTGGA AAATGACATG GTAGAACAGA TGCATGAGGA	6540
TAATATCAAT TTATGGGATC AAAGCCTAAT GCCATGTGTA AAATTAACCC CACTCTGTGT	6600
TAGTTTAAG TGCATGATT TGAAGATGA TACTAATACC AATAGTAGTA GGGGAGAT	6660
GAATATGGAG AAGGAGAGA TAAAAACTG CTCCTTCAAT ATCAGCACAA GCATAGAGA	6720
TAAGGTGCAG AAGAAATAG CATCTTTTA TAACTTGAT ATAGTACCAA TAGATAATAC	6780
CAGCTAAGG TTGATAGTT GTAAACCTTC AGTCTATACA CAGGCTGTC CAAAGGTATC	6840
CTTGAGCCA ATTCCATAC ATTATTGTGC CCGGCTGGT TTTGCGATTG TAAATGTAA	6900
TATATAGAG TTCAATGGA CAGGACCATG TACAAATGTC AGCAGCTAC AATGTACACA	6960
TGGATCAGG CCGATAGTAT CAATCAACT GCTGTAAAT GGCAGTCTAG CAGAGAGGA	7020
TGTAGTAAT AGATCTGCA ATTTCACAGA CAATGCTAAT ACCAATATAG TACAGCTGAA	7080
CACATCTGTA GAATTAAT GTACAGAGCC CAACACAT ACAGAGAAAA GTATCCGTAT	7140
CCAGAGGGGA CCAGGAGAG CATTTGTTAC AATAGGAAA ATAGGAATA TGAACAGGC	7200
ACATTGTAC ATAGTAGAG CAATATGGA TGCCACTTA AACAGATAG CTAGCAAT	7260
AAGAGACAA TTTGGAATA ATAAACAT ATCTTTAG CAATCTCAG GAGGGAGCC	7320
AGAAATGTA AGTCAAGTT TTANTGTG AGGGGAATTT TTCTACTGTA ATTCAACCA	7380
ACTGTTAAT AGTACTTGT TTANTAGTAC TTGGAGTACT GAGGGTCAA ATACACTGA	7440
AGGAAGTAC ACAATCAC TCCTATGAG AATAAACAA TTATTAACA TGTGGCAGGA	7500
AGTAGGAAA GCAATGTATG CCGCTCCAT CAGTGGCAA ATTAGATGTT CATCAATAT	7560
TACTGGGCTG CTATTACAA GAGATGGTGG TAATAACAC AATGGTCCG AGATCTTCA	7620
ACTGGAGGA GGCGATATGA GGGCAATTG GAGAGTGA TTATATAAT ATAAAGTAT	7680
AAAAATGAA CCATTAGAG TAGCACCCAC CAGGCAAG AGAAGAGTGG TGCAGAGGA	7740
AAAAAGACA GTGGGAATAG GAGCTTTGTT CTTGGGTTT TTGGGAGCAG CAGGAGCAC	7800
TATGGGCTGC ACTCAATGA GCTGAGGT ACAGGCGGA CAATTATTGT CTGATATAT	7860
GCAGCAGCAG AACATTTGC TGGGGCTAT TGGGGCAA CAGCATCTGT TGCACCTAC	7920

- 79 -

AGTCTGGGGC ATCAACAGC TCCAGGCCAG AATCCTGGCT GTGGAAAGAT ACCTAAAGGA	7980
TCAACAGCTC CTGGGATTT GGGGTGCTC TGGAAACTC ATTGCACCA CTGCTGTGC	8040
TTGGAATGCT AGTTGGAGTA ATAAATCTCT GGAACAGATT TGGATATACA TGACCTGGAT	8100
GGAGTGGGAC AGAGAAATTA ACAATTACAC AAGCTTAATA CACTCCTTAA TTGAGAAATC	8160
GCAAAACCAG CAGAAAAGA ATGACACAGA ATTATTGAA TTAGATAAAT GGCCAAGTTT	8220
GTGGAATGCG TTTAACATTA CAAATTGGCT GTGATATATA AAATTATTCA TAATGATAGT	8280
AGGAGGCTTG GTAGGTTTAA GAATAGTTTT TGCTGTACTT TCTATAGTGA ATAGAGTTAG	8340
GCAGGATAT TCACTATTAT CATTTCAGAC CCACCTCCCA ATCCCGAGGG GACCCGACAG	8400
GCCCGAAGGA ATAGAAAGAG AAGGTGGAGA GAGAGACAGA GACAGATCCA TTGATTAAT	8460
GAACTGATCC TTAGCAGTTA TCTGGGACGA TCTGGGAGC CTGTGCTCTT TCAGCTACCA	8520
CCGCTTGAGA GACTTACTCT TGATTGTAC GAGGATTGCG GACTTCTCG GACCGAGGG	8580
GTGGGAAGCC CTCAAATATT GGTGGAATCT CCTACAGTAT TGGAGTCAGG AACTAAGAA	8640
TAGTCTGTT AACTGCTCA ATGCCACAGC CATAGCATA GCTGAGGGGA CAGATAGGTT	8700
TATAGAAGTA TTACAGCAG CTTATAGAGC TATTGCCAC ATACCTAGAA GAATAAGACA	8760
GGCCTTGAA AGGATTTTGC TATAAGATGG GTGGCAAGTG GTCAAAAGT AGTGTGATTG	8820
GATGGCTTGC TGTAAAGGAA AGAATAGGAC GAGCTGAGCC AGCAGCAGAT GGGGTGGGAG	8880
CAGTATCTCG AGACCTAGAA AAACATGGAG CAATCAGAG TAGCAATACA GCAGCTAACA	8940
ATGCTGCTTG TGCTTGCTTA GAGGCACAG AGGAGGAAGA GGTGGGTTTT CCACTCACAC	9000
CTCAGGTACC TTATAGACCA AATCTTACA AGGCAGCTGT AGATCTTAGC CACTTTTAA	9060
AAGAAAGGG GGGACTGGAA GGGCTAATTC ACTCCCAAG AAGACAGAT ATCCTTGATC	9120
TGTGGATCTA CCACACACAA GGTACTTCC CTGATTGCA GACTACACA CCAGGGCCAG	9180
GGTCAAGATA TCCACTGACC TTGGATGTT GCTACAGCT AGTACCAATT GAGCCAGATA	9240
AGGTAGAAGA GGCCTATAAA GAGAGAACCA CCAGCTTGT ACACCTGTG AGCCTGCATG	9300
GAATGATGA CCTGAGAGA GAGTGTAG AGTGGAGTT TGACAGCCGC CTAGCATTC	9360
ATCAGCTGC CCGAGAGCTG CATCCGAGT ACTTCAGAA CTGCTGACAT GAGCTTGCT	9420
ACAGGGACT TTCCGCTGG GACTTCCAG GAGGCCGTG CCTGGGCGG ACTGGGGAGT	9480
GGGAGGCTT CAGATGCTGC ATATAAGCAG CTGCTTTTG CCTGTACTGG GTCTCTCAG	9540
TTAGACCAGA TCTGAGCCTG GAGCTCTCT GGTAACTAG GAAACCACT GCTTAAGCT	9600
CAATAAGCT TGCTTGAGT GCTTCAGTA GTGTGTCCC GTCTGTTGTG TGACTCTGTT	9660
AACTAGAGT CACTAGACC CTTTAGTCA GTGTGAAAA TCTTAGCA	9709

- 80 -

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGGGTGGCA

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TGGGTGGCAA

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GGGTGGCAAG

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGTGGCAAGT

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GTGGCAAGTG

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TGGCAAGTGG

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGCAAGTGGT

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GCAAGTGGTC

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

- 81 -

CAAAGTGGTCA

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AAGTGGTCAA

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AGTGGTCAAA

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTGGTCAAAA

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGGTCAAAAA

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GGTCAAAAAG

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GTCAAAAAGT

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TCAAAAAGTA

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CAAAAAGTAG

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

AAAAAGTAGT

- 82 -

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AAAAGTAGTG

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AAAGTAGTGT

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

AAGTAGTG TG

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

AGTAGTG TGA

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GTAGTGTGAT

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TAGTGTGATT

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

AGTGTGATTG

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GTGTGATTGG

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TGTGATTGGA

(2) INFORMATION FOR SEQ ID NO:29:

- 83 -

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GTGATTGGAT

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

TGATTGGATG

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GATTGGATGG

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

ATTGGATGGC

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

TTGGATGGCC

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

TGGATGGCCT

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GGATGGCCTG

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GATGGCCTGC

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

ATGGCCTGCT

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- 84 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TGGCCTGCTG

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

GGCCTGCTGT

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GCCTGCTGTA

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CCTGCTGTAA

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

CTGCTGTAAO

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

TGCTGTAAAGG

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GCTGTAAAGGG

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

CTGTAAGGGA

(2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TGTAAGGGAA

(2) INFORMATION FOR SEQ ID NO:47:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- 85 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GTAAGGGAAA

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

TAAGGGAAAG

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

AAGGGAAAGA

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

AGGGAAAGAA

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

GGGAAAGAAT

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

GGAAAGAATG

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GAAAGAATGA

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

AAAGAATGAG

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

AAGAATGAGA

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 86 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

AGAATGAGAC

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GAATGAGACG

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

AATGAGACGA

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

ATGAGACGAG

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

TGAGACGAGC

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

GAGACGAGCT

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

AGACGAGCTG

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

GACGAGCTGA

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

ACGAGCTGAG

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 87 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

CGAGCTGAGC

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

GAGCTGAGCC

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

AGCTGAGCCA

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GCTGAGCCAG

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

CTGAGCCAGC

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

TGAGCCAGCA

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

GAGCCAGCAG

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

AGCCAGCAGC

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

GCCAGCAGCA

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

- 88 -

CCAGCAGCAG

(2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CAGCAGCAQA

(2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

AGCAGCAGAT

(2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

GCAGCAGATG

(2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

CAGCAGATGG

(2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

AGCAGATGGG

(2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GCAGATGGGG

(2) INFORMATION FOR SEQ ID NO:81:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

CAGATGGGGT

(2) INFORMATION FOR SEQ ID NO:82:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

AGATGGGGTG

(2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

GATGGGGTGG

- 89 -

(2) INFORMATION FOR SEQ ID NO:84:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

ATGGGGTGGG

(2) INFORMATION FOR SEQ ID NO:85:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

TGGGGTGGGA

(2) INFORMATION FOR SEQ ID NO:86:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

GGGGTGGGAG

(2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

GGGTGGGAGC

(2) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

GGTGGGAGCA

(2) INFORMATION FOR SEQ ID NO:89:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

GTGGGAGCAG

(2) INFORMATION FOR SEQ ID NO:90:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

TGGGAGCAGT

(2) INFORMATION FOR SEQ ID NO:91:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

GGGAGCACTA

(2) INFORMATION FOR SEQ ID NO:92:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

GGAGCAGTAT

(2) INFORMATION FOR SEQ ID NO:93:

- 90 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

GAGCAGTATC

(2) INFORMATION FOR SEQ ID NO:94:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

AGCAGTATCT

(2) INFORMATION FOR SEQ ID NO:95:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

GCAGTATCTC

(2) INFORMATION FOR SEQ ID NO:96:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

CAGTATCTCG

(2) INFORMATION FOR SEQ ID NO:97:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

AGTATCTCGA

(2) INFORMATION FOR SEQ ID NO:98:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

GTATCTCGAG

(2) INFORMATION FOR SEQ ID NO:99:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

TATCTCGAGA

(2) INFORMATION FOR SEQ ID NO:100:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

ATCTCGAGAC

(2) INFORMATION FOR SEQ ID NO:101:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

TCTCGAGACC

(2) INFORMATION FOR SEQ ID NO:102:

- (i) SEQUENCE CHARACTERISTICS:

- 91 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

CTCGAGACCT

(2) INFORMATION FOR SEQ ID NO:103:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

TCGAGACCTA

(2) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

CGAGACCTAG

(2) INFORMATION FOR SEQ ID NO:105:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

GAGACCTAGA

(2) INFORMATION FOR SEQ ID NO:106:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

AGACCTAGAA

(2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

GACCTAGAAA

(2) INFORMATION FOR SEQ ID NO:108:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

ACCTAGAAAA

(2) INFORMATION FOR SEQ ID NO:109:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

CCTAGAAAAA

(2) INFORMATION FOR SEQ ID NO:110:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

CTAGAAAAAC

(2) INFORMATION FOR SEQ ID NO:111:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- 92 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

TAGAAAAACA

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

AGAAAAACAT

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

GAAAAACATG

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

AAAAACATGG

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

AAACATGGA

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

AAACATGGAG

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

AACATGGAGC

(2) INFORMATION FOR SEQ ID NO:118:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

ACATGGAGCA

(2) INFORMATION FOR SEQ ID NO:119:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

CATGGAGCAA

(2) INFORMATION FOR SEQ ID NO:120:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 93 -

(E) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

ATGGAGCAAT

(2) INFORMATION FOR SEQ ID NO:121:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

TGGAGCAATC

(2) INFORMATION FOR SEQ ID NO:122:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

GGAGCAATCA

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

GAGCAATCAC

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

AGCAATCACA

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

GCAATCACAA

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

CAATCACAAAG

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

AATCACAAAGT

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

ATCACAAAGTA

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 94 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

TCACAAGTAG

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

CACAAGTAGC

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

ACAAGTAGCA

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

CAAGTAGCAA

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

AAGTAGCAAT

(2) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

AGTAGCAATA

(2) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

GTAGCAATAC

(2) INFORMATION FOR SEQ ID NO:136:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

TAGCAATACA

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

AGCAATACAG

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

- 95 -

GCAATACAGC

(2) INFORMATION FOR SEQ ID NO:139:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

CAATACAGCA

(2) INFORMATION FOR SEQ ID NO:140:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

AATACAGCAG

(2) INFORMATION FOR SEQ ID NO:141:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

ATACAGCAGC

(2) INFORMATION FOR SEQ ID NO:142:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

TACAGCAGCT

(2) INFORMATION FOR SEQ ID NO:143:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

ACAGCAGCTA

(2) INFORMATION FOR SEQ ID NO:144:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

CAGCAGCTAA

(2) INFORMATION FOR SEQ ID NO:145:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

AGCAGCTAAC

(2) INFORMATION FOR SEQ ID NO:146:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

GCAGCTAACA

(2) INFORMATION FOR SEQ ID NO:147:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

CAGCTAACAA

- 96 -

(2) INFORMATION FOR SEQ ID NO:148:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

AGCTAACAAT

(2) INFORMATION FOR SEQ ID NO:149:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

GCTAACAATG

(2) INFORMATION FOR SEQ ID NO:150:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

CTAACAATGC

(2) INFORMATION FOR SEQ ID NO:151:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

TAACAATGCT

(2) INFORMATION FOR SEQ ID NO:152:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

AACAAATGCTG

(2) INFORMATION FOR SEQ ID NO:153:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

ACAATGCTGC

(2) INFORMATION FOR SEQ ID NO:154:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

CAATGCTGCT

(2) INFORMATION FOR SEQ ID NO:155:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

AATGCTGCTT

(2) INFORMATION FOR SEQ ID NO:156:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

ATGCTGCTTG

(2) INFORMATION FOR SEQ ID NO:157:

- 97 -

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

TGCTGCTTGT

(2) INFORMATION FOR SEQ ID NO:158:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

GCTGCTTGTG

(2) INFORMATION FOR SEQ ID NO:159:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

CTGCTTGTGC

(2) INFORMATION FOR SEQ ID NO:160:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

TGCTTGTGCC

(2) INFORMATION FOR SEQ ID NO:161:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

GCTTGTGCGT

(2) INFORMATION FOR SEQ ID NO:162:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

CTTGTGCGCTG

(2) INFORMATION FOR SEQ ID NO:163:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

TTGTGCGCTGG

(2) INFORMATION FOR SEQ ID NO:164:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

TGTCCTGGC

(2) INFORMATION FOR SEQ ID NO:165:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

GTGCGCTGGCT

(2) INFORMATION FOR SEQ ID NO:166:

(i) SEQUENCE CHARACTERISTICS:

- 98 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

TGCTGGCTA

(2) INFORMATION FOR SEQ ID NO:167:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

GCCTGGCTAG

(2) INFORMATION FOR SEQ ID NO:168:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

CCTGGCTAGA

(2) INFORMATION FOR SEQ ID NO:169:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

CTGGCTAGAA

(2) INFORMATION FOR SEQ ID NO:170:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

TGGCTAGAAAG

(2) INFORMATION FOR SEQ ID NO:171:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

GGCTAGAAAGC

(2) INFORMATION FOR SEQ ID NO:172:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

GCTAGAAAGCA

(2) INFORMATION FOR SEQ ID NO:173:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

CTAGAAGCAC

(2) INFORMATION FOR SEQ ID NO:174:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

TAGAAGCACA

(2) INFORMATION FOR SEQ ID NO:175:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- 99 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

AGAAGCACAA

(2) INFORMATION FOR SEQ ID NO:176:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

GAAGCACAAG

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

AAGCACAAGA

(2) INFORMATION FOR SEQ ID NO:178:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

AGCACAAGAG

(2) INFORMATION FOR SEQ ID NO:179:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

GCACAAGAGO

(2) INFORMATION FOR SEQ ID NO:180:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

CACAAGAGGA

(2) INFORMATION FOR SEQ ID NO:181:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

ACAAGAGGAG

(2) INFORMATION FOR SEQ ID NO:182:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

CAAGAGGAGG

(2) INFORMATION FOR SEQ ID NO:183:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

AAGAGGAGGA

(2) INFORMATION FOR SEQ ID NO:184:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 100 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

AGAGGAGGAA

(2) INFORMATION FOR SEQ ID NO:185:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

GAGGAGGAAG

(2) INFORMATION FOR SEQ ID NO:186:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

AGGAGGAAGA

(2) INFORMATION FOR SEQ ID NO:187:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

GGAGGAAGAG

(2) INFORMATION FOR SEQ ID NO:188:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

GAGGAAGAGG

(2) INFORMATION FOR SEQ ID NO:189:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

AGGAAGAGGT

(2) INFORMATION FOR SEQ ID NO:190:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

GGAAGAGGTG

(2) INFORMATION FOR SEQ ID NO:191:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

GAAGAGGTGG

(2) INFORMATION FOR SEQ ID NO:192:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

AAGAGGTGGG

(2) INFORMATION FOR SEQ ID NO:193:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 101 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:
AGAGGTGGGT

(2) INFORMATION FOR SEQ ID NO:194:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:
GAGGTGGGTT

(2) INFORMATION FOR SEQ ID NO:195:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:
AGGTGGGTTT

(2) INFORMATION FOR SEQ ID NO:196:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:
GGTGGGTTTT

(2) INFORMATION FOR SEQ ID NO:197:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:
GTGGGTTTTT

(2) INFORMATION FOR SEQ ID NO:198:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:
TGGGTTTTTC

(2) INFORMATION FOR SEQ ID NO:199:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:
GGGTTTTCCA

(2) INFORMATION FOR SEQ ID NO:200:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:
GGTTTTCCAG

(2) INFORMATION FOR SEQ ID NO:201:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:
GTTTTCCAGT

(2) INFORMATION FOR SEQ ID NO:202:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

- 102 -

TTTCCAGTC

(2) INFORMATION FOR SEQ ID NO-203:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-203:

TTTCCAGTCA

(2) INFORMATION FOR SEQ ID NO-204:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-204:

TTCCAGTCAC

(2) INFORMATION FOR SEQ ID NO-205:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-205:

TCCAGTCACA

(2) INFORMATION FOR SEQ ID NO-206:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-206:

CCAGTCACAC

(2) INFORMATION FOR SEQ ID NO-207:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-207:

CAGTCACACC

(2) INFORMATION FOR SEQ ID NO-208:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-208:

AGTCACACCT

(2) INFORMATION FOR SEQ ID NO-209:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-209:

GTCACACCTC

(2) INFORMATION FOR SEQ ID NO-210:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-210:

TCACACCTCA

(2) INFORMATION FOR SEQ ID NO-211:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-211:

CACACCTCAG

- 103 -

(2) INFORMATION FOR SEQ ID NO:212:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

ACACCTCAGG

(2) INFORMATION FOR SEQ ID NO:213:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

CACCTCAGGT

(2) INFORMATION FOR SEQ ID NO:214:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

ACCTCAGGTA

(2) INFORMATION FOR SEQ ID NO:215:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

CCTCAGGTAC

(2) INFORMATION FOR SEQ ID NO:216:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

CTCAGGTACC

(2) INFORMATION FOR SEQ ID NO:217:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

TCAGGTACCT

(2) INFORMATION FOR SEQ ID NO:218:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

CAGGTACCTT

(2) INFORMATION FOR SEQ ID NO:219:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

AGGTACCTTT

(2) INFORMATION FOR SEQ ID NO:220:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

GGTACCTTTA

(2) INFORMATION FOR SEQ ID NO:221:

- 104 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

GTACCTTTAA

(2) INFORMATION FOR SEQ ID NO:222:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

TACCTTTAAG

(2) INFORMATION FOR SEQ ID NO:223:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:

ACCTTTAAGA

(2) INFORMATION FOR SEQ ID NO:224:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:

CCTTTAAGAC

(2) INFORMATION FOR SEQ ID NO:225:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:

CTTTAAGACC

(2) INFORMATION FOR SEQ ID NO:226:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:

TTTAAGACCA

(2) INFORMATION FOR SEQ ID NO:227:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

TTAAGACCAA

(2) INFORMATION FOR SEQ ID NO:228:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

TAAGACCAAT

(2) INFORMATION FOR SEQ ID NO:229:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:

AAGACCAATG

(2) INFORMATION FOR SEQ ID NO:230:

- (i) SEQUENCE CHARACTERISTICS:

- 105 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

AGACCAATGA

(2) INFORMATION FOR SEQ ID NO:231:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:

GACCAATGAC

(2) INFORMATION FOR SEQ ID NO:232:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:

ACCAATGACT

(2) INFORMATION FOR SEQ ID NO:233:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:

CCAATGACTT

(2) INFORMATION FOR SEQ ID NO:234:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:

CAATGACTTA

(2) INFORMATION FOR SEQ ID NO:235:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:

AATGACTTAC

(2) INFORMATION FOR SEQ ID NO:236:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:

ATGACTTACA

(2) INFORMATION FOR SEQ ID NO:237:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:

TGACTTACAA

(2) INFORMATION FOR SEQ ID NO:238:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:

GACTTACAAG

(2) INFORMATION FOR SEQ ID NO:239:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- 106 -

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

ACTTACAAGG

(2) INFORMATION FOR SEQ ID NO:240:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:240:

CTTACAAGGC

(2) INFORMATION FOR SEQ ID NO:241:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:241:

TTACAAGGCA

(2) INFORMATION FOR SEQ ID NO:242:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:

TACAAGGCAG

(2) INFORMATION FOR SEQ ID NO:243:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:243:

ACAAGGCAGC

(2) INFORMATION FOR SEQ ID NO:244:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:244:

CAAGGCAGCT

(2) INFORMATION FOR SEQ ID NO:245:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:245:

AAGGCAGCTG

(2) INFORMATION FOR SEQ ID NO:246:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:246:

AGGCAGCTGT

(2) INFORMATION FOR SEQ ID NO:247:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:247:

GGCAGCTGTA

(2) INFORMATION FOR SEQ ID NO:248:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 107 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:248:

GCAGCTGTAG

(2) INFORMATION FOR SEQ ID NO:249:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:249:

CAGCTGTAGA

(2) INFORMATION FOR SEQ ID NO:250:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:250:

AGCTGTAGAT

(2) INFORMATION FOR SEQ ID NO:251:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:

GCTGTAGATC

(2) INFORMATION FOR SEQ ID NO:252:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:252:

CTGTAGATCT

(2) INFORMATION FOR SEQ ID NO:253:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:253:

TGTAGATCTT

(2) INFORMATION FOR SEQ ID NO:254:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:254:

GTAGATCTTA

(2) INFORMATION FOR SEQ ID NO:255:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:255:

TAGATCTTAG

(2) INFORMATION FOR SEQ ID NO:256:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:256:

AGATCTTAGC

(2) INFORMATION FOR SEQ ID NO:257:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 108 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:257:

GATCTTAGCC

(2) INFORMATION FOR SEQ ID NO:258:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:258:

ATCTTAGCCA

(2) INFORMATION FOR SEQ ID NO:259:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:259:

TCCTAGCCAC

(2) INFORMATION FOR SEQ ID NO:260:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:260:

CTTAGCCACT

(2) INFORMATION FOR SEQ ID NO:261:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:

TTAGCCACTT

(2) INFORMATION FOR SEQ ID NO:262:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:262:

TAGCCACTTT

(2) INFORMATION FOR SEQ ID NO:263:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:263:

AGCCACTTTT

(2) INFORMATION FOR SEQ ID NO:264:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:264:

GCCACTTTTT

(2) INFORMATION FOR SEQ ID NO:265:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:265:

CCACTTTTITA

(2) INFORMATION FOR SEQ ID NO:266:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:266:

- 109 -

CACTTTTAA

(2) INFORMATION FOR SEQ ID NO:267:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:267:

ACTTTTAA

(2) INFORMATION FOR SEQ ID NO:268:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:268:

CTTTTAAAA

(2) INFORMATION FOR SEQ ID NO:269:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:269:

TTTTTAAAG

(2) INFORMATION FOR SEQ ID NO:270:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:270:

TTTTTAAAGA

(2) INFORMATION FOR SEQ ID NO:271:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:

TTTAAAGAA

(2) INFORMATION FOR SEQ ID NO:272:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:272:

TTAAAGAAA

(2) INFORMATION FOR SEQ ID NO:273:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:273:

TAAAGAAAA

(2) INFORMATION FOR SEQ ID NO:274:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:274:

AAAAGAAAAG

(2) INFORMATION FOR SEQ ID NO:275:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:275:

AAAGAAAAG

- 110 -

(2) INFORMATION FOR SEQ ID NO:276:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:276:

AAGAAAAGGG

(2) INFORMATION FOR SEQ ID NO:277:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:277:

AGAAAAGGGG

(2) INFORMATION FOR SEQ ID NO:278:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:278:

GAAAAGGGGG

(2) INFORMATION FOR SEQ ID NO:279:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:279:

AAAAGGGGGG

(2) INFORMATION FOR SEQ ID NO:280:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:280:

AAAGGGGGGA

(2) INFORMATION FOR SEQ ID NO:281:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:281:

AAGGGGGGAC

(2) INFORMATION FOR SEQ ID NO:282:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:282:

AGGGGGGACT

(2) INFORMATION FOR SEQ ID NO:283:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:283:

GGGGGGGACTG

(2) INFORMATION FOR SEQ ID NO:284:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:284:

GGGGGACTGG

(2) INFORMATION FOR SEQ ID NO:285:

- 111 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:285:

GGGGACTGGA

(2) INFORMATION FOR SEQ ID NO:286:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:286:

GGGACTGGAA

(2) INFORMATION FOR SEQ ID NO:287:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:287:

GGACTGGAAG

(2) INFORMATION FOR SEQ ID NO:288:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:288:

GACTGGAAGG

(2) INFORMATION FOR SEQ ID NO:289:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:289:

ACTGGAAGGG

(2) INFORMATION FOR SEQ ID NO:290:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:290:

CTGGAAGGGC

(2) INFORMATION FOR SEQ ID NO:291:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:291:

TGGAAGGGCT

(2) INFORMATION FOR SEQ ID NO:292:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:292:

GGAAGGGCTA

(2) INFORMATION FOR SEQ ID NO:293:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:293:

GAAGGGCTAA

(2) INFORMATION FOR SEQ ID NO:294:

- (i) SEQUENCE CHARACTERISTICS:

- 112 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(i) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:294:

AAGGGCTAAT

(2) INFORMATION FOR SEQ ID NO:295:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:295:

AAGGCTAATT

(2) INFORMATION FOR SEQ ID NO:296:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:296:

GGGCTAATTC

(2) INFORMATION FOR SEQ ID NO:297:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:297:

GGCTAATTC

(2) INFORMATION FOR SEQ ID NO:298:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:298:

GCTAATTCAC

(2) INFORMATION FOR SEQ ID NO:299:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:299:

CTAATTCAC

(2) INFORMATION FOR SEQ ID NO:300:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:300:

TAATTCAC

(2) INFORMATION FOR SEQ ID NO:301:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:301:

AATTCAC

(2) INFORMATION FOR SEQ ID NO:302:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:302:

ATTCACTCC

(2) INFORMATION FOR SEQ ID NO:303:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- 113 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:303:

TTCACTCCCA

(2) INFORMATION FOR SEQ ID NO:304:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:304:

TCACTCCCAA

(2) INFORMATION FOR SEQ ID NO:305:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:305:

CACTCCAAA

(2) INFORMATION FOR SEQ ID NO:306:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:306:

ACTCCAAAAG

(2) INFORMATION FOR SEQ ID NO:307:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:307:

CTOCCAAAGA

(2) INFORMATION FOR SEQ ID NO:308:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:308:

TCCCAAAGAA

(2) INFORMATION FOR SEQ ID NO:309:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:309:

CCCAAAGAAG

(2) INFORMATION FOR SEQ ID NO:310:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:310:

CCAAAGAAGA

(2) INFORMATION FOR SEQ ID NO:311:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:311:

CAAAGAAGAC

(2) INFORMATION FOR SEQ ID NO:312:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 114 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:312:

AAAGAAGACA

(2) INFORMATION FOR SEQ ID NO:313:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:313:

AAGAAGACAA

(2) INFORMATION FOR SEQ ID NO:314:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:314:

AGAAGACAAG

(2) INFORMATION FOR SEQ ID NO:315:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:315:

GAAGACAAGA

(2) INFORMATION FOR SEQ ID NO:316:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:316:

AAGACAAGAT

(2) INFORMATION FOR SEQ ID NO:317:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:317:

AGACAAGATA

(2) INFORMATION FOR SEQ ID NO:318:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:318:

GACAAGATAT

(2) INFORMATION FOR SEQ ID NO:319:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:319:

ACAAGATATC

(2) INFORMATION FOR SEQ ID NO:320:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:320:

CAAGATATCC

(2) INFORMATION FOR SEQ ID NO:321:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 115 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:321:

AAGATATCCT

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(2) INFORMATION FOR SEQ ID NO:322:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:322:

AGATATCCTT

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:326:

ATCCTTGATC

(2) INFORMATION FOR SEQ ID NO:327:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:327:

TCCTTGATCT

(2) INFORMATION FOR SEQ ID NO:323:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:323:

GATATCCTTG

(2) INFORMATION FOR SEQ ID NO:328:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:328:

CCTTGATCTG

(2) INFORMATION FOR SEQ ID NO:324:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:324:

ATATCCTTGA

(2) INFORMATION FOR SEQ ID NO:329:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:329:

CTTGATCTGT

(2) INFORMATION FOR SEQ ID NO:325:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:325:

TATCCTTGAT

(2) INFORMATION FOR SEQ ID NO:330:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:330:

- 116 -

TTGATCTGTG

(2) INFORMATION FOR SEQ ID NO:331:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:331:

TGATCTGTGG

(2) INFORMATION FOR SEQ ID NO:332:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:332:

GATCTGTGGA

(2) INFORMATION FOR SEQ ID NO:333:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:333:

ATCTGTGGAT

(2) INFORMATION FOR SEQ ID NO:334:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:334:

TCTGTGGATC

(2) INFORMATION FOR SEQ ID NO:335:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:335:

CTGTGGATCT

(2) INFORMATION FOR SEQ ID NO:336:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:336:

TGTGGATCTA

(2) INFORMATION FOR SEQ ID NO:337:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:337:

GTGGATCTAC

(2) INFORMATION FOR SEQ ID NO:338:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:338:

TGGATCTACC

(2) INFORMATION FOR SEQ ID NO:339:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:339:

GGATCTACCA

- 117 -

(2) INFORMATION FOR SEQ ID NO:340:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:340:

GATCTACCAC

(2) INFORMATION FOR SEQ ID NO:341:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:341:

ATCTACCACA

(2) INFORMATION FOR SEQ ID NO:342:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:342:

TCTACCACAC

(2) INFORMATION FOR SEQ ID NO:343:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:343:

CTACCACACA

(2) INFORMATION FOR SEQ ID NO:344:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:344:

TACCACACAC

(2) INFORMATION FOR SEQ ID NO:345:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:345:

ACCACACACA

(2) INFORMATION FOR SEQ ID NO:346:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:346:

CCACACACAA

(2) INFORMATION FOR SEQ ID NO:347:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:347:

CACACACAAG

(2) INFORMATION FOR SEQ ID NO:348:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:348:

ACACACAAGG

(2) INFORMATION FOR SEQ ID NO:349:

- 118 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:349:

CACACAAGGC

(2) INFORMATION FOR SEQ ID NO:350:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:350:

ACACAAGGCT

(2) INFORMATION FOR SEQ ID NO:351:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:351:

CACAAGGCTA

(2) INFORMATION FOR SEQ ID NO:352:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:352:

ACAAGGCTAC

(2) INFORMATION FOR SEQ ID NO:353:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:353:

CAAGGCTACT

(2) INFORMATION FOR SEQ ID NO:354:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:354:

AAGGCTACTT

(2) INFORMATION FOR SEQ ID NO:355:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:355:

AGGCTACTTC

(2) INFORMATION FOR SEQ ID NO:356:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:356:

GGCTACTTCC

(2) INFORMATION FOR SEQ ID NO:357:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:357:

GCTACTTCCC

(2) INFORMATION FOR SEQ ID NO:358:

- (i) SEQUENCE CHARACTERISTICS:

- 119 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:358:

CTACTTCCCT

(2) INFORMATION FOR SEQ ID NO:359:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:359:

TACTTCCCTG

(2) INFORMATION FOR SEQ ID NO:360:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:360:

ACTTCCCTGA

(2) INFORMATION FOR SEQ ID NO:361:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:361:

CTTCCCTGAT

(2) INFORMATION FOR SEQ ID NO:362:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:362:

TTCCCTGATT

(2) INFORMATION FOR SEQ ID NO:363:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:363:

TCCCTGATTG

(2) INFORMATION FOR SEQ ID NO:364:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:364:

CCCTGATTGG

(2) INFORMATION FOR SEQ ID NO:365:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:365:

CCTGATTGGC

(2) INFORMATION FOR SEQ ID NO:366:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:366:

CTGATTGGCA

(2) INFORMATION FOR SEQ ID NO:367:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- 120 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:367:

TGATTGGCAO

(2) INFORMATION FOR SEQ ID NO:368:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:368:

GATTGGCAGA

(2) INFORMATION FOR SEQ ID NO:369:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:369:

ATTGGCAGAA

(2) INFORMATION FOR SEQ ID NO:370:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:370:

TTGGCAGAAC

(2) INFORMATION FOR SEQ ID NO:371:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:371:

TGGCAGAACT

(2) INFORMATION FOR SEQ ID NO:372:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:372:

GGCAGAACTA

(2) INFORMATION FOR SEQ ID NO:373:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:373:

GCAGAACTAC

(2) INFORMATION FOR SEQ ID NO:374:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:374:

CAGAACTACA

(2) INFORMATION FOR SEQ ID NO:375:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:375:

AGAACTACAC

(2) INFORMATION FOR SEQ ID NO:376:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 121 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:376:

GAACTACACA

(2) INFORMATION FOR SEQ ID NO:377:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:377:

AACTACACAC

(2) INFORMATION FOR SEQ ID NO:378:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:378:

ACTACACACC

(2) INFORMATION FOR SEQ ID NO:379:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:379:

CTACACACCA

(2) INFORMATION FOR SEQ ID NO:380:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:380:

TACACACCAAG

(2) INFORMATION FOR SEQ ID NO:381:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:381:

ACACACCAGG

(2) INFORMATION FOR SEQ ID NO:382:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:382:

CACACCAGGG

(2) INFORMATION FOR SEQ ID NO:383:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:383:

ACACCAGGGC

(2) INFORMATION FOR SEQ ID NO:384:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:384:

CACCAGGGCC

(2) INFORMATION FOR SEQ ID NO:385:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 122 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:385:
ACCAGGGCCA

(2) INFORMATION FOR SEQ ID NO:386:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:386:
CCAGGGCCAG

(2) INFORMATION FOR SEQ ID NO:387:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:387:
CAGGGCCAGG

(2) INFORMATION FOR SEQ ID NO:388:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:388:
AGGGCCAGGG

(2) INFORMATION FOR SEQ ID NO:389:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:389:
GGGCCAGGGG

(2) INFORMATION FOR SEQ ID NO:390:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:390:
GGCCAGGGGT

(2) INFORMATION FOR SEQ ID NO:391:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:391:
GCCAGGGGTC

(2) INFORMATION FOR SEQ ID NO:392:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:392:
CCAGGGGTCA

(2) INFORMATION FOR SEQ ID NO:393:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:393:
CAGGGGTCA

(2) INFORMATION FOR SEQ ID NO:394:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:394:

- 123 -

AGGGGTCAGA

(2) INFORMATION FOR SEQ ID NO:395:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:395:

GGGGTCAGAT

(2) INFORMATION FOR SEQ ID NO:396:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:396:

GGGTCAGATA

(2) INFORMATION FOR SEQ ID NO:397:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:397:

GGTCAGATAT

(2) INFORMATION FOR SEQ ID NO:398:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:398:

GTCAGATATC

(2) INFORMATION FOR SEQ ID NO:399:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:399:

TCAGATATCC

(2) INFORMATION FOR SEQ ID NO:400:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:400:

CAGATATCCA

(2) INFORMATION FOR SEQ ID NO:401:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:401:

AGATATCCAC

(2) INFORMATION FOR SEQ ID NO:402:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:402:

GATATCCACT

(2) INFORMATION FOR SEQ ID NO:403:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:403:

ATATCCACTG

- 124 -

(2) INFORMATION FOR SEQ ID NO:404:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:404:

TATCCACTGA

(2) INFORMATION FOR SEQ ID NO:405:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:405:

ATCCACTGAC

(2) INFORMATION FOR SEQ ID NO:406:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:406:

TCCACTGACC

(2) INFORMATION FOR SEQ ID NO:407:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:407:

CCACTGACCT

(2) INFORMATION FOR SEQ ID NO:408:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:408:

CACTGACCTT

(2) INFORMATION FOR SEQ ID NO:409:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:409:

ACTGACCTTT

(2) INFORMATION FOR SEQ ID NO:410:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:410:

CTGACCTTTG

(2) INFORMATION FOR SEQ ID NO:411:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:411:

TGAACCTTTGG

(2) INFORMATION FOR SEQ ID NO:412:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:412:

GACCTTTGGA

(2) INFORMATION FOR SEQ ID NO:413:

- 125 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:413:

ACCTTTGGAT

(2) INFORMATION FOR SEQ ID NO:414:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:414:

CCTTTGGATG

(2) INFORMATION FOR SEQ ID NO:415:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:415:

CTTTGGATGG

(2) INFORMATION FOR SEQ ID NO:416:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:416:

TTTGGATGGT

(2) INFORMATION FOR SEQ ID NO:417:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:417:

TTGGATGGTG

(2) INFORMATION FOR SEQ ID NO:418:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:418:

TGGATGGTGC

(2) INFORMATION FOR SEQ ID NO:419:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:419:

GGATGGTGCT

(2) INFORMATION FOR SEQ ID NO:420:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:420:

GATGGTGCTA

(2) INFORMATION FOR SEQ ID NO:421:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:421:

ATGGTGCTAC

(2) INFORMATION FOR SEQ ID NO:422:

- (i) SEQUENCE CHARACTERISTICS:

- 126 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:422:

TGGTGCTACA

(2) INFORMATION FOR SEQ ID NO:423:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:423:

GGTGCTACAA

(2) INFORMATION FOR SEQ ID NO:424:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:424:

GTGCTACAAG

(2) INFORMATION FOR SEQ ID NO:425:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:425:

TGCTACAAGC

(2) INFORMATION FOR SEQ ID NO:426:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:426:

GCTACAAGCT

(2) INFORMATION FOR SEQ ID NO:427:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:427:

CTACAAGCTA

(2) INFORMATION FOR SEQ ID NO:428:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:428:

TACAAGCTAG

(2) INFORMATION FOR SEQ ID NO:429:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:429:

ACAAGCTAGT

(2) INFORMATION FOR SEQ ID NO:430:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:430:

CAAGCTAGTA

(2) INFORMATION FOR SEQ ID NO:431:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid

- 127 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:431:

AAGCTAGTAC

(2) INFORMATION FOR SEQ ID NO:432:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:432:

AGCTAGTACC

(2) INFORMATION FOR SEQ ID NO:433:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:433:

OCTAGTACCA

(2) INFORMATION FOR SEQ ID NO:434:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:434:

CTAGTACCAG

(2) INFORMATION FOR SEQ ID NO:435:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:435:

TAGTACCAGT

(2) INFORMATION FOR SEQ ID NO:436:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:436:

AGTACCAGTT

(2) INFORMATION FOR SEQ ID NO:437:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:437:

GTACCAGTTG

(2) INFORMATION FOR SEQ ID NO:438:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:438:

TACCAGTTGA

(2) INFORMATION FOR SEQ ID NO:439:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:439:

ACCAGTTGAG

(2) INFORMATION FOR SEQ ID NO:440:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 128 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:440:

CCAGTTGAGC

(2) INFORMATION FOR SEQ ID NO:441:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:441:

CAGTTGAGCC

(2) INFORMATION FOR SEQ ID NO:442:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:442:

AGTTGAGCCA

(2) INFORMATION FOR SEQ ID NO:443:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:443:

GTTGAGCCAG

(2) INFORMATION FOR SEQ ID NO:444:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:444:

TTGAGCCAGA

(2) INFORMATION FOR SEQ ID NO:445:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:445:

TGAGCCAGAT

(2) INFORMATION FOR SEQ ID NO:446:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:446:

GAGCCAGATA

(2) INFORMATION FOR SEQ ID NO:447:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:447:

AGCCAGATAA

(2) INFORMATION FOR SEQ ID NO:448:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:448:

GCCAGATAAG

(2) INFORMATION FOR SEQ ID NO:449:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 129 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:449:

CCAGATAAGG

(2) INFORMATION FOR SEQ ID NO:450:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:450:

CAGATAAGGT

(2) INFORMATION FOR SEQ ID NO:451:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:451:

AGATAAGGTA

(2) INFORMATION FOR SEQ ID NO:452:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:452:

GATAAGGTAG

(2) INFORMATION FOR SEQ ID NO:453:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:453:

ATAAGGTAGA

(2) INFORMATION FOR SEQ ID NO:454:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:454:

TAAGGTAGAA

(2) INFORMATION FOR SEQ ID NO:455:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:455:

AAGGTAGAAG

(2) INFORMATION FOR SEQ ID NO:456:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:456:

AGGTAGAAGA

(2) INFORMATION FOR SEQ ID NO:457:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:457:

GGTAGAAGAG

(2) INFORMATION FOR SEQ ID NO:458:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:458:

- 130 -

GTAGAAGAGG

(2) INFORMATION FOR SEQ ID NO:459:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:459:

TAGAAGAGGC

(2) INFORMATION FOR SEQ ID NO:460:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:460:

AGAAGAGGCC

(2) INFORMATION FOR SEQ ID NO:461:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:461:

GAAGAGGCCA

(2) INFORMATION FOR SEQ ID NO:462:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:462:

AAGAGGCCAA

(2) INFORMATION FOR SEQ ID NO:463:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:463:

AGAGGCCAAT

(2) INFORMATION FOR SEQ ID NO:464:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:464:

GAGGCCAATA

(2) INFORMATION FOR SEQ ID NO:465:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:465:

AGGCCAATAA

(2) INFORMATION FOR SEQ ID NO:466:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:466:

GCCCAATAAA

(2) INFORMATION FOR SEQ ID NO:467:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:467:

GCCAATAAAG

- 131 -

(2) INFORMATION FOR SEQ ID NO:468:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:468:

CCAATAAAGO

(2) INFORMATION FOR SEQ ID NO:469:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:469:

CAATAAAGGA

(2) INFORMATION FOR SEQ ID NO:470:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:470:

AATAAAGGAG

(2) INFORMATION FOR SEQ ID NO:471:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:471:

ATAAAGGAGA

(2) INFORMATION FOR SEQ ID NO:472:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:472:

TAAAGGAGAG

(2) INFORMATION FOR SEQ ID NO:473:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:473:

AAAGGAGAGA

(2) INFORMATION FOR SEQ ID NO:474:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:474:

AAGGAGAGAA

(2) INFORMATION FOR SEQ ID NO:475:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:475:

AGGAGAGAAC

(2) INFORMATION FOR SEQ ID NO:476:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:476:

GGAGAGAACA

(2) INFORMATION FOR SEQ ID NO:477:

- 132 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:477:

GAGAGAACAC

(2) INFORMATION FOR SEQ ID NO:478:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:478:

AGAGAACACC

(2) INFORMATION FOR SEQ ID NO:479:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:479:

GAGAACAACCA

(2) INFORMATION FOR SEQ ID NO:480:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:480:

AGAACACCAG

(2) INFORMATION FOR SEQ ID NO:481:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:481:

GAACACCAGC

(2) INFORMATION FOR SEQ ID NO:482:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:482:

AACACCAGCT

(2) INFORMATION FOR SEQ ID NO:483:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:483:

ACACCAGCTT

(2) INFORMATION FOR SEQ ID NO:484:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:484:

CACCAGCTTG

(2) INFORMATION FOR SEQ ID NO:485:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:485:

ACCAGCTTGT

(2) INFORMATION FOR SEQ ID NO:486:

- (i) SEQUENCE CHARACTERISTICS:

- 133 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:486:

CCAGCTTGTT

(2) INFORMATION FOR SEQ ID NO:487:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:487:

CAGCTTGTTA

(2) INFORMATION FOR SEQ ID NO:488:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:488:

AGCTTGTTAC

(2) INFORMATION FOR SEQ ID NO:489:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:489:

GCTTGTTACA

(2) INFORMATION FOR SEQ ID NO:490:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:490:

CTTGTTACAC

(2) INFORMATION FOR SEQ ID NO:491:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:491:

TTGTTACACC

(2) INFORMATION FOR SEQ ID NO:492:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:492:

TGTTACACCC

(2) INFORMATION FOR SEQ ID NO:493:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:493:

GTTACACCT

(2) INFORMATION FOR SEQ ID NO:494:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:494:

TTACACCTG

(2) INFORMATION FOR SEQ ID NO:495:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid

- 134 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:495:

TACACCOCTGT

(2) INFORMATION FOR SEQ ID NO:496:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:496:

ACACCOCTGTG

(2) INFORMATION FOR SEQ ID NO:497:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:497:

CACCOCTGTGA

(2) INFORMATION FOR SEQ ID NO:498:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:498:

ACCOCTGTGAG

(2) INFORMATION FOR SEQ ID NO:499:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:499:

COCTGTGAGC

(2) INFORMATION FOR SEQ ID NO:500:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:500:

CCTGTGAGCC

(2) INFORMATION FOR SEQ ID NO:501:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:501:

CTGTGAGCCT

(2) INFORMATION FOR SEQ ID NO:502:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:502:

TGTGAGCCTG

(2) INFORMATION FOR SEQ ID NO:503:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(B) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:503:

GTGAGCCTGC

(2) INFORMATION FOR SEQ ID NO:504:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 135 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:504:

TGAGCCTGCA

(2) INFORMATION FOR SEQ ID NO:505:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:505:

GAGCCTGCAT

(2) INFORMATION FOR SEQ ID NO:506:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:506:

AGCCTGCATG

(2) INFORMATION FOR SEQ ID NO:507:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:507:

GCCTGCATGG

(2) INFORMATION FOR SEQ ID NO:508:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:508:

CCTGCATGGA

(2) INFORMATION FOR SEQ ID NO:509:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:509:

CTGCATGGAA

(2) INFORMATION FOR SEQ ID NO:510:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:510:

TGCAATGGAAT

(2) INFORMATION FOR SEQ ID NO:511:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:511:

GCATGGAATG

(2) INFORMATION FOR SEQ ID NO:512:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:512:

CATGGAATGG

(2) INFORMATION FOR SEQ ID NO:513:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 136 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:513:
ATGGAATGGA

(2) INFORMATION FOR SEQ ID NO:514:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:514:
TGGAATGGAT

(2) INFORMATION FOR SEQ ID NO:515:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:515:
GGAATGGATG

(2) INFORMATION FOR SEQ ID NO:516:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:516:
GAATGGATGA

(2) INFORMATION FOR SEQ ID NO:517:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:517:
AATGGATGAC

(2) INFORMATION FOR SEQ ID NO:518:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:518:
ATGGATGACC

(2) INFORMATION FOR SEQ ID NO:519:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:519:
TGGATGACCC

(2) INFORMATION FOR SEQ ID NO:520:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:520:
GGATGACCT

(2) INFORMATION FOR SEQ ID NO:521:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:521:
GATGACCTG

(2) INFORMATION FOR SEQ ID NO:522:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:522:

- 137 -

ATGACCOCTGA

(2) INFORMATION FOR SEQ ID NO:523:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:523:

TGACCOCTGAG

(2) INFORMATION FOR SEQ ID NO:524:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:524:

GACCOCTGAGA

(2) INFORMATION FOR SEQ ID NO:525:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:525:

ACCOCTGAGAG

(2) INFORMATION FOR SEQ ID NO:526:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:526:

CCOCTGAGAGA

(2) INFORMATION FOR SEQ ID NO:527:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:527:

CCTGAGAGAG

(2) INFORMATION FOR SEQ ID NO:528:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:528:

CTGAGAGAGA

(2) INFORMATION FOR SEQ ID NO:529:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:529:

TGAGAGAGAAA

(2) INFORMATION FOR SEQ ID NO:530:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:530:

GAGAGAGAAAG

(2) INFORMATION FOR SEQ ID NO:531:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:531:

AGAGAGAAAGT

- 138 -

(2) INFORMATION FOR SEQ ID NO-532:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-532:

GAGAGAAGTG

(2) INFORMATION FOR SEQ ID NO-533:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-533:

AGAGAAAGTGT

(2) INFORMATION FOR SEQ ID NO-534:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-534:

GAGAAAGTGT

(2) INFORMATION FOR SEQ ID NO-535:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-535:

AGAAGTGTTA

(2) INFORMATION FOR SEQ ID NO-536:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-536:

GAAGTGTTAG

(2) INFORMATION FOR SEQ ID NO-537:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-537:

AAGTGTTAGA

(2) INFORMATION FOR SEQ ID NO-538:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-538:

AGTGTTAGAG

(2) INFORMATION FOR SEQ ID NO-539:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-539:

GTGTTAGAGT

(2) INFORMATION FOR SEQ ID NO-540:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-540:

TGTTAGAGTG

(2) INFORMATION FOR SEQ ID NO-541:

- 139 -

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:541:

GTTAGAGTGG

(2) INFORMATION FOR SEQ ID NO:542:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:542:

TTAGAGTGGA

(2) INFORMATION FOR SEQ ID NO:543:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:543:

TAGAGTGGAG

(2) INFORMATION FOR SEQ ID NO:544:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:544:

AGAGTGGAGG

(2) INFORMATION FOR SEQ ID NO:545:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:545:

GAGTGGAGGT

(2) INFORMATION FOR SEQ ID NO:546:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:546:

AGTGGAGGTT

(2) INFORMATION FOR SEQ ID NO:547:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:547:

GTGGAGGTTT

(2) INFORMATION FOR SEQ ID NO:548:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:548:

TGGAGGTTTG

(2) INFORMATION FOR SEQ ID NO:549:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:549:

GGAGGTTTGA

(2) INFORMATION FOR SEQ ID NO:550:

(i) SEQUENCE CHARACTERISTICS:

- 140 -

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:550:

GAGGTTTGAC

(2) INFORMATION FOR SEQ ID NO:551:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:551:

AGGTTTGACA

(2) INFORMATION FOR SEQ ID NO:552:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:552:

GGTTTGACAG

(2) INFORMATION FOR SEQ ID NO:553:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:553:

GTTTGACAGC

(2) INFORMATION FOR SEQ ID NO:554:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:554:

TTTGACAGCC

(2) INFORMATION FOR SEQ ID NO:555:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:555:

TTGACAGCCG

(2) INFORMATION FOR SEQ ID NO:556:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:556:

TGACAGCCCG

(2) INFORMATION FOR SEQ ID NO:557:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:557:

GACAGCCGCG

(2) INFORMATION FOR SEQ ID NO:558:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:558:

ACAGCCGCGT

(2) INFORMATION FOR SEQ ID NO:559:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid

- 141 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:559:

CAGCCGCCTA

(2) INFORMATION FOR SEQ ID NO:560:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:560:

AGCCGCCTAG

(2) INFORMATION FOR SEQ ID NO:561:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:561:

GCCGCCTAGC

(2) INFORMATION FOR SEQ ID NO:562:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:562:

CCGCCTAGCA

(2) INFORMATION FOR SEQ ID NO:563:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:563:

CGCCTAGCAT

(2) INFORMATION FOR SEQ ID NO:564:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:564:

GCCTAGCATT

(2) INFORMATION FOR SEQ ID NO:565:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:565:

CCTAGCATTT

(2) INFORMATION FOR SEQ ID NO:566:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:566:

CTAGCATTTT

(2) INFORMATION FOR SEQ ID NO:567:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:567:

TAGCATTTCA

(2) INFORMATION FOR SEQ ID NO:568:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 142 -

(i) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:568:

AGCATTTCAT

(2) INFORMATION FOR SEQ ID NO:569:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:569:

GCATTTCATC

(2) INFORMATION FOR SEQ ID NO:570:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:570:

CATTTTCATCA

(2) INFORMATION FOR SEQ ID NO:571:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:571:

ATTTCATCAC

(2) INFORMATION FOR SEQ ID NO:572:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:572:

TTTCATCAAG

(2) INFORMATION FOR SEQ ID NO:573:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:573:

TTCATCACGT

(2) INFORMATION FOR SEQ ID NO:574:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:574:

TCATCACGTG

(2) INFORMATION FOR SEQ ID NO:575:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:575:

CATCACGTGG

(2) INFORMATION FOR SEQ ID NO:576:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:576:

ATCACGTGGC

(2) INFORMATION FOR SEQ ID NO:577:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 143 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:577:
TCACGTGGCC

(2) INFORMATION FOR SEQ ID NO:578:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:578:
CACGTGGCCC

(2) INFORMATION FOR SEQ ID NO:579:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:579:
ACGTGGCCCCG

(2) INFORMATION FOR SEQ ID NO:580:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:580:
CGTGGCCCCGA

(2) INFORMATION FOR SEQ ID NO:581:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:581:
GTGGCCCCGAG

(2) INFORMATION FOR SEQ ID NO:582:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:582:
TGGCCCCGAGA

(2) INFORMATION FOR SEQ ID NO:583:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:583:
GGCCCCGAGAG

(2) INFORMATION FOR SEQ ID NO:584:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:584:
GCCCCGAGAGC

(2) INFORMATION FOR SEQ ID NO:585:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:585:
CCCGAGAGCT

(2) INFORMATION FOR SEQ ID NO:586:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:586:

- 144 -

COGAGAGCTG

(2) INFORMATION FOR SEQ ID NO:587:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:587:

CGAGAGCTGC

(2) INFORMATION FOR SEQ ID NO:588:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:588:

GAGAGCTGCA

(2) INFORMATION FOR SEQ ID NO:589:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:589:

AGAGCTGCAT

(2) INFORMATION FOR SEQ ID NO:590:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:590:

GAGCTGCATC

(2) INFORMATION FOR SEQ ID NO:591:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:591:

AGCTGCATCC

(2) INFORMATION FOR SEQ ID NO:592:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:592:

GCTGCATCCG

(2) INFORMATION FOR SEQ ID NO:593:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:593:

CTGCATCCGG

(2) INFORMATION FOR SEQ ID NO:594:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:594:

TGCATCCGGA

(2) INFORMATION FOR SEQ ID NO:595:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:595:

GCATCCGGAG

- 145 -

(2) INFORMATION FOR SEQ ID NO:596:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:596:

CATCCGGAGT

(2) INFORMATION FOR SEQ ID NO:597:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:597:

ATCCGGAGTA

(2) INFORMATION FOR SEQ ID NO:598:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:598:

TCCGGAGTAC

(2) INFORMATION FOR SEQ ID NO:599:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:599:

CCGGAGTACT

(2) INFORMATION FOR SEQ ID NO:600:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:600:

CCGAGTACTT

(2) INFORMATION FOR SEQ ID NO:601:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:601:

GGAGTACTTC

(2) INFORMATION FOR SEQ ID NO:602:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:602:

GAGTACTTCA

(2) INFORMATION FOR SEQ ID NO:603:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:603:

AGTACTTCAA

(2) INFORMATION FOR SEQ ID NO:604:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:604:

GTACTTCAAG

(2) INFORMATION FOR SEQ ID NO:605:

- 146 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:605:

TACTTCAAGA

(2) INFORMATION FOR SEQ ID NO:606:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:606:

ACTTCAAGAA

(2) INFORMATION FOR SEQ ID NO:607:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:607:

CTTCAAGAAC

(2) INFORMATION FOR SEQ ID NO:608:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:608:

TTCAAGAACT

(2) INFORMATION FOR SEQ ID NO:609:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:609:

TCAAGAACTG

(2) INFORMATION FOR SEQ ID NO:610:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:610:

CAAGAACTGC

(2) INFORMATION FOR SEQ ID NO:611:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:611:

AAGAACTGCT

(2) INFORMATION FOR SEQ ID NO:612:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:612:

AGAACTGCTG

(2) INFORMATION FOR SEQ ID NO:613:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single

- 147 -

(D) TOPOLOGY: linear

(H) MOLECULE TYPE: DNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO:613:

GAAC TGCTGA

- 148 -

(2) INFORMATION FOR SEQ ID NO:614:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1305 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:614:

GAAGAGATT	GGGAGAACAT	GACCTGGATG	CAGTGGGAAA	AAGAAATTCA	CAATCACACA	60
AAATACATAT	ACTCCTTACT	TGAAAAATCG	CAGAACCAAC	AAGAAAGAA	TGAACAAGAA	120
CTATTGGAAT	TGGATCAATG	GGCAAGTTTG	TGGAATTGGT	TTGACATAAC	AAATGGCTG	180
TGGTATATAA	AAATATTTCAT	AATGGTAGTA	GGAGGCTTGA	TAGGTTTAAG	AATAGTTTTT	240
GCTGTACTTT	CTATAGTGAA	TAGAGTTAGG	CAGGQATACT	CACCATTGTC	GTTTCAGACC	300
CTCCTCCCAA	CCCCGAGGGG	ACCCGACAGG	CCCGAAGGAA	TCGAAGAAGA	AGGTGGAGAG	360
AGAGACAGAG	ACAGATCCAC	TCGATTAGTA	CACGGATTCT	TAGCACTTTT	CTGGGACGAC	420
CTGAGGAGCC	TGTGCCTCTT	CCTCTACCAC	CAGTTGAGAG	ACTTACTCTT	GATTGTAAAC	480
AGGATTGTGG	AACCTCTGGG	ACGCAGGGGA	TGGGAAGCCC	TCAAATATTG	GTGGAACCTC	540
CTAAGTATT	GGAGCCAGGA	ACTGCAGAAG	AGTGCTGTTA	TCTTGCTCAA	TGCCACCGCC	600
ATAGCAGTAG	CTGAGGGGAC	AGATAGAGTT	TTAGAAGTAT	TACAAAGAGC	TTATAGAGCT	660
ATCCTCCACA	TACCTAGAAG	AATAAGACAG	GGCCTCGAAA	TGGCTTTGCT	ATAAAATGGG	720
TGGCAAGTGA	GCAAAAAGTA	GTGTAGTCAG	ATAGCATGCA	TCATAAGGGG	TGGGGGCCAA	780
CAACTAACAA	TGCTGATCGT	GCCTGGCTAG	AAGCACAAGA	GAAGGAAGAA	GCGGGTTTTC	840
CAGTCAAACC	TCAGGTAGCT	GTAGATCTTA	GCCACTTTTT	AAAAGAAAAG	GGGGGACTGG	900
AAGGGCTAAT	TCACTCCCAA	AGAAGACAAG	ATACACAGTG	CTGCRAACTA	TTACCAAGTG	960
AGTCAGCGAA	GATAGAAGAG	GCCAATGGAG	GAGAAAACCA	CAGATTGTTT	TGTTGGGGAC	1020
TTTCCATCCG	TTGGGGACTT	TCCAAGGCGG	CGTGGCCTGG	GTGACTAGTT	CCGTTGGGGA	1080
CTTTCCAAGA	AGGCGCGGCC	TGGGCGGGAC	TGGGGAGTGG	CGAGCCCTCA	GATGCTGCAT	1140
ATAAGCAGCT	GCTTCTGCT	GTTACTGGGT	CTCTGGGGTT	AGACCAGATC	TGAGCCTGGG	1200
AGCTCTCTGG	CTAAGTAGGG	AACCCACTGC	TTAAGCCTCA	ATAAGCTTGG	CCTTGAGTGC	1260
TTCAAGTAGT	GTGTGCCCGT	CTGTTGTGTG	ACTCTGGTAT	CTAGA		1305

- 149 -

(2) INFORMATION FOR SEQ ID NO:615:

- (1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1208 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:615:

GAAACAATTT GGGATAACAT GACCTGGATG CAGTGGGAAA GAGAAATGA CAATTACACA	60
AACATAATAT ACACCTTAAT TGAAGAATCG CAGAACCAAC AAGAAAAAAA TGAAGTAGAA	120
TTATTGGAAT TGGATAAATG GGCAAATTG TGGAAATGGT TTAGTATATC AACTGGGCTA	180
TGGTATATAA AATTATTCAT AATGGTAGTA GGAGGCTTGG TAGGTTTAAG AATAGTTTTT	240
ACTGTACTTT CTATAGTGAA TAGAGTTAGG CAGGGATACT CACCATTGTC GTTTCAGACC	300
CACCTCCCAA CCCCGAAGGG ACCCGACAGG CCAGAAGGAA TCGAAGAGA AGGTGGAGAG	360
AGAGACAGAG GCAGCTCCAC TCGATTAGTG CACGGATTCT TAGCACTTTT CTGGGACGAC	420
CTGAGGAGTC TGTGCCTCTT CAGCTACCAC CACTTGAGAG ACTTACTCTT GATTGTAAAG	480
AGGATTGTGG AACTTCTGGG ACGCAGGGGA TGGGAAGCCC TCAAATACTG GTGGAATCTC	540
CTGCAGTATT GGAGGCAGGA ACTACAGAAG AGTGCTGTTA GCTTGTTCAG TGGCAGGGCC	600
ATAGCAGTAG CTGAGGGGAC AGATAGAGTT ATAGAAGCTT TACGAAGGGC TTATAGAGCT	660
ATTCTCCACA TACCTAGAAG AATAAGACAG GGCTTAGAAA GGGCTTTGCT ATAAATGGG	720
TGGCAAGTGG TCAGAAAGTA GTGTGGTTAG AAGGCATGTA CCTTTAAGAC AAGGCAGCTA	780
TAGATCTTAG CCGCTTTTAA AAAGAAAAGG GGGGACTGGA AGGGCTAATT CACTCACAGA	840
GAAGATCAGT TGAACCAGAA GAAGATAGAA GAGGCCATGA AGAAGAAAAC AACAGATTGT	900
TCCGTTTGTG CCGTTGGGGA CTTTCCAGGA GACGTGGCCT GAGTGATAAG CCGCTGGGGA	960
CITTCGGAAG AGGCGTGACG GGACTTTCCA AGGCGACGTG GCCTGGGCGG GACTGGGGAG	1020
TGGCGAGCCC TCAGATGCTG CATATAAGCA GCTGCTTTCT GCCTGTACTG GGTCTCTCTG	1080
GTTAGACCAG ATCTGAGCCT GGGAGCTCTC TGGCTAACTA GGGAACCCAC TGCTTAAGCC	1140
TCAATAAAGC TTGCCTTGAG TGCTCAAGT AGTGTGTGCC COTCTGTGTG GTGACTCTGG	1200
TATCTAGA	1208

- 150 -

(2) INFORMATION FOR SEQ ID NO:616:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:616:

TGGAAGGGCT AATTGGT

18

(2) INFORMATION FOR SEQ ID NO:617:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:617:

ATCTCCCTA AAAAATTAGC CTGTC

25

(2) INFORMATION FOR SEQ ID NO:618:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:618:

AGGCTCAGAT CTGGTCTAAC

20

(2) INFORMATION FOR SEQ ID NO:619:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:619:

AGCAGCAGGA AGCACTATGG

20

- 151 -

(2) INFORMATION FOR SEQ ID NO:620:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:620:

TOCTAGAGAT TTTCCACAC

19

(2) INFORMATION FOR SEQ ID NO:621:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:621:

AGTGAATAGA GTTAGGCAGG

20

(2) INFORMATION FOR SEQ ID NO:622:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:622:

GTAAGACAGT ATGATCAGAT A

21

(2) INFORMATION FOR SEQ ID NO:623:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:623:

TTGTAGGGAA TTCCAAATTC C

21

- 152 -

(2) INFORMATION FOR SEQ ID NO:624:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:624:

CAGGATCCTA CACCTGTCAA CATAAT

26

(2) INFORMATION FOR SEQ ID NO:625:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:625:

GGGAATTCTT TATTCCTGCT TG

22

(2) INFORMATION FOR SEQ ID NO:626:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:626:

CCAGAAGTTC CACAATCC

18

(2) INFORMATION FOR SEQ ID NO:627:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:627:

TTCCTCTAGG TATGTGGAG

19

- 153 -

(2) INFORMATION FOR SEQ ID NO:628:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:628:

AGTGAATTAG CCTTCCAG

19

(2) INFORMATION FOR SEQ ID NO:629:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:629:

TGCTAGAGAT TTCCACAC

19

(2) INFORMATION FOR SEQ ID NO:630:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:630:

TGCTCTGGAA AATCAT

17

(2) INFORMATION FOR SEQ ID NO:631:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:631:

CTTCTATAG TGAATAGAG

19

- 154 -

(2) INFORMATION FOR SEQ ID NO:632:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:632:

TATTGGAGTC AGGAAC

17

(2) INFORMATION FOR SEQ ID NO:633:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:633:

GGTCTAACCA GAGAGAC

17

(2) INFORMATION FOR SEQ ID NO:634:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:634:

Ala	Val	Arg	Glu	Arg	Met	Arg	Arg	Ala	Glu	Pro	Ala	Ala
1				5					10			

(2) INFORMATION FOR SEQ ID NO:635:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:635:

Pro	Thr	Ser	Gln	Ser	Arg	Gly	Asp	Pro	Thr	Gly	Pro	Lys	Glu	Lys
1				5				10				15		

Lys	Lys	Val	Glu	Arg	Glu	Thr	Glu	Thr	Asp	Pro	Phe	Asp	Thr
			20				25					30	

Asp	Pro	His
		35

- 155 -

(2) INFORMATION FOR SEQ ID NO:636:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 36 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:636:

```

Pro Ser Ser Gln Pro Arg Gly Asp Pro Thr Gly Pro Lys Glu Ser Lys
1           5           10           15
Lys Lys Val Glu Arg Glu Thr Glu Thr Asp Pro Leu Asp Tyr Thr
                20           25           30
Asp Ser His
                35

```

(2) INFORMATION FOR SEQ ID NO:637:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 36 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:637:

```

Pro Thr Ser Gln Pro Arg Arg Asp Pro Thr Gly Gln Lys Glu Ser Lys
1           5           10           15
Lys Lys Val Glu Arg Glu Thr Glu Ala Ala Pro Leu Asp Cys Thr
                20           25           30
Asp Ser His
                35

```

(2) INFORMATION FOR SEQ ID NO:638:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 110 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:638:

```

Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg
1           5           10           15
Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile His Ser Ile Ser Glu
                20           25           30
Arg Ile Leu Ser Thr Tyr Leu Gly Arg Ser Ala Glu Pro Val Pro Leu
                35           40           45
Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn Glu Asp Cys
                50           55           60
Gly Thr Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Ile Leu Val Glu
-65           70           75           80

```

- 156 -

Ser Pro Thr Val Leu Glu Ser Gly Thr Lys Glu Cys Cys Leu 95
 85 90
 Ala Gln Cys His Ser His Ser Ser Ser Gly Asp Arg 110
 100 105 110

(2) INFORMATION FOR SEQ ID NO:639:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 110 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:639:

Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg 15
 1 5 10
 Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile His Ser Ile Ser Thr 30
 20 25 30
 Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Glu Glu Pro Val Pro Leu 45
 35 40 45
 Pro Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn Lys Asp Cys 60
 50 55 60
 Gly Thr Ser Gly Thr Gln Gly Met Gly Ser Pro Gln Ile Leu Val Glu 80
 65 70 75 80
 Pro Pro Lys Val Leu Glu Pro Gly Thr Ala Glu Glu Cys Cys Tyr Leu 95
 85 90 95
 Ala Gln Cys His Arg His Ser Ser Ser Gly Asp Arg 110
 100 105 110

(2) INFORMATION FOR SEQ ID NO:640:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 110 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:640:

Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg 15
 1 5 10 15
 Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Leu His Ser Ile Ser Ala 30
 20 25 30
 Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Glu Glu Ser Val Pro Leu 45
 35 40 45
 Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn Glu Asp Cys 60
 50 55 60
 Gly Thr Ser Gly Thr Gln Gly Met Gly Ser Pro Gln Ile Leu Val Glu 80
 65 70 75 80
 Ser Pro Ala Val Leu Glu Ala Gly Thr Thr Glu Glu Cys Cys Leu 95
 85 90 95

- 157 -

Val Gln Trp His Gly His Ser Ser Ser Gly Asp Arg
 100 105 110

(2) INFORMATION FOR SEQ ID NO:641:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 237 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:641:

Glu Gln Ile Trp Asn Asn Met Thr Trp Met Glu Trp Asp Arg Glu Ile
 1 5 10 15
 Asn Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gln Asn
 20 25 30
 Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala
 35 40 45
 Ser Leu Trp Asn Trp Phe Asn Ile Thr Asn Trp Leu Trp Tyr Ile Lys
 50 55 60
 Leu Phe Ile Met Ile Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe
 65 70 75 80
 Ala Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu
 85 90 95
 Ser Phe Gln Thr His Leu Pro Ile Pro Arg Gly Pro Asp Arg Pro Glu
 100 105 110
 Gly Ile Glu Glu Glu Gly Gly Glu Arg Asp Arg Asp Arg Ser Ile Arg
 115 120 125
 Leu Val Asn Gly Ser Leu Ala Leu Ile Trp Asp Asp Leu Arg Ser Leu
 130 135 140
 Cys Leu Phe Ser Tyr His Arg Leu Arg Asp Leu Leu Leu Ile Val Thr
 145 150 155 160
 Arg Ile Val Glu Leu Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr
 165 170 175
 Trp Trp Asn Leu Leu Gln Tyr Trp Ser Gln Glu Leu Lys Asn Ser Ala
 180 185 190
 Val Asn Leu Leu Asn Ala Thr Ala Ile Ala Val Ala Glu Gly Thr Asp
 195 200 205
 Arg Val Ile Glu Val Leu Gln Ala Ala Tyr Arg Ala Ile Arg His Ile
 210 215 220
 Pro Arg Arg Ile Arg Gln Gly Leu Glu Arg Ile Leu Leu
 225 230 235

- 158 -

(2) INFORMATION FOR SEQ ID NO:642:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 237 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:642:

```

Glu Glu Ile Trp Glu Asn Met Thr Trp Met Gln Trp Glu Lys Glu Ile
1      5      10      15
His Asn His Thr Lys Tyr Ile Tyr Ser Leu Leu Glu Lys Ser Gln Asn
20     25     30
Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Gln Trp Ala
35     40     45
Ser Leu Trp Asn Trp Phe Asp Ile Thr Lys Trp Leu Trp Tyr Ile Lys
50     55     60
Ile Phe Ile Met Val Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe
65     70     75     80
Ala Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu
85     90     95
Ser Phe Gln Thr Leu Leu Pro Thr Pro Arg Gly Pro Asp Arg Pro Glu
100    105    110
Gly Ile Glu Glu Met Gly Gly Glu Arg Asp Arg Asp Arg Ser Thr Arg
115    120    125
Leu Val His Gly Phe Leu Ala Leu Phe Trp Asp Asp Leu Arg Ser Leu
130    135    140
Cys Leu Phe Leu Tyr His His Leu Arg Asp Leu Leu Leu Ile Val Thr
145    150    155    160
Arg Ile Val Glu Leu Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr
165    170    175
Trp Trp Asn Leu Leu Lys Tyr Trp Ser Gln Glu Leu Gln Lys Ser Ala
180    185    190
Val Ile Leu Leu Asn Ala Thr Ala Ile Ala Val Ala Glu Gly Thr Asp
195    200    205
Arg Val Leu Glu Val Leu Gln Arg Ala Tyr Arg Ala Ile Leu His Ile
210    215    220
Pro Arg Arg Ile Arg Gln Gly Leu Glu Met Ala Leu Leu
225    230    235

```

- 159 -

(2) INFORMATION FOR SEQ ID NO:643:

- (1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 237 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:643:

Glu Thr Ile Trp Asp Asn Met Thr Trp Met Gln Trp Glu Arg Glu Ile
 1 5 10 15
 Asp Asn Tyr Thr Asn Ile Ile Tyr Thr Leu Ile Glu Glu Ser Gln Asn
 20 25 30
 Gln Gln Glu Lys Asn Glu Leu Glu Leu Leu Glu Leu Asp Lys Trp Ala
 35 40 45
 Asn Leu Trp Asn Trp Phe Ser Ile Ser Asn Trp Leu Trp Tyr Ile Lys
 50 55 60
 Leu Phe Ile Met Val Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe
 65 70 75 80
 Thr Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu
 85 90 95
 Ser Phe Gln Thr His Leu Pro Thr Pro Lys Gly Pro Asp Arg Pro Glu
 100 105 110
 Gly Ile Glu Glu Glu Gly Gly Glu Arg Asp Arg Gly Ser Ser Thr Arg
 115 120 125
 Leu Val His Gly Phe Leu Ala Leu Phe Trp Asp Asp Leu Arg Ser Leu
 130 135 140
 Cys Leu Phe Ser Tyr His His Leu Arg Asp Leu Leu Leu Ile Val Thr
 145 150 155 160
 Arg Ile Val Glu Leu Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr
 165 170 175
 Trp Trp Asn Leu Leu Gln Tyr Trp Arg Gln Glu Leu Gln Lys Ser Ala
 180 185 190
 Val Ser Leu Phe Asn Gly Thr Ala Ile Ala Val Ala Glu Gly Thr Asp
 195 200 205
 Arg Val Ile Glu Ala Leu Arg Arg Ala Tyr Arg Ala Ile Leu His Ile
 210 215 220
 Pro Arg Arg Ile Arg Gln Gly Leu Glu Arg Ala Leu Leu
 225 230 235

- 160 -

(2) INFORMATION FOR SEQ ID NO:644:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 207 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:644:

```

Met Gly Gly Lys Trp Ser Lys Ser Ser Val Ile Gly Trp Pro Ala Val
 1           5           10           15
Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Gly Val Gly Ala
 20           25           30
Val Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr
 35           40           45
Ala Ala Asn Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu
 50           55           60
Glu Val Gly Phe Pro Val Thr Pro Gln Val Pro Leu Arg Pro Met Thr
 65           70           75           80
Tyr Lys Ala Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly
 85           90           95
Leu Glu Gly Leu Ile His Ser Gln Arg Arg Gln Asp Ile Leu Asp Leu
100           105           110
Trp Ile Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr
115           120           125
Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe Gly Trp Cys Tyr Lys
130           135           140
Leu Val Pro Val Glu Pro Asp Lys Val Glu Glu Ala Asn Lys Gly Glu
145           150           155           160
Asn Thr Ser Leu Leu His Pro Val Ser Leu His Gly Met Asp Asp Pro
165           170           175
Glu Arg Glu Val Leu Glu Trp Arg Phe Asp Ser Arg Leu Ala Phe His
180           185           190
His Val Ala Arg Glu Leu His Pro Glu Tyr Phe Lys Asn Cys
195           200           205

```

(2) INFORMATION FOR SEQ ID NO:645:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:645:

```

Met Gly Gly Lys Ala Lys Ser Ser Val Val Arg His Ala Ser
 1           5           10           15
Gly Val Gly Ala Asn Asn Gln Cys
 20           25

```


- 161 -

(2) INFORMATION FOR SEQ ID NO:646:

- (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:646:

Met Gly Gly Lys Trp Ser Glu Ser Ser Val Val Arg Arg His Val Pro
1 5 10 15
Leu Arg Gln Gly Ser Tyr Arg Ser Pro Leu
20 25

(2) INFORMATION FOR SEQ ID NO:647:

- (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 74 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:647:

CTACAAGGGA CTTTCGCTG GGGACTTTC AGGGAGGCGT GGCCTGGGCG GGACTGGGGA 60
GTGGCGAGCC CTCA 74

(2) INFORMATION FOR SEQ ID NO:648:

- (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:648:

CTGTGGGGA CTTTCCATCC GTTGGGACT TTCCAAGGCG GCGTGGCCTG GGTGACTAGT 60
TCCGGTGGGG ACTTTCCA 78

(2) INFORMATION FOR SEQ ID NO:649:

- (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:649:

CGTTTGTTT CGTTGGGGAC TTTCCAGGAG ACGTGGCCTG AGTGACTAAG CCGCTGGGGA 60
CTTCCG 67

(2) INFORMATION FOR SEQ ID NO:650:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 621 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:650:

```

ATGGGTGGCA AGTGGTCAAA AGTAGTGTG ATTGATGGC CTGCTGTAAG GGAAAGAATG      60
AGACGAGCTG AGCCAGCAGC AGATGGGGTG GGAGCAGTAT CTCGAGACCT AGAAAAACAT      120
GGAGCAATCA CAAGTAGCAA TACAGCAGCT AACAATGCTG CTGTGCTCTG GCTAGAAGCA      180
CAAGAGGAGG AAGAGGTGGG TTTTCCAGTC ACACCTCAGG TACCTTTAAG ACCAATGACT      240
TACAAGGCAG CTGTAGATCT TAGCCACTTT TTAAAGGAAA AGGGGGGGACT GGAAGGGCTA      300
ATTCACTCCC AAAGAAGACA AGATATCCTT GATCTGTGGA TCTACCACAC ACAAGGCTAC      360
TTCCCTGATT GGCAGAACTA CACACCAGGG CCAGGGGTCA GATATCCACT GACCTTTGGA      420
TGGTGCTACA AGCTAGTACC AGTTGAGCCA GATAAGTAG AAGAGGCCAA TAAAGGAGAG      480
AACACCAGCT TGTACACCC TGTGAGCCTG CATGGAATGG ATGACCCTGA GAGAGAAGTG      540
TTAGAGTGGA GGTTTGACAG CCGCCTAGCA TTTCATCAG TGGCCCGAGA GCTGCATCCG      600
GAGTACTTCA AGAACTGCTG A                                     621

```

(2) INFORMATION FOR SEQ ID NO:651:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1596 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:651:

```

GAACAGATT T GGAATAACAT GACCTGGATG GAGTGGGACA GAGAAATTAA CAATTACACA      60
AGCTTAATAC ACTCCTTAAT TGAAGAATCG CAAAACGAGC AAGAAAAGAA TGAACAAGAA      120
TTATTGGAAT TAGATAAATG GGCAAGTTTG TGGAAATTGGT TTAACATAAC AAATTGGCTG      180
TGGTATATAA AATTATTCTAT AATGATAGTA GGAGGCTTGG TAGGTTTAAG AATAGTTTTT      240
GCTGTACTTT CTATAGTGAA TAGAGTTAGG CAGGGATATT CACCATTATC GTTTCAGACC      300
CACCTCCCAA TCCCGAGGGG ACCCGACAGG CCCGAAGGAA TAGAAGAAGA AGGTGGAGAG      360
AGAGACAGAG ACAGATCCAT TCGATTAGTG AACGGATCCT TAGCACTTAT CTGGGACGAT      420
CTGCGGAGCC TGTGCTCTTT CAGCTACCAC CGCTTGAGAG ACTTACTCTT GATTGTAACG      480
AGGATTGTGG AACTTCTGGG ACGCAGGGGG TGGGAAGCCC TCAAATATTG GTGGAATCTC      540
CTACAGTATT GGAGTCAGGA ACTAAAGAAT AGTCTGTGTA ACTTGCTCAA TGCCACAGCC      600
ATAGCAGTAG CTGAGGGGAC AGATAGGGTT ATAGAAGTAT TACAAGCAGC TTATAGAGCT      660
ATTGCCCACA TACCTAGAAG AATAAGACAG GGCTTGGAAA GGATTTTGCT ATAAGATGGG      720
TGGCAAGTGG TCAAAAAGTA GTGTGATTGG ATGGCCTGCT GTAAGGGAAA GAATGAGACG      780

```

- 163 -

AGCTGAGCCA GCAGCAGATG GGGTGGGAGC AGTATCTCGA GACCTAGAAA AACATGGAGC	840
AATCACAAGT AGCAATACAG CAGCTAACAA TGCTGCTTGT GCCTGGCTAG AAGCACAAGA	900
GGAGGAAGAG GTGGGTTTTC CAGTCACACC TCAGGTACCT TTAAGACCAA TGACTTACAA	960
GGCAGCTGTA GATCTTAGCC ACTTTTAAAG AGAAAAGGGG GGAAGTGAAG GGCTAATTCA	1020
CTCCCAAAGA AGACAAGATA TCCTTGATCT GTGGATCTAC CACACACAAG GCTACTTCCC	1080
TGATTGGCAG AACTACACAC CAGGGCCAGG GGTGAGATAT CCACTGACCT TTGGATGGTG	1140
CTACAAGCTA GTACCAAGTTG AGCCAGATAA GGTAGAAGAG GCCAATAAAG GAGAGAACAC	1200
CAGCTTGTTA CACCCTGTGA GCCTGCATGG AATGGATGAC CCTGAGAGAG AAGTGTTAGA	1260
GTGGAGGTTT GACAGCCGCC TAGCATTTC ATCAGTGGCC CGAGAGCTGC ATCCGGAGTA	1320
CTTCAAGAAC TGCTGACATC GAGCTTGCTA CAAGGGACTT TCCGCTGGGG ACTTTCCAGG	1380
GAGGCGTGGC CTGGGCGGGA CTGGGGAGTG GCGAGCCCTC AGATGCTGCA TATAAGCAGC	1440
TGCTTTTTC CTGTACTGGG TCTCTCTGGT TAGACCAGAT CTGAGCCTGG GAGCTCTCTG	1500
GCTAACTAGG GAACCCACTG CTTAAGCCTC AATAAAGCTT GCCTTGAGTG CTTCAAGTAG	1560
TGTGTGCCCC TCTGTTGTGT GACTCTGGTA ACTAGA	1596

- 164 -

(2) INFORMATION FOR SEQ ID NO:652:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:652:

GCTTTTGGCC

(2) INFORMATION FOR SEQ ID NO:653:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:653:

CTTTTGGCT

(2) INFORMATION FOR SEQ ID NO:654:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:654:

TTTTTGCTG

(2) INFORMATION FOR SEQ ID NO:655:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:655:

TTTTGCTGT

(2) INFORMATION FOR SEQ ID NO:656:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:656:

TTTGCTGTA

(2) INFORMATION FOR SEQ ID NO:657:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:657:

TTGCTGTAC

(2) INFORMATION FOR SEQ ID NO:658:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:658:

TGCTGTACT

(2) INFORMATION FOR SEQ ID NO:659:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:659:

GCTGTACTG

(2) INFORMATION FOR SEQ ID NO:660:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:660:

CCTGTACTGG

- 165 -

(2) INFORMATION FOR SEQ ID NO:661:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:661:

CTGTACTGGG

(2) INFORMATION FOR SEQ ID NO:662:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:662:

TGTACTGGGT

(2) INFORMATION FOR SEQ ID NO:663:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:663:

GTACTGGGTC

(2) INFORMATION FOR SEQ ID NO:664:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:664:

TACTGGGTCT

(2) INFORMATION FOR SEQ ID NO:665:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:665:

ACTGGGTCTC

(2) INFORMATION FOR SEQ ID NO:666:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:666:

CTGGGTCTCT

(2) INFORMATION FOR SEQ ID NO:667:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:667:

TGGGTCTCTC

(2) INFORMATION FOR SEQ ID NO:668:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:668:

GGGTCTCTCT

(2) INFORMATION FOR SEQ ID NO:669:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:669:

GGTCTCTCTG

(2) INFORMATION FOR SEQ ID NO:670:

- 166 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:670:

GTCTCTCTGG

(2) INFORMATION FOR SEQ ID NO:671:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:671:

TCTCTCTGGT

(2) INFORMATION FOR SEQ ID NO:672:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:672:

CTCTCTGGTT

(2) INFORMATION FOR SEQ ID NO:673:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:673:

TCTCTGGTTA

(2) INFORMATION FOR SEQ ID NO:674:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:674:

CTCTGGTTAG

(2) INFORMATION FOR SEQ ID NO:675:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:675:

TCTCTGGTTA

(2) INFORMATION FOR SEQ ID NO:676:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:676:

CTGGTTAGAC

(2) INFORMATION FOR SEQ ID NO:677:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:677:

TGGTTAGACC

(2) INFORMATION FOR SEQ ID NO:678:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:678:

GGTTAGACCA

(2) INFORMATION FOR SEQ ID NO:679:

(i) SEQUENCE CHARACTERISTICS:

- 167 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:679:

GTTAGACCAAG

(2) INFORMATION FOR SEQ ID NO:680:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:680:

TTAGACCAGA

(2) INFORMATION FOR SEQ ID NO:681:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:681:

TAGACCAGAT

(2) INFORMATION FOR SEQ ID NO:682:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:682:

AGACCAGATC

(2) INFORMATION FOR SEQ ID NO:683:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:683:

GACCAGATCT

(2) INFORMATION FOR SEQ ID NO:684:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:684:

ACCAGATCTG

(2) INFORMATION FOR SEQ ID NO:685:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:685:

CCAGATCTGA

(2) INFORMATION FOR SEQ ID NO:686:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:686:

CAGATCTGAG

(2) INFORMATION FOR SEQ ID NO:687:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:687:

AGATCTGAGC

(2) INFORMATION FOR SEQ ID NO:688:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid

- 168 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:688:

GATCTGAGCC

(2) INFORMATION FOR SEQ ID NO:689:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:689:

ATCTGAGCCT

(2) INFORMATION FOR SEQ ID NO:690:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:690:

TCTGAGCCTG

(2) INFORMATION FOR SEQ ID NO:691:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:691:

CTGAGCCTGG

(2) INFORMATION FOR SEQ ID NO:692:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:692:

TGAGCCTGGG

(2) INFORMATION FOR SEQ ID NO:693:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:693:

GAGCCTGGGA

(2) INFORMATION FOR SEQ ID NO:694:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:694:

AGCCTGGGAG

(2) INFORMATION FOR SEQ ID NO:695:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:695:

GCCTGGGAGC

(2) INFORMATION FOR SEQ ID NO:696:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:696:

CCTGGGAGCT

(2) INFORMATION FOR SEQ ID NO:697:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 169 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:697:

CTGGGAGCTC

(2) INFORMATION FOR SEQ ID NO:698:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:698:

TGGGAGCTCT

(2) INFORMATION FOR SEQ ID NO:699:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:699:

GGGAGCTCTC

(2) INFORMATION FOR SEQ ID NO:700:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:700:

GGAGCTCTCT

(2) INFORMATION FOR SEQ ID NO:701:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:701:

GAGCTCTCTG

(2) INFORMATION FOR SEQ ID NO:702:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:702:

AGCTCTCTGG

(2) INFORMATION FOR SEQ ID NO:703:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:703:

GCTCTCTGGC

(2) INFORMATION FOR SEQ ID NO:704:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:704:

CTCTCTGGCT

(2) INFORMATION FOR SEQ ID NO:705:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:705:

TCTCTGGCTA

(2) INFORMATION FOR SEQ ID NO:706:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 170 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:706:

CTCTGGCTAA

(2) INFORMATION FOR SEQ ID NO:707:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:707:

TCTGGCTAAC

(2) INFORMATION FOR SEQ ID NO:708:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:708:

CTGGCTAACT

(2) INFORMATION FOR SEQ ID NO:709:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:709:

TGCTAACTA

(2) INFORMATION FOR SEQ ID NO:710:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:710:

GGCTAACTAG

(2) INFORMATION FOR SEQ ID NO:711:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:711:

GCTAACTAGG

(2) INFORMATION FOR SEQ ID NO:712:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:712:

CTAACTAGGG

(2) INFORMATION FOR SEQ ID NO:713:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:713:

TAACTAGGGA

(2) INFORMATION FOR SEQ ID NO:714:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:714:

AACTAGGGAA

(2) INFORMATION FOR SEQ ID NO:715:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:715:

- 171 -

ACTAGGGAAC

(2) INFORMATION FOR SEQ ID NO:716:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:716:

CTAGGGAACC

(2) INFORMATION FOR SEQ ID NO:717:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:717:

TAGGGAACCC

(2) INFORMATION FOR SEQ ID NO:718:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:718:

AGGGAACCCA

(2) INFORMATION FOR SEQ ID NO:719:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:719:

GGGAACCCAC

(2) INFORMATION FOR SEQ ID NO:720:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:720:

GGAACCCACT

(2) INFORMATION FOR SEQ ID NO:721:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:721:

GAACCCACTG

(2) INFORMATION FOR SEQ ID NO:722:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:722:

AACCCACTGC

(2) INFORMATION FOR SEQ ID NO:723:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:723:

ACCCACTGCT

(2) INFORMATION FOR SEQ ID NO:724:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:724:

CCCACTGCTT

- 172 -

(2) INFORMATION FOR SEQ ID NO:725:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:725:

CCACTGCTTA

(2) INFORMATION FOR SEQ ID NO:726:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:726:

CACTGCTTAA

(2) INFORMATION FOR SEQ ID NO:727:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:727:

ACTGCTTAAG

(2) INFORMATION FOR SEQ ID NO:728:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:728:

CTGCTTAAGC

(2) INFORMATION FOR SEQ ID NO:729:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:729:

TGCTTAAGCC

(2) INFORMATION FOR SEQ ID NO:730:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:730:

GCTTAAGCCT

(2) INFORMATION FOR SEQ ID NO:731:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:731:

CTTAAGCCTC

(2) INFORMATION FOR SEQ ID NO:732:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:732:

TTAAGCCTCA

(2) INFORMATION FOR SEQ ID NO:733:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:733:

TAAGCCTCAA

(2) INFORMATION FOR SEQ ID NO:734:

- 173 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:734:

AAGCCTCAAT

(2) INFORMATION FOR SEQ ID NO:735:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:735:

AGCCTCAATA

(2) INFORMATION FOR SEQ ID NO:736:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:736:

GCCTCAATAA

(2) INFORMATION FOR SEQ ID NO:737:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:737:

CCTCAATAAA

(2) INFORMATION FOR SEQ ID NO:738:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:738:

CTCAATAAAG

(2) INFORMATION FOR SEQ ID NO:739:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:739:

TCAATAAAGC

(2) INFORMATION FOR SEQ ID NO:740:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:740:

CAATAAAGCT

(2) INFORMATION FOR SEQ ID NO:741:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:741:

AATAAAGCTT

(2) INFORMATION FOR SEQ ID NO:742:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:742:

ATAAAGCTTG

(2) INFORMATION FOR SEQ ID NO:743:

- (i) SEQUENCE CHARACTERISTICS:

- 174 -

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:743:

TAAAGCTTGC

(2) INFORMATION FOR SEQ ID NO:744:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:744:

AAAGCTTGCC

(2) INFORMATION FOR SEQ ID NO:745:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:745:

AAGCTTGCCCT

(2) INFORMATION FOR SEQ ID NO:746:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:746:

AGCTTGCCCTT

(2) INFORMATION FOR SEQ ID NO:747:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:747:

GCTTGCCTTG

(2) INFORMATION FOR SEQ ID NO:748:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:748:

CTTGCCTTGA

(2) INFORMATION FOR SEQ ID NO:749:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:749:

TTGCCTTGAG

(2) INFORMATION FOR SEQ ID NO:750:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:750:

TGCCTTGAGT

(2) INFORMATION FOR SEQ ID NO:751:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:751:

GCCTTGAGTG

(2) INFORMATION FOR SEQ ID NO:752:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid

- 175 -

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:752:

OCTTGAGTGC

(2) INFORMATION FOR SEQ ID NO:753:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:753:

CTTGAGTGCT

(2) INFORMATION FOR SEQ ID NO:754:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:754:

TTGAGTGCTT

(2) INFORMATION FOR SEQ ID NO:755:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:755:

TGAGTGCTTC

(2) INFORMATION FOR SEQ ID NO:756:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:756:

GAGTGCTTCA

(2) INFORMATION FOR SEQ ID NO:757:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:757:

AGTGCTTCAA

(2) INFORMATION FOR SEQ ID NO:758:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:758:

GTGCTTCAAG

(2) INFORMATION FOR SEQ ID NO:759:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:759:

TGCTTCAAGT

(2) INFORMATION FOR SEQ ID NO:760:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:760:

GCTTCAAGTA

(2) INFORMATION FOR SEQ ID NO:761:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 176 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:761:

CITCAAGTAG

(2) INFORMATION FOR SEQ ID NO:762:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:762:

TTCAAGTAGT

(2) INFORMATION FOR SEQ ID NO:763:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:763:

TCAAGTAGTG

(2) INFORMATION FOR SEQ ID NO:764:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:764:

CAAGTAGTGT

(2) INFORMATION FOR SEQ ID NO:765:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:765:

AAGTAGTG

(2) INFORMATION FOR SEQ ID NO:766:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:766:

AGTAGTG

(2) INFORMATION FOR SEQ ID NO:767:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:767:

GTAGTG

(2) INFORMATION FOR SEQ ID NO:768:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:768:

TAGTG

(2) INFORMATION FOR SEQ ID NO:769:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:769:

AGTG

(2) INFORMATION FOR SEQ ID NO:770:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 177 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:770:

GTGTGTGCCC

(2) INFORMATION FOR SEQ ID NO:771:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:771:

TGTGTGCCCC

(2) INFORMATION FOR SEQ ID NO:772:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:772:

GTGTGCCCCGT

(2) INFORMATION FOR SEQ ID NO:773:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:773:

TGTGCCCGTC

(2) INFORMATION FOR SEQ ID NO:774:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:774:

GTGCCCGTCT

(2) INFORMATION FOR SEQ ID NO:775:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:775:

TGCCCCGTCTG

(2) INFORMATION FOR SEQ ID NO:776:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:776:

GCCCGTCTGT

(2) INFORMATION FOR SEQ ID NO:777:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:777:

CCCGTCTGTT

(2) INFORMATION FOR SEQ ID NO:778:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:778:

CCGTCTGTTG

(2) INFORMATION FOR SEQ ID NO:779:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:779:

- 178 -

CGTCTGTTGT

(2) INFORMATION FOR SEQ ID NO:780:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:780:

GTCTGTTGTG

(2) INFORMATION FOR SEQ ID NO:781:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:781:

TCTGTTGTGT

(2) INFORMATION FOR SEQ ID NO:782:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:782:

CTGTTGTGTG

(2) INFORMATION FOR SEQ ID NO:783:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:783:

TGTTGTGTGA

(2) INFORMATION FOR SEQ ID NO:784:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:784:

GTTGTGTGAC

(2) INFORMATION FOR SEQ ID NO:785:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:785:

TTGTGTGACT

(2) INFORMATION FOR SEQ ID NO:786:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:786:

TGTGTGACTC

(2) INFORMATION FOR SEQ ID NO:787:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:787:

GTGTGACTCT

(2) INFORMATION FOR SEQ ID NO:788:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:788:

TGTTGTGACTC

- 179 -

(2) INFORMATION FOR SEQ ID NO:789:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:789:

GTGTGACTCT

(2) INFORMATION FOR SEQ ID NO:790:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:790:

TGTGACTCTG

(2) INFORMATION FOR SEQ ID NO:791:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:791:

GTGACTCTGG

(2) INFORMATION FOR SEQ ID NO:792:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:792:

TGACTCTGGT

(2) INFORMATION FOR SEQ ID NO:793:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:793:

GACTCTGGTA

(2) INFORMATION FOR SEQ ID NO:794:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:794:

ACTCTGGTAA

(2) INFORMATION FOR SEQ ID NO:795:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:795:

CTCTGGTAAC

(2) INFORMATION FOR SEQ ID NO:796:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:796:

TCTGGTAACT

(2) INFORMATION FOR SEQ ID NO:797:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:797:

CTGGTAACTA

(2) INFORMATION FOR SEQ ID NO:798:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:798:

TGGTAACTAG

(2) INFORMATION FOR SEQ ID NO:799:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:799:

GGTAACTAGA

(2) INFORMATION FOR SEQ ID NO:800:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9207 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:800:

```

TGGAAGGGCT AATTCACTCA CGGAAAAGAC CAGTTGAACC AGAAGAAGAT AGAAGAGGCC      60
ATGAAGAAGA AAACAACAGA TTGTTCTGCT TGCTCAGCTG GGGACTTTC AGAAGGCGCG      120
GCCTGAGTGA CTAAGCCCCG TTGGGGACTT TCCGAAGAGG CATGAAGGGA CTTTCCAAGG      180
CAGGCGTGGC CTGGGCGGGA CTGGGGAGTG GCGAGCCCTC AGATGCTGCA TATAAGCAGC      240
TGCTTTCTGC CTGTACTGGG TCTCTCTGGT TAGACCAGAT CTGAGCCTGG GAGCTCTCTG      300
GCTAGCTAGG GAACCCACTG CTTAAGCCTC AATAAGCTT GCCTTGAGTG CTTCAAGTAG      360
TGTGTGCCCC TCTGTTGTGT GACTCTGGTA TCTAGAGATC CCTCAGACCA TTTTAGTCCG      420
TGTGGAAAAT CTCTAGCAGT GGCGCCCGAA CAGGGACTTG AAAGCGAAAG GAAAACCAGA      480
GGAGCTCTCT CGACGCAGGA CTCGGCTTGC TGAAGCGCGC ACGGCAAGAG GCGAGGGGCG      540
GCGACTGGTG AGTACGCCGA AAATTTTGAC TAGCGGAGGC TAGAAGGAGA GAGATGGGTG      600
CGAGAGCGTC AATATTAAGC GGGGGAAAAT TAGATAGATG GGAGAAAATT CGGTTAAGGC      660
CAGGAGGAAA GAAAAAGTAT AAATTTAAAC ATATAGTATG GGCAAGCAGG GAGCTAGAAC      720
GATTCGCAGT CAATCCTGGC CTGTTGGAAA CATCAGAAGG CTGTAGACAA ATACTGGGAC      780
AGTTACACCC GTCCCTTCAG ACAGGATCAG AAGAACTTAA ATCAGTATAT AATGCAGTAG      840
CAGTCCTCTA TTGTGTGCAT CAAAACATAG ACATAAAGGA CACCAAGGAA GCTTTAGAAA      900
AGATAGAGGA AGAGCAAAAC AAATGTAAGA AAAAAGCACA GCAAGCAGCA GCACAGCAAG      960
CAGCAGCTGG CACAGGAAAC AGCAACCCGG TCAGCCAAAA TTACCCTATA GTACAGAACA     1020
TGCAGGGGCA AATGGTACAT CAGGCCATAT CACCTAGAAC TTTAAATGCA TGGGTAAAAG     1080
TAATAGAAGA GAAGGCTTTC AGCCAGAGG TAATACCCAT GTTTTCAGCA TTATCAGAAG     1140
GAGCCACCCC ACAAGATTTA AACACCATGC TAAACACAGT GGGGGGACAT CAAGCAGCTA     1200
TGCAAATGTT AAAAGAGACC ATCAATGAGG AAGCTGCAGA ATGGGATAGA TTACATCCAG     1260
CGCAGGCAGG GCCTGTTGCA CCAGGCCAGA TGAGAGACCC AAGGGGAAGT GACATAGCAG     1320
GAACTACTAG TACCCTTCAG GAACAAATAG GATGGATGAC AGGTAATCCA GCTATCCCAG     1380
TAGGAGAAAT CTATAAAGA TGGATAATCC TGGGATTAAA TAAAATAGTA AGGATGTATA     1440
GCCCTATCAG CATTCTGGAC ATAAAACAAG GACCAAAGGA ACCCTTTAGA GACTATGTAG     1500
ACCGGTTCTA TAAACTCTA AGAGCCGAGC AAGCTACACA GGAGGTAAAA AATTGGATGA     1560
CAGAAACCTT GTTGGTCCAA AATGCAAACC CAGATTGTAA GACTATTTTA AAAGCATTGG     1620

```

GACCAGCAGC TACACTAGAA GAAATGATGA CAGCATGTCA GGGAGTGGGA GGACCCAGCC	1680
ATAAAGCAAG AGTTTGGCA GAAGCAATGA GCCAAGCAAC AAATGCAGCT ACTGTAATGA	1740
TGCAGAGAAG CAATTTTAGA AACCAAGAA AGAATGTAA GTGTTTCAAT TGTGGCAAAG	1800
AAGGGCACAT AGCCAGAAAT TGCAGGGCTC CTAGGAAAAG GGGCTGTTGG AAATGTGGAA	1860
AGGAAGGACA CCAATGAAA GATTGTACTG AGAGACAGGC TAATTTTTTA GGGAAAATCT	1920
GGCCTTCCCA CAAGGGGAGG CCAGGGAAC TCTTCAGAG CAGGCCAGAA CCAACAGCCC	1980
CTCTCCAGG CAGGCCGGAG CCATCAGCCC CGCCAGAAGA GAGCTTCAGG TTTGGGGAGG	2040
AGACAACAAC TCCCTCTCAG AAGCAGGAGC CGATAGACAG GGACAGGGAT CTGTATCCTT	2100
TAGCTTCCCT CAGATCACTC TTTGGCAACG ACCCCTCGTC ACAATAAGA TAGGGGGGCA	2160
GCTGAAGGAA GCTCTATTAG ATACAGGAGC AGATGATACA GTATTAGAAG ACATGCATTT	2220
GCCAGGAAAA TGGAACCAA AAATGATAGG GGAATTGGA GGTTTTATCA AAGTAAACA	2280
ATATGATGAA ATTCTGTAG AAATCTGTGG ACATAAGCT ATAGGTACAG TATTAGTAGG	2340
ACCTACACCT GTCAACATAA TTGGAAGAAA TCTGTTGACT CAGATTGGTT GCACTTTAA	2400
TTTTCCCAT AGTCCTATTG AAATGTACC AGTACAATTA AAGCCAGGAA TGGATGGCCC	2460
AAAGGTTAA CAATGGCCAT TGACAGAAGA GAAATAAAA GCATTAGTAG AAATTTGTAC	2520
AGAAATGGAA AAGGAAGGAA AGATTTCAA AATTGGGCCT GAAATCCAT ACAATACTCC	2580
AGTATTTGCC ATAAAGAAA AGATGGTAC TAAATGGAGA AAATTAGTAG ATTTAGAGA	2640
CCTTAATAAG AGAACTCAAG ACTTCTGGGA AGTTCAATTA GGAATACCAC ATCCCTCAGG	2700
ATTAAAAAAG AAAAAATCAG TAACAGTACT GGATGTGGGT GATGCATACT TTTCAATTCC	2760
CTTAGATGAA AACTTCAGGA AGTATACTGC ATTTACCATA CCTAGTATAA ATAATGAGAC	2820
ACCAGGGATT AGATATCAGT ACAATGTGCT TCCACAGGGA TGGAAAGGAT CACCAGCAAT	2880
ATTCCAAAGT AGCATGACAA GAATCTTAGA GCCTTTTAGA AGACAAAATC CAGACATAGT	2940
TATCTATCAA TACATGGATG ACTTGATGT AGGATCTGAT TTAGAAATAG GACAGCATAG	3000
AATAAAAATA GAGGAAGTGA GACAACATCT GTTGAAGTGG GGATTTACCA CACCAGACAA	3060
AAAGCATCAG AAAGAACCCC CATTCCTTTG GATGGGTTAT GAACTCCATC CTGATAAATG	3120
GACAGTGCAA CCTATAGTAC TGCCAGAAAA AGACAGCTGG ACTGTCAATG ACATACAGAA	3180
GTTAGTGGGT AAATTAAATT GGGCAAGTCA GATTTACCCA GGAATTAAAG TAAGGCAATT	3240
ATGTAACTC CTTAGGGGAA CCAAGCACT AACAGAAGTA ATACCACTAA CAGAAGAAGC	3300
AGAGCTAGAA CTGGCAGAAA ACAGGGAAAT TCTAAGAGAA CCAGTACATG GAGTGTATTA	3360
TGACCCATCA AAAGACTTAA TAGCAGAAAT ACAGAAGCAG GAGCAAGGCC AATGGACATA	3420
TCAAATTTAT CAAGATCAAT TTAATAATCT AAAACAGGA AAGTATGCAA GATTGAGGGG	3480
TGCCACACT AATGATGTAA AACAATTTCC AGAGGCAGTG CAAAAATAG CCACAGAAAG	3540
CATAGTAATA TGGGGAAAGA CTCCTAAATT TAGACTACCC ATACAAAAAG AAACATGGGA	3600
CGCATGGTGG ACAGAGTATT GGCAAGCCAC CTGGATTCTT GAGTGGGAGT TTGTCAATAC	3660

CCCTCCCCTA GTAAAATTAT GGTACCAGTT AGAAAAAGAA CCCATAATAG GAGCAGAAAC 3720
TTTCTATGTA GATGGGGCAG CTAACAGAGA GACTAAATTA GGAAAAGCAG GATATGTTAC 3780
TGACAGAGGA AGACAAAAG TTGTCTCCCT AACTGACACA ACAAATCAGA AGACTGAGTT 3840
ACAAGCAATT CATCTAGCTT TGCAGGATTC AGGATTAGAA GTAAACATAG TAACAGACTC 3900
ACAGTATGCA TTAGGAATCA TTCAAGCACA ACCAGATAAA AGTGAATCAG AAATAGTCAA 3960
TCAAATAATA GAGCAATTAA TAAAAAGGA AAAGGTCTAC CTGGCATGGG TACCAGCACA 4020
CAAAGGAATT GGAGGGAATG AACCAAGTAGA TAAATTAGTC AGTGCTGGAA TCAGGAAAAT 4080
ACTATTTTGA GATGGAATAG ATAAGGCACA AGAAGGCCAT GAGAAATATC ACAGTAATTG 4140
GAGAGCAATG GCTAGTGGTT TTAACCTGCC ACCTATAGTA GCAAAGAAA TAGTAGCCAG 4200
CTGTGATAAA TGTCACTAA AAGGAGAAGC CATGCATGGA CAAGTAGACT GTAGTCCAGG 4260
AATATGGCAA CTAGATTGTA CACATCTAGA AGGAAAAATT ATCCTGGTAG CAGTTCATGT 4320
AGCCAGTGGG TATATAGAAG CAGAAGTTAT TCCAGCAGAG ACAGGGCAGG AACAGCATA 4380
CTTTATCTTA AAATTAGCAG GAAGGTGGCC AGTAAACACA ATACATACAG ACAATGGCGG 4440
CAATTCATC AGTACCACGG TTAAGGCCGC CTGTTGGTGG GCAGGGATCA AGCAGGAATT 4500
TGGCATTCCT TACAATCCCC AAAGCCAAGG AGTAGTGGAA TCTATGAATA GAGAATTAAA 4560
GAAAATTATA GGACAGGTAA GAGATCAGGC TGAACATCTT AAGACAGCAG TACAAATGGC 4620
AGTATTCATC CACAATTTTA AAAGAAAAGG GGGGATGGG GGATACAGTG CAGGGGAAAG 4680
AATAGTAGAC ATAATAGCAA CAGACATACA AACTAAGAA TTACAAAAGC AAATTACAAA 4740
AATTCAAAAT TTTCGGGTTT ATTACAGGGA CAGCAGAGAT CCCTTTGGA AAGGACCAGC 4800
AAAACCTCTC TGGAAAGGCG AAGGGGCAGT AGTAATACAA GATAATAGTG ACATAAAAGT 4860
AGTGCCAAGA AGAAAAGTAA AGATCATTAG GGATTATGGA AAACAGATGG CAGGTGATGA 4920
TTGTGTGGCA AGTAGACAGG ATGAGGATTA GAACATGGAA CAGTTTAGTG AAACACCATA 4980
TGATGTGTTT AAAGAAAGCT AAGGGATGGA TTTATAGACA TCACTATGAA AACACTCATC 5040
CRAAAATAAG CTCAGAAGTA CACATCCCAC TAGGGGAAGC TAGATTGGTA ATAACAACAT 5100
ATTGGGGTCT ACATACAGGA GAAAGAGACT GGCATTGGG TCAGGGAGTC TCCATAGAAT 5160
GGAGGGAAAG GACATATAGA ACACAAGTAG ACCCCGAACT AGCAGACCAA CTAATTCATA 5220
TACATTACTT TGATTGTTTT TCAGAATCTG CCATAAGAAG TGCCATATTA GGATATAGAG 5280
TTAGGCATAG GTGTGAATAT CAAGCAGGAC ATAACAAGGT AGGATCTCTA CAGTACTTGG 5340
CACTAACAGC ATTAATAACA CCAAAGAAGA TAAAGCCACC TTTGCCTAGT GTTGCGAAAC 5400
TGACAGAGGA TAGATGGAAC AAGCCCCAGA AGACCAAGGG CCACAGAGGC AGCCATACAA 5460
TGAATGGACA CTAGAACTTT TAGAGGAGCT TAAGAATGAA GCTGTTAGGC ATTTTCCTAG 5520
GGTATGGCTC CATGGCTTAG GGCAACATAT CTATGAACT TATGGGGATA CTTGGGAAGG 5580
AGTGGAGGCC ATAACAAGAA CTCTGCAACA ACTGCTGTTT ATTCATTCA GAATTGGGTG 5640
TCAACATAGC AGAATAGGCA TTATTGACA GAGGAGAGCA AGAAATGGAG CCAGTAGATC 5700

CTAGACTAGA GCCCTGGAAG CATCCAGGAA GTCAGCCTAA GACTGCGTGT ACCACTTGCT	5760
ATTGTAAAAA GTGCTGCTTT CATTGCCAAG TTTGTTTTAT GACAAAAGGC TTAGGCATCT	5820
CCTATGGCAG GAAGAAGCGG AGACAGCGAC GAAGAGCTCC TCAAGACAGT CAGACTCATC	5880
AAGCTTATCT ATCAAAGCAG TAAGTAATAT ATGTAATGCA ACCTTTACAA ATAGTAGCAA	5940
TAGTAGCATT AGTAGTAGCA GGAATAATAG CAATAGTTGT GTGGACCATA GTATTTCATAG	6000
AATATAAGAA AATATTAAGA CAAAGAAAAA TAGACAGGTT GATTGATAGA ATAAGAGAAA	6060
GAGCAGAAGA CAGTGGCAAT GACAGTGAAG GGGATCAGGA AGAATTATCG GCACCTGTGG	6120
ACATGGGGCA CCATGATCCT TGGGATATTA ATGATCTGTA GAGCTGCAAA CAATTTGTGG	6180
GTCACAGTCT ATTATGGGGT ACCTGTGTGG AGAGAAGCAA CCACCACTCT ATTTTGTGCA	6240
TCAGATGCCA AGGCATATGA TGCAGAGGTA CATAATGTTT GGGCCACACA TGCCTGTGTA	6300
CCCACAGACC CTAACCCACA AGAAGTAGAA TTGAAAAATG TGACAGAAAA TTTTAACATG	6360
TGGAAAAATA ACATGGTAGA ACAGATGCAT GAGGATATAA TCAGTTTATG GGATCAAAGC	6420
CTGAAGCCAT GTGTAAAATT AACCCCACTC TGTGTTTCTT TAAATTGCAC TGATGCTACT	6480
AATACCACTA ATAGTAATAC CACTAGCAGC AGCGAGAAAC CGAAGGGGAC AGGGGAAATA	6540
AAAAACTGCT CTTTCAATAT CACCACAAGC ATAAGAGATA AGGTGCAGAA ACAATATGCA	6600
CTTTTTTATA GCCTTGATGT AGTACCAATG GATGATAATG ATAATAGTAC AAGCTATAGG	6660
TTAATAAGTT GTAACACCTC AATCATTACA CAGGCCTGTC CAAAGATATC CTTTGAGCCA	6720
ATTCCCATAC ATTATTGTGC CCCGGCTGGT TTTGCGATTC TAAAGTGTA AGATAAAAGG	6780
TTCAATGGAA AAGGACCATG TACAAGTGTG AGCAGAGTAC AGTGTACACA TGGAATTAGG	6840
CCAGTAGTAT CAACTCAACT GTTGTTAAAT GGCAGTCTAG CAGAAGAAGA GGTAGTAAT	6900
AGATCTGACA ATTTTACGAA CAATGCTAAA ACCATAATAG TACAGCTGAG CAAATCTGTA	6960
GAAATTACTT GTGTAAGACC CAACACAAT ACAAGAAAAA GTATAAGTAT GGGACCAGGG	7020
AGAGCATTTT ATACAACAGA AATAATAGGA GATATAAGAC AAGCATATTG TAACATTAGT	7080
AAAGCAAACCT GGA CTGACAC TTTAGAACAG ATAGCTAGAA AATTAAAGAGA ACAATTTGAG	7140
AATAAAACAA TAGTCTTTAA GCCATCCTCA GGAGGGGACC CAGAAATTGT AACACAGTTT	7200
TACAGTTTAA ATTGTGGAGG GGAATTTTTC TACTGTAAAT CAACACAACCT GTTTAATGGT	7260
ACTTGGAATG GTACTTGGGT TAATGGTACT TGGAGTAGTA ATAATACGAC TGATACTGCA	7320
AATATCACAC TCCCATGCAG AATAAAACAA TTTATAAACA TGTGGCAGGA AGTAGGAAAA	7380
GCAATGTATG CCCCTCCCAT CAAAGGACAA ATTAAATGTA CATCAAATAT TACAGGGCTG	7440
ATATTAACAA GAGATGGTGG TAACAATAAC ACCACGACG ACAACGAGAC CGAGACCTTC	7500
AGACCTGGAG GAGGAGATAT GAGGGACAAT TGGAGAAGTG AATTATATAA ATATAAGTA	7560
GTACAAGTTG AACCATTAGG AGTAGCACCC ACCAAGGCAA AGAGAAGAGT GGTGCAAGA	7620
GA AAAAAGAG CAGTGGGAAT AGGAGCTATG TTCCTTGGGT TCTTAGGAGC AGCAGGAAGC	7680
ACTATGGGCG CAGCGTCAGT GACGCTGACG GTACAAGCCA GACAATTATT GTCTGGTATA	7740

- 185 -

GTGCAGCAGC AGAACAATCT GCTGAGGGCT ATTGAGGCGC AACAGCATCT GTTGCAACTC	7800
ACAGTCTGGG GCATCAAACA GCTCCAGGCA AGAGTCCTGG CTGTGGAAAG ATACCTAAGG	7860
GATCAACAGC TCCTGGGACT TTGGGGTTGC TCTGGAAAAC TCATTGTCAC CACTACTGTG	7920
CCTTGAACA ATAGCTGGAG TAATAAATCT CTGGAACAA TTTGGGATAA CATGACCTGG	7980
ATGCAGTGGG AAAGAGAAAT TGACAATTAC ACAAACATAA TATACACCTT AATTGAAGAA	8040
TCGCAGAACC AACAAGAAAA AAATGAACTA GAATTATTGG AATTGGATAA ATGGGCAAAT	8100
TTGTGGAATT GGTTTAGTAT ATCAAACCTGG CTATGGTATA TAAATTTATT CATAATGGTA	8160
GTAGGAGGCT TGGTAGGTTT AAGAATAGTT TTTACTGTAC TTTCTATAGT TAATAGAGTT	8220
AGGCAGGGAT ACTCACCATT ATCGTTTCAG ACCCACCTCC CAACCCCGAA GGGACCCGAC	8280
AGGCCAGAAG GAATCGAAGA AGAAGGTGGA GAGAGAGACA GAGGCAGCTC CACTCGATTA	8340
GTGCACGGAT TCTTAGCACT TTTCTGGGAC GACCTGAGGA GTCTGTGCCT CTTAGCTAC	8400
CACCACTTGA GAGACTTACT CTTGATTGTA ACGAGGATTG TGGAACCTCT GGGACGCAGG	8460
GGATGGGAAG CCTTCAAATA CTGGTGGAA CTCTGCAGT ATTGGAGGCA GGAACCTACG	8520
AAGAGTGCTG TTAGCTTGTT CAATGGCAGC GCCATAGCAG TAGCTGAGGG GACAGATAGA	8580
GTTATAGAAG CTTTACGAAG GGCTTATAGA GCTATTCTCC ACATACCTAG AAGAATAAGA	8640
CAGGGCTTAG AAAGGGCTTT GCTATAAAAT GGGTGGCAAG TGGTCAGAAA GTAGTGTGGT	8700
TAGAAGGCAT GTACCTTTAA GACAAGGCAG CTATAGATCT TAGCCGCTTT TTAAGAGAAA	8760
AGGGGGGACT GGAAGGGCTA ATTCCTCAC GGAAAAGACC AGTTGAACCA GAAGAAGATA	8820
GAAGAGGCCA TGAAGAAGAA AACAACAGAT TGTCTGCTT GCTCAGCTGG GGACTTTCCA	8880
GAAGGCGCGG CCTGAGTGAC TAAGCCCCGT TGGGGACTTT CCGAAGAGGC ATGAAGGGAC	8940
TTTCCAAGGC AGGCGTGGCC TGGGCGGGAC TGGGGAGTGG CGAGCCCTCA GATGCTGCAT	9000
ATAAGCAGCT GCTTTCTGCC TGTACTGGGT CTCTCTGGTT AGACCAGATC TGAGCCTGGG	9060
AGCTCTCTGG CTAGCTAGGG AACCCTGTC TTAAGCCTCA ATAAAGCTTG CCTTGAGTGC	9120
TTCAAGTAGT GTGTGCCCCG CTGTTGTGTG ACTCTGGTAT CTAGAGATCC CTCAGACCAT	9180
TTTAGTCCGT GTGAAAATC TCTAGCA	9207

CLAIMS:

1. An isolated HIV-1 strain or a component, part, fragment or derivative thereof which is substantially non-pathogenic.
2. A strain of HIV-1 according to claim 1 wherein said strain is capable of stimulating an immune response in a human or primate against at least one glycoprotein on HIV-1 whilst not substantially reducing proliferative responses and cytokine production to a mitogen in said human or primate compared to a healthy, non-infected human or primate subject.
3. A strain of HIV-1 according to claim 2 which carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one polypeptide or protein from a pathogenic strain of HIV-1 or results in reduced synthesis of said polypeptide or protein.
4. A strain of HIV-1 according to claim 2 which carries one or more mutations in its genome resulting in the said genome directing synthesis of a truncated form of a polypeptide or protein from a pathogenic strain of HIV-1.
5. A strain of HIV-1 according to claim 3 or 4 wherein said strain carries a mutation in its *nef* gene and/or long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome.
6. A strain of HIV-1 according to claim 5 wherein said strain is reactive to antibodies to gp41-45, gp120 and/or gp160 of HIV-1 and carries a deletion of at least ten contiguous nucleotides in a region corresponding to the *nef* gene and/or LTR region of pathogenic HIV-1.
7. A strain of HIV-1 according to claim 6 wherein said strain is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env*.

- 187 -

8. A strain of HIV-1 according to claim 7 wherein said strain carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.

9. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(i)	8830-8862;
	(ii)	9009-9035;
	(iii)	9019-9029; and
	(iv)	9033-9049.

10. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(v)	9281-9371;
	(vi)	9281-9362;
	(vii)	9105-9224; and
	(viii)	9271-9370.

11. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(ix)	8882-8928;
	(x)	8850-9006;
	(xi)	8792-9041; and
	(xii)	9112-9204.

12. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(xiii)	9105-9224
	(xiv)	9389-9395; and
	(xv)	9281-9366.

13. A strain of HIV-1 according to claim 8 wherein said deletion encompasses at least one of the following decanucleotides from the *nef* gene of HIV-1 strain NL4-3:

ATGGGTGGCA (SEQ ID NO:2);	TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4);	GGTGGCAAGT (SEQ ID NO:5);
GTGGCAAGTG (SEQ ID NO:6);	TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8);	GCAAGTGGTC (SEQ ID NO:9);
CAAGTGGTCA (SEQ ID NO:10);	AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12);	GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAAA (SEQ ID NO:14);	GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16);	TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18);	AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20);	AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22);	AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24);	TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26);	GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28);	GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30);	GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32);	TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34);	GGATGGCCTG (SEQ ID NO:35);
GATGGCCTGC (SEQ ID NO:36);	ATGGCCTGCT (SEQ ID NO:37);
TGGCCTGCTG (SEQ ID NO:38);	GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40);	CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42);	TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44);	CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46);	GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48);	AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50);	GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52);	GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54);	AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56);	GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58);	ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60);	GAGACGAGCT (SEQ ID NO:61);

- 189 -

AGACGAGCTG (SEQ ID NO:62);	GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64);	CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66);	AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68);	CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70);	GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72);	GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74);	CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76);	GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78);	AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80);	CAGATGGGGT (SEQ ID NO:81);
AGATGGGGTG (SEQ ID NO:82);	GATGGGGTGG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84);	TGGGGTGGGA (SEQ ID NO:85);
GGGGTGGGAG (SEQ ID NO:86);	GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88);	GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90);	GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92);	GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94);	GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96);	AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98);	TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100);	TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102);	TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104);	GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106);	GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108);	CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110);	TAGAAAAACA (SEQ ID NO:111);
AGAAAAACAT (SEQ ID NO:112);	GAAAAACATG (SEQ ID NO:113);
AAAAACATGG (SEQ ID NO:114);	AAACATGGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116);	AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118);	CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120);	TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122);	GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124);	GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126);	AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128);	TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130);	ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132);	AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134);	GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136);	AGCAATACAG (SEQ ID NO:137);

- 190 -

GCAATACAGC (SEQ ID NO:138);	CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140);	ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142);	ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144);	AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146);	CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148);	GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150);	TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152);	ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154);	AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156);	TGCTGCTTGT (SEQ ID NO:157);
GCTGCTTGTG (SEQ ID NO:158);	CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160);	GCTTGTGCCT (SEQ ID NO:161);
CTTGTGCCTG (SEQ ID NO:162);	TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164);	GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166);	GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168);	CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170);	GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172);	CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174);	AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAAG (SEQ ID NO:176);	AAGCACAAAG (SEQ ID NO:177);
AGCACAAAGAG (SEQ ID NO:178);	GCACAAAGAGG (SEQ ID NO:179);
CACAAAGAGGA (SEQ ID NO:180);	ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182);	AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184);	GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186);	GGAGGAAGAG (SEQ ID NO:187);
GAGGAAGAGG (SEQ ID NO:188);	AGGAAGAGGT (SEQ ID NO:189);
GGAAGAGGTG (SEQ ID NO:190);	GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192);	AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194);	AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196);	GTGGGTTTTT (SEQ ID NO:197);
TGGGTTTTTCC (SEQ ID NO:198);	GGGTTTTTCCA (SEQ ID NO:199);
GGTTTTTCCAG (SEQ ID NO:200);	GTTTTTCCAGT (SEQ ID NO:201);
TTTTTCCAGTC (SEQ ID NO:202);	TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204);	TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206);	CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208);	GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210);	CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212);	CACCTCAGGT (SEQ ID NO:213);

ACCTCAGGTA (SEQ ID NO:214);	CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216);	TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218);	AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220);	GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222);	ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224);	CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226);	TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228);	AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230);	GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232);	CCAATGACTT (SEQ ID NO:233);
CAATGACTTA (SEQ ID NO:234);	AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236);	TGACTTACAA (SEQ ID NO:237);
GACTTACAAG (SEQ ID NO:238);	ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240);	TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242);	ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244);	AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246);	GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248);	CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250);	GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252);	TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254);	TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256);	GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258);	TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260);	TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262);	AGCCACTTTT (SEQ ID NO:263);
GCCACTTTTT (SEQ ID NO:264);	CCACTTTTTA (SEQ ID NO:265);
CACTTTTTAA (SEQ ID NO:266);	ACTTTTTTAA (SEQ ID NO:267);
CTTTTTAAAA (SEQ ID NO:268);	TTTTTAAAG (SEQ ID NO:269);
TTTTAAAGA (SEQ ID NO:270);	TTTAAAGAA (SEQ ID NO:271);
TTAAAGAAA (SEQ ID NO:272);	TAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274);	AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276);	AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278);	AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280);	AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282);	GGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284);	GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286);	GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288);	ACTGGAAGGG (SEQ ID NO:289);

CTGGAAGGGC (SEQ ID NO:290);	TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292);	GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294);	AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296);	GGCTAATTC A (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298);	CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300);	AATTCACTCC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302);	TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304);	CACTCCCAAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306);	CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308);	CCCAAAGAAG (SEQ ID NO:309);
CCAAAGAAGA (SEQ ID NO:310);	CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312);	AAGAAGACAA (SEQ ID NO:313);
AGAAGACAAG (SEQ ID NO:314);	GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316);	AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318);	ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320);	AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322);	GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324);	TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326);	TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328);	CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330);	TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332);	ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334);	CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336);	GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338);	GGATCTACCA (SEQ ID NO:339);
GATCTACCAC (SEQ ID NO:340);	ATCTACCACA (SEQ ID NO:341);
TCTACCACAC (SEQ ID NO:342);	CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344);	ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346);	CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348);	CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350);	CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352);	CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354);	AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356);	GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358);	TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360);	CTTCCCTGAT (SEQ ID NO:361);
TTCCTGATT (SEQ ID NO:362);	TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364);	CCTGATTGGC (SEQ ID NO:365);

- 193 -

CTGATTGGCA (SEQ ID NO:366);	TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368);	ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370);	TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372);	GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374);	AGAACTACAC (SEQ ID NO:375);
GAACTACACA (SEQ ID NO:376);	AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378);	CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380);	ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382);	ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384);	ACCAGGGCCA (SEQ ID NO:385);
CCAGGGCCAG (SEQ ID NO:386);	CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388);	GGGCCAGGGG (SEQ ID NO:389);
GGCCAGGGGT (SEQ ID NO:390);	GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392);	CAGGGGTCAG (SEQ ID NO:393);
AGGGGTCAGA (SEQ ID NO:394);	GGGGTCAGAT (SEQ ID NO:395);
GGGTCAGATA (SEQ ID NO:396);	GGTCAGATAT (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398);	TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400);	AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402);	ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404);	ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406);	CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408);	ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410);	TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412);	ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414);	CTTTGGATGG (SEQ ID NO:415);
TTTGGATGGT (SEQ ID NO:416);	TTGGATGGTG (SEQ ID NO:417);
TGGATGGTGC (SEQ ID NO:418);	GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420);	ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422);	GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424);	TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426);	CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428);	ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430);	AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432);	GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434);	TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436);	GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438);	ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440);	CAGTTGAGCC (SEQ ID NO:441);

AGTTGAGCCA (SEQ ID NO:442);	GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444);	TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446);	AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448);	CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450);	AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452);	ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454);	AAGGTAGAAG (SEQ ID NO:455);
AGGTAGAAGA (SEQ ID NO:456);	GGTAGAAGAG (SEQ ID NO:457);
GTAGAAGAGG (SEQ ID NO:458);	TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460);	GAAGAGGCCA (SEQ ID NO:461);
AAGAGGCCAA (SEQ ID NO:462);	AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464);	AGGCCAATAA (SEQ ID NO:465);
GGCCAATAAA (SEQ ID NO:466);	GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468);	CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470);	ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472);	AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474);	AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476);	GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478);	GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480);	GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482);	ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484);	ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486);	CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488);	GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490);	TTGTTACACC (SEQ ID NO:491);
TGTTACACCC (SEQ ID NO:492);	GTTACACCCCT (SEQ ID NO:493);
TTACACCCTG (SEQ ID NO:494);	TACACCCTGT (SEQ ID NO:495);
ACACCCTGTG (SEQ ID NO:496);	CACCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498);	CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500);	CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502);	GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504);	GAGCCTGCAT (SEQ ID NO:505);
AGCCTGCATG (SEQ ID NO:506);	GCCTGCATGG (SEQ ID NO:507);
CCTGCATGGA (SEQ ID NO:508);	CTGCATGGAA (SEQ ID NO:509);
TGCATGGAAT (SEQ ID NO:510);	GCATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512);	ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514);	GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516);	AATGGATGAC (SEQ ID NO:517);

- 195 -

ATGGATGACC (SEQ ID NO:518);	TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520);	GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522);	TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524);	ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526);	CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528);	TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530);	AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532);	AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534);	AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536);	AAGTGTTAGA (SEQ ID NO:537);
AGTGTTAGAG (SEQ ID NO:538);	GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540);	GTTAGAGTGG (SEQ ID NO:541);
TTAGAGTGGA (SEQ ID NO:542);	TAGAGTGAG (SEQ ID NO:543);
AGAGTGAGG (SEQ ID NO:544);	GAGTGAGGT (SEQ ID NO:545);
AGTGAGGTT (SEQ ID NO:546);	GTGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548);	GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550);	AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552);	GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554);	TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556);	GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558);	CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560);	GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562);	CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564);	CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTT (SEQ ID NO:566);	TAGCATTTCA (SEQ ID NO:567);
AGCATTTTCAT (SEQ ID NO:568);	GCATTTTCATC (SEQ ID NO:569);
CATTTTCATCA (SEQ ID NO:570);	ATTTTCATCAC (SEQ ID NO:571);
TTCATCACAG (SEQ ID NO:572);	TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574);	CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576);	TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578);	ACGTGGCCCC (SEQ ID NO:579);
CGTGGCCCGA (SEQ ID NO:580);	GTGGCCCGAG (SEQ ID NO:581);
TGGCCCGAGA (SEQ ID NO:582);	GGCCCGAGAG (SEQ ID NO:583);
GCCCGAGAGC (SEQ ID NO:584);	CCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586);	CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588);	AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590);	AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592);	CTGCATCCGG (SEQ ID NO:593);

- 196 -

TGCATCCGGA (SEQ ID NO:594); GCATCCGGAG (SEQ ID NO:595);
 CATCCGGAGT (SEQ ID NO:596); ATCCGGAGTA (SEQ ID NO:597);
 TCCGGAGTAC (SEQ ID NO:598); CCGGAGTACT (SEQ ID NO:599);
 CGGAGTACTT (SEQ ID NO:600); GGAGTACTTC (SEQ ID NO:601);
 GAGTACTTCA (SEQ ID NO:602); AGTACTTCAA (SEQ ID NO:603);
 GTACTTCAAG (SEQ ID NO:604); TACTTCAAGA (SEQ ID NO:605);
 ACTTCAAGAA (SEQ ID NO:606); CTTCAAGAAC (SEQ ID NO:607);
 TTCAAGAACT (SEQ ID NO:608); TCAAGAACTG (SEQ ID NO:609);
 CAAGAACTGC (SEQ ID NO:610); AAGAACTGCT (SEQ ID NO:611);
 AGAACTGCTG (SEQ ID NO:612); GAACTGCTGA (SEQ ID NO:613).

14. A strain of HIV-1 according to claim 8 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTGGCC (SEQ ID NO:652); CTTTTTGCCT (SEQ ID NO:653);
 TTTTGCCTG (SEQ ID NO:654); TTTTGCCTGT (SEQ ID NO:655);
 TTTGCCTGTA (SEQ ID NO:656); TTGCCTGTAC (SEQ ID NO:657);
 TGCTGTACT (SEQ ID NO:658); GCCTGTACTG (SEQ ID NO:659);
 CCTGTACTGG (SEQ ID NO:660); CTGTACTGGG (SEQ ID NO:661);
 TGTACTGGGT (SEQ ID NO:662); GTACTGGGTC (SEQ ID NO:663);
 TACTGGGTCT (SEQ ID NO:664); ACTGGGTCTC (SEQ ID NO:665);
 CTGGGTCTCT (SEQ ID NO:666); TGGGTCTCTC (SEQ ID NO:667);
 GGGTCTCTCT (SEQ ID NO:668); GGTCTCTCTG (SEQ ID NO:669);
 GTCTCTCTGG (SEQ ID NO:670); TCTCTCTGGT (SEQ ID NO:671);
 CTCTCTGGTT (SEQ ID NO:672); TCTCTGGTTA (SEQ ID NO:673);
 CTCTGGTTAG (SEQ ID NO:674); TCTCTGGTTA (SEQ ID NO:675);
 CTGGTTAGAC (SEQ ID NO:676); TGGTTAGACC (SEQ ID NO:677);
 GGTTAGACCA (SEQ ID NO:678); GTTAGACCAG (SEQ ID NO:679);
 TTAGACCAGA (SEQ ID NO:680); TAGACCAGAT (SEQ ID NO:681);
 AGACCAGATC (SEQ ID NO:682); GACCAGATCT (SEQ ID NO:683);
 ACCAGATCTG (SEQ ID NO:684); CCAGATCTGA (SEQ ID NO:685);
 CAGATCTGAG (SEQ ID NO:686); AGATCTGAGC (SEQ ID NO:687);
 GATCTGAGCC (SEQ ID NO:688); ATCTGAGCCT (SEQ ID NO:689);
 TCTGAGCCTG (SEQ ID NO:690); CTGAGCCTGG (SEQ ID NO:691);
 TGAGCCTGGG (SEQ ID NO:692); GAGCCTGGGA (SEQ ID NO:693);
 AGCCTGGGAG (SEQ ID NO:694); GCCTGGGAGC (SEQ ID NO:695);
 CCTGGGAGCT (SEQ ID NO:696); CTGGGAGCTC (SEQ ID NO:697);
 TGGGAGCTCT (SEQ ID NO:698); GGGAGCTCTC (SEQ ID NO:699);

- 197 -

GGAGCTCTCT	(SEQ ID NO:700);	GAGCTCTCTG	(SEQ ID NO:701);
AGCTCTCTGG	(SEQ ID NO:702);	GCTCTCTGGC	(SEQ ID NO:703);
CTCTCTGGCT	(SEQ ID NO:704);	TCTCTGGCTA	(SEQ ID NO:705);
CTCTGGCTAA	(SEQ ID NO:706);	TCTGGCTAAC	(SEQ ID NO:707);
CTGGCTAACT	(SEQ ID NO:708);	TGGCTAACTA	(SEQ ID NO:709);
GGCTAACTAG	(SEQ ID NO:710);	GCTAACTAGG	(SEQ ID NO:711);
CTAACTAGGG	(SEQ ID NO:712);	TAACTAGGGA	(SEQ ID NO:713);
AACTAGGGAA	(SEQ ID NO:714);	ACTAGGGAAC	(SEQ ID NO:715);
CTAGGGGAACC	(SEQ ID NO:716);	TAGGGGAACCC	(SEQ ID NO:717);
AGGGGAACCCA	(SEQ ID NO:718);	GGGAACCCAC	(SEQ ID NO:719);
GGAACCCACT	(SEQ ID NO:720);	GAACCCACTG	(SEQ ID NO:721);
AACCCACTGC	(SEQ ID NO:722);	ACCCACTGCT	(SEQ ID NO:723);
CCCACTGCTT	(SEQ ID NO:724);	CCACTGCTTA	(SEQ ID NO:725);
CACTGCTTAA	(SEQ ID NO:726);	ACTGCTTAAG	(SEQ ID NO:727);
CTGCTTAAGC	(SEQ ID NO:728);	TGCTTAAGCC	(SEQ ID NO:729);
GCTTAAGCCT	(SEQ ID NO:730);	CTTAAGCCTC	(SEQ ID NO:731);
TTAAGCCTCA	(SEQ ID NO:732);	TAAGCCTCAA	(SEQ ID NO:733);
AAGCCTCAAT	(SEQ ID NO:734);	AGCCTCAATA	(SEQ ID NO:735);
GCCTCAATAA	(SEQ ID NO:736);	CCTCAATAAA	(SEQ ID NO:737);
CTCAATAAAG	(SEQ ID NO:738);	TCAATAAAGC	(SEQ ID NO:739);
CAATAAAGCT	(SEQ ID NO:740);	AATAAAGCTT	(SEQ ID NO:741);
ATAAAGCTTG	(SEQ ID NO:742);	TAAAGCTTGC	(SEQ ID NO:743);
AAAGCTTGCC	(SEQ ID NO:744);	AAGCTTGCCCT	(SEQ ID NO:745);
AGCTTGCCCT	(SEQ ID NO:746);	GCTTGCCCTTG	(SEQ ID NO:747);
CTTGCCCTTGA	(SEQ ID NO:748);	TTGCCCTTGAG	(SEQ ID NO:749);
TGCCCTTGAGT	(SEQ ID NO:750);	GCCTTGAGTG	(SEQ ID NO:751);
CCTTGAGTGC	(SEQ ID NO:752);	CTTGAGTGCT	(SEQ ID NO:753);
TTGAGTGCTT	(SEQ ID NO:754);	TGAGTGCTTC	(SEQ ID NO:755);
GAGTGCTTCA	(SEQ ID NO:756);	AGTGCTTCAA	(SEQ ID NO:757);
GTGCTTCAAG	(SEQ ID NO:758);	TGCTTCAAGT	(SEQ ID NO:759);
GCCTTCAAGTA	(SEQ ID NO:760);	CTTCAAGTAG	(SEQ ID NO:761);
TTCAAGTAGT	(SEQ ID NO:762);	TCAAGTAGTG	(SEQ ID NO:763);
CAAGTAGTGT	(SEQ ID NO:764);	AAGTAGTGTG	(SEQ ID NO:765);
AGTAGTGTGT	(SEQ ID NO:766);	GTAGTGTGTG	(SEQ ID NO:767);
TAGTGTGTGC	(SEQ ID NO:768);	AGTGTGTGCC	(SEQ ID NO:769);
GTGTGTGCCC	(SEQ ID NO:770);	TGTGTGCCCCG	(SEQ ID NO:771);
GTGTGCCCCGT	(SEQ ID NO:772);	TGTGCCCCGTC	(SEQ ID NO:773);
GTGCCCCGTCT	(SEQ ID NO:774);	TGCCCCGTCTG	(SEQ ID NO:775);

- 198 -

GCCCGTCTGT (SEQ ID NO:776); CCCGTCTGTT (SEQ ID NO:777);
 CCGTCTGTTG (SEQ ID NO:778); CGTCTGTTGT (SEQ ID NO:779);
 GTCTGTTGTG (SEQ ID NO:780); TCTGTTGTGT (SEQ ID NO:781);
 CTGTTGTGTG (SEQ ID NO:782); TGTGTGTGA (SEQ ID NO:783);
 GTTGTGTGAC (SEQ ID NO:784); TTGTGTGACT (SEQ ID NO:785);
 TGTGTGACTC (SEQ ID NO:786); GTGTGACTCT (SEQ ID NO:787);
 TGTGTGACTC (SEQ ID NO:788); GTGTGACTCT (SEQ ID NO:789);
 TGTGACTCTG (SEQ ID NO:790); GTGACTCTGG (SEQ ID NO:791);
 TGA CTCTGGT (SEQ ID NO:792); GACTCTGGTA (SEQ ID NO:793);
 ACTCTGGTAA (SEQ ID NO:794); CTCTGGTAAC (SEQ ID NO:795);
 TCTGGTAACT (SEQ ID NO:796); CTGGTAACTA (SEQ ID NO:797);
 TGGTAACTAG (SEQ ID NO:798); GGTA ACTAGA (SEQ ID NO:799).

15. A strain of HIV-1 according to claim 8 having the identifying characteristics of HIV-1 isolate ECACC V94101706 or HIV-1 isolate ECACC V941031169 or isolate C54 deposited at ECACC on 14 February, 1995 under Accession Number _____.

16. An isolated strain of HIV-1 which is reactive to antibodies to a glycoprotein of HIV-1, is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env* and which is incapable of directing synthesis of a *nef* gene product or a full length *nef* gene product.

17. An isolated strain of HIV-1 according to claim 16 wherein the glycoprotein is at least one of gp41-45, gp120 and/or gp160.

18. A nucleic acid molecule or a part, fragment or derivative thereof from an HIV-1 isolate defined in any one of claims 1 to 16.

19. A molecular infectious clone comprising a nucleic acid molecule according to claim 18.

20. A method for inhibiting or reducing productive infection of an individual by a pathogenic strain of HIV-1, said method comprising administering to a subject a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate

- 199 -

target cells carrying DNA derived from said non-pathogenic HIV-1.

21. A method according to claim 20 wherein said isolate is capable of stimulating an immune response in a human or primate against at least one glycoprotein on HIV-1 whilst not substantially reducing proliferative responses and cytokine production to a mitogen in said human or primate compared to a healthy, non-infected human or primate subject.

22. A method according to claim 21 wherein said isolate carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one polypeptide or protein from a pathogenic strain of HIV-1.

23. A method according to claim 17 wherein said isolate carries one or more mutations in its genome resulting in said genome directing synthesis of a truncated form of a polypeptide or protein from a pathogenic strain of HIV-1.

24. A method according to claim 22 or 23 wherein said HIV-1 isolate carries a mutation in its *nef* gene and/or long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome.

25. A method according to claim 24 wherein said HIV-1 isolate is reactive to antibodies to gp41-45, gp120 and/or gp160 of HIV-1 and carries a deletion of at least ten contiguous nucleotides in a region corresponding to the *nef* gene and/or LTR region of pathogenic HIV-1.

26. A method according to claim 25 wherein said HIV-1 isolate is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env*.

27. A method according to claim 26 wherein said HIV-1 isolate carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.

- 200 -

28. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(i)	8830-8862;
	(ii)	9009-9035;
	(iii)	9019-9029; and
	(iv)	9033-9049.

29. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(v)	9281-9371;
	(vi)	9281-9362;
	(vii)	9105-9224; and
	(viii)	9271-9370.

30. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(ix)	8882-8928;
	(x)	8850-9006;
	(xi)	8792-9041; and
	(xii)	9112-9204.

31. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(xiii)	9105-9224;
	(xiv)	9389-9395; and
	(xv)	9281-9366.

32. A method according to claim 27 wherein said deletion encompasses at least one of the following decanucleotides from the nef gene of HIV-1 strain NL43:

ATGGGTGGCA (SEQ ID NO:2);	TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4);	GGTGGCAAGT (SEQ ID NO:5);
GTGGCAAGTG (SEQ ID NO:6);	TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8);	GCAAGTGGTC (SEQ ID NO:9);

- 201 -

CAAGTGGTCA (SEQ ID NO:10);	AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12);	GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAAA (SEQ ID NO:14);	GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16);	TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18);	AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20);	AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22);	AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24);	TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26);	GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28);	GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30);	GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32);	TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34);	GGATGGCCTG (SEQ ID NO:35);
GATGGCCTGC (SEQ ID NO:36);	ATGGCCTGCT (SEQ ID NO:37);
TGGCCTGCTG (SEQ ID NO:38);	GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40);	CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42);	TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44);	CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46);	GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48);	AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50);	GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52);	GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54);	AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56);	GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58);	ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60);	GAGACGAGCT (SEQ ID NO:61);
AGACGAGCTG (SEQ ID NO:62);	GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64);	CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66);	AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68);	CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70);	GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72);	GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74);	CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76);	GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78);	AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80);	CAGATGGGGT (SEQ ID NO:81);
AGATGGGGTG (SEQ ID NO:82);	GATGGGGTGG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84);	TGGGGTGGGA (SEQ ID NO:85);

- 202 -

GGGGTGGGAG (SEQ ID NO:86);	GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88);	GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90);	GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92);	GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94);	GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96);	AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98);	TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100);	TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102);	TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104);	GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106);	GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108);	CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110);	TAGAAAAACA (SEQ ID NO:111);
AGAAAAACAT (SEQ ID NO:112);	GAAAAACATG (SEQ ID NO:113);
AAAAACATGG (SEQ ID NO:114);	AAAACATGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116);	AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118);	CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120);	TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122);	GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124);	GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126);	AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128);	TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130);	ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132);	AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134);	GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136);	AGCAATACAG (SEQ ID NO:137);
GCAATACAGC (SEQ ID NO:138);	CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140);	ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142);	ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144);	AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146);	CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148);	GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150);	TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152);	ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154);	AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156);	TGCTGCTTGT (SEQ ID NO:157);
GCTGCTTGTG (SEQ ID NO:158);	CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160);	GCTTGTGCCT (SEQ ID NO:161);

- 203 -

CTTGTGCCTG (SEQ ID NO:162);	TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164);	GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166);	GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168);	CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170);	GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172);	CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174);	AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAAG (SEQ ID NO:176);	AAGCACAAAG (SEQ ID NO:177);
AGCACAAAGAG (SEQ ID NO:178);	GCACAAGAGG (SEQ ID NO:179);
CACAAGAGGA (SEQ ID NO:180);	ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182);	AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184);	GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186);	GGAGGAAGAG (SEQ ID NO:187);
GAGGAAGAGG (SEQ ID NO:188);	AGGAAGAGGT (SEQ ID NO:189);
GGAAGAGGTG (SEQ ID NO:190);	GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192);	AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194);	AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196);	GTGGGTTTTC (SEQ ID NO:197);
TGGGTTTTCC (SEQ ID NO:198);	GGGTTTTCCA (SEQ ID NO:199);
GGTTTTCCAG (SEQ ID NO:200);	GTTTTCCAGT (SEQ ID NO:201);
TTTTCCAGTC (SEQ ID NO:202);	TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204);	TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206);	CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208);	GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210);	CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212);	CACCTCAGGT (SEQ ID NO:213);
ACCTCAGGTA (SEQ ID NO:214);	CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216);	TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218);	AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220);	GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222);	ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224);	CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226);	TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228);	AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230);	GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232);	CCAATGACTT (SEQ ID NO:233);
CAATGACTTA (SEQ ID NO:234);	AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236);	TGACTTACAA (SEQ ID NO:237);

- 204 -

GACTTACAAG (SEQ ID NO:238);	ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240);	TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242);	ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244);	AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246);	GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248);	CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250);	GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252);	TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254);	TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256);	GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258);	TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260);	TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262);	AGCCACTTTT (SEQ ID NO:263);
GCCACTTTTT (SEQ ID NO:264);	CCACTTTTTA (SEQ ID NO:265);
CACTTTTTAA (SEQ ID NO:266);	ACTTTTTAAA (SEQ ID NO:267);
CTTTTTAAAA (SEQ ID NO:268);	TTTTTAAAAG (SEQ ID NO:269);
TTTTAAAAGA (SEQ ID NO:270);	TTTAAAAGAA (SEQ ID NO:271);
TAAAAGAAA (SEQ ID NO:272);	TAAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274);	AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276);	AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278);	AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280);	AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282);	GGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284);	GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286);	GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288);	ACTGGAAGGG (SEQ ID NO:289);
CTGGAAGGGC (SEQ ID NO:290);	TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292);	GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294);	AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296);	GGCTAATTCA (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298);	CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300);	AATTCACTCC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302);	TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304);	CACTCCCAAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306);	CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308);	CCCAAAGAAG (SEQ ID NO:309);
CCAAAGAAGA (SEQ ID NO:310);	CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312);	AAGAAGACAA (SEQ ID NO:313);

- 205 -

AGAAGACAAG (SEQ ID NO:314);	GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316);	AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318);	ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320);	AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322);	GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324);	TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326);	TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328);	CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330);	TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332);	ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334);	CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336);	GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338);	GGATCTACCA (SEQ ID NO:339);
GATCTACCAC (SEQ ID NO:340);	ATCTACCACA (SEQ ID NO:341);
TCTACCACAC (SEQ ID NO:342);	CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344);	ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346);	CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348);	CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350);	CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352);	CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354);	AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356);	GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358);	TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360);	CTTCCCTGAT (SEQ ID NO:361);
TTCCCTGATT (SEQ ID NO:362);	TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364);	CCTGATTGGC (SEQ ID NO:365);
CTGATTGGCA (SEQ ID NO:366);	TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368);	ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370);	TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372);	GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374);	AGAACTACAC (SEQ ID NO:375);
GAAGTACACA (SEQ ID NO:376);	AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378);	CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380);	ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382);	ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384);	ACCAGGGCCA (SEQ ID NO:385);
CCAGGGCCAG (SEQ ID NO:386);	CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388);	GGGCCAGGGG (SEQ ID NO:389);

GGCCAGGGGT (SEQ ID NO:390);	GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392);	CAGGGGTCA (SEQ ID NO:393);
AGGGGTCAGA (SEQ ID NO:394);	GGGGTCAGAT (SEQ ID NO:395);
GGGTCAGATA (SEQ ID NO:396);	GGTCAGATAT (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398);	TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400);	AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402);	ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404);	ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406);	CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408);	ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410);	TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412);	ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414);	CTTTGGATGG (SEQ ID NO:415);
TTTGGATGGT (SEQ ID NO:416);	TTGGATGGTG (SEQ ID NO:417);
TGGATGGTGC (SEQ ID NO:418);	GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420);	ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422);	GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424);	TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426);	CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428);	ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430);	AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432);	GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434);	TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436);	GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438);	ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440);	CAGTTGAGCC (SEQ ID NO:441);
AGTTGAGCCA (SEQ ID NO:442);	GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444);	TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446);	AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448);	CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450);	AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452);	ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454);	AAGGTAGAA (SEQ ID NO:455);
AGGTAGAA (SEQ ID NO:456);	GGTAGAAGAG (SEQ ID NO:457);
GTAAGAGAGG (SEQ ID NO:458);	TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460);	GAAGAGGCCA (SEQ ID NO:461);
AAGAGGCCAA (SEQ ID NO:462);	AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464);	AGGCCAATAA (SEQ ID NO:465);

- 207 -

GGCCAATAAA (SEQ ID NO:466);	GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468);	CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470);	ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472);	AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474);	AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476);	GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478);	GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480);	GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482);	ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484);	ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486);	CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488);	GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490);	TTGTTACACC (SEQ ID NO:491);
TGTTACACCC (SEQ ID NO:492);	GTTACACCCCT (SEQ ID NO:493);
TTACACCCCTG (SEQ ID NO:494);	TACACCCCTGT (SEQ ID NO:495);
ACACCCCTGTG (SEQ ID NO:496);	CACCCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498);	CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500);	CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502);	GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504);	GAGCCTGCAT (SEQ ID NO:505);
AGCCTGCATG (SEQ ID NO:506);	GCCTGCATGG (SEQ ID NO:507);
CCTGCATGGA (SEQ ID NO:508);	CTGCATGGAA (SEQ ID NO:509);
TGCATGGAAT (SEQ ID NO:510);	GCATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512);	ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514);	GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516);	AATGGATGAC (SEQ ID NO:517);
ATGGATGACC (SEQ ID NO:518);	TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520);	GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522);	TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524);	ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526);	CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528);	TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530);	AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532);	AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534);	AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536);	AAGTGTTAGA (SEQ ID NO:537);
AGTGTTAGAG (SEQ ID NO:538);	GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540);	GTTAGAGTGG (SEQ ID NO:541);

- 208 -

TTAGAGTGGGA (SEQ ID NO:542);	TAGAGTGGAG (SEQ ID NO:543);
AGAGTGGAGG (SEQ ID NO:544);	GAGTGGAGGT (SEQ ID NO:545);
AGTGGAGGTT (SEQ ID NO:546);	GTGGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548);	GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550);	AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552);	GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554);	TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556);	GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558);	CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560);	GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562);	CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564);	CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTT (SEQ ID NO:566);	TAGCATTTCA (SEQ ID NO:567);
AGCATTTTCAT (SEQ ID NO:568);	GCATTTTCATC (SEQ ID NO:569);
CATTTTCATCA (SEQ ID NO:570);	ATTTTCATCAC (SEQ ID NO:571);
TTTCATCACG (SEQ ID NO:572);	TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574);	CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576);	TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578);	ACGTGGCCCC (SEQ ID NO:579);
CGTGGCCCGA (SEQ ID NO:580);	GTGGCCCGAG (SEQ ID NO:581);
TGGCCCGAGA (SEQ ID NO:582);	GGCCCGAGAG (SEQ ID NO:583);
GCCCGAGAGC (SEQ ID NO:584);	CCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586);	CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588);	AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590);	AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592);	CTGCATCCGG (SEQ ID NO:593);
TGCATCCGGA (SEQ ID NO:594);	GCATCCGGAG (SEQ ID NO:595);
CATCCGGAGT (SEQ ID NO:596);	ATCCGGAGTA (SEQ ID NO:597);
TCCGGAGTAC (SEQ ID NO:598);	CCGGAGTACT (SEQ ID NO:599);
CGGAGTACTT (SEQ ID NO:600);	GGAGTACTTC (SEQ ID NO:601);
GAGTACTTCA (SEQ ID NO:602);	AGTACTTCAA (SEQ ID NO:603);
GTACTTCAAG (SEQ ID NO:604);	TACTTCAAGA (SEQ ID NO:605);
ACTTCAAGAA (SEQ ID NO:606);	CTTCAAGAAC (SEQ ID NO:607);
TTCAAGAACT (SEQ ID NO:608);	TCAAGAACTG (SEQ ID NO:609);
CAAGAACTGC (SEQ ID NO:610);	AAGAACTGCT (SEQ ID NO:611);
AGAACTGCTG (SEQ ID NO:612);	GAACTGCTGA (SEQ ID NO:613).

33. A method according to claim 27 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTTTGCC	(SEQ ID NO:652);	CTTTTTGCCT	(SEQ ID NO:653);
TTTTTGCCCTG	(SEQ ID NO:654);	TTTTCGCCTGT	(SEQ ID NO:655);
TTTGCCTGTA	(SEQ ID NO:656);	TTGCCTGTAC	(SEQ ID NO:657);
TGCCTGTACT	(SEQ ID NO:658);	GCCTGTACTG	(SEQ ID NO:659);
CCTGTACTGG	(SEQ ID NO:660);	CTGTACTGGG	(SEQ ID NO:661);
TGTACTGGGT	(SEQ ID NO:662);	GTACTGGGTC	(SEQ ID NO:663);
TACTGGGTCT	(SEQ ID NO:664);	ACTGGGTCTC	(SEQ ID NO:665);
CTGGGTCTCT	(SEQ ID NO:666);	TGGGTCTCTC	(SEQ ID NO:667);
GGGTCTCTCT	(SEQ ID NO:668);	GGTCTCTCTG	(SEQ ID NO:669);
GTCTCTCTGG	(SEQ ID NO:670);	TCTCTCTGGT	(SEQ ID NO:671);
CTCTCTGGTT	(SEQ ID NO:672);	TCTCTGGTTA	(SEQ ID NO:673);
CTCTGGTTAG	(SEQ ID NO:674);	TCTCTGGTTA	(SEQ ID NO:675);
CTGGTTAGAC	(SEQ ID NO:676);	TGGTTAGACC	(SEQ ID NO:677);
GGTTAGACCA	(SEQ ID NO:678);	GTTAGACCAG	(SEQ ID NO:679);
TTAGACCAGA	(SEQ ID NO:680);	TAGACCAGAT	(SEQ ID NO:681);
AGACCAGATC	(SEQ ID NO:682);	GACCAGATCT	(SEQ ID NO:683);
ACCAGATCTG	(SEQ ID NO:684);	CCAGATCTGA	(SEQ ID NO:685);
CAGATCTGAG	(SEQ ID NO:686);	AGATCTGAGC	(SEQ ID NO:687);
GATCTGAGCC	(SEQ ID NO:688);	ATCTGAGCCT	(SEQ ID NO:689);
TCTGAGCCTG	(SEQ ID NO:690);	CTGAGCCTGG	(SEQ ID NO:691);
TGAGCCTGGG	(SEQ ID NO:692);	GAGCCTGGGA	(SEQ ID NO:693);
AGCCTGGGAG	(SEQ ID NO:694);	GCCTGGGAGC	(SEQ ID NO:695);
CCTGGGAGCT	(SEQ ID NO:696);	CTGGGAGCTC	(SEQ ID NO:697);
TGGGAGCTCT	(SEQ ID NO:698);	GGGAGCTCTC	(SEQ ID NO:699);
GGAGCTCTCT	(SEQ ID NO:700);	GAGCTCTCTG	(SEQ ID NO:701);
AGCTCTCTGG	(SEQ ID NO:702);	GCTCTCTGGC	(SEQ ID NO:703);
CTCTCTGGCT	(SEQ ID NO:704);	TCTCTGGCTA	(SEQ ID NO:705);
CTCTGGCTAA	(SEQ ID NO:706);	TCTGGCTAAC	(SEQ ID NO:707);
CTGGCTAACT	(SEQ ID NO:708);	TGGCTAACTA	(SEQ ID NO:709);
GGCTAACTAG	(SEQ ID NO:710);	GCTAACTAGG	(SEQ ID NO:711);
CTAACTAGGG	(SEQ ID NO:712);	TAACTAGGGA	(SEQ ID NO:713);
AACTAGGGAA	(SEQ ID NO:714);	ACTAGGGAAC	(SEQ ID NO:715);
CTAGGGAAACC	(SEQ ID NO:716);	TAGGGAAACC	(SEQ ID NO:717);
AGGGAAACCCA	(SEQ ID NO:718);	GGGAACCCAC	(SEQ ID NO:719);

- 210 -

GGAACCCACT	(SEQ ID NO:720);	GAACCCACTG	(SEQ ID NO:721);
AACCCACTGC	(SEQ ID NO:722);	ACCCACTGCT	(SEQ ID NO:723);
CCCACTGCTT	(SEQ ID NO:724);	CCACTGCTTA	(SEQ ID NO:725);
CACTGCTTAA	(SEQ ID NO:726);	ACTGCTTAAG	(SEQ ID NO:727);
CTGCTTAAGC	(SEQ ID NO:728);	TGCTTAAGCC	(SEQ ID NO:729);
GCTTAAGCCT	(SEQ ID NO:730);	CTTAAGCCTC	(SEQ ID NO:731);
TTAAGCCTCA	(SEQ ID NO:732);	TAAGCCTCAA	(SEQ ID NO:733);
AAGCCTCAAT	(SEQ ID NO:734);	AGCCTCAATA	(SEQ ID NO:735);
GCCTCAATAA	(SEQ ID NO:736);	CCTCAATAAA	(SEQ ID NO:737);
CTCAATAAAG	(SEQ ID NO:738);	TCAATAAAGC	(SEQ ID NO:739);
CAATAAAGCT	(SEQ ID NO:740);	AATAAAGCTT	(SEQ ID NO:741);
ATAAAGCTTG	(SEQ ID NO:742);	TAAAGCTTGC	(SEQ ID NO:743);
AAAGCTTGCC	(SEQ ID NO:744);	AAGCTTGCCT	(SEQ ID NO:745);
AGCTTGCCTT	(SEQ ID NO:746);	GCTTGCCTTG	(SEQ ID NO:747);
CTTGCCTTGA	(SEQ ID NO:748);	TTGCCTTGAG	(SEQ ID NO:749);
TGCCTTGAGT	(SEQ ID NO:750);	GCCTTGAGTG	(SEQ ID NO:751);
CCTTGAGTGC	(SEQ ID NO:752);	CTTGAGTGCT	(SEQ ID NO:753);
TTGAGTGCTT	(SEQ ID NO:754);	TGAGTGCTTC	(SEQ ID NO:755);
GAGTGCTTCA	(SEQ ID NO:756);	AGTGCTTCAA	(SEQ ID NO:757);
GTGCTTCAAG	(SEQ ID NO:758);	TGCTTCAAGT	(SEQ ID NO:759);
GCTTCAAGTA	(SEQ ID NO:760);	CTTCAAGTAG	(SEQ ID NO:761);
TTCAAGTAGT	(SEQ ID NO:762);	TCAAGTAGTG	(SEQ ID NO:763);
CAAGTAGTGT	(SEQ ID NO:764);	AAGTAGTGTG	(SEQ ID NO:765);
AGTAGTGTGT	(SEQ ID NO:766);	GTAGTGTGTG	(SEQ ID NO:767);
TAGTGTGTGC	(SEQ ID NO:768);	AGTGTGTGCC	(SEQ ID NO:769);
GTGTGTGCCC	(SEQ ID NO:770);	TGTGTGCCCCG	(SEQ ID NO:771);
GTGTGCCCCGT	(SEQ ID NO:772);	TGTGCCCCGTC	(SEQ ID NO:773);
GTGCCCCGTCT	(SEQ ID NO:774);	TGCCCCGTCTG	(SEQ ID NO:775);
GCCCCGTCTGT	(SEQ ID NO:776);	CCCGTCTGTT	(SEQ ID NO:777);
CCGTCTGTTG	(SEQ ID NO:778);	CGTCTGTTGT	(SEQ ID NO:779);
GTCTGTTGTG	(SEQ ID NO:780);	TCTGTTGTGT	(SEQ ID NO:781);
CTGTTGTGTG	(SEQ ID NO:782);	TGTTGTGTGA	(SEQ ID NO:783);
GTTGTGTGAC	(SEQ ID NO:784);	TTGTGTGACT	(SEQ ID NO:785);
TGTGTGACTC	(SEQ ID NO:786);	GTGTGACTCT	(SEQ ID NO:787);
TGTGTGACTC	(SEQ ID NO:788);	GTGTGACTCT	(SEQ ID NO:789);
TGTGACTCTG	(SEQ ID NO:790);	GTGACTCTGG	(SEQ ID NO:791);
TGACTCTGGT	(SEQ ID NO:792);	GACTCTGGTA	(SEQ ID NO:793);
ACTCTGGTAA	(SEQ ID NO:794);	CTCTGGTAAC	(SEQ ID NO:795);

- 211 -

TCTGGTAACT (SEQ ID NO:796); CTGGTAACTA (SEQ ID NO:797);
TGGTAACTAG (SEQ ID NO:798); GGTAAGTAGA (SEQ ID NO:799).

34. A method according to claim 24 wherein said HIV-1 isolate has the identifying characteristics of HIV-1 isolate ECACC V94101706 or HIV-1 isolate ECACC V941031169 or isolate C54 deposited at ECACC on 14 February, 1995 under Accession Number _____.

35. A method according to claim 20 wherein the HIV-1 isolate is reactive to antibodies to a glycoprotein of HIV-1, is capable of inducing an immune response of *gag*, *pol* and/or *env* and which is incapable of directing synthesis of a *nef* gene product or a full length *nef* gene product.

36. A method according to claim 35 wherein the glycoprotein is at least one of gp41-45, gp120 and/or gp160.

37. A method for vaccinating an individual against the development of AIDS or AIDS related diseases, said method comprising administering to said individual a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying DNA derived from said non-pathogenic HIV-1.

38. A method according to claim 37 wherein said isolate is capable of stimulating an immune response in a human or primate against at least one glycoprotein on HIV-1 whilst not substantially reducing proliferative responses and cytokine production to a mitogen in said human or primate compared to a healthy, non-infected human or primate subject.

39. A method according to claim 38 wherein said isolate carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one polypeptide or protein from a pathogenic strain of HIV-1.

40. A method according to claim 17 wherein said isolate carried one or more mutations in its genome resulting in said genome directing synthesis of a truncated form of a polypeptide or protein from a pathogenic strain of HIV-1.
41. A method according to claim 39 or 40 wherein said HIV-1 isolate carries a mutation in its *nef* gene and/or long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome.
42. A method according to claim 40 wherein said HIV-1 isolate is reactive to antibodies to gp41-45, gp120 and/or gp160 of HIV-1 and carries a deletion of at least ten contiguous nucleotides in a region corresponding to the *nef* gene and/or LTR region of pathogenic HIV-1.
43. A method according to claim 42 wherein said HIV-1 isolate is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env*.
44. A method according to claim 43 wherein said HIV-1 isolate carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.
45. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:
- | | | |
|------------|-------|----------------|
| nucleotide | (i) | 8830-8862; |
| | (ii) | 9009-9035; |
| | (iii) | 9019-9029; and |
| | (iv) | 9033-9049. |
46. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:
- | | | |
|------------|------|------------|
| nucleotide | (v) | 9281-9371; |
| | (vi) | 9281-9362; |

- 213 -

(vii) 9105-9224; and

(viii) 9271-9370.

47. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(ix)	8882-8928;
	(x)	8850-9006;
	(xi)	8792-9041; and
	(xii)	9112-9204.

47. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(xiii)	9105-9224;
	(xiv)	9389-9395; and
	(xv)	9281-9366.

48. A method according to claim 44 wherein said deletion encompasses at least one of the following decanucleotides from the nef gene of HIV-1 strain NL43:

ATGGGTGGCA (SEQ ID NO:2);	TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4);	GGTGGCAAGT (SEQ ID NO:5);
GTGGCAAGTG (SEQ ID NO:6);	TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8);	GCAAGTGGTC (SEQ ID NO:9);
CAAGTGGTCA (SEQ ID NO:10);	AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12);	GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAA (SEQ ID NO:14);	GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16);	TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18);	AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20);	AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22);	AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24);	TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26);	GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28);	GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30);	GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32);	TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34);	GGATGGCCTG (SEQ ID NO:35);

- 214 -

GATGGCCTGC (SEQ ID NO:36);	ATGGCCTGCT (SEQ ID NO:37);
TGGCCTGCTG (SEQ ID NO:38);	GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40);	CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42);	TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44);	CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46);	GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48);	AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50);	GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52);	GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54);	AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56);	GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58);	ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60);	GAGACGAGCT (SEQ ID NO:61);
AGACGAGCTG (SEQ ID NO:62);	GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64);	CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66);	AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68);	CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70);	GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72);	GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74);	CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76);	GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78);	AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80);	CAGATGGGGT (SEQ ID NO:81);
AGATGGGGTG (SEQ ID NO:82);	GATGGGGTGG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84);	TGGGGTGGGA (SEQ ID NO:85);
GGGGTGGGAG (SEQ ID NO:86);	GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88);	GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90);	GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92);	GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94);	GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96);	AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98);	TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100);	TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102);	TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104);	GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106);	GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108);	CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110);	TAGAAAAACA (SEQ ID NO:111);

AGAAAAACAT (SEQ ID NO:112);	GAAAAACATG (SEQ ID NO:113);
AAAAACATGG (SEQ ID NO:114);	AAAACATGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116);	AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118);	CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120);	TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122);	GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124);	GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126);	AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128);	TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130);	ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132);	AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134);	GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136);	AGCAATACAG (SEQ ID NO:137);
GCAATACAGC (SEQ ID NO:138);	CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140);	ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142);	ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144);	AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146);	CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148);	GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150);	TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152);	ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154);	AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156);	TGCTGCTTGT (SEQ ID NO:157);
GCTGCTTGTG (SEQ ID NO:158);	CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160);	GCTTGTGCCT (SEQ ID NO:161);
CTTGTGCCTG (SEQ ID NO:162);	TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164);	GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166);	GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168);	CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170);	GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172);	CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174);	AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAAG (SEQ ID NO:176);	AAGCACAAAG (SEQ ID NO:177);
AGCACAAAGAG (SEQ ID NO:178);	GCACAAAGAGG (SEQ ID NO:179);
CACAAAGAGGA (SEQ ID NO:180);	ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182);	AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184);	GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186);	GGAGGAAGAG (SEQ ID NO:187);

- 216 -

GAGGAAGAGG (SEQ ID NO:188);	AGGAAGAGGT (SEQ ID NO:189);
GGAAGAGGTG (SEQ ID NO:190);	GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192);	AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194);	AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196);	GTGGGTTTTC (SEQ ID NO:197);
TGGGTTTTTC (SEQ ID NO:198);	GGGTTTTCCA (SEQ ID NO:199);
GGTTTTCCAG (SEQ ID NO:200);	GTTTTCCAGT (SEQ ID NO:201);
TTTTCCAGTC (SEQ ID NO:202);	TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204);	TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206);	CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208);	GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210);	CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212);	CACCTCAGGT (SEQ ID NO:213);
ACCTCAGGTA (SEQ ID NO:214);	CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216);	TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218);	AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220);	GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222);	ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224);	CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226);	TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228);	AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230);	GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232);	CCAATGACTT (SEQ ID NO:233);
CAATGACTTA (SEQ ID NO:234);	AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236);	TGACTTACAA (SEQ ID NO:237);
GACTTACAAG (SEQ ID NO:238);	ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240);	TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242);	ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244);	AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246);	GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248);	CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250);	GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252);	TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254);	TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256);	GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258);	TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260);	TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262);	AGCCACTTTT (SEQ ID NO:263);

- 217 -

GCCACTTTTTT (SEQ ID NO:264);	CCACTTTTTTA (SEQ ID NO:265);
CACTTTTTTAA (SEQ ID NO:266);	ACTTTTTTAAA (SEQ ID NO:267);
CTTTTTTAAAA (SEQ ID NO:268);	TTTTTTAAAAG (SEQ ID NO:269);
TTTTTAAAAGA (SEQ ID NO:270);	TTTAAAAGAA (SEQ ID NO:271);
TTAAAAGAAA (SEQ ID NO:272);	TAAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274);	AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276);	AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278);	AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280);	AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282);	GGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284);	GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286);	GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288);	ACTGGAAGGG (SEQ ID NO:289);
CTGGAAGGGC (SEQ ID NO:290);	TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292);	GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294);	AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296);	GGCTAATTCA (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298);	CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300);	AATTCACCTC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302);	TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304);	CACTCCCAAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306);	CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308);	CCCAAAGAAG (SEQ ID NO:309);
CCAAAGAAGA (SEQ ID NO:310);	CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312);	AAGAAGACAA (SEQ ID NO:313);
AGAAGACAAG (SEQ ID NO:314);	GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316);	AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318);	ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320);	AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322);	GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324);	TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326);	TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328);	CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330);	TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332);	ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334);	CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336);	GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338);	GGATCTACCA (SEQ ID NO:339);

- 218 -

GATCTACCAC (SEQ ID NO:340);	ATCTACCACA (SEQ ID NO:341);
TCTACCACAC (SEQ ID NO:342);	CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344);	ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346);	CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348);	CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350);	CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352);	CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354);	AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356);	GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358);	TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360);	CTTCCCTGAT (SEQ ID NO:361);
TTCCCTGATT (SEQ ID NO:362);	TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364);	CCTGATTGGC (SEQ ID NO:365);
CTGATTGGCA (SEQ ID NO:366);	TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368);	ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370);	TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372);	GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374);	AGAACTACAC (SEQ ID NO:375);
GAACTACACA (SEQ ID NO:376);	AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378);	CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380);	ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382);	ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384);	ACCAGGGCCA (SEQ ID NO:385);
CCAGGGCCAG (SEQ ID NO:386);	CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388);	GGGCCAGGGG (SEQ ID NO:389);
GGCCAGGGGT (SEQ ID NO:390);	GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392);	CAGGGGTCAG (SEQ ID NO:393);
AGGGGTCAGA (SEQ ID NO:394);	GGGGTCAGAT (SEQ ID NO:395);
GGGTCAGATA (SEQ ID NO:396);	GGTCAGATAT (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398);	TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400);	AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402);	ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404);	ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406);	CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408);	ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410);	TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412);	ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414);	CTTTGGATGG (SEQ ID NO:415);

TTTGGATGGT (SEQ ID NO:416);	TTGGATGGTG (SEQ ID NO:417);
TGGATGGTGC (SEQ ID NO:418);	GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420);	ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422);	GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424);	TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426);	CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428);	ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430);	AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432);	GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434);	TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436);	GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438);	ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440);	CAGTTGAGCC (SEQ ID NO:441);
AGTTGAGCCA (SEQ ID NO:442);	GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444);	TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446);	AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448);	CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450);	AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452);	ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454);	AAGGTAGAAG (SEQ ID NO:455);
AGGTAGAAGA (SEQ ID NO:456);	GGTAGAAGAG (SEQ ID NO:457);
GTAGAAGAGG (SEQ ID NO:458);	TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460);	GAAGAGGCCA (SEQ ID NO:461);
AAGAGGCCAA (SEQ ID NO:462);	AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464);	AGGCCAATAA (SEQ ID NO:465);
GGCCAATAAA (SEQ ID NO:466);	GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468);	CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470);	ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472);	AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474);	AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476);	GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478);	GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480);	GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482);	ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484);	ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486);	CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488);	GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490);	TTGTTACACC (SEQ ID NO:491);

- 220 -

TGTTACACCC (SEQ ID NO:492);	GTTACACCCT (SEQ ID NO:493);
TTACACCCTG (SEQ ID NO:494);	TACACCCTGT (SEQ ID NO:495);
ACACCCTGTG (SEQ ID NO:496);	CACCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498);	CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500);	CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502);	GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504);	GAGCCTGCGT (SEQ ID NO:505);
AGCCTGCGATG (SEQ ID NO:506);	GCCTGCGATG (SEQ ID NO:507);
CCTGCGATGA (SEQ ID NO:508);	CTGCGATGAA (SEQ ID NO:509);
TGCGATGGAAT (SEQ ID NO:510);	GCGATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512);	ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514);	GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516);	AATGGATGAC (SEQ ID NO:517);
ATGGATGACC (SEQ ID NO:518);	TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520);	GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522);	TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524);	ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526);	CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528);	TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530);	AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532);	AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534);	AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536);	AAGTGTTAGA (SEQ ID NO:537);
AGTGTTAGAG (SEQ ID NO:538);	GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540);	GTTAGAGTGG (SEQ ID NO:541);
TTAGAGTGGA (SEQ ID NO:542);	TAGAGTGGAG (SEQ ID NO:543);
AGAGTGGAGG (SEQ ID NO:544);	GAGTGGAGGT (SEQ ID NO:545);
AGTGGAGGTT (SEQ ID NO:546);	GTGGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548);	GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550);	AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552);	GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554);	TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556);	GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558);	CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560);	GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562);	CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564);	CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTT (SEQ ID NO:566);	TAGCATTTCA (SEQ ID NO:567);

- 221 -

AGCATTTTCAT (SEQ ID NO:568);	GCATTTTCATC (SEQ ID NO:569);
CATTTTCATCA (SEQ ID NO:570);	ATTTTCATCAC (SEQ ID NO:571);
TTTCATCACG (SEQ ID NO:572);	TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574);	CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576);	TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578);	ACGTGGCCCCG (SEQ ID NO:579);
CGTGGCCCCG (SEQ ID NO:580);	GTGGCCCCGAG (SEQ ID NO:581);
TGGCCCCGAGA (SEQ ID NO:582);	GGCCCCGAGAG (SEQ ID NO:583);
GCCCCGAGAGC (SEQ ID NO:584);	CCCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586);	CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588);	AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590);	AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592);	CTGCATCCGG (SEQ ID NO:593);
TGCATCCGGA (SEQ ID NO:594);	GCATCCGGAG (SEQ ID NO:595);
CATCCGGAGT (SEQ ID NO:596);	ATCCGGAGTA (SEQ ID NO:597);
TCCGGAGTAC (SEQ ID NO:598);	CCGGAGTACT (SEQ ID NO:599);
CGGAGTACTT (SEQ ID NO:600);	GGAGTACTTC (SEQ ID NO:601);
GAGTACTTCA (SEQ ID NO:602);	AGTACTTCAA (SEQ ID NO:603);
GTACTTCAAG (SEQ ID NO:604);	TACTTCAAGA (SEQ ID NO:605);
ACTTCAAGAA (SEQ ID NO:606);	CTTCAAGAAC (SEQ ID NO:607);
TTCAAGAACT (SEQ ID NO:608);	TCAAGAACTG (SEQ ID NO:609);
CAAGAACTGC (SEQ ID NO:610);	AAGAACTGCT (SEQ ID NO:611);
AGAACTGCTG (SEQ ID NO:612);	GAACTGCTGA (SEQ ID NO:613).

49. A method according to claim 44 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTTGCC (SEQ ID NO:652);	CTTTTTGCCT (SEQ ID NO:653);
TTTTTGCCTG (SEQ ID NO:654);	TTTTCGCCTGT (SEQ ID NO:655);
TTTGCCGTGA (SEQ ID NO:656);	TTGCCTGTAC (SEQ ID NO:657);
TGCCTGTACT (SEQ ID NO:658);	GCCTGTACTG (SEQ ID NO:659);
CCTGTACTGG (SEQ ID NO:660);	CTGTACTGGG (SEQ ID NO:661);
TGTACTGGGT (SEQ ID NO:662);	GTACTGGGTC (SEQ ID NO:663);
TACTGGGTCT (SEQ ID NO:664);	ACTGGGTCTC (SEQ ID NO:665);
CTGGGTCTCT (SEQ ID NO:666);	TGGGTCTCTC (SEQ ID NO:667);
GGGTCTCTCT (SEQ ID NO:668);	GGTCTCTCTG (SEQ ID NO:669);
GTCTCTCTGG (SEQ ID NO:670);	TCTCTCTGGT (SEQ ID NO:671);
CTCTCTGGTT (SEQ ID NO:672);	TCTCTGGTTA (SEQ ID NO:673);

- 222 -

CTCTGGTTAG	(SEQ ID NO:674);	TCTCTGGTTA	(SEQ ID NO:675);
CTGGTTAGAC	(SEQ ID NO:676);	TGGTTAGACC	(SEQ ID NO:677);
GGTTAGACCA	(SEQ ID NO:678);	GTTAGACCAG	(SEQ ID NO:679);
TTAGACCAGA	(SEQ ID NO:680);	TAGACCAGAT	(SEQ ID NO:681);
AGACCAGATC	(SEQ ID NO:682);	GACCAGATCT	(SEQ ID NO:683);
ACCAGATCTG	(SEQ ID NO:684);	CCAGATCTGA	(SEQ ID NO:685);
CAGATCTGAG	(SEQ ID NO:686);	AGATCTGAGC	(SEQ ID NO:687);
GATCTGAGCC	(SEQ ID NO:688);	ATCTGAGCCT	(SEQ ID NO:689);
TCTGAGCCTG	(SEQ ID NO:690);	CTGAGCCTGG	(SEQ ID NO:691);
TGAGCCTGGG	(SEQ ID NO:692);	GAGCCTGGGA	(SEQ ID NO:693);
AGCCTGGGAG	(SEQ ID NO:694);	GCCTGGGAGC	(SEQ ID NO:695);
CCTGGGAGCT	(SEQ ID NO:696);	CTGGGAGCTC	(SEQ ID NO:697);
TGGGAGCTCT	(SEQ ID NO:698);	GGGAGCTCTC	(SEQ ID NO:699);
GGAGCTCTCT	(SEQ ID NO:700);	GAGCTCTCTG	(SEQ ID NO:701);
AGCTCTCTGG	(SEQ ID NO:702);	GCTCTCTGGC	(SEQ ID NO:703);
CTCTCTGGCT	(SEQ ID NO:704);	TCTCTGGCTA	(SEQ ID NO:705);
CTCTGGCTAA	(SEQ ID NO:706);	TCTGGCTAAC	(SEQ ID NO:707);
CTGGCTAACT	(SEQ ID NO:708);	TGGCTAACTA	(SEQ ID NO:709);
GGCTAACTAG	(SEQ ID NO:710);	GCTAACTAGG	(SEQ ID NO:711);
CTAACTAGGG	(SEQ ID NO:712);	TAACTAGGGA	(SEQ ID NO:713);
AACTAGGGAA	(SEQ ID NO:714);	ACTAGGGAAC	(SEQ ID NO:715);
CTAGGGAACC	(SEQ ID NO:716);	TAGGGAACCC	(SEQ ID NO:717);
AGGGAACCCA	(SEQ ID NO:718);	GGGAACCCAC	(SEQ ID NO:719);
GGAACCCACT	(SEQ ID NO:720);	GAACCCACTG	(SEQ ID NO:721);
AACCCACTGC	(SEQ ID NO:722);	ACCCACTGCT	(SEQ ID NO:723);
CCCACTGCTT	(SEQ ID NO:724);	CCACTGCTTA	(SEQ ID NO:725);
CACTGCTTAA	(SEQ ID NO:726);	ACTGCTTAAG	(SEQ ID NO:727);
CTGCTTAAGC	(SEQ ID NO:728);	TGCTTAAGCC	(SEQ ID NO:729);
GCTTAAGCCT	(SEQ ID NO:730);	CTTAAGCCTC	(SEQ ID NO:731);
TTAAGCCTCA	(SEQ ID NO:732);	TAAGCCTCAA	(SEQ ID NO:733);
AAGCCTCAAT	(SEQ ID NO:734);	AGCCTCAATA	(SEQ ID NO:735);
GCCTCAATAA	(SEQ ID NO:736);	CCTCAATAAA	(SEQ ID NO:737);
CTCAATAAAG	(SEQ ID NO:738);	TCAATAAAGC	(SEQ ID NO:739);
CAATAAAGCT	(SEQ ID NO:740);	AATAAAGCTT	(SEQ ID NO:741);
ATAAAGCTTG	(SEQ ID NO:742);	TAAAGCTTGC	(SEQ ID NO:743);
AAAGCTTGCC	(SEQ ID NO:744);	AAGCTTGCCCT	(SEQ ID NO:745);
AGCTTGCCCT	(SEQ ID NO:746);	GCTTGCCCTTG	(SEQ ID NO:747);
CTTGCCCTGA	(SEQ ID NO:748);	TTGCCCTTGAG	(SEQ ID NO:749);

- 223 -

TGCCTTGAGT	(SEQ ID NO:750);	GCCTTGAGTG	(SEQ ID NO:751);
CCTTGAGTGC	(SEQ ID NO:752);	CTTGAGTGCT	(SEQ ID NO:753);
TTGAGTGCTT	(SEQ ID NO:754);	TGAGTGCTTC	(SEQ ID NO:755);
GAGTGCTTCA	(SEQ ID NO:756);	AGTGCTTCAA	(SEQ ID NO:757);
GTGCTTCAAG	(SEQ ID NO:758);	TGCTTCAAGT	(SEQ ID NO:759);
GCTTCAAGTA	(SEQ ID NO:760);	CTTCAAGTAG	(SEQ ID NO:761);
TTCAAGTAGT	(SEQ ID NO:762);	TCAAGTAGTG	(SEQ ID NO:763);
CAAGTAGTGT	(SEQ ID NO:764);	AAGTAGTGTG	(SEQ ID NO:765);
AGTAGTGTGT	(SEQ ID NO:766);	GTAGTGTGTG	(SEQ ID NO:767);
TAGTGTGTGC	(SEQ ID NO:768);	AGTGTGTGCC	(SEQ ID NO:769);
GTGTGTGCCC	(SEQ ID NO:770);	TGTGTGCCCCG	(SEQ ID NO:771);
GTGTGCCCCGT	(SEQ ID NO:772);	TGTGCCCCGTC	(SEQ ID NO:773);
GTGCCCCGTCT	(SEQ ID NO:774);	TGCCCCGTCTG	(SEQ ID NO:775);
GCCCCGTCTGT	(SEQ ID NO:776);	CCCGTCTGTT	(SEQ ID NO:777);
CCGTCTGTTG	(SEQ ID NO:778);	CGTCTGTTGT	(SEQ ID NO:779);
GTCTGTTGTG	(SEQ ID NO:780);	TCTGTTGTGT	(SEQ ID NO:781);
CTGTTGTGTG	(SEQ ID NO:782);	TGTTGTGTGA	(SEQ ID NO:783);
GTTGTGTGAC	(SEQ ID NO:784);	TTGTGTGACT	(SEQ ID NO:785);
TGTGTGACTC	(SEQ ID NO:786);	GTGTGACTCT	(SEQ ID NO:787);
TGTGTGACTC	(SEQ ID NO:788);	GTGTGACTCT	(SEQ ID NO:789);
TGTGACTCTG	(SEQ ID NO:790);	GTGACTCTGG	(SEQ ID NO:791);
TGACTCTGGT	(SEQ ID NO:792);	GACTCTGGTA	(SEQ ID NO:793);
ACTCTGGTAA	(SEQ ID NO:794);	CTCTGGTAAC	(SEQ ID NO:795);
TCTGGTAACT	(SEQ ID NO:796);	CTGGTAACTA	(SEQ ID NO:797);
TGGTAACTAG	(SEQ ID NO:798);	GGTAACTAGA	(SEQ ID NO:799).

50. A method according to claim 24 wherein said HIV-1 isolate has the identifying characteristics of HIV-1 isolate ECACC V94101706 or HIV-1 isolate ECACC V941031169 or isolate C54 deposited at ECACC on 14 February, 1995 under Accession Number _____.

51. A method according to claim 20 wherein the HIV-1 isolate is reactive to antibodies to a glycoprotein of HIV-1, is capable of inducing an immune response of *gag*, *pol* and/or *env* and which is incapable of directing synthesis of a *nef* gene product or a full length *nef* gene product.

52. A method according to claim 51 wherein the glycoprotein is at least one of gp41-45, gp120 and/or gp160.
53. A method for obtaining a preparation of non-pathogenic HIV-1 from a biological sample, said method comprising co-culturing PBMCs from said biological sample from an individual putatively infected with said non-pathogenic HIV-1 with HIV-1 seronegative donor PBMCs depleted for CD8+ cells, harvesting the PBMCs and supernatant fluid every from about 5 to about 10 days and adding fresh medium with CD8+ depleted PBMCs with said fresh medium and isolating said virus from the supernatant fluid.
54. A method according to claim 53 wherein the seronegative PBMCs are pretreated with a cytokine for a time and under conditions sufficient to enhance HIV-1 replication.
55. A method according to claim 54 wherein the cytokine is M-CSF.
56. A method according to claim 53 or 54 or 55 wherein the HIV-1 seronegative donor PBMCs are first stimulated with PHA and/or IL-2.
57. A method according to claim 53 wherein the PBMCs from a putative infected individual are also CD8+ depleted prior to coculturing with seronegative donor PBMCs.
58. A method according to claim 53 or 57 wherein the cocultured cells are subjected to UV irradiation.
59. A method for obtaining a preparation of non-pathogenic HIV-1 from a biological sample, said method comprising co-culturing monocytes from said biological sample from an individual putatively infected with said non-pathogenic HIV-1 with HIV-1 seronegative donor PBMCs depleted for CD8+ cells, harvesting the monocytes and PBMCs and supernatant fluid every from about 5 to about 10 days and adding fresh medium with CD8+ depleted PBMCs with said fresh medium and isolating said virus from the supernatant fluid.

- 225 -

60. A method according to claim 59 wherein the seronegative PBMCs are pretreated with a cytokine for a time and under conditions sufficient to enhance HIV-1 replication.
61. A method according to claim 60 wherein the cytokine is M-CSF.
62. A method according to claim 59 or 60 or 61 wherein the HIV-1 seronegative donor PBMCs are first stimulated with PHA and/or IL-2.
63. A method according to claim 59 wherein the monocytes from a putative infected individual are also CD8+ depleted prior to coculturing with seronegative donor PBMCs.
64. A method according to claim 59 or 63 wherein the cocultured cells are subjected to UV irradiation.
65. A method for identifying or screening for compounds capable of reducing or otherwise interfering with HIV-1 replication, said method comprising contacting a compound to be tested with a cell or cell extract containing or capable of containing a *nef* gene product fused to a reporter molecule capable of giving an identifiable signal and screening for a compound which inhibits said signal.
66. A method according to claim 65 wherein the compound is an antibody to *nef* gene product or a part thereof.
67. A method according to claim 65 wherein the compound is a DNA targeting agent and inhibits transcription of the *nef* gene.
68. A compound capable of inhibiting *nef* gene product function or *nef* gene transcription.
69. A compound capable of inhibiting *nef* gene product function or *nef* gene transcription identified according to the method of claim 65 or 66 or 67.

70. A therapeutic composition useful for inhibiting or reducing productive infection by a pathogenic strain of HIV-1 and/or for vaccinating an individual against the development of AIDS or AIDS-related diseases, said composition comprising a non-pathogenic strain of HIV-1 according to any one of claims 1 to 16 and one or more pharmaceutical acceptable carriers and/or diluents.
71. A therapeutic composition according to claim 70 wherein said HIV-1 isolate comprises genetic material that directs expression of antisense or ribozyme nucleotide sequences which inhibit production of one or more proteins encoded by a pathogenic strain of HIV-1.
72. A viral isolate which:
- (i) is genetically or immunologically related to a pathogenic strain of HIV-1;
 - (ii) is substantially non-pathogenic in human subjects;
 - (iii) comprises a first nucleotide sequence constituting its genome which is capable of hybridising under medium stringency conditions to SEQ ID NO: 1 or a complementary form thereof; and
 - (iv) comprises a second nucleotide sequence within said first nucleotide sequence and which second nucleotide sequence directs expression of a mRNA molecule capable of inhibiting, reducing or otherwise down-regulating translation of a protein or polypeptide encoded by a pathogenic strain of HIV-1 or inhibit, reduce or otherwise down regulate operation of a non-protein encoding a region of a pathogenic strain of HIV-1.
73. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of *gag* or *pol*.
74. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of *env* or *tat*.
75. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of *rev* or *vpu*.

- 227 -

76. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of *vpr*, *vif* or *nef*.

77. A viral isolate according to claim 72 wherein the targeted protein is *nef*.

78. A method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising determining the presence of a deletion mutation in the genome of said HIV-1 wherein said deletion mutation results in said genome being unable to synthesise a polypeptide or protein from a pathogenic strain of HIV-1 or directing the synthesis of a truncated form of said polypeptide or protein wherein the presence of a such a mutation is indicative of the presence of a non-pathogenic strain of HIV-1.

79. The method according to claim 78 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.

80. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- | | | |
|------------|-------|----------------|
| nucleotide | (i) | 8830-8862; |
| | (ii) | 9009-9035; |
| | (iii) | 9019-9029; and |
| | (iv) | 9033-9049. |

81. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- | | | |
|------------|--------|----------------|
| nucleotide | (v) | 9281-9371; |
| | (vi) | 9281-9362; |
| | (vii) | 9105-9224; and |
| | (viii) | 9271-9370. |

- 228 -

82. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(ix)	8882-8928;
	(x)	8850-9006;
	(xi)	8792-9041; and
	(xii)	9112-9204.

83. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(xiii)	9105-9224;
	(xiv)	9389-9395; and
	(xv)	9281-9366.

84. A strain of HIV-1 according to claim 79 wherein said deletion encompasses at least one of the following decanucleotides from the *nef* gene of HIV-1 strain NL4-3:

ATGGGTGGCA (SEQ ID NO:2);	TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4);	GGTGGCAAGT (SEQ ID NO:5);
GTGGCAAGTG (SEQ ID NO:6);	TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8);	GCAAGTGGTC (SEQ ID NO:9);
CAAGTGGTCA (SEQ ID NO:10);	AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12);	GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAA (SEQ ID NO:14);	GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16);	TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18);	AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20);	AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22);	AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24);	TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26);	GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28);	GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30);	GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32);	TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34);	GGATGGCCTG (SEQ ID NO:35);
GATGGCCTGC (SEQ ID NO:36);	ATGGCCTGCT (SEQ ID NO:37);

- 229 -

TGGCCTGCTG (SEQ ID NO:38);	GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40);	CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42);	TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44);	CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46);	GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48);	AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50);	GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52);	GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54);	AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56);	GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58);	ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60);	GAGACGAGCT (SEQ ID NO:61);
AGACGAGCTG (SEQ ID NO:62);	GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64);	CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66);	AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68);	CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70);	GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72);	GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74);	CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76);	GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78);	AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80);	CAGATGGGGT (SEQ ID NO:81);
AGATGGGGTG (SEQ ID NO:82);	GATGGGGTGG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84);	TGGGGTGGGA (SEQ ID NO:85);
GGGGTGGGAG (SEQ ID NO:86);	GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88);	GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90);	GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92);	GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94);	GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96);	AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98);	TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100);	TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102);	TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104);	GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106);	GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108);	CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110);	TAGAAAAACA (SEQ ID NO:111);
AGAAAAACAT (SEQ ID NO:112);	GAAAAACATG (SEQ ID NO:113);

- 230 -

AAAAACATGG (SEQ ID NO:114);	AAAACATGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116);	AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118);	CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120);	TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122);	GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124);	GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126);	AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128);	TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130);	ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132);	AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134);	GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136);	AGCAATACAG (SEQ ID NO:137);
GCAATACAGC (SEQ ID NO:138);	CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140);	ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142);	ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144);	AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146);	CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148);	GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150);	TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152);	ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154);	AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156);	TGCTGCTTGT (SEQ ID NO:157);
GCTGCTTGTG (SEQ ID NO:158);	CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160);	GCTTGTGCCT (SEQ ID NO:161);
CTTGTGCCTG (SEQ ID NO:162);	TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164);	GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166);	GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168);	CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170);	GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172);	CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174);	AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAG (SEQ ID NO:176);	AAGCACAAGA (SEQ ID NO:177);
AGCACAAGAG (SEQ ID NO:178);	GCACAAGAGG (SEQ ID NO:179);
CACAAGAGGA (SEQ ID NO:180);	ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182);	AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184);	GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186);	GGAGGAAGAG (SEQ ID NO:187);
GAGGAAGAGG (SEQ ID NO:188);	AGGAAGAGGT (SEQ ID NO:189);

- 231 -

GGAAGAGGTG (SEQ ID NO:190);	GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192);	AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194);	AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196);	GTGGGTTTTC (SEQ ID NO:197);
TGGGTTTTCC (SEQ ID NO:198);	GGGTTTTCCA (SEQ ID NO:199);
GGTTTTCCAG (SEQ ID NO:200);	GTTTTCCAGT (SEQ ID NO:201);
TTTTCCAGTC (SEQ ID NO:202);	TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204);	TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206);	CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208);	GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210);	CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212);	CACCTCAGGT (SEQ ID NO:213);
ACCTCAGGTA (SEQ ID NO:214);	CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216);	TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218);	AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220);	GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222);	ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224);	CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226);	TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228);	AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230);	GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232);	CCAATGACTT (SEQ ID NO:233);
CAATGACTTA (SEQ ID NO:234);	AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236);	TGACTTACAA (SEQ ID NO:237);
GACTTACAAG (SEQ ID NO:238);	ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240);	TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242);	ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244);	AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246);	GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248);	CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250);	GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252);	TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254);	TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256);	GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258);	TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260);	TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262);	AGCCACTTTT (SEQ ID NO:263);
GCCACTTTTT (SEQ ID NO:264);	CCACTTTTTA (SEQ ID NO:265);

CACTTTTTTAA (SEQ ID NO:266);	ACTTTTTTAAA (SEQ ID NO:267);
CTTTTTTAAAA (SEQ ID NO:268);	TTTTTTAAAAG (SEQ ID NO:269);
TTTTTAAAAGA (SEQ ID NO:270);	TTTTAAAAGAA (SEQ ID NO:271);
TTAAAAGAAA (SEQ ID NO:272);	TAAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274);	AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276);	AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278);	AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280);	AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282);	GGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284);	GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286);	GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288);	ACTGGAAGGG (SEQ ID NO:289);
CTGGAAGGGC (SEQ ID NO:290);	TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292);	GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294);	AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296);	GGCTAATTCA (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298);	CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300);	AATTCACTCC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302);	TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304);	CACTCCCAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306);	CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308);	CCCAAAGAAG (SEQ ID NO:309);
CCAAAGAAGA (SEQ ID NO:310);	CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312);	AAGAAGACAA (SEQ ID NO:313);
AGAAGACAAG (SEQ ID NO:314);	GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316);	AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318);	ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320);	AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322);	GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324);	TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326);	TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328);	CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330);	TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332);	ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334);	CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336);	GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338);	GGATCTACCA (SEQ ID NO:339);
GATCTACCAC (SEQ ID NO:340);	ATCTACCACA (SEQ ID NO:341);

- 233 -

TCTACCACAC (SEQ ID NO:342);	CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344);	ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346);	CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348);	CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350);	CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352);	CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354);	AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356);	GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358);	TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360);	CTTCCCTGAT (SEQ ID NO:361);
TTCCCTGATT (SEQ ID NO:362);	TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364);	CCTGATTGGC (SEQ ID NO:365);
CTGATTGGCA (SEQ ID NO:366);	TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368);	ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370);	TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372);	GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374);	AGAACTACAC (SEQ ID NO:375);
GAACTACACA (SEQ ID NO:376);	AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378);	CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380);	ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382);	ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384);	ACCAGGGCCA (SEQ ID NO:385);
CCAGGGCCAG (SEQ ID NO:386);	CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388);	GGGCCAGGGG (SEQ ID NO:389);
GGCCAGGGGT (SEQ ID NO:390);	GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392);	CAGGGGTCAG (SEQ ID NO:393);
AGGGGTCAGA (SEQ ID NO:394);	GGGGTCAGAT (SEQ ID NO:395);
GGGTCAGATA (SEQ ID NO:396);	GGTCAGATAT (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398);	TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400);	AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402);	ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404);	ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406);	CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408);	ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410);	TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412);	ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414);	CTTTGGATGG (SEQ ID NO:415);
TTTGGATGGT (SEQ ID NO:416);	TTGGATGGTG (SEQ ID NO:417);

TGGATGGTGCT (SEQ ID NO:418);	GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420);	ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422);	GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424);	TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426);	CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428);	ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430);	AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432);	GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434);	TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436);	GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438);	ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440);	CAGTTGAGCC (SEQ ID NO:441);
AGTTGAGCCA (SEQ ID NO:442);	GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444);	TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446);	AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448);	CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450);	AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452);	ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454);	AAGGTAGAAG (SEQ ID NO:455);
AGGTAGAAGA (SEQ ID NO:456);	GGTAGAAGAG (SEQ ID NO:457);
GTAGAAGAGG (SEQ ID NO:458);	TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460);	GAAGAGGCCA (SEQ ID NO:461);
AAGAGGCCAA (SEQ ID NO:462);	AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464);	AGGCCAATAA (SEQ ID NO:465);
GGCCAATAAA (SEQ ID NO:466);	GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468);	CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470);	ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472);	AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474);	AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476);	GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478);	GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480);	GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482);	ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484);	ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486);	CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488);	GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490);	TTGTTACACC (SEQ ID NO:491);
TGTTACACCC (SEQ ID NO:492);	GTTACACCCT (SEQ ID NO:493);

TTACACCCTG (SEQ ID NO:494);	TACACCCTGT (SEQ ID NO:495);
ACACCCTGTG (SEQ ID NO:496);	CACCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498);	CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500);	CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502);	GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504);	GAGCCTGCAT (SEQ ID NO:505);
AGCCTGCATG (SEQ ID NO:506);	GCCTGCATGG (SEQ ID NO:507);
CCTGCATGGA (SEQ ID NO:508);	CTGCATGGAA (SEQ ID NO:509);
TGCATGGAAT (SEQ ID NO:510);	GCATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512);	ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514);	GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516);	AATGGATGAC (SEQ ID NO:517);
ATGGATGACC (SEQ ID NO:518);	TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520);	GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522);	TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524);	ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526);	CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528);	TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530);	AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532);	AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534);	AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536);	AAGTGTTAGA (SEQ ID NO:537);
AGTGTTAGAG (SEQ ID NO:538);	GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540);	GTTAGAGTGG (SEQ ID NO:541);
TTAGAGTGGA (SEQ ID NO:542);	TAGAGTGGAG (SEQ ID NO:543);
AGAGTGGAGG (SEQ ID NO:544);	GAGTGGAGGT (SEQ ID NO:545);
AGTGGAGGTT (SEQ ID NO:546);	GTGGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548);	GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550);	AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552);	GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554);	TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556);	GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558);	CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560);	GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562);	CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564);	CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTT (SEQ ID NO:566);	TAGCATTTCA (SEQ ID NO:567);
AGCATTTTCAT (SEQ ID NO:568);	GCATTTTCATC (SEQ ID NO:569);

- 236 -

CATTTTCATCA (SEQ ID NO:570);	ATTTTCATCAC (SEQ ID NO:571);
TTTCATCACG (SEQ ID NO:572);	TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574);	CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576);	TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578);	ACGTGGCCCC (SEQ ID NO:579);
CGTGGCCCGA (SEQ ID NO:580);	GTGGCCCGAG (SEQ ID NO:581);
TGGCCCGAGA (SEQ ID NO:582);	GGCCCGAGAG (SEQ ID NO:583);
GCCCGAGAGC (SEQ ID NO:584);	CCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586);	CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588);	AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590);	AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592);	CTGCATCCGG (SEQ ID NO:593);
TGCATCCGGA (SEQ ID NO:594);	GCATCCGGAG (SEQ ID NO:595);
CATCCGGAGT (SEQ ID NO:596);	ATCCGGAGTA (SEQ ID NO:597);
TCCGGAGTAC (SEQ ID NO:598);	CCGGAGTACT (SEQ ID NO:599);
CGGAGTACTT (SEQ ID NO:600);	GGAGTACTTC (SEQ ID NO:601);
GAGTACTTCA (SEQ ID NO:602);	AGTACTTCAA (SEQ ID NO:603);
GTACTTCAAG (SEQ ID NO:604);	TACTTCAAGA (SEQ ID NO:605);
ACTTCAAGAA (SEQ ID NO:606);	CTTCAAGAAC (SEQ ID NO:607);
TTCAAGAACT (SEQ ID NO:608);	TCAAGAACTG (SEQ ID NO:609);
CAAGAACTGC (SEQ ID NO:610);	AAGAACTGCT (SEQ ID NO:611);
AGAACTGCTG (SEQ ID NO:612);	GAACTGCTGA (SEQ ID NO:613);

85. A strain of HIV-1 according to claim 79 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTTGCCC (SEQ ID NO:652);	CTTTTTGCCTT (SEQ ID NO:653);
TTTTTGCCTG (SEQ ID NO:654);	TTTTGCCTGT (SEQ ID NO:655);
TTTGCCGTGA (SEQ ID NO:656);	TGCGCTGTAC (SEQ ID NO:657);
TGCCTGTACT (SEQ ID NO:658);	GCCTGTACTG (SEQ ID NO:659);
CCTGTACTGG (SEQ ID NO:660);	CTGTACTGGG (SEQ ID NO:661);
TGTACTGGGT (SEQ ID NO:662);	GTACTGGGTC (SEQ ID NO:663);
TACTGGGTCT (SEQ ID NO:664);	ACTGGGTCTC (SEQ ID NO:665);
CTGGGTCTCT (SEQ ID NO:666);	TGGGTCTCTC (SEQ ID NO:667);
GGGTCTCTCT (SEQ ID NO:668);	GGTCTCTCTG (SEQ ID NO:669);
GTCTCTCTGG (SEQ ID NO:670);	TCTCTCTGGT (SEQ ID NO:671);
CTCTCTGGTT (SEQ ID NO:672);	TCTCTGGTTA (SEQ ID NO:673);
CTCTGGTTAG (SEQ ID NO:674);	TCTCTGGTTA (SEQ ID NO:675);

CTGGTTAGAC	(SEQ ID NO:676);	TGGTTAGACC	(SEQ ID NO:677);
GGTTAGACCA	(SEQ ID NO:678);	GTTAGACCAG	(SEQ ID NO:679);
TTAGACCAGA	(SEQ ID NO:680);	TAGACCAGAT	(SEQ ID NO:681);
AGACCAGATC	(SEQ ID NO:682);	GACCAGATCT	(SEQ ID NO:683);
ACCAGATCTG	(SEQ ID NO:684);	CCAGATCTGA	(SEQ ID NO:685);
CAGATCTGAG	(SEQ ID NO:686);	AGATCTGAGC	(SEQ ID NO:687);
GATCTGAGCC	(SEQ ID NO:688);	ATCTGAGCCT	(SEQ ID NO:689);
TCTGAGCCTG	(SEQ ID NO:690);	CTGAGCCTGG	(SEQ ID NO:691);
TGAGCCTGGG	(SEQ ID NO:692);	GAGCCTGGGA	(SEQ ID NO:693);
AGCCTGGGAG	(SEQ ID NO:694);	GCCTGGGAGC	(SEQ ID NO:695);
CCTGGGAGCT	(SEQ ID NO:696);	CTGGGAGCTC	(SEQ ID NO:697);
TGGGAGCTCT	(SEQ ID NO:698);	GGGAGCTCTC	(SEQ ID NO:699);
GGAGCTCTCT	(SEQ ID NO:700);	GAGCTCTCTG	(SEQ ID NO:701);
AGCTCTCTGG	(SEQ ID NO:702);	GCTCTCTGGC	(SEQ ID NO:703);
CTCTCTGGCT	(SEQ ID NO:704);	TCTCTGGCTA	(SEQ ID NO:705);
CTCTGGCTAA	(SEQ ID NO:706);	TCTGGCTAAC	(SEQ ID NO:707);
CTGGCTAACT	(SEQ ID NO:708);	TGGCTAACTA	(SEQ ID NO:709);
GGCTAACTAG	(SEQ ID NO:710);	GCTAACTAGG	(SEQ ID NO:711);
CTAACTAGGG	(SEQ ID NO:712);	TAACTAGGGA	(SEQ ID NO:713);
AACTAGGGAA	(SEQ ID NO:714);	ACTAGGGAAC	(SEQ ID NO:715);
CTAGGGAACC	(SEQ ID NO:716);	TAGGGAACCC	(SEQ ID NO:717);
AGGGAACCCA	(SEQ ID NO:718);	GGGAACCCAC	(SEQ ID NO:719);
GGAACCCACT	(SEQ ID NO:720);	GAACCCACTG	(SEQ ID NO:721);
AACCCACTGC	(SEQ ID NO:722);	ACCCACTGCT	(SEQ ID NO:723);
CCCACTGCTT	(SEQ ID NO:724);	CCACTGCTTA	(SEQ ID NO:725);
CACTGCTTAA	(SEQ ID NO:726);	ACTGCTTAAG	(SEQ ID NO:727);
CTGCTTAAGC	(SEQ ID NO:728);	TGCTTAAGCC	(SEQ ID NO:729);
GCTTAAGCCT	(SEQ ID NO:730);	CTTAAGCCTC	(SEQ ID NO:731);
TTAAGCCTCA	(SEQ ID NO:732);	TAAGCCTCAA	(SEQ ID NO:733);
AAGCCTCAAT	(SEQ ID NO:734);	AGCCTCAATA	(SEQ ID NO:735);
GCCTCAATAA	(SEQ ID NO:736);	CCTCAATAAA	(SEQ ID NO:737);
CTCAATAAAG	(SEQ ID NO:738);	TCAATAAAGC	(SEQ ID NO:739);
CAATAAAGCT	(SEQ ID NO:740);	AATAAAGCTT	(SEQ ID NO:741);
ATAAAGCTTG	(SEQ ID NO:742);	TAAAGCTTGC	(SEQ ID NO:743);
AAAGCTTGCC	(SEQ ID NO:744);	AAGCTTGCCCT	(SEQ ID NO:745);
AGCTTGCCCTT	(SEQ ID NO:746);	GCTTGCCCTG	(SEQ ID NO:747);
CTTGCCCTTGA	(SEQ ID NO:748);	TTGCCCTTGAG	(SEQ ID NO:749);
TGCCTTGAGT	(SEQ ID NO:750);	GCCTTGAGTG	(SEQ ID NO:751);

- 238 -

CCTTGAGTGC	(SEQ ID NO:752);	CTTGAGTGCT	(SEQ ID NO:753);
TTGAGTGCTT	(SEQ ID NO:754);	TGAGTGCTTC	(SEQ ID NO:755);
GAGTGCTTCA	(SEQ ID NO:756);	AGTGCTTCAA	(SEQ ID NO:757);
GTGCTTCAAG	(SEQ ID NO:758);	TGCTTCAAGT	(SEQ ID NO:759);
GCTTCAAGTA	(SEQ ID NO:760);	CTTCAAGTAG	(SEQ ID NO:761);
TTCAAGTAGT	(SEQ ID NO:762);	TCAAGTAGTG	(SEQ ID NO:763);
CAAGTAGTGT	(SEQ ID NO:764);	AAGTAGTGTG	(SEQ ID NO:765);
AGTAGTGTGT	(SEQ ID NO:766);	GTAGTGTGTG	(SEQ ID NO:767);
TAGTGTGTGC	(SEQ ID NO:768);	AGTGTGTGCC	(SEQ ID NO:769);
GTGTGTGCCC	(SEQ ID NO:770);	TGTGTGCCCCG	(SEQ ID NO:771);
GTGTGCCCCG	(SEQ ID NO:772);	TGTGCCCCGTC	(SEQ ID NO:773);
GTGCCCCGTCT	(SEQ ID NO:774);	TGCCCCGTCTG	(SEQ ID NO:775);
GCCCCGTCTGT	(SEQ ID NO:776);	CCCGTCTGTT	(SEQ ID NO:777);
CCGTCTGTTG	(SEQ ID NO:778);	CGTCTGTTGT	(SEQ ID NO:779);
GTCTGTTGTG	(SEQ ID NO:780);	TCTGTTGTGT	(SEQ ID NO:781);
CTGTTGTGTG	(SEQ ID NO:782);	TGTTGTGTGA	(SEQ ID NO:783);
GTTGTGTGAC	(SEQ ID NO:784);	TTGTGTGACT	(SEQ ID NO:785);
TGTGTGACTC	(SEQ ID NO:786);	GTGTGACTCT	(SEQ ID NO:787);
TGTGTGACTC	(SEQ ID NO:788);	GTGTGACTCT	(SEQ ID NO:789);
TGTGACTCTG	(SEQ ID NO:790);	GTGACTCTGG	(SEQ ID NO:791);
TGACTCTGGT	(SEQ ID NO:792);	GACTCTGGTA	(SEQ ID NO:793);
ACTCTGGTAA	(SEQ ID NO:794);	CTCTGGTAAC	(SEQ ID NO:795);
TCTGGTAACT	(SEQ ID NO:796);	CTGGTAACTA	(SEQ ID NO:797);
TGGTAACTAG	(SEQ ID NO:798);	GGTAACTAGA	(SEQ ID NO:799).

86. A method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising determining the presence of a deletion mutation in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3 wherein the presence of said deletion mutation is indicative of the presence of a non-pathogenic strain of HIV-1.

87. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- 239 -

- | | | |
|------------|-------|----------------|
| nucleotide | (i) | 8830-8862; |
| | (ii) | 9009-9035; |
| | (iii) | 9019-9029; and |
| | (iv) | 9033-9049. |

88. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- | | | |
|------------|--------|----------------|
| nucleotide | (v) | 9281-9371; |
| | (vi) | 9281-9362; |
| | (vii) | 9105-9224; and |
| | (viii) | 9271-9370. |

89. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- | | | |
|------------|-------|----------------|
| nucleotide | (ix) | 8882-8928; |
| | (x) | 8850-9006; |
| | (xi) | 8792-9041; and |
| | (xii) | 9112-9204. |

90. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

- | | | |
|------------|--------|----------------|
| nucleotide | (xiii) | 9105-9224; |
| | (xiv) | 9389-9395; and |
| | (xv) | 9281-9366. |

91. A strain of HIV-1 according to claim 86 wherein said deletion encompasses at least one of the following decanucleotides from the *nef* gene of HIV-1 strain NL4-3:

ATGGGTGGCA (SEQ ID NO:2);	TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4);	GGTGGCAAGT (SEQ ID NO:5);

GTGGCAAGTG (SEQ ID NO:6);	TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8);	GCAAGTGGTC (SEQ ID NO:9);
CAAGTGGTCA (SEQ ID NO:10);	AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12);	GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAAA (SEQ ID NO:14);	GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16);	TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18);	AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20);	AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22);	AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24);	TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26);	GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28);	GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30);	GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32);	TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34);	GGATGGCCTG (SEQ ID NO:35);
GATGGCCTGC (SEQ ID NO:36);	ATGGCCTGCT (SEQ ID NO:37);
TGGCCTGCTG (SEQ ID NO:38);	GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40);	CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42);	TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44);	CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46);	GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48);	AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50);	GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52);	GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54);	AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56);	GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58);	ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60);	GAGACGAGCT (SEQ ID NO:61);
AGACGAGCTG (SEQ ID NO:62);	GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64);	CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66);	AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68);	CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70);	GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72);	GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74);	CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76);	GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78);	AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80);	CAGATGGGGT (SEQ ID NO:81);

- 241 -

AGATGGGGTG (SEQ ID NO:82);	GATGGGGTG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84);	TGGGGTGGGA (SEQ ID NO:85);
GGGGTGGGAG (SEQ ID NO:86);	GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88);	GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90);	GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92);	GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94);	GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96);	AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98);	TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100);	TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102);	TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104);	GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106);	GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108);	CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110);	TAGAAAAACA (SEQ ID NO:111);
AGAAAAACAT (SEQ ID NO:112);	GAAAAACATG (SEQ ID NO:113);
AAAAACATGG (SEQ ID NO:114);	AAAACATGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116);	AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118);	CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120);	TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122);	GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124);	GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126);	AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128);	TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130);	ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132);	AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134);	GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136);	AGCAATACAG (SEQ ID NO:137);
GCAATACAGC (SEQ ID NO:138);	CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140);	ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142);	ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144);	AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146);	CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148);	GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150);	TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152);	ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154);	AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156);	TGCTGCTTGT (SEQ ID NO:157);

- 242 -

GCTGCTTGTG (SEQ ID NO:158);	CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160);	GCTTGTGCCT (SEQ ID NO:161);
CTTGTGCCTG (SEQ ID NO:162);	TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164);	GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166);	GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168);	CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170);	GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172);	CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174);	AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAG (SEQ ID NO:176);	AAGCACAAGA (SEQ ID NO:177);
AGCACAAGAG (SEQ ID NO:178);	GCACAAGAGG (SEQ ID NO:179);
CACAAGAGGA (SEQ ID NO:180);	ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182);	AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184);	GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186);	GGAGGAAGAG (SEQ ID NO:187);
GAGGAAGAGG (SEQ ID NO:188);	AGGAAGAGGT (SEQ ID NO:189);
GGAAGAGGTG (SEQ ID NO:190);	GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192);	AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194);	AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196);	GTGGGTTTTTC (SEQ ID NO:197);
TGGGTTTTTCC (SEQ ID NO:198);	GGGTTTTTCCA (SEQ ID NO:199);
GGTTTTTCCAG (SEQ ID NO:200);	GTTTTTCCAGT (SEQ ID NO:201);
TTTTTCCAGTC (SEQ ID NO:202);	TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204);	TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206);	CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208);	GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210);	CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212);	CACCTCAGGT (SEQ ID NO:213);
ACCTCAGGTA (SEQ ID NO:214);	CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216);	TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218);	AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220);	GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222);	ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224);	CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226);	TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228);	AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230);	GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232);	CCAATGACTT (SEQ ID NO:233);

- 243 -

CAATGACTTA (SEQ ID NO:234);	AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236);	TGACTTACAA (SEQ ID NO:237);
GACTTACAAG (SEQ ID NO:238);	ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240);	TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242);	ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244);	AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246);	GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248);	CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250);	GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252);	TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254);	TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256);	GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258);	TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260);	TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262);	AGCCACTTTT (SEQ ID NO:263);
GCCACTTTTT (SEQ ID NO:264);	CCACTTTTTA (SEQ ID NO:265);
CACTTTTTAA (SEQ ID NO:266);	ACTTTTTTAA (SEQ ID NO:267);
CTTTTTAAAA (SEQ ID NO:268);	TTTTTAAAG (SEQ ID NO:269);
TTTTAAAGA (SEQ ID NO:270);	TTTAAAGAA (SEQ ID NO:271);
TTAAAGAAA (SEQ ID NO:272);	TAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274);	AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276);	AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278);	AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280);	AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282);	GGGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284);	GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286);	GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288);	ACTGGAAGGG (SEQ ID NO:289);
CTGGAAGGGC (SEQ ID NO:290);	TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292);	GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294);	AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296);	GGCTAATTCA (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298);	CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300);	AATTCACTCC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302);	TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304);	CACTCCCAAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306);	CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308);	CCCAAAGAAG (SEQ ID NO:309);

CCAAAGAAGA (SEQ ID NO:310);	CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312);	AAGAAGACAA (SEQ ID NO:313);
AGAAGACAAG (SEQ ID NO:314);	GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316);	AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318);	ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320);	AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322);	GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324);	TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326);	TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328);	CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330);	TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332);	ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334);	CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336);	GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338);	GGATCTACCA (SEQ ID NO:339);
GATCTACCAC (SEQ ID NO:340);	ATCTACCACA (SEQ ID NO:341);
TCTACCACAC (SEQ ID NO:342);	CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344);	ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346);	CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348);	CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350);	CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352);	CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354);	AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356);	GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358);	TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360);	CTTCCCTGAT (SEQ ID NO:361);
TTCCCTGATT (SEQ ID NO:362);	TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364);	CCTGATTGGC (SEQ ID NO:365);
CTGATTGGCA (SEQ ID NO:366);	TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368);	ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370);	TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372);	GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374);	AGAACTACAC (SEQ ID NO:375);
GAACTACACA (SEQ ID NO:376);	AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378);	CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380);	ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382);	ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384);	ACCAGGGCCA (SEQ ID NO:385);

- 245 -

CCAGGGCCAG (SEQ ID NO:386);	CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388);	GGGCCAGGGG (SEQ ID NO:389);
GGCCAGGGGT (SEQ ID NO:390);	GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392);	CAGGGGTCA (SEQ ID NO:393);
AGGGGTCA (SEQ ID NO:394);	GGGGTCA (SEQ ID NO:395);
GGGTCA (SEQ ID NO:396);	GGTCA (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398);	TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400);	AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402);	ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404);	ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406);	CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408);	ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410);	TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412);	ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414);	CTTTGGATGG (SEQ ID NO:415);
TTTGGATGGT (SEQ ID NO:416);	TTGGATGGTG (SEQ ID NO:417);
TGGATGGTG (SEQ ID NO:418);	GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420);	ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422);	GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424);	TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426);	CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428);	ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430);	AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432);	GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434);	TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436);	GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438);	ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440);	CAGTTGAGCC (SEQ ID NO:441);
AGTTGAGCCA (SEQ ID NO:442);	GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444);	TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446);	AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448);	CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450);	AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452);	ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454);	AAGGTAGAAG (SEQ ID NO:455);
AGGTAGAAGA (SEQ ID NO:456);	GGTAGAAGAG (SEQ ID NO:457);
GTAGAAGAGG (SEQ ID NO:458);	TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460);	GAAGAGGCCA (SEQ ID NO:461);

- 246 -

AAGAGGCCAA (SEQ ID NO:462);	AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464);	AGGCCAATAA (SEQ ID NO:465);
GGCCAATAAA (SEQ ID NO:466);	GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468);	CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470);	ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472);	AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474);	AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476);	GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478);	GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480);	GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482);	ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484);	ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486);	CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488);	GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490);	TTGTTACACC (SEQ ID NO:491);
TGTTACACCC (SEQ ID NO:492);	GTTACACCCCT (SEQ ID NO:493);
TTACACCCCTG (SEQ ID NO:494);	TACACCCCTGT (SEQ ID NO:495);
ACACCCCTGTG (SEQ ID NO:496);	CACCCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498);	CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500);	CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502);	GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504);	GAGCCTGCAT (SEQ ID NO:505);
AGCCTGCATG (SEQ ID NO:506);	GCCTGCATGG (SEQ ID NO:507);
CCTGCATGGA (SEQ ID NO:508);	CTGCATGGAA (SEQ ID NO:509);
TGCATGGAAT (SEQ ID NO:510);	GCATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512);	ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514);	GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516);	AATGGATGAC (SEQ ID NO:517);
ATGGATGACC (SEQ ID NO:518);	TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520);	GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522);	TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524);	ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526);	CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528);	TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530);	AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532);	AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534);	AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536);	AAGTGTTAGA (SEQ ID NO:537);

AGTGTTAGAG (SEQ ID NO:538);	GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540);	GTTAGAGTGG (SEQ ID NO:541);
TTAGAGTGGG (SEQ ID NO:542);	TAGAGTGGAG (SEQ ID NO:543);
AGAGTGGAGG (SEQ ID NO:544);	GAGTGGAGGT (SEQ ID NO:545);
AGTGGAGGTT (SEQ ID NO:546);	GTGGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548);	GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550);	AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552);	GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554);	TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556);	GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558);	CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560);	GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562);	CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564);	CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTT (SEQ ID NO:566);	TAGCATTTCA (SEQ ID NO:567);
AGCATTTTCAT (SEQ ID NO:568);	GCATTTTCATC (SEQ ID NO:569);
CATTTTCATCA (SEQ ID NO:570);	ATTTTCATCAC (SEQ ID NO:571);
TTTCATCACG (SEQ ID NO:572);	TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574);	CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576);	TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578);	ACGTGGCCCC (SEQ ID NO:579);
CGTGGCCCCG (SEQ ID NO:580);	GTGGCCCCGAG (SEQ ID NO:581);
TGGCCCCGAGA (SEQ ID NO:582);	GGCCCCGAGAG (SEQ ID NO:583);
GCCCCGAGAGC (SEQ ID NO:584);	CCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586);	CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588);	AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590);	AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592);	CTGCATCCGG (SEQ ID NO:593);
TGCATCCGGA (SEQ ID NO:594);	GCATCCGGAG (SEQ ID NO:595);
CATCCGGAGT (SEQ ID NO:596);	ATCCGGAGTA (SEQ ID NO:597);
TCCGGAGTAC (SEQ ID NO:598);	CCGGAGTACT (SEQ ID NO:599);
CGGAGTACTT (SEQ ID NO:600);	GGAGTACTTC (SEQ ID NO:601);
GAGTACTTCA (SEQ ID NO:602);	AGTACTTCAA (SEQ ID NO:603);
GTACTTCAAG (SEQ ID NO:604);	TACTTCAAGA (SEQ ID NO:605);
ACTTCAAGAA (SEQ ID NO:606);	CTTCAAGAAC (SEQ ID NO:607);
TTCAAGAACT (SEQ ID NO:608);	TCAAGAACTG (SEQ ID NO:609);
CAAGAACTGC (SEQ ID NO:610);	AAGAACTGCT (SEQ ID NO:611);
AGAACTGCTG (SEQ ID NO:612);	GAACTGCTGA (SEQ ID NO:613).

92. A method according to claim 86 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTTGCC	(SEQ ID NO:652);	CTTTTTGCCT	(SEQ ID NO:653);
TTTTTGCCCTG	(SEQ ID NO:654);	TTTTCCTGT	(SEQ ID NO:655);
TTTGCCCTGTA	(SEQ ID NO:656);	TTGCCTGTAC	(SEQ ID NO:657);
TGCCTGTACT	(SEQ ID NO:658);	GCCTGTACTG	(SEQ ID NO:659);
CCTGTACTGG	(SEQ ID NO:660);	CTGTACTGGG	(SEQ ID NO:661);
TGTACTGGGT	(SEQ ID NO:662);	GTACTGGGTC	(SEQ ID NO:663);
TACTGGGTCT	(SEQ ID NO:664);	ACTGGGTCTC	(SEQ ID NO:665);
CTGGGTCTCT	(SEQ ID NO:666);	TGGGTCTCTC	(SEQ ID NO:667);
GGGTCTCTCT	(SEQ ID NO:668);	GGTCTCTCTG	(SEQ ID NO:669);
GTCTCTCTGG	(SEQ ID NO:670);	TCTCTCTGGT	(SEQ ID NO:671);
CTCTCTGGTT	(SEQ ID NO:672);	TCTCTGGTTA	(SEQ ID NO:673);
CTCTGGTTAG	(SEQ ID NO:674);	TCTCTGGTTA	(SEQ ID NO:675);
CTGGTTAGAC	(SEQ ID NO:676);	TGGTTAGACC	(SEQ ID NO:677);
GGTTAGACCA	(SEQ ID NO:678);	GTTAGACCAG	(SEQ ID NO:679);
TTAGACCAGA	(SEQ ID NO:680);	TAGACCAGAT	(SEQ ID NO:681);
AGACCAGATC	(SEQ ID NO:682);	GACCAGATCT	(SEQ ID NO:683);
ACCAGATCTG	(SEQ ID NO:684);	CCAGATCTGA	(SEQ ID NO:685);
CAGATCTGAG	(SEQ ID NO:686);	AGATCTGAGC	(SEQ ID NO:687);
GATCTGAGCC	(SEQ ID NO:688);	ATCTGAGCCT	(SEQ ID NO:689);
TCTGAGCCTG	(SEQ ID NO:690);	CTGAGCCTGG	(SEQ ID NO:691);
TGAGCCTGGG	(SEQ ID NO:692);	GAGCCTGGGA	(SEQ ID NO:693);
AGCCTGGGAG	(SEQ ID NO:694);	GCCTGGGAGC	(SEQ ID NO:695);
CCTGGGAGCT	(SEQ ID NO:696);	CTGGGAGCTC	(SEQ ID NO:697);
TGGGAGCTCT	(SEQ ID NO:698);	GGGAGCTCTC	(SEQ ID NO:699);
GGAGCTCTCT	(SEQ ID NO:700);	GAGCTCTCTG	(SEQ ID NO:701);
AGCTCTCTGG	(SEQ ID NO:702);	GCTCTCTGGC	(SEQ ID NO:703);
CTCTCTGGCT	(SEQ ID NO:704);	TCTCTGGCTA	(SEQ ID NO:705);
CTCTGGCTAA	(SEQ ID NO:706);	TCTGGCTAAC	(SEQ ID NO:707);
CTGGCTAACT	(SEQ ID NO:708);	TGGCTAACTA	(SEQ ID NO:709);
GGCTAACTAG	(SEQ ID NO:710);	GCTAACTAGG	(SEQ ID NO:711);
CTAACTAGGG	(SEQ ID NO:712);	TAAC TAGGGA	(SEQ ID NO:713);
AACTAGGGAA	(SEQ ID NO:714);	ACTAGGGAAC	(SEQ ID NO:715);
CTAGGGAAACC	(SEQ ID NO:716);	TAGGGAAACCC	(SEQ ID NO:717);
AGGGAACCCA	(SEQ ID NO:718);	GGGAACCCAC	(SEQ ID NO:719);

GGAACCCACT	(SEQ ID NO:720);	GAACCCACTG	(SEQ ID NO:721);
AACCCACTGC	(SEQ ID NO:722);	ACCCACTGCT	(SEQ ID NO:723);
CCCACTGCTT	(SEQ ID NO:724);	CCACTGCTTA	(SEQ ID NO:725);
CACTGCTTAA	(SEQ ID NO:726);	ACTGCTTAAG	(SEQ ID NO:727);
CTGCTTAAGC	(SEQ ID NO:728);	TGCTTAAGCC	(SEQ ID NO:729);
GCTTAAGCCT	(SEQ ID NO:730);	CTTAAGCCTC	(SEQ ID NO:731);
TTAAGCCTCA	(SEQ ID NO:732);	TAAGCCTCAA	(SEQ ID NO:733);
AAGCCTCAAT	(SEQ ID NO:734);	AGCCTCAATA	(SEQ ID NO:735);
GCCTCAATAA	(SEQ ID NO:736);	CCTCAATAAA	(SEQ ID NO:737);
CTCAATAAAG	(SEQ ID NO:738);	TCAATAAAGC	(SEQ ID NO:739);
CAATAAAGCT	(SEQ ID NO:740);	AATAAAGCTT	(SEQ ID NO:741);
ATAAAGCTTG	(SEQ ID NO:742);	TAAAGCTTGC	(SEQ ID NO:743);
AAAGCTTGCC	(SEQ ID NO:744);	AAGCTTGCCCT	(SEQ ID NO:745);
AGCTTGCCCT	(SEQ ID NO:746);	GCTTGCCCTTG	(SEQ ID NO:747);
CTTGCCCTGA	(SEQ ID NO:748);	TTGCCCTTGAG	(SEQ ID NO:749);
TGCCCTTGAGT	(SEQ ID NO:750);	GCCTTGAGTG	(SEQ ID NO:751);
CCTTGAGTGC	(SEQ ID NO:752);	CTTGAGTGCT	(SEQ ID NO:753);
TTGAGTGCTT	(SEQ ID NO:754);	TGAGTGCTTC	(SEQ ID NO:755);
GAGTGCTTCA	(SEQ ID NO:756);	AGTGCTTCAA	(SEQ ID NO:757);
GTGCTTCAAG	(SEQ ID NO:758);	TGCTTCAAGT	(SEQ ID NO:759);
GCTTCAAGTA	(SEQ ID NO:760);	CTTCAAGTAG	(SEQ ID NO:761);
TTCAAGTAGT	(SEQ ID NO:762);	TCAAGTAGTG	(SEQ ID NO:763);
CAAGTAGTGT	(SEQ ID NO:764);	AAGTAGTGTG	(SEQ ID NO:765);
AGTAGTGTGT	(SEQ ID NO:766);	GTAGTGTGTG	(SEQ ID NO:767);
TAGTGTGTGC	(SEQ ID NO:768);	AGTGTGTGCC	(SEQ ID NO:769);
GTGTGTGCCC	(SEQ ID NO:770);	TGTGTGCCCCG	(SEQ ID NO:771);
GTGTGCCCCGT	(SEQ ID NO:772);	TGTGCCCCGTC	(SEQ ID NO:773);
GTGCCCCGTCT	(SEQ ID NO:774);	TGCCCCGTCTG	(SEQ ID NO:775);
GCCCCGTCTGT	(SEQ ID NO:776);	CCCGTCTGTT	(SEQ ID NO:777);
CCGTCTGTTG	(SEQ ID NO:778);	CGTCTGTTGT	(SEQ ID NO:779);
GTCTGTTGTG	(SEQ ID NO:780);	TCTGTTGTGT	(SEQ ID NO:781);
CTGTTGTGTG	(SEQ ID NO:782);	TGTTGTGTGA	(SEQ ID NO:783);
GTTGTGTGAC	(SEQ ID NO:784);	TTGTGTGACT	(SEQ ID NO:785);
TGTGTGACTC	(SEQ ID NO:786);	GTGTGACTCT	(SEQ ID NO:787);
TGTGTGACTC	(SEQ ID NO:788);	GTGTGACTCT	(SEQ ID NO:789);
TGTGACTCTG	(SEQ ID NO:790);	GTGACTCTGG	(SEQ ID NO:791);

TGACTCTGGT	(SEQ ID NO:792);	GACTCTGGTA	(SEQ ID NO:793);
ACTCTGGTAA	(SEQ ID NO:794);	CTCTGGTAAC	(SEQ ID NO:795);
TCTGGTAACT	(SEQ ID NO:796);	CTGGTAACTA	(SEQ ID NO:797);
TGGTAACTAG	(SEQ ID NO:798);	GGTAACTAGA	(SEQ ID NO:799).

FIGURE 1

1/47

2/47
3/47
4/47
5/47
6/47
7/47
8/47
9/47
10/47
11/47
12/47
13/47
14/47
15/47
16/47
17/47
18/47
19/47

2/47

FIGURE 1

8072

NL43 GAACAGATTGTGGAATAACATGACCTGGATGGAGTGGGACAGAGAAATTAA 8121
 *** ***** * ***** * ***** * ***** *
 D36P GAAGAGATTGGGAGAAACATGACCTGGATGCAGTGGGAAAGAAATTCA
 *** ***** * ***** * ***** * ***** *
 C18S GAAACAATTGGGATAACATGACCTGGATGCAGTGGGAAAGAGAAATTGA
 *** ***** * ***** * ***** * ***** *
 C18M GAAACAATTGGGATAACATGACCTGGATGCAGTGGGAAAGAGAAATTGA

 C98H GAAATTAA

NL43 CAATTACACAAGCTTAATACACTCCTTAAATTGAAGAATCGCAAAACCAGC 8171
 *** ***** * ***** * ***** * ***** *
 D36P CAATCACACAAAATACATATACCTTACTTGAATAATCGCAGAACCAAC
 ***** * ***** * ***** * ***** *
 C18S CAATTACACAACATAATATACACCTTAAATTGAAGAATCGCAGAACCAAC
 ***** * ***** * ***** * ***** *
 C18M CAATTACACAACATAATATACACCTTAAATTGAAGAATCGCAGAACCAAC
 ***** * ***** * ***** * ***** *
 C98H CAATTACACAAGATTAAATATACAACCTTAAATTGAAGAATCGCAGAACCAAC

3/47

FIGURE 1

NL43	AAGAAAAGAAATGAACAAGAAATTATTGGAATTAGATAAATGGGCAAGTTTG *****	8221
D36P	AAGAAAAGAAATGAACAAGAACTATTGGAATTGGATCAATGGGCAAGTTTG *****	
C18S	AAGAAAAGAAATGAACCTAGAAATTATTGGAATTGGATAAATGGGCAAAATTG *****	
C18M	AAGAAAAGAAATGAACCTAGAAATTATTGGAATTGGATAAATGGGCAAAATTG *****	
C98H	AAGAAAAGAAATGAACAAGACTTATTGGAATTAGATAAATGGGCAAGTTTG *****	
NL43	TGGAAATTGGTTTAACATAACAAGAAATGGCTGTGGTATAATAAAATTATTTCAT *****	8271
D36P	TGGAAATTGGTTTGACATAACAAGAAATGGCTGTGGTATAATAAAATTATTTCAT *****	
C18S	TGGAAATTGGTTTAGTATATCAAACTGGCTATGGTATAATAAAATTATTTCAT *****	
C18M	TGGAAATTGGTTTAGTATATCAAACTGGCTATGGTATAATAAAATTATTTCAT *****	
C98H	TGGAAATTGGTTTGACATAACAAGTGGGCTGTGGTATAATAAAATTATTTCAT *****	

4/47

FIGURE 1

NL43	AATGATAGTAGGAGGCTTGGTAGGTTTAAGAAATAGTTTTTGGCTGTACTTT	8321
D36P	AATGGTAGTAGGAGGCTTGATAGGTTTAAGAAATAGTTTTTGGCTGTACTTT	
C18S	AATGGTAGTAGGAGGCTTGGTAGGTTTAAGAAATAGTTTTTACTGTACTTT	
C18M	AATGGTAGTAGGAGGCTTGGTAGGTTTAAGAAATAGTTTTTACTGTACTTT	
C98H	AATGATAGTAGGAGGCTTGGTAGGTTTAAGAAATAGTTTTTACTGTACTTT	
	SA8 SA9 SA10	
NL43	CTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACC	8371
D36P	CTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTGTCTTCAGACC	
C18S	CTATAGTTAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACC	
C18M	CTATAGTTAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACC	
C98H	CTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACC	

5/47

FIGURE 1

Tat termination NL43

NL43 CACCTCCCAATCCGAGGGACCCGACAGGCCCGAAGGAATAGAAAGA 8421
 * * * * *
 D36P CTCCTCCCAACCCGAGGGACCCGACAGGCCCGAAGGAATCGAAGAAGA
 * * * * *
 C18S CACCTCCCAACCCGAGGGACCCGACAGGCCCGAAGGAATCGAAGAAGA
 * * * * *
 C18M CACCTCCCAACCCGAGGGACCCGACAGGCCCGAAGGAATCGAAGAAGA
 * * * * *
 C98H CACCTCCCAACCCGAGGGACCCGACAGGCCCGAAGGAATCGAAGAAGA

NL43 AGGTGGAGAGAGACAGAGACAGATCCATTGATTAGTGAACGGATCCT 8471
 * * * * *
 D36P AGGTGGAGAGAGACAGAGACAGATCCACTCGATTAGTACACGGATTCT
 * * * * *
 C18S AGGTGGAGAGAGACAGAGAGCGCTCCACTCGATTAGTGCACGGATTCT
 * * * * *
 C18M AGGTGGAGAGAGAGCGAGAGCGCTCCACTCGATTAGTGCACGGATTCT
 * * * * *
 C98H AGGTGGAGAGAGACAGAGACAGATCCAGTCGATTAGTGCACGGATTCT
 D36P, C18S, C18M & C98H Tat termination

6/47

FIGURE 1

NL43	TAGCACTTATCTGGACGATCTGCGGAGCCTGTGCTCTTTCAGCTACCAC	8521
D36P	*****	
C18S	TAGCACTTTTCTGGACGACCTGAGGAGCCTGTGCTCTTTCAGCTACCAC	
C18M	*****	
C98H	TAGCACTTTTCTGGGTCGACCTGAGGAGCCTGTGCTCTTTCAGCTACCAC	
NL43	CGCTTGAGAGACTTACTCTTGATTGTAAACGAGGATTGTGGAACCTTCTGGG	8571
D36P	*****	
C18S	CACCTTGAGAGACTTACTCTTGATTGTAAACGAGGATTGTGGAACCTTCTGGG	
C18M	*****	
C98H	CGCTTGAGAGACTTACTCTTGATTGTAAACGAGGATTGTGGAACCTTCTGGG	

7/47

FIGURE 1

NL43 ACGCAGGGGTGGGAAGCCCTCAAATATTGGTGGAAATCTCCTACAGTATT 8621

 D36P ACGCAGGGGATGGGAAGCCCTCAAATATTGGTGGAACTCCTAAAGTATT

 C18S ACGCAGGGGATGGGAAGCCCTCAAATACTGGTGGAAATCTCCTGCAGTATT

 C18M ACGCGGGGATGGGAAGCCCTCAAATACTGGTGGAAATCTCCTGCAGTATT

 C98H ACGCAGGGGTGGGAAGCCCTCAAATATTGGTGGAAATCTCCTACAAATATT

NL43 Rev termination

NL43 GGAGTCAGGAACTAAAGAATAGTGCTGTGTTAACTTGCTCAATGCCACAGCC 8671

 D36P GGAGCCAGGAACTGCAGAAGAGTGCTGTGTTATCTTGCTCAATGCCACCGCC

 C18S GGAGGCAGGAACTACAGAAGAGTGCTGTGTTAGCTTGTTCAATGGCACGGCC

 C18M GGAGACAGGAACTACAGAAGAGTGCACTTAGCTTGTTCAATGCCATAGCC

 C98H GGAGTCAGGAACCAAGAAGAGTGCTATTAGCTTGTTCAATGCCACCGCC
 C18S, C18M & C98H Rev termination

8/47

FIGURE 1

NL43 ATAGCAGTAGCTGAGGGGACAGATAGGTTATAGAAGTATTACAAGCAGC 8721

 D36P ATAGCAGTAGCTGAGGGGACAGATAGAGTTTATAGAAGTATTACAAGAGC

 C18S ATAGCAGTAGCTGAGGGGACAGATAGAGTTATAGAAGCTTTACGAAGGC

 C18M ATAGCAGTAGCTGAGGGGACAGATAGAGCTATAGAAGGATTACAAGAGC

 C98H ATAGCAGTAGCTGAGGGGACAGATAGAGTTATAGAAGTATTACAAGAGC

 D36P Rev termination

NL43 TTATAGAGCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTGGAAA 8771

 D36P TTATAGAGCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTCGAAA

 C18S TTATAGAGCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTAGAAA

 C18M TTATAGAGCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTAGAAA

 C98H TTGTAGAGCTGTTCTCCACATACCTAGAAGAATAAGACAGGGCTTCGAAA

9/47

FIGURE 1

	Env termination	Nef start	
NL43	GGATTTTGCTATAAGATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGG	8821	
D36P	* **** *		
	TGGCTTTGCTATAAAATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATCAG		
C18S	** **** *		
	GGGCTTTGCTATAAAATGGGTGGCAAGTGGTCAAAAAGTAGTGTGGTTAG		
C18M	** **** *		
	GGGCTTTGCTGTAAATGGG-----		
C98H	** **** *		
	GGGCTATGCTATAAAATGGGTGGCAAGTGGTTAAAAAGTAGTATGGTTAG		
	D36P Nef termination		
NL43	nef duplication region		
	ATGGCCTGCTGTAAAGGGAAGAATGAGACGAGCTGAGCCAGCAGCAGATG	8871	
D36P	** ** * *		
	ATAGCATG-----CATCATAAG		
C18S	* ** * *		
	AAGGCATG-----		
C18M	-----		
	***** ** *****		
C98H	ATGGCCTGCTGTAAAGGGAAGAATGAACAAGCTGAGCCAGCAGCAGAAG		

10/47

FIGURE 1

NL43 GGGTGGGAGCAGTATCTCGAGACCTAGAAACAATGGAGCAATCACAAGT 8921
 ***** **

D36P GGGTGGGGGC-----

C18S -----

C18M -----

C98H *****
 GGGTGGGAGCAATATCTCGAGACCTAGGAAACAATGGAGCAATCCCAAGT

SIV_{mac}239 IPTC

NL43 AGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGCTAGAAAGCACAAGA 8971
 ** ** ***** * *****

D36P -----CAACAATAACAATGCTGATCGTGCCTGGCTAGAAAGCACAAGA

C18S -----

C18M -----

C98H *****
 AGCAATACAACAATAACAATGCTAATTGTGCCTGGCTAGAAAGCACAAGA

FIGURE 1

NL43 GGAGGAAGAGGTGGGTTTTCAGTCACACCTCAGGTACCTTTAAGACCAA 9021
 * * * * *
 D36P GAAGGAAGAAGCGGGTTTTCAGTCAAACCTCAGGTA-----
 * * * * *
 C18S -----TACCTTTAAGAC-----
 C18M -----
 C98H *****
 GGAGGAGGAAGTGGGTTTTCAGTCAAACCTCAGGTACCTTTAAGACCAA

poly purine tract

9071
 9071
 TGA CTTACAAGGCAGCTGTAGATCTTAGCCACTTTTAAAGAAAAGGGG

 ---GCTGTAGATCTTAGCCACTTTTAAAGAAAAGGGG

 ---AAGGCAGCTATAGATCTTAGCCGCTTTTAAAGAAAAGGGG

 ---GATCTTAGCCACTTTTAAAGAAAAGGGG

 TGACTTACAAG-----GCCACTTTTAAAGAAAAGGGG

 AGCCACTTTTAAAGAAAAGGGG
 C18S & C18F nef termination
 C18M and C98H nef Termination

12/47

FIGURE 1

	[U3	
NL43	<u>GGACTGGAAGGCTAATTC</u> ACTCCAAAGAAGACAAGATATCCTTGATCT	9121

D36P	<u>GGACTGGAAGGCTAATTC</u> ACTCCAAAGAAGACAAGATA-----	

C18S	<u>GGACTGGAAGGCTAATTC</u> ACTCACAGAGAAGA-----	

C18M	<u>GGACTGGAAGGCTAATTC</u> ACTCACAGAGAAGA-----	

C98H	<u>GGACTGGAAGGCTAATTC</u> ACTCCTAAAGAAGACAAGATATCCTTGATCT	

C54P	<u>GGACTGGAAGGCTAATTC</u> GCTCCCAAGAAGACAAGATATCCTTGATCT	

	SA12	
NL43	GTGGATCTACCACACACAGGCTACTTCCCTGATTGGCAGAACTACACAC	9171
D36P	-----	
C18S	-----	
C18M	-----	

C98H	TTGGATCTACCACACACAGGCTACT-----	

C54P	GTGGGTCTACCACACACAGGCTACTTCCCTGAGTGGCAGAACTACACAC	

14/47

FIGURE 1

NF-AT

NL43 CAGCTTGTTACACCCCTGTGAGCCCTGCAATGGAATGATGACCCCTGAGAGAG 9321

D36P *** ****
CAGATTGTT-----

C18S *** ****
CAGATTGTT-----

C18M *** ****
CAGATTGTT-----
**

C98H -----
*** ****

C54P CAGACTGTT-----

USF

<-- NRX]

NL43 AAGTGTTAGAGTGGAGGTTTGACAGCCGCTAGCATTTCATCAGTG GCC 9371

D36P -----
* * *

C18S -----
CCGTTGTT
**

C18M -----
CTGCT

C98H -----
A

C54P -----

15/47

FIGURE 1

TCF-1 α

NL43 CGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTGACATCGAGCTTGCTA 9421 Nef termination
 * * * * *
 D36P CTGTTGGGGACTTTCCATCCGTTGGGGACTTTCCAGCGCGGTGGCCTG
 * * * * *
 C18S CCGTTGGGGACTTTCCA, , , , , GGAGACGTGGCCCTGAGTGATAAGCCG
 * * * * *
 C18M TGCTCAGCTGGGGACTTTCCAGAAGCGCGGCTGAGTGAAGCCCG
 * * * * *
 C98H CAGAGTGTGGGGACTCTCCACAACAGAGTGTGGGGACTTTCCAGGAGGC
 * * * * *
 C54P -----CCGTTGGGGACTTTCCAGGAGCGGTGGCCCTGAGTGACTAAGTTCC

D36P, C18S, C18M, & C98H extra NFKB

D36P & C98H extra NFKB

17/47

FIGURE 1

	Sp1	Sp1	TATA box	
NL43	CTGGCGGGGACTGGGAGTGGCGAGCCC, TCAGATGCTGCATATAAGCAG			9510
D36P	CTGGCGGGGACTGGGAGTGGCGAGCCC, TCAGATGCTGCATATAAGCAG			
C18S	CTGGCGGGGACTGGGAGTGGCGAGCCC, TCAGATGCTGCATATAAGCAG			
C18M	CTGGCGGGGACTGGGAGTGGCGAGCCC, TCAGATGCTGCATATAAGCAG			
C98H	CTGGCGGGA-CTGGGGAGTGC-GAGCC-, TCAGATGCTGCATATAAGCAG			
C54P	CTGGCGGGGACTGGGAGGGGCGAGCCC, TCAGATGCTGCATATAAGCAG	Sp1		
	U3]	R	
NL43	CTGCTTTTGCCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG		TAR	9560
D36P	CTGCTTTTGCCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG			
C18S	CTGCTTTTGCCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG			
C18M	CTGCTTTTGCCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG			
C98H	CTGCTTTTGCCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG			
C54P	CTGCTTTTGCCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG			

18/47

FIGURE 1

	Polyadenylation	
NL43	<u>GGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCCTCAATAAAGCT</u> *****	9610
D36P	<u>GGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCCTCAATAAAGCT</u> *****	
C18S	<u>GGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCCTCAATAAAGCT</u> **	
C18M	<u>GGAGCTCTCTGGCTAGCTAGGGACCCACTCCTTAAGCCCTCAATAAAGCT</u> *****	
C98H	<u>GGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCCTCAATAAAGCT</u> *	
C54P	G incomplete	
NL43	R] [U5 TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGACTCTGGT *****	9660
D36P	TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGACTCTGGT *****	
C18S	TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGACTCTGGT *****	
C18M	TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGACTCTGGT *****	
C98H	TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGACTCTGGT *****	


19/47

FIGURE 1

NL43	AACTAGAGATCCCTCAGACCCCTTTTAGTCAGTGTGGAATACTCTAGCA	9709
	* * * * *	
D36P	ATCTAGA	1305
	* * * * *	
C18S	ATCTAGA	1209
	* * * * *	
C18M	ATCTAGAGATCCCTCAGACCATTTTAGTCCGTGTGGAATACTCTAGCA	END
	* * * * *	
C98H	ATCTAGA	1399

20/47

FIGURE 2



21/47

FIGURE 2A

NL43 73 PTSQSRGDPPTGPKKE# 86

D36P BMC PSSQPRGDPPTGPKESKKKVERETETDPLD#

C18 HIV_{stV} PTSQPRRDPTGQESKKKVERETEAAAPLD#C18 HIV_{MBC} PTSQPRRDPTGQESKKKVERETEAAAPLD#

C98 HIV PTSQPRRDPTGQESKKKVERETETDPPVD#

FIGURE 2B

NL43 26 DPPNPEGTRQARRNRRRRWRERQRQIHISERILSTYLG 65

D36P BMC DPPNPEGTRQARRNRRRRWRERQRQIHISIRILSTFLG

C18 HIV_{stV} DPPNPEGTRQARRNRRRRWRERQRQLHSISARILSTFLGC18 HIV_{MBC} DPPNPEGTRQARRNRRRRWRERQRQLHSISARILSTFLG

C98 HIV DPPNPEGTRQARRNRRRRWRERQRQIQSISARILSTFLG


22/47

FIGURE 2B

NL43	RS AEPVPLQLPPLERLTLD CNEDCGTSGTQGVGSPQILVE	105
D36 P BMC	RPEEPVPLPLPPLERLTLD CNKDCGTSGTQGMGSPQILVE	
C18 HIV _{stv}	RPEESVPLQLPPLERLTLD CNEDCGTSGTQGMGSPQILVE	
C18 HIV _{MB}	RPEESVPLQLPPLERLTLD CNEDCGTSGTQGMGSPQILVE	
C98 HIV	RPEEPVPLQLPPLERLTLD CNEDCGTSGTQGVGSPQILVE	
NL43	SPTVLESGTKE#	116
D36P BMC	PPKVLEPGTAEECCYLAQCHRHSSS#	
C18 HIV _{stv}	SPAVLEAGTTEEC#	
C18 HIV _{MB}	SPAVLEAGTTEEC#	
C98 HIV	SPTILESGTQEECY#	

23/47

FIGURE 3



24/47

FIGURE 3

NL43	EQIWNMTWMEWDREINNNTSLIHSLIEESQNQEKNEQELLELDKWASL	639
D36P BMC	EEIWENMTWMQWEKEIHNTKYIYSLLEKSNQEKNEQELLELDQWASL	
C18 HIV _{stv}	ETIWDNMTWMQWEREIDNYTNIITYTLIEESQNQEKNELELDKWANL	
C18 HIV _{MBC}		
C98 HIV	EINNYTRTIYNLIEESQNQEKNEQDLELDKWASL	
NL43	WNWFENITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQT	689
D36 P BMC	WNWFDITKWLWYIKLFIMVVGGLIGLRIVFAVLSIVNRVRQGYSPLSFQT	
C18 HIV _{stv}	WNWFSISNWLWYIKLFIMVVGGLVGLRIVFTVLSIVNRVRQGYSPLSFQT	
C18 HIV _{MBC}		
C98 HIV	WNWFDITSGWLWYIKLFIMIVGGLVGLRIVLAVLSIVNRVRQGYSPLSFQT	

25/47

FIGURE 3

NL43	HLPIPRGPDPRPEGIEEEGGERDRDRSIRLVNGSLALIWDLRSCLFSYH	739
D36 PBMC	LLPTPRGPDPRPEGIEEEGGERDRDRSTRLVHGFLALFWDDLRSCLFLYH	
C18 HIV _{Stv}	HLPTPKGPDPRPEGIEEEGGERDRGSSSTRLVHGFLALFWDDLRSCLFSYH	
C18 HIV _{MBC}		
C98 HIV	HLPTPRGPDPRPEGIEEEGGERDRDRSSRSLVHGFLALFWVDLRSCLFSYH	
NL43	RLRDLLLIIVTRIVELLGRRGWEALKYWNLLQYWSQELKNSAVNLLNATA	789
D36 PBMC	HLRDLLLIIVTRIVELLGRRGWEALKYWNLLKYWSQELQKSAVILLNATA	
C18 HIV _{Stv}	HLRDLLLIIVTRIVELLGRRGWEALKYWNLLQYWRQELQKSAVSLFNGTA	
C18 HIV _{MBC}		
C98 HIV	RLRDLLLIIVTRIVELLGRRGWEALKYWNLLQYWSQELKKSASISLFNATA	
NL43	IAVAEGTDRVIEVLQAAYRAIRHIPRRIRQGLERILL#	839
D36 PBMC	IAVAEGTDRVIEVLQRAYRAILHIPRRIRQGLEMALL#	
C18 HIV _{Stv}	IAVAEGTDRVIEALRRAYRAILHIPRRIRQGLERALL#	
C18 HIV _{MBC}		
C98 HIV	IAVAEGTDRVIEVLQACRAVLHIPRRIRQGFERAML#	

26/47

FIGURE 4

NL43	MGGKWSKSSVIGWPAVRERMRRRAEPADGVGAVSRDLEKHGAITSSNTAA ***	50
D36 PBMC	MGGK# *****	4
C18.HIV _{stv}	MGGKSESSVRRRHVPLRQGSYRS# *	24
C18 HIV _{MBC}	MRILATF# *****	7
C98 HIV	MGGKWLKSSMVRWPAVREKMKQAEPAEGVGAI SRDLGKHGAIPSSNTTT *****	50
NL43	NNAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL ***	100
C98 HIV	NNANCAWLEAQEEEEVGFPVKPQVPLRPMTYKATF# *****	85
NL43	IHSQRRQDILDNIYHTQGYFFPDWQNYTPGPGVRYPLTFGWCYKLVPEP	150
NL43	DKVEEANKGENTSLHHPVSLHGMDDDPEREVLEWRFD SRLAFHHVARELHP	200
NL43	EYFKNC*	206

27/47


FIGURE 5

9419		NFkB		NFkB
NL43				CGAGCTTGCTACAAGGGACTTTCC,, , GCTGGGACTTTCCAGGGA
D36	PBMC			*** ***** * ***** **
				ACTGTGGGGACTTTCCATCCGTGGGGACTTTCCAAAGGC
C18	HIV _{StV}			* ** * ***** **
				ACCCTTGTTCCTGGGGACTTTCCA-GGA
C18	HIV _{MB}			* ***** **
				ACTGCTTGTCTCAGCTGGGGACTTTCCA-GAA
C98	HIV			* * * ***** **
				AACAGAGTGTGGGACTCTCCACAACAGAGTGTGGGGACTTTCCAAGGA
C54	PBMC			* ***** **
				ACCCTTGGGGACTTTCCAAGGA
		NFkB		NFkB
		Sp1	Sp1	Sp1
NL43				9492
				GGCGTGGCCCTGGGCGGGACTGGGGAGTGGCG-AGCCCTCA
				***** ** * ** *
DC36	PBMC			GGCGTGGCCCTGGGTGACTAGTTCGGTGGGG-ACTTTCCA
				* ***** ** * ** *
C18	HIV _{StV}			GACGTGGCCTGAGTGACTAAG-CCGCTGGGG-ACTTTCCG
				*** ***** * * ** * *
C18	HIV _{MB}			GGCGGGCCTGAGTGACTAAGCCCGTTGGG-ACTTTCCG
				***** ** * ** *
C98	HIV			GGCGTGGCCTGAGTGACTAAGTTCGTTGGGGACTTTCCA
				***** ** * ** *
C54	PBMC			GGCGTGGCCTGAGTGACTAAGTTCGTTGGGGACTTTCCA
				Sp1 3' half NFkB NFkB

28/47

FIG 6


Replication of Sydney Asymptomatic
Patients Isolates in PHA-stimulated PBMCs



29/47


FIG 7

Replication of Sydney Asymptomatic
Patient Isolates in non-PHA stimulated PBMCs



30/47

FIG 8



31/47

FIGURE 9

32/47
33/47
34/47
35/47
36/47
37/47

FIGURE 9

32/47

TGGAAGGGCTAATTCACCTCACGGAAAAGACCAGTTGAACCAG
AAGAAGATAGAAGAGGCCATGAAGAAGAAAACAACAGATTGT
TCTGCTTGCTCAGCTGGGGACTTTCCAGAAGGCGCGGCCTGA
GTGACTAAGCCCCGTTGGGGACTTTCCGAAGAGGCATGAAGG
GACTTTCCAAGGCAGGCGTGGCCTGGGCGGGACTGGGGAGTG
GCGAGCCCTCAGATGCTGCATATAAGCAGCTGCTTTCTGCCT
GTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGC
TCTCTGGCTAGCTAGGGAACCCACTGCTTAAGCCTCAATAAA
GCTTGCCCTTGAGTGCTTCAAGTAGTGTGTGCCCCGTCTGTTGT
GTGACTCTGGTATCTAGAGATCCCTCAGACCATTTTAGTCCG
TGTGGAAAATCTCTAGCAGTGGCGCCCCGAACAGGGACTTGAA
AGCGAAAGGAAAACCAGAGGAGCTCTCTCGACGCAGGACTCG
GCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACT
GGTGAGTACGCCGAAAATTTTGACTAGCGGAGGCTAGAAGGA
GAGAGATGGGTGCGAGAGCGTCAATATTAAGCGGGGAAAAT
TAGATAGATGGGAGAAAATTCGGTTAAGGCCAGGAGGAAAGA
AAAAGTATAAATTAAAACATATAGTATGGGCAAGCAGGGAGC
TAGAACGATTTCGCAGTCAATCCTGGCCTGTTGGAAACATCAG
AAGGCTGTAGACAAATACTGGGACAGTTACACCCGTCCCTTC
AGACAGGATCAGAAGAACTTAAATCAGTATATAATGCAGTAG
CAGTCCTCTATTGTGTGCATCAAAACATAGACATAAAGGACA
CCAAGGAAGCTTTAGAAAAGATAGAGGAAGAGCAAAACAAAT
GTAAGAAAAAAGCACAGCAAGCAGCAGCACAGCAAGCAGCAG
CTGGCACAGGAAACAGCAACCCGGTCAGCCAAAATTACCCTA
TAGTACAGAACATGCAGGGGCAAATGGTACATCAGGCCATAT
CACCTAGAACTTTAAATGCATGGGTAAAAGTAATAGAAGAGA
AGGCTTTCAGCCCAGAGGTAATACCCATGTTTTTCAGCATTAT
CAGAAGGAGCCACCCACAAGATTTAAACACCATGCTAAACA
CAGTGGGGGGACATCAAGCAGCTATGCAAATGTTAAAAGAGA
CCATCAATGAGGAAGCTGCAGAATGGGATAGATTACATCCAG
CGCAGGCAGGGCCTGTTGCACCAGGCCAGATGAGAGACCCAA
GGGGAAGTGACATAGCAGGAACTACTAGTACCCTTCAGGAAC
AAATAGGATGGATGACAGGTAATCCAGCTATCCAGTAGGAG
AAATCTATAAAAGATGGATAATCCTGGGATTAAATAAAATAG
TAAGGATGTATAGCCCTATCAGCATTCTGGACATAAAACAAG
GACCAAAGGAACCTTTAGAGACTATGTAGACCGGTTCTATA
AACTCTAAGAGCCGAGCAAGCTACACAGGAGGTAAAAAATT
GGATGACAGAAACCTTGTTGGTCCAAAATGCAAACCCAGATT
GTAAGACTATTTTAAAAGCATTGGGACCAGCAGCTACACTAG

FIGURE 9

33/47

AAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCCAGCC
ATAAAGCAAGAGTTTTGGCAGAAGCAATGAGCCAAGCAACAA
ATGCAGCTACTGTAATGATGCAGAGAAGCAATTTTAGAAACC
AAAGAAAGAATGTTAAGTGTTTCAATTGTGGCAAAGAAGGGC
ACATAGCCAGAAATTGCAGGGCTCCTAGGAAAAGGGGCTGTT
GGAAATGTGGAAAGGAAGGACACCAAATGAAAGATTGTACTG
AGAGACAGGCTAATTTTTTAGGGAAAATCTGGCCTTCCCACA
AGGGGAGGCCAGGGAACTTTCTTCAGAGCAGGCCAGAACCAA
CAGCCCCCTCTCCAGGGCAGGCCGGAGCCATCAGCCCCGCCAG
AAGAGAGCTTCAGGTTTGGGGAGGAGACAACAACCTCCCTCTC
AGAAGCAGGAGCCGATAGACAGGGACAGGGATCTGTATCCTT
TAGCTTCCCTCAGATCACTCTTTGGCAACGACCCCTCGTCAC
AATAAAGATAGGGGGGCAGCTGAAGGAAGCTCTATTAGATAC
AGGAGCAGATGATACAGTATTAGAAGACATGCATTTGCCAGG
AAAATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTAT
CAAAGTAAACAATATGATGAAATTCTTGTAAGAAATCTGTGG
ACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGT
CAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCAC
TTTAAATTTTCCCATTAGTCCTATTGAAACTGTACCAGTACA
ATTAAAGCCAGGAATGGATGGCCCAAAGGTAAACAATGGCC
ATTGACAGAAGAGAAAATAAAAGCATTAGTAGAAATTTGTAC
AGAAATGGAAAAGGAAGGAAAGATTTCAAAAATTGGGCCTGA
AAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAGA
TGGTACTAAATGGAGAAAATTAGTAGATTTTCAGAGACCTTAA
TAAGAGAACTCAAGACTTCTGGGAAGTTCAATTAGGAATACC
ACATCCCTCAGGATTAAAAAAGAAAAAATCAGTAACAGTACT
GGATGTGGGTGATGCATACTTTTCAGTTCCCTTAGATGAAAA
CTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAATAA
TGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACA
GGGATGGAAAGGATCACCAGCAATATTCCAAAGTAGCATGAC
AAGAATCTTAGAGCCTTTTAGAAGACAAAATCCAGACATAGT
TATCTATCAATACATGGATGACTTGTATGTAGGATCTGATTT
AGAAATAGGACAGCATAGAATAAAAATAGAGGAACTGAGACA
ACATCTGTTGAAGTGGGGATTTACCACACCAGACAAAAGCA
TCAGAAAGAACCCCCATTCTTTGGATGGGTTATGAACTCCA
TCCTGATAAATGGACAGTGCAACCTATAGTACTGCCAGAAAA
AGACAGCTGGACTGTCAATGACATACAGAAGTTAGTGGGTAA
ATTAAATTGGGCAAGTCAGATTTACCCAGGAATTAAAGTAAG
GCAATTATGTAAACTCCTTAGGGGAACCAAAGCACTAACAGA

FIGURE 9

34/47

AGTAATACCACTAACAGAAGAAGCAGAGCTAGAACTGGCAGA
AAACAGGGAAATTCTAAGAGAACCAGTACATGGAGTGTATTA
TGACCCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGA
GCAAGGCCAATGGACATATCAAATTTATCAAGATCAATTTAA
AAATCTAAAAACAGGAAAGTATGCAAGATTGAGGGGTGCCCA
CACTAATGATGTAAAACAATTTCCAGAGGCAGTGCAAAAAAT
AGCCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATT
TAGACTACCCATACAAAAAGAAACATGGGACGCATGGTGGAC
AGAGTATTGGCAAGCCACCTGGATTCTTGAGTGGGAGTTTGT
CAATACCCCTCCCCTAGTAAAATTATGGTACCAGTTAGAAAA
AGAACCCATAATAGGAGCAGAACTTTCTATGTAGATGGGGC
AGCTAACAGAGAGACTAAATTAGGAAAAGCAGGATATGTTAC
TGACAGAGGAAGACAAAAAGTTGTCTCCCTAACTGACACAAC
AAATCAGAAGACTGAGTTACAAGCAATTCATCTAGCTTTGCA
GGATTCAGGATTAGAAGTAAACATAGTAACAGACTCACAGTA
TGCATTAGGAATCATTCAAGCACAACCAGATAAAAGTGAATC
AGAAATAGTCAATCAAATAATAGAGCAATTAATAAAAAAGGA
AAAGGTCTACCTGGCATGGGTACCAGCACACAAAGGAATTGG
AGGGAATGAACAAGTAGATAAATTAGTCAGTGCTGGAATCAG
GAAAATACTATTTTTTAGATGGAATAGATAAGGCACAAGAAGG
CCATGAGAAATATCACAGTAATTGGAGAGCAATGGCTAGTGG
TTTTAACCTGCCACCTATAGTAGCAAAAGAAATAGTAGCCAG
CTGTGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACA
AGTAGACTGTAGTCCAGGAATATGGCAACTAGATTGTACACA
TCTAGAAGGAAAAATTATCCTGGTAGCAGTTCATGTAGCCAG
TGGATATATAGAAGCAGAAGTTATTCCAGCAGAGACAGGGCA
GGAAACAGCATACTTTATCTTAAAATTAGCAGGAAGGTGGCC
AGTAAACACAATACATACAGACAATGGCGGCAATTTTCATCAG
TACCACGGTTAAGGCCCGCCTGTTGGTGGGCAGGGATCAAGCA
GGAATTTGGCATTCCCTACAATCCCCAAAGCCAAGGAGTAGT
GGAATCTATGAATAGAGAATTAAAGAAAATTATAGGACAGGT
AAGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGC
AGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGG
ATACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGA
CATACAACTAAAGAATTACAAAAGCAAATTACAAAAATTCA
AAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCACTTTG
GAAAGGACCAGCAAACTTCTCTGGAAAGGCGAAGGGGCAGT
AGTAATACAAGATAATAGTGACATAAAAGTAGTGCCAAGAAG
AAAAGTAAAGATCATTAGGGATTATGGAAAACAGATGGCAGG

FIGURE 9

35/47

TGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAGAACAT
GGAACAGTTT TAGTGAAACACCATATGTATGTTTCAAAGAAAG
CTAAGGGGATGGATTTATAGACATCACTATGAAAACACTCATC
CAAAAATAAGCTCAGAAGTACACATCCCACTAGGGGAAGCTA
GATTGGTAATAACAACATATTGGGGTCTACATACAGGAGAAA
GAGACTGGCATT TGGGTCAGGGAGTCTCCATAGAATGGAGGG
AAAGGACATATAGAACACAAGTAGACCCCGAACTAGCAGACC
AACTAATTCATATACATTACTTTGATTGTTTTTCAGAATCTG
CCATAAGAAGTGCCATATTAGGATATAGAGTTAGGCATAGGT
GTGAATATCAAGCAGGACATAACAAGGTAGGATCTCTACAGT
ACTTGGCACTAACAGCATT AATAACACCAAAGAAGATAAAGC
CACCTTTGCCTAGTGTTGCGAACTGACAGAGGATAGATGGA
ACAAGCCCCAGAAGACCAAGGGCCACAGAGGCAGCCATACAA
TGAATGGACACTAGAACTTTTAGAGGAGCTTAAGAATGAAGC
TGTTAGGCATTTT CCTAGGGTATGGCTCCATGGCTTAGGGCA
ACATATCTATGAACTTATGGGGTACTTGGGAAGGAGTGGA
GGCCATAACAAGAACTCTGCAACAACCTGCTGTTTATTCATTT
CAGAATTGGGTGTCAACATAGCAGAATAGGCATTATT CGACA
GAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAGAGC
CCTGGAAGCATCCAGGAAGTCAGCCTAAGACTGCGTGTACCA
CTTGCTATTGTAAAAAGTGCTGCTTT CATTGCCAAGTTTGT
TTATGACAAAAGGCTTAGGCATCTCCTATGGCAGGAAGAAGC
GGAGACAGCGACGAAGAGCTCCTCAAGACAGTCAGACTCATC
AAGCTTATCTATCAAAGCAGTAAGTAATATATGTAATGCAAC
CTTTACAAATAGTAGCAATAGTAGCATTAGTAGTAGCAGGAA
TAATAGCAATAGTTGTGTGGACCATAGTATTCATAGAATATA
AGAAAATATTAAGACAAAGAAAAATAGACAGGTTGATTGATA
GAATAAGAGAAAGAGCAGAAGACAGTGGCAATGACAGTGAAG
GGGATCAGGAAGAATTATCGGCACTTGTGGACATGGGGCACC
ATGATCCTTGGGATATTAATGATCTGTAGAGCTGCAAACAAT
TTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAGAGAA
GCAACCACCCTCTATTTTGTGCATCAGATGCCAAGGCATAT
GATGCAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTA
CCCACAGACCCTAACCACACAAGAAGTAGAATTGAAAAATGTG
ACAGAAAATTTTAACATGTGGAAAAATAACATGGTAGAACAG
ATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTGAAG
CCATGTGTAAAATTAACCCCACTCTGTGTTTCTTTAAATTGC
ACTGATGCTACTAATAACCACTAATAGTAATACCACTAGCAGC
AGCGAGAAACCGAAGGGGACAGGGGAAATAAAAACTGCTCT

FIGURE 9

36/47


TTCAATATCACCACAAGCATAAGAGATAAGGTGCAGAAACAA
TATGCACTTTTTTTATAGCCTTGATGTAGTACCAATGGATGAT
AATGATAATAGTACAAGCTATAGGTTAATAAGTTGTAACACC
TCAATCATTACACAGGCCTGTCCAAAGATATCCTTTGAGCCA
ATTCCCATACATTATTGTGCCCGGCTGGTTTTGCGATTCTA
AAGTGTAAGATAAAAGGTTCAATGGAAAAGGACCATGTACA
AGTGTCAGCACAGTACAGTGTACACATGGAATTAGGCCAGTA
GTATCAACTCAACTGTTGTAAATGGCAGTCTAGCAGAAGAA
GAGGTAGTAATTAGATCTGACAATTTTACGAACAATGCTAAA
ACCATAATAGTACAGCTGAGCAAATCTGTAGAAATTACTTGT
GTAAGACCCAACAACAATACAAGAAAAAGTATAAGTATGGGA
CCAGGGAGAGCATTTTATACAACAGAAATAATAGGAGATATA
AGACAAGCATATTGTAACATTAGTAAAGCAAACCTGGACTGAC
ACTTTAGAACAGATAGCTAGAAAATTAAGAGAACAATTTGAG
AATAAAACAATAGTCTTTAAGCCATCCTCAGGAGGGGACCCA
GAAATTGTAACACAGTTTTTACAGTTTTTAATTGTGGAGGGGAA
TTTTTCTACTGTAATTCAACACAACCTGTTTAAATGGTACTTGG
AATGGTACTTGGGTAAATGGTACTTGGAGTAGTAATAATACG
ACTGATACTGCAAATATCACACTCCCATGCAGAATAAAACAA
TTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCC
CCTCCCATCAAAGGACAAATTAATGTACATCAAATATTACA
GGGCTGATATTAACAAGAGATGGTGGTAACAATAACACCACG
AACGACAACGAGACCGAGACCTTCAGACCTGGAGGAGGAGAT
ATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTA
GTACAAGTTGAACCATTAGGAGTAGCACCCACCAAGGCAAAG
AGAAGAGTGGTGCAAAGAGAAAAAAGAGCAGTGGGAATAGGA
GCTATGTTCTTGGGTCTTAGGAGCAGCAGGAAGCACTATG
GGCGCAGCGTCAGTGACGCTGACGGTACAAGCCAGACAATTA
TTGTCTGGTATAGTGCAGCAGCAGAACAATCTGCTGAGGGCT
ATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGC
ATCAAACAGCTCCAGGCAAGAGTCCTGGCTGTGGAAAGATAC
CTAAGGGATCAACAGCTCCTGGGACTTTGGGGTTGCTCTGGA
AAACTCATTTGCACCACTACTGTGCCTTGGAAACAATAGCTGG
AGTAATAAATCTCTGGAAACAATTTGGGATAACATGACCTGG
ATGCAGTGGGAAAGAGAAATTGACAATTACACAAACATAATA
TACACCTTAATTGAAGAATCGCAGAACCAACAAGAAAAAAT
GAACTAGAATTATTGGAATTGGATAAATGGGCAAATTTGTGG
AATTGGTTTTAGTATATCAAACCTGGCTATGGTATATAAAATTA
TTCATAATGGTAGTAGGAGGCTTGGTAGGTTTAAGAATAGTT


FIGURE 9

37/47

TTTACTGTACTTTCTATAGTTAATAGAGTTAGGCAGGGATAC
TCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAAGGGA
CCCGACAGGCCAGAAGGAATCGAAGAAGAAGGTGGAGAGAGA
GACAGAGGCAGCTCCACTCGATTAGTGCACGGATTCTTAGCA
CTTTTCTGGGACGACCTGAGGAGTCTGTGCCTCTTCAGCTAC
CACCATTGAGAGACTTACTCTTGATTGTAACGAGGATTGTG
GAACTTCTGGGACGCAGGGGATGGGAAGCCCTCAAATACTGG
TGGAATCTCCTGCAGTATTGGAGGCAGGAACCTACAGAAGAGT
GCTGTTAGCTTGTTCAATGGCACGGCCATAGCAGTAGCTGAG
GGGACAGATAGAGTTATAGAAGCTTTACGAAGGGCTTATAGA
GCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTAGAA
AGGGCTTTGCTATAAAATGGGTGGCAAGTGGTCAGAAAGTAG
TGTGGTTAGAAGGCATGTACCTTTAAGACAAGGCAGCTATAG
ATCTTAGCCGCTTTTTTAAAGAAAAGGGGGGACTGGAAGGGC
TAATTCACCTCACGGAAAAGACCAGTTGAACCAGAAGAAGATA
GAAGAGGCCATGAAGAAGAAAACAACAGATTGTTCTGCTTGC
TCAGCTGGGGACTTTCCAGAAGGCGCGGCCTGAGTGAATAAG
CCCCGTTGGGGACTTTCCGAAGAGGCATGAAGGGACTTTCCA
AGGCAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCT
CAGATGCTGCATATAAGCAGCTGCTTTCTGCCTGTACTGGGT
CTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCT
AGCTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTT
GAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTG
GTATCTAGAGATCCCTCAGACCATTTTAGTCCGTGTGGAAAA
TCTCTAGCA


38/47

**FIG 10(a)**




40/47

FIG 10(b)(ii) trends in CD4% since seroconversion



41/47


FIG 10(c)(i) trends in CD8 since seroconversion




42/47

trends in CD8% since seroconversion


FIG 10(c)(ii)



43/47




44/47



45/47


trends in beta-2 microglobulin since seroconversion

FIG 10 (f)



beta-2 microglobulin plotted on a log scale


46/47



47/47

FIG 11


Diagrammatic sequence alignment against HIV NL4-3 showing deletions in HIV-1 asymptomatic cohort.
Deletions shown as gaps in sequence blocks.



INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 95/00063

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁶ C12N 7/02, 7/04, 15/48; C12Q 1/68, 1/70; A61K 39/21 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) ELECTRONIC DATABASES AS BELOW Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU IPC C12N 7/02, 7/04 Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) DERWENT - WPAT, BIOT: CHEMICAL ABSTRACTS - CASM, KEYWORDS: HIV, LAV, ARV, HTLV, AVIRULENT, ATTENUATED, NON PATHOGENIC, DELETION, NEF, LTR				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.		
P, X	WO,A, 94/17825 (UNIVERSITY OF CALIFORNIA) 18 August 1994, see entire document.	1-92		
X	WO,A, 91/19795 (IMMUVAX) 26 December 1991, see entire document.	1-92		
X	WO,A, 92/00987 (HARVARD COLLEGE) 23 January 1992, see entire document.	1-92		
X	WO,A, 92/05864 (CONNAUGHT LABORATORIES LTD) 2 May 1991 see pages 8-9, figures 1-2, claims.	1-92		
<div style="display: flex; justify-content: space-between;"> <div> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. </div> <div> <input checked="" type="checkbox"/> See patent family annex. </div> </div>				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 50%; vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </td> </tr> </table>			<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>			
Date of the actual completion of the international search 1 May 1995	Date of mailing of the international search report 3 May 1995 (03.05.95)			
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No. 06 2853929	Authorized officer  ROSS OSBORNE Telephone No. (06) 2832404			

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU 95/00063

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
X	WO,A, 90/13641 (SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH) 15 November 1990.	68
Y		70-71
X	The Lancet, Volume 340, issued October 10, 1992, J. Learmont et al, "Long term symptom less HIV-1 infection in recipients of blood products from a single donor". pages 863-867 see entire article.	1-92
Y	Cell, Volume 65, issued May 17, 1991, H.W. Kestler et al "Importance of the nef gene for maintenance of high virus loads and for development of AIDS". pages 651-662. See page 59 column 2 line 54 to page 660 column 1 line 3.	5-19,24-36,40-69,71-92
Y	Science, Volume 258, issued 18 December 1992, M.D. Daniel et al "Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene". pages 1938-1941.	5-19,24-36,40-69,71-92
X	Derwent WPAT Online Abstract Accession Number 93-146253 JP,A, 5078386 (SANYO KOKUSAKU PULP CO) 30 March 1993.	68
X	US 5221610 (INSTITUT PASTEUR) 22 June 1993, see column 5 lines 26-43 and column 16 line 39 to column 20 claim 5.	65-69
X	AU-B-73582/87 (588462) (U.S. DEPARTMENT OF COMMERCE) 9 November 1987	1-4,20-23,37-39,70
Y	whole document.	5-19,24-36,40-69,71-92
Y	Proc. Natl. Acad. Sci. USA. Volume 89 issued November 1992, J.O. Ojwang et al "Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme". pages 10802-10806, see entire article.	68,70-71
P,X	WO,A, 94/29437 (UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY) 22 December 1994.	1-7,20-26,37-39,70

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 95/00063

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This international search report has not established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1.	<input type="checkbox"/> Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.	<input type="checkbox"/> Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.	<input type="checkbox"/> Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:	
1.	<input type="checkbox"/> As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2.	<input checked="" type="checkbox"/> As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	<input type="checkbox"/> As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	<input type="checkbox"/> No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <div style="text-align: center;"><input type="checkbox"/></div> <div>The additional search fees were accompanied by the applicant's protest.</div> </div> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <div style="text-align: center;"><input type="checkbox"/></div> <div>No protest accompanied the payment of additional search fees.</div> </div>	

Information on patent family members

PCT/AU 95/00063

天

三

THIS PAGE BLANK (USPTO)